{"77c4ca231603fd9e0cbd5b2eadc2170453dbc443": [["poor security management, incorrect implementation, Internet technology vulnerability, the nature of intruder activity, the difficulty of fixing vulnerable systems, the limits of the effectiveness of reactive solutions, and social engineering [2] .Design FlawsThe two major components of a computer system, hardware and software, quite often have design flaws.", [["poor security management", "TREATMENT", 0, 24], ["intruder activity", "PROBLEM", 101, 118], ["fixing vulnerable systems", "PROBLEM", 138, 163], ["reactive solutions", "TREATMENT", 200, 218], ["two", "OBSERVATION_MODIFIER", 264, 267], ["major", "OBSERVATION_MODIFIER", 268, 273], ["components", "OBSERVATION_MODIFIER", 274, 284], ["hardware", "OBSERVATION", 307, 315]]], ["Hardware systems are less susceptible to design flaws than their software counterparts owing to less complexity, which makes them easier to test; a limited number of possible inputs and expected outcomes, again making it easy to test and verify; and the long history of hardware engineering.", [["Hardware systems", "TREATMENT", 0, 16], ["hardware engineering", "TREATMENT", 270, 290], ["less complexity", "OBSERVATION_MODIFIER", 96, 111], ["hardware", "OBSERVATION", 270, 278]]], ["But even with all these factors backing up hardware engineering, because of the complexity in the new computer systems, design flaws are still common.Design FlawsHowever, the biggest problems in system security vulnerability are due to software design flaws.", [["hardware engineering", "TREATMENT", 43, 63], ["biggest", "OBSERVATION_MODIFIER", 175, 182]]], ["However, three major factors contribute a great deal to software design flaws: human factors, software complexity, and trustworthy software sources [3] .Human FactorsIn the human factor category, poor software performance can be a result of the following:Human Factors1.", [["human", "ORGANISM", 79, 84], ["Human", "ORGANISM", 153, 158], ["human", "ORGANISM", 173, 178], ["Human", "ORGANISM", 255, 260], ["Factors1", "GENE_OR_GENE_PRODUCT", 261, 269], ["human factors", "PROTEIN", 79, 92], ["Human Factors1", "PROTEIN", 255, 269], ["human", "SPECIES", 79, 84], ["Human", "SPECIES", 153, 158], ["human", "SPECIES", 173, 178], ["Human", "SPECIES", 255, 260], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 173, 178]]], ["Memory lapses and attentional failures: For example, someone was supposed to have removed or added a line of code, tested, or verified, but did not because of simple forgetfulness.", [["Memory lapses and attentional failures", "DISEASE", 0, 38], ["forgetfulness", "DISEASE", 166, 179], ["Memory lapses", "PROBLEM", 0, 13], ["attentional failures", "PROBLEM", 18, 38], ["simple forgetfulness", "PROBLEM", 159, 179], ["attentional failures", "OBSERVATION", 18, 38], ["forgetfulness", "OBSERVATION", 166, 179]]], ["Rush to finish: The result of pressure, most often from management, to get the product on the market either to cut development costs or to meet a client deadline, can cause problems.", [["pressure", "PROBLEM", 30, 38], ["management", "TREATMENT", 56, 66], ["pressure", "OBSERVATION_MODIFIER", 30, 38]]], ["Malice: Software developers, like any other professionals, have malicious people in their ranks.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80]]], ["Bugs, viruses, and worms have been known to be embedded and downloaded in software, as is the case with Trojan horse software, which boots itself at a timed location.", [["horse", "ORGANISM", 111, 116], ["worms", "SPECIES", 19, 24], ["Trojan horse", "SPECIES", 104, 116], ["viruses", "PROBLEM", 6, 13], ["boots", "TREATMENT", 133, 138], ["viruses", "OBSERVATION", 6, 13]]], ["8.4, malice has traditionally been used for vendetta, personal gain (especially monetary), and just irresponsible amusement.", [["malice", "TREATMENT", 5, 11], ["vendetta", "PROBLEM", 44, 52]]], ["Although it is possible to safeguard against other types of human errors, it is very difficult to prevent malice.", [["malice", "DISEASE", 106, 112], ["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["human errors", "PROBLEM", 60, 72], ["human errors", "OBSERVATION", 60, 72]]], ["Complacency: When either an individual or a software producer has significant experience in software development, it is easy to overlook certain testing and other error control measures in those parts of software that were tested previously in a similar or related product, forgetting that no one software product can conform to all requirements in all environments.Software ComplexityBoth software professionals and nonprofessionals who use software know the differences between software programming and hardware engineering.", [["certain testing", "TEST", 137, 152], ["other error control measures", "PROBLEM", 157, 185], ["hardware engineering", "TREATMENT", 505, 525], ["hardware", "OBSERVATION", 505, 513]]], ["In these differences underlie many of the causes of software failure and poor performance.", [["software failure", "PROBLEM", 52, 68], ["software failure", "OBSERVATION", 52, 68]]], ["Difficult testing: There will never be a complete set of test programs to check software exhaustively for all bugs for a given input sequence.", [["test programs", "TREATMENT", 57, 70], ["a given input sequence", "TEST", 119, 141]]], ["Ease of programming: The fact that software programming is easy to learn encourages many people with little formal training and education in the field to start developing programs, but many are not knowledgeable about good programming practices or able to check for errors.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["little formal training", "TREATMENT", 101, 123]]], ["Misunderstanding of basic design specifications: This affects the subsequent 5. design phases, including coding, documenting, and testing.", [["testing", "TEST", 130, 137]]], ["It also results in improper and ambiguous specifications of major components of the software and in ill-chosen and poorly defined internal program structures.Trustworthy Software SourcesThere are thousands of software sources for the millions of software products on the market today.", [["the software", "TEST", 80, 92], ["improper", "OBSERVATION_MODIFIER", 19, 27], ["major", "OBSERVATION_MODIFIER", 60, 65], ["components", "OBSERVATION_MODIFIER", 66, 76], ["ill", "OBSERVATION_MODIFIER", 100, 103]]], ["Chances are when a software product is 2 years old, its producer is likely to be out of business.", [["likely to be", "UNCERTAINTY", 68, 80]]], ["In addition to the difficulties in tracing the producers of software who go out of business as fast as they come in, there is also fear that such software may not even have been tested at all.Trustworthy Software SourcesThe growth of the Internet and the escalating costs of software production have led many small in-house software developers to use the marketplace as a giant testing laboratory through the use of beta testing, shareware, and freeware.", [["beta", "GENE_OR_GENE_PRODUCT", 416, 420], ["beta testing", "TEST", 416, 428], ["growth", "OBSERVATION_MODIFIER", 224, 230], ["small", "OBSERVATION_MODIFIER", 309, 314]]], ["Shareware and freeware have a high potential of bringing hostile code into trusted systems.Trustworthy Software SourcesFor some strange reason, the more popular the software product gets, the less it is tested.", [["high", "OBSERVATION_MODIFIER", 30, 34]]], ["This leads to the growth of what is called a common genesis software product, where all its versions and releases are based on a common code.", [["growth", "OBSERVATION_MODIFIER", 18, 24]]], ["Despite the wails of the critics, major open-source products such as Linux operating system have turned out with few security flaws; still, there are fears that hackers can look at the code and perhaps find a way to cause mischief or steal information.Trustworthy Software SourcesThere has been a rise recently in Trojan horses inserted into open-source code.", [["the critics", "TREATMENT", 21, 32]]], ["In fact, security experts are not recommending running readily available programs such as MD5 hashes to ensure that the code has not been altered.", [["MD5", "PROTEIN", 90, 93]]], ["Using MD5 hashes and similar programs such as MD4, SHA, and SHA-1 continually compares codes generated by \"healthy\" software to hashes of programs in the field, thus exposing the Trojans.", [["MD5", "GENE_OR_GENE_PRODUCT", 6, 9], ["MD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["SHA-1", "GENE_OR_GENE_PRODUCT", 60, 65], ["MD5", "PROTEIN", 6, 9]]], ["According to the recent CERT advisory, crackers are increasingly inserting Trojans into the source code for tcpdump, a utility that monitors network traffic, and libpcap, a packet capture library tool [4] .Trustworthy Software SourcesHowever, according to the recent study by the Aberdeen Group, open-source software now accounts for more than half of all security advisories published in the past year by the Computer Emergency Response Team (CERT).", [["the recent study", "TEST", 256, 272]]], ["Also according to industry study reports, open-source software commonly used in Linux, Unix, and network routing equipment accounted for 16 of the 29 security advisories during the first 10 months of 2002, and there is an upswing in new virus and Trojan horse warnings for Unix, Linux, Mac OS X, and open-source software [4] .Software Reuse, Reengineering, and Outlived DesignNew developments in software engineering are spearheading new developments such as software reuse and software reengineering.", [["horse", "SPECIES", 254, 259], ["industry study", "TEST", 18, 32]]], ["Among some of the security flaws that have been introduced into programming is first the mismatch where reused requirement specifications and designs may not completely match the real situation at hand and nonfunctional characteristics of code may not match those of the intended recipient.", [["hand", "ORGANISM_SUBDIVISION", 197, 201]]], ["6, we will discuss the many security problems associated with script programming.", [["script programming", "TREATMENT", 62, 80]]], ["Scripting suffers from a list of problems, including inadequate searching and/or browsing mechanisms before any interaction between the script code and the server or client software, side effects from software assets that are too large or too small for the projected interface, and undocumented interfaces.Poor Security ManagementSecurity management is both a technical and an administrative security process that involves security policies and controls that the organization decides to put in place to provide the required level of protection.", [["browsing mechanisms", "PROBLEM", 81, 100], ["Poor Security ManagementSecurity management", "TREATMENT", 306, 349], ["an administrative security process", "TREATMENT", 374, 408], ["too large", "OBSERVATION_MODIFIER", 226, 235], ["too small", "OBSERVATION_MODIFIER", 239, 248]]], ["In addition, it also involves security monitoring and evaluation of the effectiveness of those policies.", [["security monitoring", "TEST", 30, 49], ["evaluation", "TEST", 54, 64]]], ["The most effective way to meet these goals is to implement security risk assessment through a security policy and secure access to network resources through the use of firewalls and strong cryptography.", [["security risk assessment", "TEST", 59, 83], ["a security policy", "TREATMENT", 92, 109]]], ["Security management by itself is a complex process; however, if it is not well organized, it can result in a security nightmare for the organization.Poor Security ManagementPoor security management is a result of little control over security implementation, administration, and monitoring.", [["Security management", "TREATMENT", 0, 19], ["security management", "TREATMENT", 178, 197], ["administration", "TREATMENT", 258, 272], ["monitoring", "TEST", 278, 288]]], ["It is a failure in having solid control of the security situation of the organization when the security administrator does not know who is setting the organization's security policy, administering security compliance, and who manages system security configurations and is in charge of security event and incident handling.Poor Security ManagementIn addition to the disarray in the security administration, implementation, and monitoring, a poor security administration team may even lack a plan for the wireless component of the network.", [["a failure", "PROBLEM", 6, 15], ["the wireless component", "TREATMENT", 499, 521], ["failure", "OBSERVATION", 8, 15]]], ["17, the rapid growth of wireless communication has brought with it serious security problems.", [["rapid", "OBSERVATION_MODIFIER", 8, 13], ["growth", "OBSERVATION_MODIFIER", 14, 20]]], ["Unless the organization has a solid security administration team with a sound security policy and secure security implementation, the organization's security may be compromised.", [["secure security implementation", "TREATMENT", 98, 128]]], ["An organization's system security is as good as its security policy and its access control policies and procedures and their implementation.Poor Security ManagementGood security management is made up of a number of implementable security components that include risk management, information security policies and procedures, standards, guidelines, information classification, security monitoring, and security education.", [["Poor Security Management", "TREATMENT", 140, 164], ["risk management", "TREATMENT", 262, 277], ["security monitoring", "TEST", 376, 395]]], ["These core components serve to protect the organization's resources:Poor Security Management\u2022 A risk analysis will identify these assets, discover the threats that put them at risk, and estimate the possible damage and potential loss a company could endure if any of these threats become real.", [["These core components", "TREATMENT", 0, 21], ["A risk analysis", "TEST", 94, 109]]], ["The results of the risk analysis help management construct a budget with the necessary funds to protect the recognized assets from their identified threats and develop applicable security policies that provide direction for security activities.", [["the risk analysis", "TEST", 15, 32], ["the necessary funds", "TREATMENT", 73, 92]]], ["Security education takes this information to each and every employee. \u2022 Security policies and procedures to create, implement, and enforce security issues that may include people and technology. \u2022 Standards and guidelines to find ways, including automated solution for creating, updating, and tracking compliance of security policies across the organization. \u2022 Information classification to manage the search, identification, and reduction of system vulnerabilities by establishing security configurations. \u2022 Security monitoring to prevent and detect intrusions, consolidate event logs for future log and trend analysis, manage security events in real time, manage parameter security including multiple firewall reporting systems, and analyze security events enterprise-wide. \u2022 Security education to bring security awareness to every employee of the organization and teach them their individual security responsibility.Incorrect ImplementationIncorrect implantation very often is a result of incompatible interfaces.", [["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178], ["Security monitoring", "TEST", 509, 528], ["intrusions", "PROBLEM", 551, 561], ["trend analysis", "TEST", 605, 619], ["Incorrect implantation", "TREATMENT", 943, 965], ["incompatible interfaces", "OBSERVATION", 992, 1015]]], ["That means that the module must be additive, that is, the environment of the interface needs to remain intact.", [["intact", "OBSERVATION", 103, 109]]], ["An incompatible interface, on the other hand, means that the introduction of the module has changed the existing interface in such a way that existing references to the interface can fail or behave incorrectly.", [["An incompatible interface", "PROBLEM", 0, 25], ["incompatible interface", "OBSERVATION", 3, 25]]], ["For example, ordinary addition of a software or even an addition or removal of an argument to an existing software module may cause an imbalanced interface.", [["removal", "TREATMENT", 68, 75], ["an imbalanced interface", "PROBLEM", 132, 155], ["software", "OBSERVATION", 106, 114], ["may cause", "UNCERTAINTY", 122, 131], ["imbalanced interface", "OBSERVATION", 135, 155]]], ["This interface sensitivity tells us that it is possible because of interposition that the addition of a simple thing like a symbol or an additional condition can result in an incompatible interface, leading the new symbol or condition to conflict with all applications that have been without problems.Incorrect ImplementationTo put the interface concept into a wide system framework, consider a systemwide integration of both hardware and software components with differing technologies with no standards.", [["This interface sensitivity", "TEST", 0, 26], ["interposition", "TREATMENT", 67, 80], ["a symbol", "TREATMENT", 122, 130], ["an additional condition", "PROBLEM", 134, 157], ["all applications", "TREATMENT", 252, 268], ["problems", "PROBLEM", 292, 300], ["a systemwide integration of both hardware", "TREATMENT", 393, 434], ["interposition", "OBSERVATION", 67, 80], ["incompatible interface", "OBSERVATION", 175, 197], ["new", "OBSERVATION_MODIFIER", 211, 214], ["hardware", "OBSERVATION", 426, 434]]], ["No information system products, whether hardware or software, are based on a standard that the industry has to follow.", [["hardware", "OBSERVATION", 40, 48]]], ["Because of this, manufacturers and consumers must contend with the constant problems of system compatibility.", [["the constant problems of system compatibility", "PROBLEM", 63, 108]]], ["Because of the vast number of variables in information systems, especially network systems, involving both hardware and software, it is not possible to test or verify all combinations of hardware and software.", [["network systems", "MULTI-TISSUE_STRUCTURE", 75, 90], ["hardware", "TREATMENT", 187, 195], ["hardware", "OBSERVATION", 107, 115], ["not possible", "UNCERTAINTY", 136, 148], ["hardware", "OBSERVATION", 187, 195]]], ["Products are heterogeneous both semantically and syntactically.Incorrect ImplementationWhen two or more software modules are to interface one another in the sense that one may feed into the other or one may use the outputs of the other, incompatibility conditions may result from such an interaction.", [["incompatibility conditions", "PROBLEM", 237, 263], ["heterogeneous", "OBSERVATION_MODIFIER", 13, 26]]], ["Unless there are methodologies and algorithms for checking for interface compatibility, errors are transmitted from one module into another.", [["algorithms", "TEST", 35, 45]]], ["Such an interface always makes assumptions about the environment having the necessary availability constraints for the accessibility of local methods to certain states of the module.", [["local methods", "TREATMENT", 136, 149]]], ["If such availability constraints are not checked before the modules are allowed to pass parameters via method calls, errors may result.Incorrect ImplementationIncompatibility in system interfaces may be caused by a variety of conditions usually created by things such as:Incorrect Implementation\u2022 Too much detail \u2022 Not enough understanding of the underlying parameters \u2022 Poor communication during design \u2022 Selecting the software or hardware modules before understanding the receiving software \u2022 Ignoring integration issues \u2022 Error in manual entry Many security problems result from the incorrect implementation of both hardware and software.", [["Incompatibility in system interfaces", "PROBLEM", 159, 195], ["hardware modules", "TREATMENT", 432, 448], ["both hardware", "TREATMENT", 614, 627], ["hardware", "OBSERVATION", 432, 440], ["hardware", "OBSERVATION", 619, 627]]], ["In fact, system reliability in both software and hardware is based on correct implementation, as is the security of the system.Internet Technology VulnerabilityIn Sect.", [["hardware", "TREATMENT", 49, 57], ["reliability", "OBSERVATION_MODIFIER", 16, 27], ["hardware", "OBSERVATION", 49, 57]]], ["In fact, we pointed out that systems are composed of software, hardware, and humanware.", [["hardware", "TREATMENT", 63, 71], ["hardware", "OBSERVATION", 63, 71]]], ["There are problems in each one of these components.", [["problems", "OBSERVATION", 10, 18], ["components", "OBSERVATION_MODIFIER", 40, 50]]], ["Since the humanware component is influenced by the technology in the software and hardware, we will not discuss this any further.Internet Technology VulnerabilityThe fact that computer and telecommunication technologies have developed at such an amazing and frightening speed, and people have overwhelmingly embraced both of them, has caused security experts to worry about the side effects of these booming technologies.", [["people", "ORGANISM", 281, 287], ["people", "SPECIES", 281, 287], ["hardware", "TREATMENT", 82, 90], ["these booming technologies", "TREATMENT", 394, 420], ["hardware", "OBSERVATION", 82, 90]]], ["Internet technology has been and continues to be vulnerable.", [["vulnerable", "OBSERVATION", 49, 59]]], ["There have been reports of all sorts of loopholes, weaknesses, and gaping holes in both software and hardware technologies.Internet Technology VulnerabilityAccording to the National Vulnerability Database (NVD), a US government repository of standards-based vulnerability management data using the Security Content Automation Protocol (SCAP), system vulnerabilities have been on the rise ever since system vulnerability data was first captured.", [["weaknesses", "PROBLEM", 51, 61], ["gaping holes", "PROBLEM", 67, 79], ["hardware technologies", "TREATMENT", 101, 122], ["gaping holes", "OBSERVATION", 67, 79], ["hardware", "OBSERVATION", 101, 109]]], ["The system vulnerability data captured by NVD enables automation of vulnerability management, security measurement, and compliance.", [["vulnerability management", "TREATMENT", 68, 92], ["security measurement", "TEST", 94, 114]]], ["NVD includes databases of security checklists, security-related software flaws, misconfigurations, product names, and impact metrics.", [["NVD", "PROBLEM", 0, 3]]], ["Read more about NVD at https://nvd.nist.gov/home.cfm.Internet Technology VulnerabilityThere is agreement among security experts that what is reported represents the tip of the iceberg.", [["NVD", "PROBLEM", 16, 19], ["tip", "OBSERVATION_MODIFIER", 165, 168], ["iceberg", "OBSERVATION", 176, 183]]], ["Many vulnerabilities are discovered and, for various reasons, are not reported.Internet Technology VulnerabilityBecause these technologies are used by many who are not security experts (in fact the majority of users are not security literate), one can say that many vulnerabilities are observed and probably not reported because those who observe them do not have the knowledge to classify what has been observed as a vulnerability.", [["vulnerabilities", "OBSERVATION", 5, 20]]], ["Even if they do, they may not know how and where to report.Internet Technology VulnerabilityNo one knows how many of these vulnerabilities there are in both software and hardware.", [["hardware", "OBSERVATION", 170, 178]]], ["Although the list spans both hardware and software, the problem is more prevalent with software.", [["hardware", "OBSERVATION", 29, 37], ["more prevalent", "OBSERVATION_MODIFIER", 67, 81]]], ["Going by the SysAdmin, Audit, Network, and Security (SANS) Institute, a cooperative research and education organization serving security professionals, auditors, system administrators, and network administrators, together with the Common Weakness Enumeration (CWE), a community-developed dictionary of weaknesses of software types, has been issuing lists annually: \"CWE/SANS Top 25 Most Dangerous Software Errors.\"", [["the Common Weakness", "PROBLEM", 227, 246]]], ["Popular operating systems cause many of the vulnerabilities.", [["vulnerabilities", "OBSERVATION", 44, 59]]], ["This is always so because hackers tend to take the easiest route by exploiting the best-known flaws with the most effective and widely known and available attack tools. \u2022 Port-based vulnerabilities: Besides operating systems, network service ports take second place in sourcing system vulnerabilities.", [["network service ports", "TREATMENT", 226, 247], ["vulnerabilities", "OBSERVATION", 182, 197]]], ["For system administrators, knowing the list of most vulnerable ports can go a long way to help enhance system security by blocking those known ports at the firewall.", [["most vulnerable ports", "TREATMENT", 47, 68]]], ["Such an operation, though not comprehensive, adds an extra layer of security to the network.", [["an operation", "TREATMENT", 5, 17], ["operation", "OBSERVATION", 8, 17]]], ["In fact, it is advisable that in addition to blocking and deny-everything filtering, security administrators should also monitor all ports, including the blocked ones for intruders who entered the system by some other means.", [["all ports", "TREATMENT", 129, 138], ["the blocked ones", "TREATMENT", 150, 166]]], ["For the most common vulnerable port numbers, the reader is referred to the latest SANS at: https://www. sans.org/security-resources/idfaq/which-backdoors-live-on-which-ports/8/4. \u2022 Application software-based errors.Internet Technology Vulnerability\u2022 System protocol software such as client and server browser.Internet Technology VulnerabilityIn addition to highlighting the need for system administrators to patch the most common vulnerabilities, we hope this will also help many organizations that lack the resources to train security personnel to have a choice of either focusing on the most current or the most persistent vulnerability.", [["system administrators", "TREATMENT", 383, 404]]], ["However, there is a stubborn persistence of a number of vulnerabilities making the list year after year.", [["stubborn", "OBSERVATION_MODIFIER", 20, 28], ["persistence", "OBSERVATION_MODIFIER", 29, 40], ["number", "OBSERVATION_MODIFIER", 46, 52]]], ["This observation, together with the nature of software, as we have explored in Sect.", [["This observation", "TEST", 0, 16]]], ["4.2.1, means it is possible that what has been observed so far is a very small fraction of a potential sea of vulnerabilities; many of them probably will never be discovered because software will ever be subjected to either unexpected input sequences or operated in unexpected environments.Internet Technology VulnerabilityBesides the inherently embedded vulnerabilities resulting from flawed designs, there are also vulnerabilities introduced in the operating environments as a result of incorrect implementations by operators.", [["flawed designs", "PROBLEM", 386, 400], ["small", "OBSERVATION_MODIFIER", 73, 78], ["fraction", "OBSERVATION", 79, 87], ["flawed designs", "OBSERVATION", 386, 400]]], ["The products may not have weaknesses initially, but such weaknesses may be introduced as a result of bad or careless installations.", [["weaknesses", "PROBLEM", 26, 36], ["may not have", "UNCERTAINTY", 13, 25]]], ["For example, quite often, products are shipped to customers with security features disabled, forcing the technology users to go through the difficult and errorprone process of properly enabling the security features by oneself.Changing Nature of Hacker Technologies and ActivitiesIt is ironic that as \"useful\" technology develops so does the \"bad\" technology.", [["Hacker Technologies", "TREATMENT", 246, 265]]], ["\"Bad\" technology is the technology that system intruders are using to attack systems.", [["Bad", "GENE_OR_GENE_PRODUCT", 1, 4]]], ["One thing is clear, though: hacker technology is flourishing.Changing Nature of Hacker Technologies and ActivitiesAlthough it used to take intelligence, determination, enthusiasm, and perseverance to become a hacker, it now requires a good search engine, time, a little bit of knowledge of what to do, and owning a computer.", [["Hacker Technologies", "TREATMENT", 80, 99], ["clear", "OBSERVATION", 13, 18]]], ["There are thousands of hacker Web sites with the latest in script technologies and hundreds of recipe books and sources on how to put together an impact virus or a worm and how to upload it.Changing Nature of Hacker Technologies and ActivitiesThe ease of availability of these hacker tools; the ability of hackers to disguise their identities and locations; the automation of attack technology which further distances the attacker from the attack; the fact that attackers can go unidentified, limiting the fear of prosecution; and the ease of hacker knowledge acquisition have put a new twist in the art of hacking, making it seem easy and hence attracting more and younger disciples.Changing Nature of Hacker Technologies and ActivitiesBesides the ease of becoming a hacker and acquiring hacker tools, because of the Internet sprawl, hacker impact has become overwhelming, impressive, and more destructive in shorter times than ever before.", [["an impact virus", "PROBLEM", 143, 158], ["Hacker Technologies", "TREATMENT", 209, 228], ["these hacker tools", "PROBLEM", 271, 289], ["attack technology", "TREATMENT", 376, 393], ["Hacker Technologies", "TREATMENT", 703, 722], ["thousands", "OBSERVATION_MODIFIER", 10, 19], ["overwhelming", "OBSERVATION_MODIFIER", 860, 872], ["impressive", "OBSERVATION_MODIFIER", 874, 884], ["more", "OBSERVATION_MODIFIER", 890, 894], ["destructive", "OBSERVATION_MODIFIER", 895, 906]]], ["Take, for example, recent virus incidents such as the \"I Love You,\" \"Code Red,\" \"Slammer,\" and the \"Blaster\" worms' spread.", [["worms", "SPECIES", 109, 114], ["recent virus incidents", "PROBLEM", 19, 41]]], ["These worms and viruses probably spread around the world much faster than the human cold virus and the dreaded severe acute respiratory syndrome (SARS).Changing Nature of Hacker Technologies and ActivitiesWhat these incidents have demonstrated is that the turnaround time, the time a virus is first launched in the wild and the time it is first cited as affecting the system, is becoming incredibly shorter.", [["acute respiratory syndrome", "DISEASE", 118, 144], ["SARS", "DISEASE", 146, 150], ["human", "ORGANISM", 78, 83], ["cold virus", "ORGANISM", 84, 94], ["worms", "SPECIES", 6, 11], ["human", "SPECIES", 78, 83], ["human cold virus", "SPECIES", 78, 94], ["These worms", "PROBLEM", 0, 11], ["viruses", "PROBLEM", 16, 23], ["the human cold virus", "PROBLEM", 74, 94], ["the dreaded severe acute respiratory syndrome", "PROBLEM", 99, 144], ["Hacker Technologies", "TREATMENT", 171, 190], ["a virus", "PROBLEM", 282, 289], ["viruses", "OBSERVATION", 16, 23], ["dreaded", "OBSERVATION_MODIFIER", 103, 110], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory syndrome", "OBSERVATION", 124, 144], ["incredibly", "OBSERVATION_MODIFIER", 388, 398], ["shorter", "OBSERVATION_MODIFIER", 399, 406]]], ["Both the turnaround time and the speed at which the virus or a worm spreads reduce the response time, the time a security incident is first cited in the system, and the time an effective response to the incident should have been initiated.", [["the virus", "PROBLEM", 48, 57]]], ["In a broader framework, when the turnaround time is very short, system security experts who develop patches do not have enough time to reverse engineer and analyze the attack in order to produce counter immunization codes.", [["immunization codes", "TREATMENT", 203, 221]]], ["It has been and it is still the case in many security incidents for antivirus companies to take hours and sometimes days, such as in the case of the Code Red virus, to come up with an effective cure.", [["Red virus", "SPECIES", 154, 163], ["antivirus companies", "TREATMENT", 68, 87], ["Red virus", "PROBLEM", 154, 163]]], ["However, even after a patch is developed, it takes time before it is filtered down to the system managers.", [["a patch", "TREATMENT", 20, 27]]], ["Meantime, the damage has already been done, and it is multiplying.", [["the damage", "PROBLEM", 10, 20]]], ["Likewise, system administrators and users have little time to protect their systems.Difficulty of Fixing Vulnerable SystemsIn his testimony to the Subcommittee on Government Efficiency, Financial Management, and Intergovernmental Relations of the US House Committee on Government Reform, Richard D. Pethia, Director, CERT Centers, pointed out the difficulty in fixing known system vulnerabilities as one of the sources of system vulnerabilities.", [["the difficulty in fixing known system vulnerabilities", "PROBLEM", 343, 396]]], ["Patches can be difficult to apply and might even have unexpected side effects as a result of compatibility issues [2] .Difficulty of Fixing Vulnerable SystemsBesides the problem of keeping abreast of the number of vulnerabilities and the corresponding patches, there are also logistic problems between the time at which a vendor releases a security patch and the time at which a system administrator fixes the vulnerable computer system.", [["Patches", "MULTI-TISSUE_STRUCTURE", 0, 7], ["unexpected side effects", "PROBLEM", 54, 77], ["a security patch", "TREATMENT", 338, 354]]], ["There are several factors affecting the quick fixing of patches.", [["several factors", "PROBLEM", 10, 25], ["several", "OBSERVATION_MODIFIER", 10, 17], ["quick", "OBSERVATION_MODIFIER", 40, 45]]], ["Many vendors disseminate the patches on their Web sites; others send e-mail alerts.", [["patches", "OBSERVATION_MODIFIER", 29, 36]]], ["Sometimes, it can be months or years before the patches are implemented on a majority of the vulnerable computers.Difficulty of Fixing Vulnerable SystemsMany system administrators are facing the same chronic problems: the neverending system maintenance, limited resources, and highly demanding management.", [["Difficulty of Fixing Vulnerable Systems", "PROBLEM", 114, 153], ["highly demanding management", "TREATMENT", 277, 304]]], ["Under these conditions, the ever-increasing security system complexity, increasing system vulnerabilities, and the fact that many administrators do not fully understand the security risks, system administrators neither give security a high enough priority nor assign adequate resources.", [["increasing system vulnerabilities", "PROBLEM", 72, 105]]], ["Exacerbating the problem is the fact that the demand for skilled system administrators far exceeds the supply [2] .Limits of Effectiveness of Reactive SolutionsGoing by daily reports of system attacks and hacks, the number of system attacks is steadily on the rise.", [["skilled system administrators", "TREATMENT", 57, 86], ["Reactive Solutions", "TREATMENT", 142, 160], ["system attacks", "PROBLEM", 186, 200], ["Reactive", "OBSERVATION_MODIFIER", 142, 150]]], ["However, a small percentage of all attacks are reported, indicating a serious and growing system security problem.", [["a small percentage of all attacks", "PROBLEM", 9, 42], ["a serious and growing system security problem", "PROBLEM", 68, 113], ["small", "OBSERVATION_MODIFIER", 11, 16], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["all", "OBSERVATION_MODIFIER", 31, 34], ["attacks", "OBSERVATION", 35, 42], ["serious", "OBSERVATION_MODIFIER", 70, 77]]], ["All these indicate that urgent action is needed to find an effective solution to this monstrous problem.Limits of Effectiveness of Reactive SolutionsThe security community, including scrupulous vendors, have come up with various solutions, some good and others not.", [["an effective solution", "TREATMENT", 56, 77], ["this monstrous problem", "PROBLEM", 81, 103], ["Reactive Solutions", "TREATMENT", 131, 149], ["Reactive", "OBSERVATION_MODIFIER", 131, 139]]], ["In fact, in an unexpected reversal of fortunes, one of the new security problems is to find a \"good\" solution from among thousands of solutions and to find an \"expert\" security option from the many different views.Limits of Effectiveness of Reactive SolutionsAre we reaching the limits of our efforts, as a community, to come up with a few good and effective solutions to this security problem?", [["Reactive Solutions", "TREATMENT", 241, 259], ["new", "OBSERVATION_MODIFIER", 59, 62], ["Reactive", "OBSERVATION_MODIFIER", 241, 249]]], ["It is clear that we are reaching the limits of the effectiveness of our reactive solutions.", [["our reactive solutions", "TREATMENT", 68, 90], ["clear", "OBSERVATION", 6, 11]]], ["Richard D. Pethia gives the following reasons [2] :Limits of Effectiveness of Reactive Solutions\u2022 The number of vulnerabilities in commercial off-the-shelf software is now at the level that it is virtually impossible for any but the best-resourced organizations to keep up with the vulnerability fixes. \u2022 Attack technology has now advanced to the point where it is easy for attackers to take advantage of these vulnerable machines and harness them together to launch high-powered attacks. \u2022 Many attacks are now fully automated, thus reducing the turnaround time even further as they spread around cyberspace. \u2022 The attack technology has become increasingly complex and, in some cases, intentionally stealthy, thus reducing the turnaround time and increasing the time it takes to discover and analyze the attack mechanisms in order to produce antidotes. \u2022 Internet users have become increasingly dependent on the Internet and now use it for many critical applications so that a relatively minor attack has the potential to cause huge damages.Limits of Effectiveness of Reactive SolutionsWithout being overly pessimistic, these factors, taken together, indicate that there is a high probability that more attacks are likely, and since they are getting more complex and attacking more computers, they are likely to cause significant devastating economic losses and service disruptions.Social EngineeringAccording to John Palumbo, social engineering is an outside hacker's use of psychological tricks on legitimate users of a computer system in order to gain the information (usernames and passwords) one needs to gain access to the system [5] .Social EngineeringMany have classified social engineering as a diversion, in the process of system attack, on people's intelligence to utilize two human weaknesses: first, no one wants to be considered ignorant, and second is human trust.", [["people", "ORGANISM", 1752, 1758], ["human", "ORGANISM", 1789, 1794], ["human", "ORGANISM", 1868, 1873], ["people", "SPECIES", 1752, 1758], ["human", "SPECIES", 1789, 1794], ["human", "SPECIES", 1868, 1873], ["human", "SPECIES", 1789, 1794], ["human", "SPECIES", 1868, 1873], ["Reactive Solutions", "TREATMENT", 78, 96], ["these vulnerable machines", "TREATMENT", 405, 430], ["many critical applications", "TREATMENT", 941, 967], ["a relatively minor attack", "PROBLEM", 976, 1001], ["huge damages", "PROBLEM", 1029, 1041], ["Reactive Solutions", "TREATMENT", 1069, 1087], ["significant devastating economic losses", "PROBLEM", 1319, 1358], ["a diversion", "TREATMENT", 1703, 1714], ["increasingly", "OBSERVATION_MODIFIER", 645, 657], ["complex", "OBSERVATION", 658, 665], ["Reactive", "OBSERVATION_MODIFIER", 1069, 1077], ["likely to cause", "UNCERTAINTY", 1303, 1318], ["significant", "OBSERVATION_MODIFIER", 1319, 1330], ["devastating", "OBSERVATION_MODIFIER", 1331, 1342], ["economic losses", "OBSERVATION", 1343, 1358]]], ["The reliance on and excessive use of the Internet have resulted in people having several online accounts.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73]]], ["Dumpster diving can recover from dumpsters and trash cans individual social security numbers, bank accounts, individual vital records, and a whole list of personal and work-related information that gives the hackers the exact keys they need to unlock the network. \u2022 In person is the oldest of the information-stealing techniques that predates computers.", [["person", "SPECIES", 269, 275]]], ["It involves a person physically walking into an organization's offices and casually checking out note boards, trash diving into bathroom trash cans and company hallway dumpsters, and eating lunches together and initiating conversations with employees.", [["person", "SPECIES", 14, 20]]], ["From such friendships, information can be passed unconsciously. \u2022 Snail mail is done in several ways and is not limited only to social engineering but has also been used in identity theft and a number of other crimes.", [["Snail", "GENE_OR_GENE_PRODUCT", 66, 71], ["Snail", "PROTEIN", 66, 71]]], ["From the intercepted mail, the hacker can gather a great deal of information that may include the victim's bank and credit card account numbers and access control codes and pins by claiming to have forgotten his or her password or pin and requesting a reissue in the mail.", [["pins", "TREATMENT", 173, 177]]], ["In large organizations with hundreds or thousands of employees scattered around the globe, it is very easy to impersonate a vice president or a chief operations officer.", [["large", "OBSERVATION_MODIFIER", 3, 8], ["organizations", "OBSERVATION", 9, 22], ["hundreds", "OBSERVATION_MODIFIER", 28, 36], ["thousands", "OBSERVATION_MODIFIER", 40, 49], ["scattered", "OBSERVATION_MODIFIER", 63, 72], ["globe", "ANATOMY", 84, 89]]], ["Since most employees always want to look good to their bosses, they will end up supplying the requested information to the imposter.Social EngineeringOverall, social engineering is a cheap but rather threatening security problem that is very difficult to deal with.Vulnerability AssessmentVulnerability assessment is a process that works on a system to identify, track, and manage the repair of vulnerabilities on the system.", [["Vulnerability assessment", "TEST", 289, 313], ["the repair", "TREATMENT", 381, 391], ["vulnerabilities on the system", "PROBLEM", 395, 424], ["repair", "OBSERVATION", 385, 391]]], ["It may include all desktops, servers, routers, and firewalls.", [["firewalls", "DISEASE", 51, 60]]], ["Most vulnerability assessment services will provide system administrators with:Vulnerability Assessment\u2022 Network mapping and system fingerprinting of all known vulnerabilities.Vulnerability Assessment\u2022 A complete vulnerability analysis and ranking of all exploitable weaknesses based on potential impact and likelihood of occurrence for all services on each host. \u2022 Prioritized list of misconfigurations.Vulnerability AssessmentIn addition, at the end of the process, a final report is always produced detailing the findings and the best way to go about overcoming such vulnerabilities.", [["Vulnerability Assessment", "TEST", 79, 103], ["Vulnerability Assessment", "TEST", 176, 200], ["A complete vulnerability analysis", "TEST", 202, 235], ["all exploitable weaknesses", "PROBLEM", 251, 277], ["misconfigurations", "PROBLEM", 386, 403]]], ["This report consists of prioritized recommendations for mitigating or eliminating weaknesses, and based on an organization's operational schedule, it also contains recommendations of further reassessments of the system within given time intervals or on a regular basis.Vulnerability Assessment ServicesDue to the massive growth of the number of companies and organizations owning their own networks, the growth of vulnerability monitoring technologies, the increase in network intrusions and attacks with viruses, and worldwide publicity of such attacks, there is a growing number of companies offering system vulnerability services.", [["further reassessments of the system", "TREATMENT", 183, 218], ["attacks", "PROBLEM", 492, 499], ["viruses", "PROBLEM", 505, 512], ["such attacks", "PROBLEM", 541, 553], ["massive", "OBSERVATION_MODIFIER", 313, 320], ["growth", "OBSERVATION_MODIFIER", 321, 327], ["increase", "OBSERVATION_MODIFIER", 457, 465], ["network intrusions", "OBSERVATION", 469, 487]]], ["These services, targeting the internals and perimeter of the system, Web-based applications, and providing a baseline to measure subsequent attacks against, include scanning, assessment and penetration testing, and application assessment.Vulnerability ScanningVulnerability scanning services provide a comprehensive security review of the system, including both the perimeter and system internals.", [["scanning, assessment", "TEST", 165, 185], ["penetration testing", "TEST", 190, 209], ["application assessment", "TEST", 215, 237]]], ["Comprehensive system scanning usually results in a number of both false positives and negatives.", [["Comprehensive system scanning", "TEST", 0, 29], ["false positives", "OBSERVATION", 66, 81]]], ["It is the job of the system administrator to find ways of dealing with these false positives and negatives.", [["these false positives", "PROBLEM", 71, 92]]], ["The final report produced after each scan consists of strategic advice and prioritized recommendations to ensure that critical holes are addressed first.", [["each scan", "TEST", 32, 41], ["strategic advice", "TREATMENT", 54, 70], ["critical holes", "PROBLEM", 118, 132]]], ["System scanning can be scheduled, depending on the level of the requested scan, by the system user or the service provider, to run automatically and report by either automated or periodic e-mail to a designated user.", [["System scanning", "TEST", 0, 15], ["the requested scan", "TEST", 60, 78]]], ["The scans can also be stored on a secure server for future review.Vulnerability Assessment and Penetration TestingThis phase of vulnerability assessment is a hands-on testing of a system for identified and unidentified vulnerabilities.", [["The scans", "TEST", 0, 9], ["future review", "TEST", 52, 65], ["Vulnerability Assessment", "TEST", 66, 90], ["Penetration Testing", "TEST", 95, 114], ["vulnerability assessment", "TEST", 128, 152], ["a system", "TEST", 178, 186]]], ["All known hacking techniques and tools are tested during this phase to reproduce real-world attack scenarios.", [["All known hacking techniques", "PROBLEM", 0, 28]]], ["One of the outcomes of these real-life testings is that new and sometimes obscure vulnerabilities are found, processes and procedures of attack are identified, and sources and severity of vulnerabilities are categorized and prioritized based on the user-provided risks.Application AssessmentAs Web applications become more widespread and more entrenched into e-commerce and all other commercial and business areas, applications are slowly becoming the main interface between the user and the network.", [["these real-life testings", "TEST", 23, 47], ["attack", "PROBLEM", 137, 143], ["severity of vulnerabilities", "PROBLEM", 176, 203]]], ["The increased demands on applications have resulted in new directions in automation and dynamism of these applications.", [["The increased demands", "PROBLEM", 0, 21], ["these applications", "TREATMENT", 100, 118], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["new", "OBSERVATION_MODIFIER", 55, 58]]], ["As we saw in Chap.", [["Chap", "PROTEIN", 13, 17]]], ["Assessing the security of system applications is, therefore, becoming a special skills requirement needed to secure critical systems.Advantages of Vulnerability Assessment ServicesVulnerability online services have many advantages for system administrators.", [["a special skills requirement", "PROBLEM", 70, 98], ["system administrators", "TREATMENT", 235, 256]]], ["They can, and actually always do, provide and develop signatures and updates for new vulnerabilities and automatically include them in the next scan.", [["the next scan", "TEST", 135, 148]]], ["This eliminates the need for the system administrator to schedule periodic updates.Advantages of Vulnerability Assessment ServicesReports from these services are very detailed not only on the vulnerabilities, sources of vulnerabilities, and existence of false positives, but they also focus on vulnerability identification and provide more information on system configuration that may not be readily available to system administrators.", [["the system administrator", "TREATMENT", 29, 53], ["false positives", "PROBLEM", 254, 269], ["vulnerability identification", "TEST", 294, 322], ["false positives", "OBSERVATION", 254, 269]]]], "PMC7384897": [["I read with interest the article on misinformation on coronavirus disease 2019 (COVID-19) by an international team of journal editors.1 The COVID-19 pandemic has been paralleled by an \u201cinfodemic\u201d on social media.", [["coronavirus disease", "DISEASE", 54, 73], ["coronavirus", "ORGANISM", 54, 65], ["coronavirus disease", "PROBLEM", 54, 73]]], ["The index survey included at least a third of participants who have had the experience of working on editorial boards of various medical journals.", [["participants", "SPECIES", 46, 58]]], ["Equality ensures that all participants have equal access, but justice determines fair access.2 Thus, a basic principle for justice is access to trustworthy sources.", [["participants", "SPECIES", 26, 38]]]], "PMC7094406": [["Infectiousness ::: Role of the gastrointestinal tract mucosa in HIV-1 transmissionNew information on the infectiousness of HIV-1 from persons who carry the virus is based largely on studies of heterosexual transmission.", [["gastrointestinal tract mucosa", "ANATOMY", 31, 60], ["Infectiousness", "DISEASE", 0, 14], ["gastrointestinal tract mucosa", "MULTI-TISSUE_STRUCTURE", 31, 60], ["HIV-1", "ORGANISM", 64, 69], ["HIV-1", "ORGANISM", 123, 128], ["persons", "ORGANISM", 134, 141], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 123, 128], ["persons", "SPECIES", 134, 141], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 123, 128], ["Infectiousness", "PROBLEM", 0, 14], ["HIV", "PROBLEM", 123, 126], ["the virus", "PROBLEM", 152, 161], ["gastrointestinal tract", "ANATOMY", 31, 53], ["virus", "OBSERVATION", 156, 161]]], ["Nevertheless, many factors that promote transmission across the vaginal mucosa probably also enhance transmission across the gastrointestinal mucosa (Table 1).For example, infectiousness, defined as the probability of transmitting HIV-1 from one person to another, is greatest when the index partner has primary HIV-1 infection, which corresponds to the period of infection between exposure to the virus and development of circulating anti\u2013HIV-1 antibodies.9 Primary infection is associated with the highest plasma levels of HIV-1.10, 11 Although the levels of HIV-1 in genital secretions during primary infection have not been reported, virus has been detected in genital secretions in all stages of disease.", [["vaginal mucosa", "ANATOMY", 64, 78], ["gastrointestinal mucosa", "ANATOMY", 125, 148], ["plasma", "ANATOMY", 508, 514], ["genital secretions", "ANATOMY", 570, 588], ["genital secretions", "ANATOMY", 665, 683], ["HIV-1 infection", "DISEASE", 312, 327], ["infection", "DISEASE", 364, 373], ["Primary infection", "DISEASE", 459, 476], ["primary infection", "DISEASE", 596, 613], ["vaginal mucosa", "MULTI-TISSUE_STRUCTURE", 64, 78], ["gastrointestinal mucosa", "MULTI-TISSUE_STRUCTURE", 125, 148], ["HIV-1", "ORGANISM", 231, 236], ["HIV-1", "ORGANISM", 312, 317], ["HIV-1 antibodies", "GENE_OR_GENE_PRODUCT", 440, 456], ["plasma", "ORGANISM_SUBSTANCE", 508, 514], ["HIV-1.10", "ORGANISM", 525, 533], ["HIV-1", "ORGANISM", 561, 566], ["genital secretions", "ORGANISM", 570, 588], ["genital secretions", "ORGANISM_SUBSTANCE", 665, 683], ["circulating anti\u2013HIV-1 antibodies", "PROTEIN", 423, 456], ["HIV-1", "SPECIES", 231, 236], ["person", "SPECIES", 246, 252], ["HIV-1", "SPECIES", 312, 317], ["HIV-1", "SPECIES", 440, 445], ["HIV-1", "SPECIES", 561, 566], ["HIV-1", "SPECIES", 231, 236], ["HIV-1", "SPECIES", 312, 317], ["HIV-1", "SPECIES", 440, 445], ["HIV-1", "SPECIES", 561, 566], ["infectiousness", "PROBLEM", 172, 186], ["primary HIV-1 infection", "PROBLEM", 304, 327], ["infection", "PROBLEM", 364, 373], ["the virus", "PROBLEM", 394, 403], ["circulating anti\u2013HIV", "TEST", 423, 443], ["Primary infection", "PROBLEM", 459, 476], ["the highest plasma levels", "TEST", 496, 521], ["HIV", "TEST", 525, 528], ["the levels", "TEST", 547, 557], ["HIV", "PROBLEM", 561, 564], ["genital secretions", "PROBLEM", 570, 588], ["primary infection", "PROBLEM", 596, 613], ["virus", "PROBLEM", 638, 643], ["genital secretions", "PROBLEM", 665, 683], ["disease", "PROBLEM", 701, 708], ["vaginal mucosa", "ANATOMY", 64, 78], ["gastrointestinal mucosa", "ANATOMY", 125, 148], ["infectiousness", "OBSERVATION", 172, 186], ["infection", "OBSERVATION", 318, 327], ["infection", "OBSERVATION", 364, 373], ["infection", "OBSERVATION", 467, 476], ["genital", "ANATOMY", 570, 577], ["secretions", "OBSERVATION", 578, 588], ["infection", "OBSERVATION", 604, 613], ["genital", "ANATOMY", 665, 672], ["secretions", "OBSERVATION", 673, 683], ["disease", "OBSERVATION", 701, 708]]], ["Thus, the presence of cell-free and cell-associated virus in genital secretions probably contributes to its increased infectiousness during this stage of the disease.12", [["cell", "ANATOMY", 22, 26], ["cell", "ANATOMY", 36, 40], ["genital secretions", "ANATOMY", 61, 79], ["cell", "CELL", 22, 26], ["cell", "CELL", 36, 40], ["genital secretions", "ORGAN", 61, 79], ["cell-free and cell-associated virus in genital secretions", "PROBLEM", 22, 79], ["its increased infectiousness", "PROBLEM", 104, 132], ["the disease", "PROBLEM", 154, 165], ["free", "OBSERVATION_MODIFIER", 27, 31], ["cell", "OBSERVATION", 36, 40], ["virus", "OBSERVATION", 52, 57], ["genital", "ANATOMY", 61, 68], ["secretions", "OBSERVATION", 69, 79], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["infectiousness", "OBSERVATION", 118, 132], ["disease", "OBSERVATION", 158, 165]]]], "56887ae37144d9905717468c2a3fa3277a29b396": [["Transmission of coronavirus generally occurs through respiratory droplets and contact.", [["respiratory droplets", "ANATOMY", 53, 73], ["coronavirus", "DISEASE", 16, 27], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus", "PROBLEM", 16, 27], ["coronavirus", "OBSERVATION", 16, 27], ["respiratory droplets", "OBSERVATION", 53, 73]]], ["Current evidence suggests that SARS-CoV-2 may remain viable for hours to days on surfaces made from a variety of materials.", [["SARS", "DISEASE", 31, 35], ["SARS-CoV-2", "ORGANISM", 31, 41], ["SARS", "PROBLEM", 31, 35], ["SARS", "OBSERVATION", 31, 35]]], ["In the house, care must be taken for open outside doors and windows and the use of ventilating fans to increase air circulation.", [["ventilating fans", "TREATMENT", 83, 99], ["air circulation", "OBSERVATION", 112, 127]]], ["We recommend using masks to self-protect and to protect others around, during the COVID-19 pandemic, mainly in inside closed spaces as buildings and malls.", [["masks", "TREATMENT", 19, 24]]], ["Also, maintaining distance between each person helps us to control the transmission of coronavirus.", [["coronavirus", "DISEASE", 87, 98], ["coronavirus", "ORGANISM", 87, 98], ["person", "SPECIES", 40, 46], ["coronavirus", "PROBLEM", 87, 98]]]], "793b536ecc395ee1bc57ae28bf28094922718a84": [["IntroductionThe COVID-19 pandemic has significantly changed people's living conditions.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["Wearing a face mask has become a mandatory requirement of physical distancing and health protection.", [["a face mask", "TREATMENT", 8, 19], ["physical distancing", "TREATMENT", 58, 77], ["health protection", "TREATMENT", 82, 99]]], ["China was the first country to face this new threat and to introduce state regulation to control the spread of infection.IntroductionFor this cross-cultural comparison of decision to wear a mask or to remain without it when going to public places we chose three countries that differ in tradition, a dominant religion and a degree of state regulation on the implementation of the restrictions -Russia, Azerbaijan and China.IntroductionThe study took place from the end of April till the end of May 2020 when China had announced overcoming pandemic but wearing masks remained mandatory.", [["infection", "DISEASE", 111, 120], ["state regulation", "TREATMENT", 69, 85], ["infection", "PROBLEM", 111, 120], ["a mask", "TREATMENT", 188, 194], ["The study", "TEST", 435, 444], ["infection", "OBSERVATION", 111, 120]]], ["In Azerbaijan the pandemic just started and in Russia it was reaching its peak.IntroductionIt is reported that on the collectivism-individualism scale where higher scores refer to individualism China has the score of 20, Azerbaijan -22, Russia -39 out of 100 (Web Reference 1, 2020).", [["the collectivism-individualism scale", "TEST", 114, 150], ["the score", "TEST", 204, 213]]], ["Azerbaijani men showed higher intolerance of uncertainty than Russian men (Kornilova, Chumakova, & Izmailova, 2015) .IntroductionThe main research question in this study is to what extent prosocial behavior is guided by individual differences in a number of personality characteristics.Introductionchoose between the two programs of saving people from an epidemic on a ship.", [["intolerance of uncertainty", "DISEASE", 30, 56], ["men", "ORGANISM", 12, 15], ["men", "ORGANISM", 70, 73], ["people", "ORGANISM", 340, 346], ["men", "SPECIES", 12, 15], ["men", "SPECIES", 70, 73], ["people", "SPECIES", 340, 346], ["higher intolerance", "PROBLEM", 23, 41], ["this study", "TEST", 159, 169], ["higher intolerance", "OBSERVATION", 23, 41], ["main", "OBSERVATION_MODIFIER", 133, 137]]], ["Later Kahneman introduced the concept of emotional framing (Kahneman, 2011) .", [["Kahneman", "TREATMENT", 6, 14]]], ["Jordan, Yoeli, and Rand (2020) showed that prosocial framing was more effective than self-focused framing in promoting physical distancing intentions only early on in the pandemic.IntroductionEmotional response to the coronavirus, not moral or political orientation, predicts compliance with the norms (Harper, Satchell, Fido, & Latzman, 2020) .", [["coronavirus", "ORGANISM", 218, 229], ["coronavirus", "SPECIES", 218, 229], ["the coronavirus", "PROBLEM", 214, 229]]], ["Functioning implicitly, they influence interpretations of situations and behavioral strategies.", [["behavioral strategies", "TREATMENT", 73, 94]]], ["Fixed IT of emotions correlate with avoidance of negative experiences (Kappes & Schikowski, 2013) .Implicit theories (IT)Nationwide research in China (Qiu et al., 2020) and meta-analysis of data from all over the world (Luo, Guo, Yu, Jiang, & Wang, 2020) have shown a prevalence of depression and anxiety during the pandemic.", [["depression", "DISEASE", 282, 292], ["anxiety", "DISEASE", 297, 304], ["depression", "PROBLEM", 282, 292], ["anxiety", "PROBLEM", 297, 304], ["the pandemic", "PROBLEM", 312, 324], ["depression", "OBSERVATION", 282, 292]]], ["Presumably, ability to manage one's emotions might improve adaptation to a changed reality.Risk readinessThe categorization of risks doesn't determine the direction of behavior by themselves, neither do personality dispositions.", [["Risk readiness", "PROBLEM", 91, 105]]], ["In recent years, researchers work on improving risk literacy, in particular, in medical risks (Gigerenzer, 2015) .Risk readinessThe concept of risk intelligence (Evans, 2012) emphasizes cognitive control of judgments on risk.", [["Risk readiness", "PROBLEM", 114, 128]]], ["Perception of threat is influenced by its representation in the media (Slovic, 2000) , and individual differences (Chauvin, 2018; Kornilova, Pavlova, Bogacheva, Kamenev, & Krasavtseva, 2020) .", [["Kornilova", "TREATMENT", 130, 139], ["Pavlova", "TREATMENT", 141, 148], ["Bogacheva", "TREATMENT", 150, 159]]], ["Moreover, the presence of affect impairs judgment on the probability of events (Slovic & Peters, 2006) .The Dark Triad (DT)The DT traits include Machiavellianism, subclinical psychopathy, and narcissism which have different etiologies and closeness of interconnections in different countries .", [["Machiavellianism", "DISEASE", 145, 161], ["subclinical psychopathy", "DISEASE", 163, 186], ["narcissism", "DISEASE", 192, 202], ["The DT traits", "PROBLEM", 123, 136], ["Machiavellianism", "PROBLEM", 145, 161], ["subclinical psychopathy", "PROBLEM", 163, 186], ["narcissism", "PROBLEM", 192, 202], ["Dark Triad", "OBSERVATION", 108, 118], ["subclinical psychopathy", "OBSERVATION", 163, 186]]], ["\u0410ll three aversive traits characterize the so-called \"unstable\" emotional core and are related to the need for social domination and utilitarian solutions of moral dilemmas.The Dark Triad (DT)Narcissism might be the brightest from all DT traits because it is positively associated with intelligence and tolerance of uncertainty (Krasavtseva & Kornilova, 2019) .", [["social domination", "TREATMENT", 111, 128], ["utilitarian solutions", "TREATMENT", 133, 154], ["moral dilemmas", "PROBLEM", 158, 172]]], ["Some data suggest that narcissism is a more \"distinctive\" trait (Savard, Simard, & Jonason, 2017) .The Dark Triad (DT)Dark Triad traits predict lower adherence to COVID-19-related restrictions (Zajenkowski, Jonason, Leniarska, & Kozakiewicz, 2020; Zettler, Schild, Lau, & B\u00f6hm, 2020) .EmpathyEmotional regulation is studied less in eastern cultures.", [["narcissism", "DISEASE", 23, 33], ["COVID-19", "CHEMICAL", 163, 171], ["eastern cultures", "CELL_LINE", 332, 348], ["The Dark Triad (DT)", "PROBLEM", 99, 118], ["Dark Triad traits", "PROBLEM", 118, 135], ["COVID", "TEST", 163, 168], ["EmpathyEmotional regulation", "TEST", 285, 312], ["eastern cultures", "TEST", 332, 348], ["Dark Triad", "OBSERVATION", 103, 113]]], ["Indirect conclusions stem from the emotional attitude to another person and how empathy changes when moving along the collectivism-individualism scale.", [["person", "SPECIES", 65, 71], ["empathy changes", "PROBLEM", 80, 95], ["the collectivism", "TEST", 114, 130]]], ["Empathy differs depending on whether the person we experience empathy for belongs to our in-group or not (Abu-Akel, Fischer-Shofty, Levkovitz, Decety, & Shamay-Tsoory, 2014) .", [["person", "SPECIES", 41, 47]]], ["Assuming that relationships between people in Chinese society are closer than in individualistic cultures, we can expect that during the pandemic Chinese people will show high emotional empathy.", [["high emotional empathy", "DISEASE", 171, 193], ["people", "ORGANISM", 36, 42], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 36, 42], ["people", "SPECIES", 154, 160], ["individualistic cultures", "TEST", 81, 105], ["high emotional empathy", "PROBLEM", 171, 193]]], ["Empathy to the most vulnerable to the coronavirus was related to compliance with social distancing in Western countries (Pfattheicher, Nockur, B\u00f6hm, & Sassenrath, 2020) .EmpathyEmpathy, risk readiness, and rationality regulate decision making through the interaction with a person's world view which is largely influenced by the media.", [["coronavirus", "DISEASE", 38, 49], ["EmpathyEmpathy", "DISEASE", 170, 184], ["coronavirus", "ORGANISM", 38, 49], ["person", "SPECIES", 274, 280], ["the coronavirus", "PROBLEM", 34, 49], ["EmpathyEmpathy", "PROBLEM", 170, 184], ["coronavirus", "OBSERVATION", 38, 49]]], ["Contextual variables of cultural traditions influence behavior, and since health threats are probabilistic by nature, the role of emotional and personality factors in decision making is important to investigate.Hypotheses1.", [["emotional and personality factors", "PROBLEM", 130, 163]]], ["Personality measures of empathy, rationality, and malleable IT of emotions are positive predictors of physical distancing compliance while risk readiness and DT traits are negative predictors.ParticipantsThe overall study sample included 1077 online participants recruited using snowball technique.ProcedureAfter providing informed consent to participate in the study, participants were asked if they trust information from the media that they might be asymptomatically infected with coronavirus.", [["coronavirus", "DISEASE", 484, 495], ["coronavirus", "ORGANISM", 484, 495], ["Participants", "SPECIES", 192, 204], ["participants", "SPECIES", 250, 262], ["participants", "SPECIES", 369, 381], ["DT traits", "PROBLEM", 158, 167], ["the study", "TEST", 358, 367], ["coronavirus", "PROBLEM", 484, 495]]], ["Then they made choices in verbal tasks-vignettes and filled out questionnaires.Verbal tasksWe developed 5 verbal tasks -situations where decisions on whether to wear a mask (reasons A1 and A2) or not (B1 and B2) were made by choosing from four given reasons.", [["A1", "PROTEIN", 182, 184], ["A2", "PROTEIN", 189, 191], ["B1", "PROTEIN", 201, 203], ["B2", "PROTEIN", 208, 210], ["Verbal tasks", "TEST", 79, 91], ["a mask", "TREATMENT", 166, 172]]], ["We used a quasi-experimental design: all participants received one of four tasks with different framing in reasons for and against wearing a mask and one other tasks that was as a control task for every participant (see example Task 2, Appendix 1).", [["participants", "SPECIES", 41, 53], ["a mask", "TREATMENT", 139, 145]]], ["In different tasks, reasons for wearing a mask represented the following categories: 1, 2 and 3) Care for Self vs Others, 4) High risk for Self vs Lawabidingness, 5) High risk for others vs Law-abidingness.", [["a mask", "TREATMENT", 40, 46], ["Self vs Lawabidingness", "PROBLEM", 139, 161]]], ["Reasons for choice not to wear a mask also varied across tasks: 1 and 4) Autonomy for Oneself vs Others, 2) Risk for Oneself vs Others, 3) Risk Underestimation vs Autonomy for Others, 5) Autonomy for Oneself vs Risk Underestimation.", [["a mask", "TREATMENT", 31, 37], ["Risk Underestimation", "PROBLEM", 211, 231]]], ["(Tamir et al., 2007) The two last measures weren't administered in China.", [["The two last measures", "TREATMENT", 21, 42]]], ["All measures in Azerbaijan were presented in Russian language.Descriptive statisticsDescriptive statistics on personality measures and results of Kruskal-Wallis Test are presented in the table below.Descriptive statisticsCultural groups showed significant differences in all measures except for affective empathy and narcissism (Table 1) .Frequencies of choices on trusting the mediaParticipant groups from different countries differed in theirs answer on trusting the media (\u03c7 2 =176.55, p < .001) ( Table 2 ).", [["narcissism", "DISEASE", 317, 327], ["personality measures", "TEST", 110, 130], ["Cultural groups", "TEST", 221, 236], ["significant differences in all measures", "PROBLEM", 244, 283], ["affective empathy", "PROBLEM", 295, 312], ["Wallis", "ANATOMY", 154, 160], ["significant", "OBSERVATION_MODIFIER", 244, 255], ["differences", "OBSERVATION_MODIFIER", 256, 267]]], ["The answer \"I don't trust the media\" was more frequently observed in Azerbaijan where the pandemic was just starting (hundreds of cases daily), while \"I trust the media, but I couldn't be infected\" -in China where the pandemic has decreased.Frequencies of choice alternative preferences to wear a mask or remain without itUsing chi-square test, we examined the differences between choices of reasons for wearing or not wearing a face mask in cultural groups (see Fig. 1 ).Frequencies of choice alternative preferences to wear a mask or remain without itIn Tasks 1, 2, and 3 in all countries the choice to wear a mask for a reason \"care for self\" prevailed over\"care for others\", more often in the Chinese sample (79.5 vs 19.6%, 72 vs 28% and 87.3 vs 11.8%) compared to the Russian and Azerbaijani samples (\u03c7 2 =62.488, p = .001 for Task 1, \u03c7 2 =103.262, p = .001 for Task 2, \u03c7 2 =44.377, p = .000 for Task 3).", [["a mask", "TREATMENT", 295, 301], ["chi-square test", "TEST", 328, 343], ["a face mask", "TREATMENT", 427, 438], ["a mask", "TREATMENT", 526, 532], ["a mask", "TREATMENT", 610, 616], ["vs", "TEST", 718, 720], ["vs", "TEST", 731, 733], ["vs", "TEST", 747, 749], ["Azerbaijani samples", "TEST", 785, 804], ["p", "TEST", 819, 820], ["Task", "TEST", 832, 836], ["p", "TEST", 854, 855], ["Task", "TEST", 867, 871], ["p", "TEST", 888, 889], ["Task", "TEST", 901, 905], ["decreased", "OBSERVATION_MODIFIER", 231, 240]]], ["The choice to remain without a mask was very rare in the Chinese data (less than 1% in Tasks 1-3) while in Azerbaijani and Russian samples it was made with the reasons of autonomy for oneself over autonomy for others (Task 1), low fear of getting infected (Task 2) and risk underestimation over autonomy for others (Task 3).Frequencies of choice alternative preferences to wear a mask or remain without itIn Task 4, as reasons for wearing a mask high risk assessment and lawabidingness were chosen with almost equal frequency in Russia (38.6 vs 40.4%), in Azerbaijan prevailed law-abidingness (22.2% vs 46.7), and in China -high risk assessment (71.6 vs 28.4).", [["low fear of getting infected", "DISEASE", 227, 255], ["a mask", "TREATMENT", 29, 35], ["a mask", "TREATMENT", 378, 384], ["a mask", "TREATMENT", 439, 445], ["lawabidingness", "PROBLEM", 471, 485]]], ["Not wearing a mask was explained predominantly by autonomy for oneself (not for others) in both Russia (15.8 vs 5.3%) and Azerbaijan (24.4 vs 6.7%).", [["a mask", "TREATMENT", 12, 18], ["Azerbaijan", "TREATMENT", 122, 132]]], ["Among the Chinese participants, no one chose to remain without the mask.Frequencies of choice alternative preferences to wear a mask or remain without itIn Task 5, law-abidingness prevailed over the risk of infecting others in all groups.", [["participants", "SPECIES", 18, 30], ["the mask", "TREATMENT", 63, 71], ["a mask", "TREATMENT", 126, 132], ["infecting", "OBSERVATION", 207, 216]]], ["When choosing not to wear a mask, Russians more often chose personal autonomy over risk underestimation (13.3 vs 9.7%), Azerbaijani participants showed the opposite trend (10.2 vs 17.9% of personal autonomy).", [["participants", "SPECIES", 132, 144], ["a mask", "TREATMENT", 26, 32], ["risk underestimation", "TEST", 83, 103], ["Azerbaijani participants", "TEST", 120, 144]]], ["Only 0.2% of Chinese participants chose not to wear a mask.Intercorrelations of personality traits in cultural samplesCorrelations between personality traits for Russian and Azerbaijani participants are presented In Table 3 ; for Chinese participants -in Appendix 2 (see Table 5 ).Intercorrelations of personality traits in cultural samplesOn the Azerbaijani sample ITE showed positive associations with Note.", [["participants", "ORGANISM", 21, 33], ["participants", "SPECIES", 21, 33], ["participants", "SPECIES", 186, 198], ["participants", "SPECIES", 238, 250], ["a mask", "TREATMENT", 52, 58], ["personality traits", "PROBLEM", 80, 98], ["cultural samples", "TEST", 102, 118], ["personality traits", "PROBLEM", 302, 320], ["Appendix", "ANATOMY", 255, 263]]], ["Dashes indicate variables for which we haven't collected data. online simulation and cognitive empathy, and negative -with emotion contagion (Table 3) .", [["cognitive empathy, and negative -with emotion contagion", "DISEASE", 85, 140], ["cognitive empathy", "TEST", 85, 102]]], ["On the Chinese sample, ITE was positively associated with cognitive empathy, and overall score of empathy.", [["cognitive empathy", "PROBLEM", 58, 75], ["empathy", "PROBLEM", 98, 105]]], ["Risk readiness was positively associated with Machiavellianism and perspective taking in both samples, with proximal responsivity and cognitive empathy in Azerbaijan, with affective empathy and narcissism in Russia; and negatively -with rationality and emotion contagion in both samples.Personality predictors of choices to wear or not to wear a maskWe ran individual logistic regression analyses for each of the personality measures as independent variables and a binary variable \"wear a mask\" or \"remain without a mask\" as dependent variable (regardless of reasons for the decision).", [["samples", "ANATOMY", 279, 286], ["cognitive empathy", "DISEASE", 134, 151], ["narcissism", "DISEASE", 194, 204], ["proximal responsivity", "PROBLEM", 108, 129], ["affective empathy", "PROBLEM", 172, 189], ["narcissism", "PROBLEM", 194, 204], ["emotion contagion", "PROBLEM", 253, 270]]], ["The Chinese participants rarely chose \"remain without a mask\" therefore regressions weren't performed.Personality predictors of choices to wear or not to wear a maskRationality was a positive predictor of the choice to \"wear a mask\" in Russia (Tasks 2 and 5) and in Azerbaijan (Task 1) (see Table 4 ).", [["participants", "SPECIES", 12, 24], ["a mask", "TREATMENT", 54, 60]]], ["Narcissism was a positive predictor in Russia (Task 3) and a negative predictor in three out of five tasks in Azerbaijan.", [["Narcissism", "DISEASE", 0, 10]]], ["Risk readiness and psychopathy were negative predictors in three cases.Personality predictors of choices to wear or not to wear a maskDifferent empathy subscales and scales were positive predictors for Russian and Azerbaijani participants.Personality predictors of reasons to wear a maskUsing a mixed logistic regression, we investigated personality variables as predictors of the probability of making the choice \"care for others\" vs the reference level \"care for self\" across Tasks 1-3.", [["psychopathy", "DISEASE", 19, 30], ["participants", "SPECIES", 226, 238], ["Risk readiness", "PROBLEM", 0, 14], ["psychopathy", "PROBLEM", 19, 30], ["a maskDifferent empathy subscales", "TREATMENT", 128, 161]]], ["The baseline model included fixed effects of sex, age, and group (Russian as the reference level and dummy-coded Chinese and Azerbaijani group status).", [["fixed effects of sex", "PROBLEM", 28, 48]]], ["Analysis was focused on establishing the main effects of personality variables on choice as well as the interaction effect between personality variables and the group that would reflect the moderation of the relationship conditional on group status.Personality predictors of reasons to wear a maskTwo sets of analyses were performed: 1) using variables measured in both Russian and Azerbaijani samples, and 2) using variables measured in all three samples (see Fig. 2 ).", [["Analysis", "TEST", 0, 8], ["personality variables", "PROBLEM", 57, 78], ["a mask", "TREATMENT", 291, 297], ["analyses", "TEST", 309, 317]]], ["First, the baseline model revealed lower probability of this choice in the Chinese group overall (B = -1.03, SE = 0.21, Z = -4.83, P = .0000014).Personality predictors of reasons to wear a maskSecond, we found that several variables positively predicted the probability of choice \"care for others\": using the Russian sample as the baseline, we established that this choice was positively predicted by ITEDiscussionIn Russia and Azerbaijan we observed similar relationships between empathy and risk readiness, rationality, and DT traits.", [["the baseline model", "TEST", 7, 25], ["B", "TEST", 98, 99], ["SE", "TEST", 109, 111], ["Z", "TEST", 120, 121], ["P", "TEST", 131, 132], ["lower", "OBSERVATION_MODIFIER", 35, 40]]], ["Previous crosscultural study showed that DT traits and emotional intelligence do not correlate in these cultural samples (Kornilova, Chumakova, & Gadjieva, 2016) , therefore, the observed relationship between empathy and DT traits is not likely to be mediated by emotional intelligence which we didn't measure in this study.DiscussionThe Chinese sample was characterized by higher cognitive empathy, but the three groups didn't differ in affective empathy.", [["affective empathy", "DISEASE", 438, 455], ["Previous crosscultural study", "TEST", 0, 28], ["DT traits and emotional intelligence", "PROBLEM", 41, 77], ["empathy and DT traits", "PROBLEM", 209, 230], ["this study", "TEST", 313, 323], ["not likely to be", "UNCERTAINTY", 234, 250]]], ["On Azerbaijani and Chinese samples IT of emotions correlated with cognitive empathy, suggesting IT of emotions is rather a cognitive than affective component of emotion regulation.DiscussionSince Chinese sample didn't receive the measures of risk readiness, rationality, and DT traits, we couldn't build a more distinctive personality profile.", [["cognitive empathy", "DISEASE", 66, 83], ["Azerbaijani", "TREATMENT", 3, 14], ["cognitive empathy", "PROBLEM", 66, 83], ["emotion regulation", "PROBLEM", 161, 179], ["DT traits", "PROBLEM", 275, 284]]], ["And since extremely low percentage of Chinese participants chose to \"remain without a mask\" we couldn't identify predictors of this choice.DiscussionThe choice to wear a mask was most often made for a reason of care for self in all countries.", [["participants", "SPECIES", 46, 58], ["a mask", "TREATMENT", 168, 174], ["low percentage", "OBSERVATION_MODIFIER", 20, 34]]], ["This reason prevailed mostly among the Chinese participants, less -among Azerbaijanis and less so -among Russians.", [["participants", "SPECIES", 47, 59]]], ["For Russians, as representatives of a more individualistic culture, the gap between the frequency of choosing this reason and care for others was the smallest.DiscussionThis result contradicts hypothesis 1 and suggests that the concepts of collectivism and individualism as characteristics of cultures may not correspond to the individual reasons of decision making.", [["collectivism", "DISEASE", 240, 252], ["a more individualistic culture", "PROBLEM", 36, 66], ["collectivism", "PROBLEM", 240, 252], ["cultures", "TEST", 293, 301]]], ["At the same time, the Chinese participants showed higher trust in the M. Zirenko, et al. Personality and Individual Differences 170 (2021) 110418 media message that they may be asymptomatically infected, therefore these results on choice of reasons could be due to varying risk representation in different countries.", [["participants", "SPECIES", 30, 42], ["varying risk representation", "PROBLEM", 265, 292], ["infected", "OBSERVATION", 194, 202]]], ["Contrary to hypothesis 1, Azerbaijani participants chose \"not to wear a mask\" most often and for the reasons of risk underestimation and autonomy for themselves (the latter is contrary to showing concern for others, which we expected to observe in collectivistic cultures).DiscussionWe assumed that the risks of contracting a virus with and without symptoms are equal, therefore, this factor couldn't be the one influencing the asymmetry in choice reasons.DiscussionRisk readiness influenced the decision not to wear a mask for Russians and Azerbaijanis which allows us to accept hypothesis 2.", [["collectivistic cultures", "CELL_LINE", 248, 271], ["participants", "SPECIES", 38, 50], ["a mask", "TREATMENT", 70, 76], ["collectivistic cultures", "TEST", 248, 271], ["a virus", "PROBLEM", 324, 331], ["symptoms", "PROBLEM", 349, 357], ["a mask", "TREATMENT", 517, 523], ["Azerbaijanis", "TREATMENT", 541, 553], ["asymmetry", "OBSERVATION", 428, 437]]], ["Rationality was a positive predictor of complying with the norms which corresponds to the US data (Stanley, Barr, Peters, & Seli, 2020) .", [["the US data", "TEST", 86, 97]]], ["Our findings on the positive role of empathy are also consistent with data from the USA, UK, and Germany (Pfattheicher et al., 2020) .", [["empathy", "PROBLEM", 37, 44], ["consistent with", "UNCERTAINTY", 54, 69]]], ["ITE wasn't a significant predictor of decision to wear a mask, contrary to what we expected.DiscussionIn line with the Danish study (Zettler et al., 2020) , we assumed the negative role of the DT traits in adhering to the restrictions.", [["a mask", "TREATMENT", 55, 61], ["the DT traits", "PROBLEM", 189, 202]]], ["The difference was that in the Russian sample psychopathy was a negative predictor of3 wearing a mask while narcissism was a positive predictor, corroborating the idea of it being \"the lightest\" trait in DT (Krasavtseva & Kornilova, 2019) while in Azerbaijani sample narcissism was a negative predictor.", [["psychopathy", "DISEASE", 46, 57], ["a mask", "TREATMENT", 95, 101], ["DT (Krasavtseva & Kornilova", "TREATMENT", 204, 231], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["It could be possible that cultural context mediates whether narcissism leads to protesting restrictions (seen as an ego threat) and disregarding for caring for others.LimitationsThe results of this study might be influenced by the different severity of the epidemic in three countries.", [["narcissism", "DISEASE", 60, 70], ["this study", "TEST", 193, 203], ["could be possible", "UNCERTAINTY", 3, 20], ["epidemic", "OBSERVATION_MODIFIER", 257, 265]]], ["Moreover, we found that strict normative regulation of behavior makes it almost impossible to reveal personality regulation of choices.LimitationsIT of emotions and subscales of cognitive empathy emerged as the variables that predict caring for others over caring for self as reasons for wearing a mask suggesting these components of emotional regulation play a role in prosocial behavior.", [["a mask", "TREATMENT", 296, 302], ["emotional regulation", "TREATMENT", 334, 354]]], ["But further studies are needed to understand why IT of emotions didn't influence decision to wear a Table 3 Partial correlations for the Russian and Azerbaijani samples (adjusted for sex and age).", [["further studies", "TEST", 4, 19], ["the Russian and Azerbaijani samples", "TREATMENT", 133, 168]]], ["1) p < .001; 2) correlations on Russian sample are presented below the diagonal, correlations on Azerbaijani sample -above the diagonal.Table 4Personality variables as predictors of wearing or not wearing a mask.mask.We also need to study further why in comparison with Russia collectivist countries (Azerbaijan and China) have shown higher indices of cognitive, but not emotional empathy which could be expected in cultures with closer interpersonal relationships. \u22120.02 0.19*** 0.17*** 0.85*** 0.78*** 0.65*** 0.20*** 1 9.", [["Russian sample", "TEST", 32, 46], ["Azerbaijani sample", "TEST", 97, 115], ["a mask", "TREATMENT", 205, 211], ["mask", "TREATMENT", 212, 216], ["higher indices of cognitive", "PROBLEM", 334, 361], ["emotional empathy", "PROBLEM", 371, 388], ["cultures", "TEST", 416, 424], ["diagonal", "ANATOMY_MODIFIER", 71, 79], ["diagonal", "ANATOMY_MODIFIER", 127, 135]]]], "PMC4623713": [["Reference profiles ::: First-generation HTR Connectivity Map ::: ResultsAfter preliminary screening (see Methods), 82 gene expression datasets (including 1,353 gene expression profiles representing 893 infection-control pairs) encompassing HTRs to 50 pathogens (21 bacterial, 23 viral, 5 protozoan, and 1 fungal) were collected cumulatively (Supplementary Table S1).", [["infection", "DISEASE", 202, 211], ["preliminary screening", "TEST", 78, 99], ["gene expression datasets", "TEST", 118, 142], ["expression profiles", "TEST", 165, 184], ["infection", "PROBLEM", 202, 211], ["HTRs", "TEST", 240, 244], ["pathogens", "TEST", 251, 260], ["bacterial", "TEST", 265, 274], ["viral", "TEST", 279, 284], ["protozoan", "TEST", 288, 297]]], ["These 50 pathogens represent a broad range of clinically important pathogenic (sub)types and strains, and each was tested with its primary target tissue/cell tropism.Reference profiles ::: First-generation HTR Connectivity Map ::: ResultsThe HTRs of specific cell types to infection with particular pathogens were collated in a phenotype rank list (PRL) (infection-control matching strategy detailed in the Methods).", [["tissue", "ANATOMY", 146, 152], ["cell", "ANATOMY", 153, 157], ["cell", "ANATOMY", 259, 263], ["infection", "DISEASE", 273, 282], ["infection", "DISEASE", 355, 364], ["tissue", "TISSUE", 146, 152], ["cell", "CELL", 153, 157], ["cell", "CELL", 259, 263], ["PRL", "PROTEIN", 349, 352], ["strains", "PROBLEM", 93, 100], ["cell tropism", "PROBLEM", 153, 165], ["infection", "PROBLEM", 273, 282], ["particular pathogens", "PROBLEM", 288, 308], ["infection", "PROBLEM", 355, 364], ["broad range", "OBSERVATION_MODIFIER", 31, 42], ["cell tropism", "OBSERVATION", 153, 165], ["specific cell types", "OBSERVATION", 250, 269], ["infection", "OBSERVATION", 273, 282]]], ["And the Spearman correlations between each PRLs were presented as a heat map (Supplementary Figure S1).", [["PRLs", "DNA", 43, 47], ["a heat map", "TEST", 66, 76]]], ["The Spearman correlations (mean value = 0.1164) between PRLs of a specific pathogen type were significantly higher than those (mean value = 0.0108) across different pathogen types (P < 10\u2212100, two-sample t-test), and the corresponding area under curve (AUC) in the receiver operating characteristic (ROC) curve was 0.6625 (Supplementary Figures S2 and S3).", [["The Spearman correlations", "TEST", 0, 25], ["mean value", "TEST", 27, 37], ["a specific pathogen type", "TEST", 64, 88], ["mean value", "TEST", 127, 137], ["P", "TEST", 181, 182], ["two-sample t-test", "TEST", 193, 210], ["AUC", "TEST", 253, 256], ["ROC) curve", "TEST", 300, 310], ["higher", "OBSERVATION_MODIFIER", 108, 114]]], ["The mean Spearman correlation coefficient for comparisons between PRLs of the same cell types across infections by different pathogens was 0.0349, with an AUC of 0.5614 (Supplementary Figures S2 and S4).", [["cell", "ANATOMY", 83, 87], ["infections", "DISEASE", 101, 111], ["cell", "CELL", 83, 87], ["different pathogens", "TEST", 115, 134], ["an AUC", "TEST", 152, 158], ["infections", "OBSERVATION", 101, 111]]], ["Therefore, HTRs of a specific cell type had relatively weak correlations across different pathogens compared to HTRs of different cell types infected with the same pathogen (Supplementary Figures S1\u2013S4 and Supplementary Data S1).Reference profiles ::: First-generation HTR Connectivity Map ::: ResultsEmploying a hierarchical majority-voting scheme1213, we developed merged PRLs (mPRLs) (Supplementary Data S2) for each pathogen\u2019s HTRs.", [["cell", "ANATOMY", 30, 34], ["cell", "ANATOMY", 130, 134], ["HTRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["cell type", "CELL", 30, 39], ["cell", "CELL", 130, 134], ["scheme1213", "DNA", 342, 352], ["PRLs", "PROTEIN", 374, 378], ["mPRLs", "PROTEIN", 380, 385], ["a specific cell type", "PROBLEM", 19, 39], ["different pathogens", "PROBLEM", 80, 99], ["different cell types infected", "PROBLEM", 120, 149], ["the same pathogen", "PROBLEM", 155, 172], ["each pathogen", "PROBLEM", 415, 428]]], ["We further proved that the mPRLs captured the consensus and common transcriptional responses to pathogens across settings (i.e., pathogen strain/subtype, infected cell line and laboratory) (Supplementary Figure S5 and Supplementary Data S3).Fifty-pathogen HTR Connectivity Map ::: First-generation HTR Connectivity Map ::: ResultsThe 250 top- and bottom-ranked genes of each PRL for the signature HTRs for each pathogenic infection were selected (Supplementary Figure S6 and Supplementary Data S4; size of 250 based on estimated influence of signature size as detailed in the Methods).", [["cell line", "ANATOMY", 163, 172], ["infection", "DISEASE", 422, 431], ["mPRLs", "GENE_OR_GENE_PRODUCT", 27, 32], ["cell line", "CELL", 163, 172], ["PRL", "GENE_OR_GENE_PRODUCT", 375, 378], ["mPRLs", "DNA", 27, 32], ["250 top- and bottom-ranked genes", "DNA", 334, 366], ["PRL", "PROTEIN", 375, 378], ["signature HTRs", "DNA", 387, 401], ["pathogen strain/subtype", "PROBLEM", 129, 152], ["infected cell line", "TREATMENT", 154, 172], ["Connectivity Map", "TEST", 302, 318], ["top", "TEST", 338, 341], ["bottom", "TEST", 347, 353], ["the signature HTRs", "PROBLEM", 383, 401], ["each pathogenic infection", "PROBLEM", 406, 431], ["Supplementary Data S4", "TEST", 475, 496], ["size", "TEST", 498, 502], ["infected cell line", "OBSERVATION", 154, 172], ["infection", "OBSERVATION", 422, 431], ["size", "OBSERVATION_MODIFIER", 552, 556]]], ["The pathogen-to-pathogen HTR connections were represented as an \u201cassociation score\u201d and computed with a PRL comparing method based on gene set enrichment analysis (GSEA)101114.Fifty-pathogen HTR Connectivity Map ::: First-generation HTR Connectivity Map ::: ResultsA heat map (Fig. 2a) was produced from 1,225 pairs of HTR connections among these 50 pathogens (Supplementary Data S5).", [["PRL", "GENE_OR_GENE_PRODUCT", 104, 107], ["PRL", "PROTEIN", 104, 107], ["The pathogen", "TEST", 0, 12], ["a PRL", "TREATMENT", 102, 107], ["gene set enrichment analysis", "TEST", 134, 162], ["Connectivity Map", "TEST", 195, 211], ["ResultsA heat map", "TEST", 258, 275], ["HTR connections", "PROBLEM", 319, 334]]], ["The association scores had a Gaussian distribution with a mean value (0.0447) that differed significantly from zero (Fig. 2b; t-test P = 7.67 \u00d7 10\u221252), indicating a tendency for similar HTRs across infections.", [["infections", "DISEASE", 198, 208], ["a mean value", "TEST", 56, 68], ["t-test P", "TEST", 126, 134], ["a tendency", "PROBLEM", 163, 173], ["similar HTRs across infections", "PROBLEM", 178, 208], ["Gaussian distribution", "OBSERVATION", 29, 50], ["infections", "OBSERVATION", 198, 208]]], ["Meanwhile, HTR similarity for non-viral pathogens (mean = 0.0711) was greater than that for viral pathogens (mean = 0.0278) (Fig. 2c,d; two-sample t-test P = 2.25 \u00d7 10\u22127).Fifty-pathogen HTR Connectivity Map ::: First-generation HTR Connectivity Map ::: ResultsTo identify infection attributes underlying HTR similarities across pathogen pairs, we collected the following four categories of information for each pathogen: (i) Medical Subject Headings (MeSH)15 biological classification code; (ii) infection-affected organ/tissues/cell(s); (iii) manifestation of infectious disease; and (iv) other literature-based laboratory and clinical characteristics (Supplementary Tables S1 and S2).", [["organ", "ANATOMY", 515, 520], ["tissues", "ANATOMY", 521, 528], ["cell", "ANATOMY", 529, 533], ["infection", "DISEASE", 272, 281], ["infection", "DISEASE", 496, 505], ["infectious disease", "DISEASE", 561, 579], ["organ", "ORGAN", 515, 520], ["tissues", "TISSUE", 521, 528], ["cell", "CELL", 529, 533], ["HTR", "PROBLEM", 11, 14], ["non-viral pathogens", "PROBLEM", 30, 49], ["mean", "TEST", 51, 55], ["viral pathogens", "PROBLEM", 92, 107], ["mean", "TEST", 109, 113], ["sample t-test P", "TEST", 140, 155], ["Connectivity Map", "TEST", 232, 248], ["infection", "PROBLEM", 272, 281], ["underlying HTR similarities across pathogen pairs", "PROBLEM", 293, 342], ["Medical Subject Headings (MeSH)", "TREATMENT", 425, 456], ["infection", "PROBLEM", 496, 505], ["affected organ/tissues", "PROBLEM", 506, 528], ["infectious disease", "PROBLEM", 561, 579], ["infection", "OBSERVATION", 272, 281], ["infection", "OBSERVATION", 496, 505], ["organ", "ANATOMY", 515, 520], ["tissues", "ANATOMY", 521, 528], ["infectious", "OBSERVATION", 561, 571], ["S2", "ANATOMY", 682, 684]]], ["Infection attribute labeling uncovers crucial factors underlying HTR similarity, while validating its reliability.", [["Infection", "PROBLEM", 0, 9]]], ["We found that HTR similarity was not simply closely related to the benchmarks for each of the above attribute categories (Supplementary Figure S7a).Fifty-pathogen HTR Connectivity Map ::: First-generation HTR Connectivity Map ::: ResultsTo identify individual infection attributes that associate strongly with particular significant HTR similarities between pathogen pairs, we calculated HTR-attribute association scores (range, \u22121 to +1), and obtained permutation P values through comparison with those in random trials using a Kolmogorov-Smirnov statistic-based approach.", [["infection", "DISEASE", 260, 269], ["HTR similarity", "PROBLEM", 14, 28], ["individual infection", "PROBLEM", 249, 269], ["particular significant HTR similarities between pathogen pairs", "PROBLEM", 310, 372], ["HTR", "TEST", 388, 391], ["permutation P values", "TEST", 453, 473], ["a Kolmogorov-Smirnov statistic-based approach", "TREATMENT", 527, 572], ["infection", "OBSERVATION", 260, 269]]], ["The association scores for the similarity features of taxonomy, cell tropism, infectious disease, and laboratory/clinical characteristics were 0.181, 0.167, 0.213 and 0.240, respectively (permutation P = 0.06, 0.16, 1 \u00d7 10\u22125, and 7 \u00d7 10\u22125, respectively).", [["cell", "ANATOMY", 64, 68], ["infectious disease", "DISEASE", 78, 96], ["cell", "CELL", 64, 68], ["cell tropism", "PROBLEM", 64, 76], ["infectious disease", "PROBLEM", 78, 96], ["permutation P", "TEST", 188, 201], ["cell tropism", "OBSERVATION", 64, 76], ["infectious", "OBSERVATION_MODIFIER", 78, 88]]], ["Thus, disease manifestation and laboratory/clinical characteristic similarities associated significantly (P < 0.01) with HTR similarity.", [["disease manifestation", "PROBLEM", 6, 27], ["HTR similarity", "PROBLEM", 121, 135]]], ["Calculation of each infection attribute\u2019s HTR-association score and corresponding permutation P value (minimum, five-pathogen commonality to assure the reliability; threshold false discovery rate (FDR) < 0.01), revealed 23 highly HTR-associated infection attributes (Supplementary Table S3), including intracellular infection, commensalism, Gram-negative bacteria, droplet contact transmission, non-motile bacteria, and manifestation of lung diseases (Supplementary Figure S7b).HTR communities ::: First-generation HTR Connectivity Map ::: ResultsApplication of an automated, parameter-free clustering algorithm16 yielded eight pathogen groups with prominent consensus internal HTR similarities.", [["intracellular", "ANATOMY", 302, 315], ["lung", "ANATOMY", 437, 441], ["infection", "DISEASE", 20, 29], ["infection", "DISEASE", 245, 254], ["infection", "DISEASE", 316, 325], ["commensalism", "DISEASE", 327, 339], ["lung diseases", "DISEASE", 437, 450], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 302, 315], ["lung", "ORGAN", 437, 441], ["algorithm16", "DNA", 602, 613], ["each infection", "PROBLEM", 15, 29], ["HTR", "PROBLEM", 42, 45], ["permutation P value", "TEST", 82, 101], ["the reliability", "TEST", 148, 163], ["23 highly HTR-associated infection", "PROBLEM", 220, 254], ["intracellular infection", "PROBLEM", 302, 325], ["commensalism", "PROBLEM", 327, 339], ["Gram-negative bacteria", "PROBLEM", 341, 363], ["droplet contact transmission", "PROBLEM", 365, 393], ["non-motile bacteria", "PROBLEM", 395, 414], ["lung diseases", "PROBLEM", 437, 450], ["prominent consensus internal HTR similarities", "PROBLEM", 649, 694], ["infection", "OBSERVATION", 20, 29], ["highly HTR", "OBSERVATION_MODIFIER", 223, 233], ["infection", "OBSERVATION", 245, 254], ["intracellular", "ANATOMY", 302, 315], ["infection", "OBSERVATION", 316, 325], ["negative bacteria", "OBSERVATION", 346, 363], ["non-motile bacteria", "OBSERVATION_MODIFIER", 395, 414], ["lung", "ANATOMY", 437, 441], ["diseases", "OBSERVATION", 442, 450], ["prominent", "OBSERVATION_MODIFIER", 649, 658], ["internal HTR", "OBSERVATION", 669, 681]]], ["Our enrichment analysis identified significant (P < 0.05) enriched community-specific infection attributes for each HTR community (Fig. 3 and Supplementary Table S4).", [["infection", "DISEASE", 86, 95], ["Our enrichment analysis", "TEST", 0, 23], ["significant (P < 0.05) enriched community-specific infection", "PROBLEM", 35, 95], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["infection", "OBSERVATION", 86, 95]]], ["Notably, Communities 1, 2, 3, 4, and 5 were enriched with cryptosporidium, RNA viruses, chronic/oncogenic infection pathogens, enveloped DNA viruses, and DNA tumor viruses, respectively.", [["tumor", "ANATOMY", 158, 163], ["chronic/oncogenic infection", "DISEASE", 88, 115], ["tumor", "DISEASE", 158, 163], ["3", "GENE_OR_GENE_PRODUCT", 27, 28], ["5", "ORGANISM", 37, 38], ["cryptosporidium", "GENE_OR_GENE_PRODUCT", 58, 73], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["DNA tumor", "CANCER", 154, 163], ["cryptosporidium", "PROBLEM", 58, 73], ["RNA viruses", "PROBLEM", 75, 86], ["chronic/oncogenic infection pathogens", "PROBLEM", 88, 125], ["DNA viruses", "PROBLEM", 137, 148], ["DNA tumor viruses", "PROBLEM", 154, 171], ["cryptosporidium", "OBSERVATION", 58, 73], ["RNA viruses", "OBSERVATION", 75, 86], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["oncogenic", "OBSERVATION_MODIFIER", 96, 105], ["infection", "OBSERVATION", 106, 115], ["DNA viruses", "OBSERVATION", 137, 148], ["tumor viruses", "OBSERVATION", 158, 171]]], ["Meanwhile, Communities 6 and 7 were enriched with proteobacteria, whereas Community 8 was enriched with Picornaviridae and commensal bacteria.HTR communities ::: First-generation HTR Connectivity Map ::: ResultsCommunity-specific infection attributes overlapped for 14 (60.9%) of the 23 highly HTR-associated infection attributes, including enrichment of intracellular pathogens in Community 3 and enrichment of commensal pathogens in Community 8 (Supplementary Figure S7, Supplementary Tables S3 and S4).", [["intracellular", "ANATOMY", 355, 368], ["infection", "DISEASE", 230, 239], ["infection", "DISEASE", 309, 318], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 355, 368], ["proteobacteria", "PROBLEM", 50, 64], ["Picornaviridae", "TREATMENT", 104, 118], ["commensal bacteria", "PROBLEM", 123, 141], ["specific infection", "PROBLEM", 221, 239], ["the 23 highly HTR-associated infection", "PROBLEM", 280, 318], ["intracellular pathogens", "PROBLEM", 355, 378], ["commensal pathogens", "PROBLEM", 412, 431], ["commensal bacteria", "OBSERVATION", 123, 141], ["infection", "OBSERVATION", 230, 239], ["highly HTR", "OBSERVATION_MODIFIER", 287, 297], ["infection", "OBSERVATION", 309, 318], ["intracellular pathogens", "OBSERVATION", 355, 378], ["commensal pathogens", "OBSERVATION", 412, 431]]], ["These results indicated that HTR similarities between pathogens within an HTR community were indeed related to certain highly HTR-associated infection attributes shared by these pathogens.", [["infection", "DISEASE", 141, 150], ["HTR similarities between pathogens", "PROBLEM", 29, 63], ["an HTR community", "PROBLEM", 71, 87], ["associated infection", "PROBLEM", 130, 150], ["these pathogens", "PROBLEM", 172, 187], ["infection", "OBSERVATION", 141, 150], ["pathogens", "OBSERVATION", 178, 187]]], ["The HTR community-delineated infection attributes counts exceeded those of the random divisions significantly (Supplementary Figure S8), suggesting that the HTR similarities of community component pathogens were robust and reliable.HTR communities ::: First-generation HTR Connectivity Map ::: ResultsTo examine whether genes in a designated Gene Ontology Biological Process (GO BP) were consistently dysregulated to a significant extent in HTRs to pathogens within an HTR community, we calculated the enrichment scores of GO BPs in relation to pathogen mPRLs using GSEA (cutoff FDR < 0.01)11.", [["infection", "DISEASE", 29, 38], ["HTRs", "GENE_OR_GENE_PRODUCT", 441, 445], ["The HTR community-delineated infection", "PROBLEM", 0, 38], ["the HTR", "PROBLEM", 153, 160], ["community component pathogens", "PROBLEM", 177, 206], ["BP", "TEST", 379, 381], ["pathogens", "PROBLEM", 449, 458], ["GO BPs", "TEST", 523, 529], ["GSEA (cutoff FDR", "TEST", 566, 582], ["infection", "OBSERVATION", 29, 38]]], ["We identified significantly dysregulated GO BPs in the HTRs to each pathogen as well as enriched GO BPs for particular HTR communities (Supplementary Data S6).", [["BPs", "CHEMICAL", 44, 47], ["HTRs", "GENE_OR_GENE_PRODUCT", 55, 59], ["HTRs", "DNA", 55, 59], ["significantly dysregulated GO BPs", "PROBLEM", 14, 47], ["particular HTR communities", "PROBLEM", 108, 134], ["significantly", "OBSERVATION_MODIFIER", 14, 27], ["dysregulated", "OBSERVATION", 28, 40]]], ["In total, we identified 50 distinct community-specific GO BPs (Fig. 4a, Supplementary Table S5), some of which were functionallay related to corresponding infections.", [["infections", "DISEASE", 155, 165], ["Supplementary Table S5", "TREATMENT", 72, 94], ["corresponding infections", "PROBLEM", 141, 165], ["infections", "OBSERVATION", 155, 165]]], ["For example, catabolic process and intracellular protein transport are specifically activated in HTR Community 2, whereas mRNA metabolic process and intracellular transport are specifically inhibited in HTR Community 8; the immune/defense response, positive regulation of I KappaB/NF-KappaB cascade, and negative regulation of apoptosis/programmed cell death are highly activated in HTRs to oncogenic pathogens in Community 31718, but not in HTRs to the DNA tumor viruses in Community 5, in which G protein-coupled receptor signaling and sensory perception are specifically down regulated1920.", [["intracellular", "ANATOMY", 35, 48], ["intracellular", "ANATOMY", 149, 162], ["cell", "ANATOMY", 348, 352], ["HTRs", "ANATOMY", 383, 387], ["tumor", "ANATOMY", 458, 463], ["tumor", "DISEASE", 458, 463], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 149, 162], ["KappaB", "GENE_OR_GENE_PRODUCT", 274, 280], ["NF-KappaB", "GENE_OR_GENE_PRODUCT", 281, 290], ["cell", "CELL", 348, 352], ["HTRs", "GENE_OR_GENE_PRODUCT", 383, 387], ["HTRs", "CANCER", 442, 446], ["DNA", "CELLULAR_COMPONENT", 454, 457], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 497, 523], ["I KappaB", "PROTEIN", 272, 280], ["NF", "PROTEIN", 281, 283], ["KappaB", "PROTEIN", 284, 290], ["G protein-coupled receptor", "PROTEIN", 497, 523], ["catabolic process", "PROBLEM", 13, 30], ["intracellular protein transport", "PROBLEM", 35, 66], ["mRNA metabolic process", "PROBLEM", 122, 144], ["intracellular transport", "TEST", 149, 172], ["I KappaB", "TEST", 272, 280], ["KappaB cascade", "TEST", 284, 298], ["apoptosis", "PROBLEM", 327, 336], ["programmed cell death", "PROBLEM", 337, 358], ["oncogenic pathogens", "PROBLEM", 391, 410], ["the DNA tumor viruses", "PROBLEM", 450, 471], ["catabolic process", "OBSERVATION", 13, 30], ["metabolic process", "OBSERVATION", 127, 144], ["defense response", "OBSERVATION", 231, 247], ["tumor", "OBSERVATION", 458, 463]]], ["Notably, the same G protein-coupled receptor signaling is specifically activated in both HTR Communities 6 and 721.", [["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 18, 44], ["G protein-coupled receptor", "PROTEIN", 18, 44]]], ["However, pathogens in Community 6 cause additional diverse HTR dysregualtions, including specifically up regulated cell signaling and second messenger mediated signaling, as well as down regulated DNA metabolic process and repair, cell cycle (including M phase, mitosis), and response to DNA damage and endogenous stimulus.", [["cell", "ANATOMY", 115, 119], ["cell", "ANATOMY", 231, 235], ["dysregualtions", "DISEASE", 63, 77], ["cell", "CELL", 115, 119], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["cell", "CELL", 231, 235], ["DNA", "CELLULAR_COMPONENT", 288, 291], ["pathogens", "PROBLEM", 9, 18], ["additional diverse HTR dysregualtions", "PROBLEM", 40, 77], ["second messenger mediated signaling", "PROBLEM", 134, 169], ["repair", "TREATMENT", 223, 229], ["cell cycle", "TEST", 231, 241], ["DNA damage", "PROBLEM", 288, 298], ["endogenous stimulus", "TEST", 303, 322], ["diverse HTR dysregualtions", "OBSERVATION", 51, 77], ["cell signaling", "OBSERVATION", 115, 129], ["metabolic process", "OBSERVATION", 201, 218], ["endogenous stimulus", "OBSERVATION", 303, 322]]], ["To some extent, these gene functional features helped distinguish proteobateria in Community 6 to those in Community 7.", [["some extent", "OBSERVATION_MODIFIER", 3, 14]]], ["Together with annotated infection attributes, the gene expression pattern analysis validated our within-HTR community pathogen associations, further demonstrating the host response patterns to infections of different pathogen types are limited and differential.HTR communities ::: First-generation HTR Connectivity Map ::: ResultsMeanwhile, several GO BPs showed overlaps in dysregulated HTRs to multiple pathogen types (Fig. 4b), though not enriched in any particular HTR community.", [["infection", "DISEASE", 24, 33], ["infections", "DISEASE", 193, 203], ["BPs", "CHEMICAL", 352, 355], ["HTRs", "GENE_OR_GENE_PRODUCT", 388, 392], ["HTRs", "PROTEIN", 388, 392], ["annotated infection", "PROBLEM", 14, 33], ["the gene expression pattern analysis", "PROBLEM", 46, 82], ["different pathogen types", "PROBLEM", 207, 231], ["several GO BPs", "TEST", 341, 355], ["dysregulated HTRs", "PROBLEM", 375, 392], ["multiple pathogen types", "PROBLEM", 396, 419], ["infection", "OBSERVATION", 24, 33], ["host response", "OBSERVATION", 167, 180], ["multiple", "OBSERVATION_MODIFIER", 396, 404], ["pathogen", "OBSERVATION", 405, 413]]], ["For example, genes involved in apoptosis are significantly up regulated in HTRs to pathogens in communities 2 (enriched of Mononegavirales) and 6 (enriched of respiratory flora bacteria), the pathogenicity of which have been reported to be highly related to this particular bioprocess2223; genes involved in cell cycles are significantly down regulated in HTRs to pathogens in communities 6, 7, and 8 (enriched of proteobacteria and oral commensal bacteria, respectively), the effectors of which have been observed to inhibit proliferation and cause atrophy of epithelial cells2425 These consistently dysregulated processes may be common HTRs4 that may facilitate our understanding of associations among pathogens in distinct case types.Proteobacteria ::: Associations among HTR community pathogens ::: ResultsNotably, 10 of the 21 bacterial pathogens in our HTR Connectivity Map are proteobacteria, which is a taxonomic class composed of a variety of Gram-negative (i.e., with outer membrane) pathogenic genuses.", [["HTRs", "ANATOMY", 75, 79], ["cell", "ANATOMY", 308, 312], ["HTRs", "ANATOMY", 356, 360], ["communities", "ANATOMY", 377, 388], ["oral", "ANATOMY", 433, 437], ["epithelial cells", "ANATOMY", 561, 577], ["outer membrane", "ANATOMY", 978, 992], ["atrophy", "DISEASE", 550, 557], ["HTRs", "GENE_OR_GENE_PRODUCT", 75, 79], ["cell", "CELL", 308, 312], ["HTRs", "GENE_OR_GENE_PRODUCT", 356, 360], ["oral commensal bacteria", "ORGANISM", 433, 456], ["epithelial cells", "CELL", 561, 577], ["HTRs4", "GENE_OR_GENE_PRODUCT", 638, 643], ["Gram", "GENE_OR_GENE_PRODUCT", 952, 956], ["outer membrane", "CELLULAR_COMPONENT", 978, 992], ["epithelial cells", "CELL_TYPE", 561, 577], ["HTRs4", "PROTEIN", 638, 643], ["apoptosis", "PROBLEM", 31, 40], ["Mononegavirales", "TEST", 123, 138], ["respiratory flora bacteria", "PROBLEM", 159, 185], ["proteobacteria", "PROBLEM", 414, 428], ["oral commensal bacteria", "PROBLEM", 433, 456], ["atrophy of epithelial cells", "PROBLEM", 550, 577], ["the 21 bacterial pathogens", "PROBLEM", 825, 851], ["our HTR Connectivity Map", "TEST", 855, 879], ["proteobacteria", "PROBLEM", 884, 898], ["Gram", "TEST", 952, 956], ["outer membrane) pathogenic genuses", "PROBLEM", 978, 1012], ["respiratory flora", "ANATOMY", 159, 176], ["cell cycles", "OBSERVATION", 308, 319], ["epithelial cells", "OBSERVATION", 561, 577], ["dysregulated", "OBSERVATION", 601, 613], ["proteobacteria", "OBSERVATION", 884, 898], ["pathogenic genuses", "OBSERVATION", 994, 1012]]], ["These 10 proteobacteria species presented with significant HTR similarities (Supplementary Figure S7 and Supplementary Table S3), and all 10 are in HTR Community 6 or 7, with this classification pattern representing an enriched infection attribute (Supplementary Table S4).Proteobacteria ::: Associations among HTR community pathogens ::: ResultsTo determine whether query signatures of HTRs to external proteobacteria (rough and simple gene sets) could be identified through HTR comparisons, we collected gene-expression profiles of cultured cells infected with wild-type and mutant Salmonella enterica subspecies typhimurium (Supplementary Signatures S1\u20135 and Supplementary Table S6), and analyzed in vivo gene-expression responses to Burkholderia cepacia infection (Supplementary Signature S6 and Supplementary Table S6).Proteobacteria ::: Associations among HTR community pathogens ::: ResultsUpon querying, we observed marked positive associations of B. cepacia with HTR Communities 6 and 7 (Fig. 5a,c).", [["cells", "ANATOMY", 543, 548], ["infection", "DISEASE", 228, 237], ["Burkholderia cepacia infection", "DISEASE", 737, 767], ["B. cepacia", "DISEASE", 956, 966], ["HTRs", "GENE_OR_GENE_PRODUCT", 387, 391], ["cells", "CELL", 543, 548], ["mutant", "ORGANISM", 577, 583], ["Salmonella enterica subspecies typhimurium", "ORGANISM", 584, 626], ["Burkholderia cepacia", "ORGANISM", 737, 757], ["B. cepacia", "ORGANISM", 956, 966], ["HTRs", "DNA", 387, 391], ["cultured cells", "CELL_LINE", 534, 548], ["S6", "PROTEIN", 820, 822], ["Salmonella enterica", "SPECIES", 584, 603], ["subspecies typhimurium", "SPECIES", 604, 626], ["Burkholderia cepacia", "SPECIES", 737, 757], ["B. cepacia", "SPECIES", 956, 966], ["Salmonella enterica subspecies typhimurium", "SPECIES", 584, 626], ["Burkholderia cepacia", "SPECIES", 737, 757], ["B. cepacia", "SPECIES", 956, 966], ["These 10 proteobacteria species", "PROBLEM", 0, 31], ["significant HTR similarities", "PROBLEM", 47, 75], ["an enriched infection", "PROBLEM", 216, 237], ["Proteobacteria", "PROBLEM", 273, 287], ["HTRs", "PROBLEM", 387, 391], ["external proteobacteria (rough and simple gene sets", "PROBLEM", 395, 446], ["cultured cells", "PROBLEM", 534, 548], ["mutant Salmonella enterica subspecies typhimurium", "PROBLEM", 577, 626], ["Supplementary Table S6)", "TREATMENT", 662, 685], ["Burkholderia cepacia infection", "PROBLEM", 737, 767], ["Proteobacteria", "PROBLEM", 824, 838], ["B. cepacia", "PROBLEM", 956, 966], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["HTR", "OBSERVATION", 59, 62], ["enriched", "OBSERVATION_MODIFIER", 219, 227], ["infection", "OBSERVATION", 228, 237], ["marked", "OBSERVATION_MODIFIER", 924, 930], ["positive", "OBSERVATION_MODIFIER", 931, 939], ["cepacia", "OBSERVATION", 959, 966]]], ["Analogous results were seen for four out of the five S. typhimurium query signatures generated on four different microarray platforms (Fig. 5b,c).", [["S. typhimurium", "ORGANISM", 53, 67], ["S. typhimurium", "SPECIES", 53, 67], ["S. typhimurium", "SPECIES", 53, 67]]], ["One S. typhimurium query signature (derived from an experiment using a phoP::Tn10 mutant strain that replicates intracellularly but is defective for killing cultured and primary human macrophages) was also associated strongly with HTR community 6 (Fig. 5b,c), demonstrating the high sensitivity of HTR Community analysis for identifying characteristic HTRs to a specific pathogen class.", [["macrophages", "ANATOMY", 184, 195], ["S. typhimurium", "ORGANISM", 4, 18], ["phoP", "GENE_OR_GENE_PRODUCT", 71, 75], ["Tn10", "GENE_OR_GENE_PRODUCT", 77, 81], ["human", "ORGANISM", 178, 183], ["macrophages", "CELL", 184, 195], ["HTRs", "GENE_OR_GENE_PRODUCT", 352, 356], ["primary human macrophages", "CELL_TYPE", 170, 195], ["S. typhimurium", "SPECIES", 4, 18], ["human", "SPECIES", 178, 183], ["S. typhimurium", "SPECIES", 4, 18], ["human", "SPECIES", 178, 183], ["Tn10 mutant strain", "PROBLEM", 77, 95], ["killing cultured", "PROBLEM", 149, 165], ["primary human macrophages", "PROBLEM", 170, 195], ["typhimurium", "OBSERVATION", 7, 18]]], ["As a whole, these results indicate that a query signature derived from a class of microorganisms with consensus HTRs can be used to pull up other taxonomically aligned microorganisms.Streptococcus ::: Associations among HTR community pathogens ::: ResultsThe four spherical Gram-positive Streptococcus species in the HTR Connectivity Map\u2014S. gordonii, S. pneumonia, S. suis, and S. agalactiae\u2014have varied pathogenicity related to their differing hemolytic properties26.", [["S. pneumonia", "DISEASE", 351, 363], ["hemolytic", "DISEASE", 445, 454], ["HTRs", "SIMPLE_CHEMICAL", 112, 116], ["Gram-", "GENE_OR_GENE_PRODUCT", 274, 279], ["Map\u2014S. gordonii", "ORGANISM", 334, 349], ["S. pneumonia", "ORGANISM", 351, 363], ["S. suis", "ORGANISM", 365, 372], ["S. agalactiae\u2014have", "ORGANISM", 378, 396], ["consensus HTRs", "DNA", 102, 116], ["Map\u2014S. gordonii", "SPECIES", 334, 349], ["S. pneumonia", "SPECIES", 351, 363], ["S. suis", "SPECIES", 365, 372], ["S. agalactiae\u2014have", "SPECIES", 378, 396], ["Map\u2014S. gordonii", "SPECIES", 334, 349], ["S. pneumonia", "SPECIES", 351, 363], ["S. suis", "SPECIES", 365, 372], ["S. agalactiae\u2014have", "SPECIES", 378, 396], ["microorganisms", "PROBLEM", 82, 96], ["consensus HTRs", "PROBLEM", 102, 116], ["The four spherical Gram-positive Streptococcus species", "TEST", 255, 309], ["the HTR Connectivity", "TEST", 313, 333], ["gordonii", "PROBLEM", 341, 349], ["S. pneumonia", "PROBLEM", 351, 363], ["S. suis", "PROBLEM", 365, 372], ["S. agalactiae\u2014have varied pathogenicity", "PROBLEM", 378, 417], ["spherical", "OBSERVATION_MODIFIER", 264, 273], ["positive Streptococcus species", "OBSERVATION", 279, 309], ["pneumonia", "OBSERVATION", 354, 363]]], ["S. agalactiae is a beta-hemolytic species that causes complete hemolysis, whereas the three others are alpha-hemolytic species that cause partial hemolysis.", [["hemolysis", "DISEASE", 63, 72], ["hemolysis", "DISEASE", 146, 155], ["S. agalactiae", "ORGANISM", 0, 13], ["S. agalactiae", "SPECIES", 0, 13], ["S. agalactiae", "SPECIES", 0, 13], ["S. agalactiae", "PROBLEM", 0, 13], ["a beta-hemolytic species", "PROBLEM", 17, 41], ["complete hemolysis", "PROBLEM", 54, 72], ["alpha-hemolytic species", "PROBLEM", 103, 126], ["partial hemolysis", "PROBLEM", 138, 155], ["agalactiae", "OBSERVATION", 3, 13], ["beta-hemolytic", "OBSERVATION_MODIFIER", 19, 33], ["complete", "OBSERVATION_MODIFIER", 54, 62], ["hemolysis", "OBSERVATION", 63, 72], ["alpha-hemolytic species", "OBSERVATION", 103, 126], ["partial", "OBSERVATION_MODIFIER", 138, 145], ["hemolysis", "OBSERVATION", 146, 155]]], ["Herein, we tried to evaluate the ability of annotated HTR Community analysis to differentiate the pathogenicity of internal and external Streptococcus species.Streptococcus ::: Associations among HTR community pathogens ::: ResultsThe internal Streptococcus species S. gordonii, an oral commensal bacterium, and S. pneumonia, carried asymptomatically in the nasopharynx, can be pathogenic in susceptible individuals27.", [["oral", "ANATOMY", 282, 286], ["nasopharynx", "ANATOMY", 358, 369], ["S. pneumonia", "DISEASE", 312, 324], ["internal Streptococcus species", "ORGANISM", 235, 265], ["S. gordonii", "ORGANISM", 266, 277], ["oral", "ORGANISM_SUBDIVISION", 282, 286], ["S. pneumonia", "ORGANISM", 312, 324], ["nasopharynx", "ORGAN", 358, 369], ["S. gordonii", "SPECIES", 266, 277], ["S. pneumonia", "SPECIES", 312, 324], ["S. gordonii", "SPECIES", 266, 277], ["S. pneumonia", "SPECIES", 312, 324], ["annotated HTR Community analysis", "TEST", 44, 76], ["the pathogenicity of internal and external Streptococcus species", "PROBLEM", 94, 158], ["The internal Streptococcus species S. gordonii", "TEST", 231, 277], ["an oral commensal bacterium", "PROBLEM", 279, 306], ["S. pneumonia", "PROBLEM", 312, 324], ["internal", "ANATOMY_MODIFIER", 115, 123], ["Streptococcus species", "OBSERVATION", 137, 158], ["internal", "ANATOMY", 235, 243], ["Streptococcus species", "OBSERVATION", 244, 265], ["pneumonia", "OBSERVATION", 315, 324], ["nasopharynx", "ANATOMY", 358, 369]]], ["Accordingly, they were both classified into HTR Community 8 (Fig. 3), which is enriched with alpha-hemolytic and commensal bacteria.", [["alpha-hemolytic", "PROBLEM", 93, 108], ["commensal bacteria", "PROBLEM", 113, 131], ["alpha-hemolytic", "OBSERVATION_MODIFIER", 93, 108], ["commensal bacteria", "OBSERVATION", 113, 131]]], ["Formerly classified as part of the Group D Streptococcus system, Enterococcus faecalis is an alpha-hemolytic commensal inhabitant in the human gastrointestinal tract28.", [["gastrointestinal", "ANATOMY", 143, 159], ["Group D Streptococcus system", "ORGANISM", 35, 63], ["Enterococcus faecalis", "ORGANISM", 65, 86], ["human", "ORGANISM", 137, 142], ["gastrointestinal tract28", "CANCER", 143, 167], ["Enterococcus faecalis", "SPECIES", 65, 86], ["human", "SPECIES", 137, 142], ["Enterococcus faecalis", "SPECIES", 65, 86], ["human", "SPECIES", 137, 142], ["Enterococcus faecalis", "PROBLEM", 65, 86], ["Enterococcus faecalis", "OBSERVATION", 65, 86], ["alpha-hemolytic", "OBSERVATION_MODIFIER", 93, 108]]], ["When we queried our HTR Community dataset with collected signatures from gene expression profiles generated from E. faecali-infected human urothelial cells (Supplementary Signatures S7 and Supplementary Table S6), we confirmed that indeed this external Streptococcus specie also showed strongest positive associations with HTR Community 8 (Fig. 6a,c).Streptococcus ::: Associations among HTR community pathogens ::: ResultsBeta-hemolytic Streptococcus species are subdivided into 20 serotypes (Lancefield groups A to V) describing their cell-wall carbohydrates, with Lancefield groups A and B being the most clinically important groups26.", [["urothelial cells", "ANATOMY", 139, 155], ["cell", "ANATOMY", 537, 541], ["wall", "ANATOMY", 542, 546], ["carbohydrates", "CHEMICAL", 547, 560], ["E. faecali", "ORGANISM", 113, 123], ["human", "ORGANISM", 133, 138], ["urothelial cells", "CELL", 139, 155], ["Beta-hemolytic Streptococcus species", "ORGANISM", 423, 459], ["cell", "CELL", 537, 541], ["E. faecali-infected human urothelial cells", "CELL_TYPE", 113, 155], ["S6", "PROTEIN", 209, 211], ["E. faecali", "SPECIES", 113, 123], ["human", "SPECIES", 133, 138], ["E. faecali", "SPECIES", 113, 123], ["human", "SPECIES", 133, 138], ["collected signatures", "TEST", 47, 67], ["gene expression profiles", "TEST", 73, 97], ["E. faecali", "TEST", 113, 123], ["infected human urothelial cells", "PROBLEM", 124, 155], ["this external Streptococcus specie", "TEST", 239, 273], ["Beta-hemolytic Streptococcus species", "PROBLEM", 423, 459], ["their cell-wall carbohydrates", "TREATMENT", 531, 560], ["Lancefield groups", "TREATMENT", 567, 584], ["urothelial cells", "OBSERVATION", 139, 155]]], ["The internal species S. agalactiae, also known as Group B streptococcus (GBS), is an opportunistic pathogen of the normal gut and genital tract flora, with a polysaccharide antiphagocytic capsule being its main virulence factor29.", [["gut", "ANATOMY", 122, 125], ["genital tract flora", "ANATOMY", 130, 149], ["GBS", "DISEASE", 73, 76], ["S. agalactiae", "ORGANISM", 21, 34], ["Group B streptococcus", "ORGANISM", 50, 71], ["gut", "ORGANISM_SUBDIVISION", 122, 125], ["genital tract", "ORGANISM_SUBDIVISION", 130, 143], ["flora", "PATHOLOGICAL_FORMATION", 144, 149], ["capsule", "CANCER", 188, 195], ["factor29", "GENE_OR_GENE_PRODUCT", 221, 229], ["virulence factor29", "PROTEIN", 211, 229], ["S. agalactiae", "SPECIES", 21, 34], ["B streptococcus", "SPECIES", 56, 71], ["S. agalactiae", "SPECIES", 21, 34], ["Group B streptococcus", "SPECIES", 50, 71], ["The internal species S. agalactiae", "PROBLEM", 0, 34], ["Group B streptococcus (GBS", "TEST", 50, 76], ["an opportunistic pathogen", "PROBLEM", 82, 107], ["genital tract flora", "PROBLEM", 130, 149], ["a polysaccharide antiphagocytic capsule", "TREATMENT", 156, 195], ["agalactiae", "OBSERVATION", 24, 34], ["gut", "ANATOMY", 122, 125], ["genital tract", "ANATOMY", 130, 143], ["main", "OBSERVATION_MODIFIER", 206, 210], ["virulence factor29", "OBSERVATION", 211, 229]]], ["Consequently, it was classified in HTR Community 6 (Fig. 3), which is enriched with encapsulated human flora bacteria.Streptococcus ::: Associations among HTR community pathogens ::: ResultsS. pyogenes, an external Streptococcus also known as Group A streptococcus (GAS), causes many diseases, ranging from mild superficial skin infections to life-threatening systemic diseases30.", [["skin", "ANATOMY", 324, 328], ["skin infections", "DISEASE", 324, 339], ["systemic diseases", "DISEASE", 360, 377], ["human", "ORGANISM", 97, 102], ["pyogenes", "ORGANISM", 193, 201], ["Group A streptococcus", "ORGANISM", 243, 264], ["GAS", "ORGANISM", 266, 269], ["skin", "ORGAN", 324, 328], ["human", "SPECIES", 97, 102], ["pyogenes", "SPECIES", 193, 201], ["A streptococcus", "SPECIES", 249, 264], ["human", "SPECIES", 97, 102], ["pyogenes", "SPECIES", 193, 201], ["encapsulated human flora bacteria", "PROBLEM", 84, 117], ["pyogenes", "PROBLEM", 193, 201], ["an external Streptococcus", "PROBLEM", 203, 228], ["Group A streptococcus (GAS)", "PROBLEM", 243, 270], ["many diseases", "PROBLEM", 279, 292], ["mild superficial skin infections", "PROBLEM", 307, 339], ["threatening systemic diseases", "PROBLEM", 348, 377], ["flora bacteria", "OBSERVATION", 103, 117], ["external Streptococcus", "OBSERVATION", 206, 228], ["many", "OBSERVATION_MODIFIER", 279, 283], ["diseases", "OBSERVATION", 284, 292], ["mild", "OBSERVATION_MODIFIER", 307, 311], ["superficial", "ANATOMY_MODIFIER", 312, 323], ["skin", "ANATOMY", 324, 328], ["infections", "OBSERVATION", 329, 339]]], ["It also causes post infectious non-pyogenic syndromes, including rheumatic fever and acute post infectious glomerulonephritis31.", [["rheumatic fever", "DISEASE", 65, 80], ["post infectious non-pyogenic syndromes", "PROBLEM", 15, 53], ["rheumatic fever", "PROBLEM", 65, 80], ["acute post infectious glomerulonephritis31", "PROBLEM", 85, 127], ["post", "OBSERVATION_MODIFIER", 15, 19], ["infectious", "OBSERVATION_MODIFIER", 20, 30], ["non-pyogenic syndromes", "OBSERVATION", 31, 53], ["rheumatic", "OBSERVATION_MODIFIER", 65, 74], ["fever", "OBSERVATION", 75, 80], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["post", "OBSERVATION_MODIFIER", 91, 95], ["infectious", "OBSERVATION", 96, 106]]], ["Its pathogenicity is associated with several GASs common (e.g., Streptolysin O and S) and specific (e.g., Streptococcal pyrogenic exotoxin A and C32, and Streptococcal chemokine protease33) virulence factors that enable the bacterium to attach to host tissues, evade immune responses, and spread by penetrating into tissue layers.Streptococcus ::: Associations among HTR community pathogens ::: ResultsGiven its distinct characteristics, we hypothesized that S. pyogenes would not co-segregate with S. agalactiae in HTR Community 6.", [["tissues", "ANATOMY", 252, 259], ["tissue layers", "ANATOMY", 316, 329], ["GASs", "GENE_OR_GENE_PRODUCT", 45, 49], ["Streptolysin O", "GENE_OR_GENE_PRODUCT", 64, 78], ["Streptococcal pyrogenic exotoxin A", "GENE_OR_GENE_PRODUCT", 106, 140], ["C32", "GENE_OR_GENE_PRODUCT", 145, 148], ["Streptococcal chemokine protease33) virulence factors", "GENE_OR_GENE_PRODUCT", 154, 207], ["tissues", "TISSUE", 252, 259], ["tissue layers", "TISSUE", 316, 329], ["S. pyogenes", "ORGANISM", 459, 470], ["S. agalactiae", "ORGANISM", 499, 512], ["Streptococcal pyrogenic exotoxin A", "PROTEIN", 106, 140], ["C32", "PROTEIN", 145, 148], ["Streptococcal chemokine protease33", "PROTEIN", 154, 188], ["virulence factors", "PROTEIN", 190, 207], ["S. pyogenes", "SPECIES", 459, 470], ["S. agalactiae", "SPECIES", 499, 512], ["S. pyogenes", "SPECIES", 459, 470], ["S. agalactiae", "SPECIES", 499, 512], ["Its pathogenicity", "PROBLEM", 0, 17], ["several GASs common", "PROBLEM", 37, 56], ["Streptococcal pyrogenic exotoxin A", "TEST", 106, 140], ["C32", "TEST", 145, 148], ["Streptococcal chemokine protease33", "TREATMENT", 154, 188], ["virulence factors", "PROBLEM", 190, 207], ["the bacterium", "PROBLEM", 220, 233], ["S. pyogenes", "PROBLEM", 459, 470], ["pathogenicity", "OBSERVATION", 4, 17], ["several", "OBSERVATION_MODIFIER", 37, 44], ["GASs", "OBSERVATION", 45, 49], ["distinct", "OBSERVATION_MODIFIER", 412, 420]]], ["Thus, we collected the only available gene expression profiles generated from samples of blood, saliva, and throat swabs from S. agalactiae-infected Cynomolgus macaques (Supplementary Signatures S8 and Table S6), queried the HTR Communities, and indeed found that S. pyogenes associated most strongly with Community 3 (permutation P = 0.0027, Fig. 6b,c), in which immune-related BPs are significantly activated.", [["samples", "ANATOMY", 78, 85], ["blood", "ANATOMY", 89, 94], ["saliva", "ANATOMY", 96, 102], ["throat swabs", "ANATOMY", 108, 120], ["BPs", "CHEMICAL", 379, 382], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["saliva", "ORGANISM_SUBSTANCE", 96, 102], ["throat", "ORGANISM_SUBDIVISION", 108, 114], ["swabs", "ORGANISM_SUBSTANCE", 115, 120], ["S. agalactiae", "ORGANISM", 126, 139], ["Cynomolgus macaques", "ORGANISM", 149, 168], ["S. pyogenes", "ORGANISM", 264, 275], ["BPs", "GENE_OR_GENE_PRODUCT", 379, 382], ["S. agalactiae", "SPECIES", 126, 139], ["Cynomolgus macaques", "SPECIES", 149, 168], ["S. pyogenes", "SPECIES", 264, 275], ["S. agalactiae", "SPECIES", 126, 139], ["Cynomolgus macaques", "SPECIES", 149, 168], ["S. pyogenes", "SPECIES", 264, 275], ["blood, saliva", "PROBLEM", 89, 102], ["throat swabs", "TEST", 108, 120], ["S. agalactiae", "PROBLEM", 126, 139], ["infected Cynomolgus macaques", "PROBLEM", 140, 168], ["S. pyogenes", "PROBLEM", 264, 275], ["permutation P", "TEST", 319, 332], ["throat", "ANATOMY", 108, 114], ["infected", "OBSERVATION_MODIFIER", 140, 148], ["Cynomolgus macaques", "OBSERVATION", 149, 168], ["pyogenes", "OBSERVATION", 267, 275]]], ["Collectively, these results show that HTR community analysis can identify distinguishable associations among phylogenetically related pathogens with differential underlying pathogenicity, at least in the present sample.Oral commensal bacteria ::: Associations among HTR community pathogens ::: ResultsTo further test the capacity of the HTR community method for identifying distinct mode of functional associations among pathogens, we then explored genetically unrelated bacterial pathogens with significant HTR similarities.Oral commensal bacteria ::: Associations among HTR community pathogens ::: ResultsOral commensal bacteria are highly diverse and inhabit the various surfaces of the mouth.", [["mouth", "ANATOMY", 690, 695], ["mouth", "ORGANISM_SUBDIVISION", 690, 695], ["HTR community analysis", "TEST", 38, 60], ["differential underlying pathogenicity", "PROBLEM", 149, 186], ["genetically unrelated bacterial pathogens", "PROBLEM", 449, 490], ["significant HTR similarities", "PROBLEM", 496, 524], ["ResultsOral commensal bacteria", "PROBLEM", 600, 630], ["pathogenicity", "OBSERVATION", 173, 186], ["bacteria", "OBSERVATION", 234, 242], ["bacteria", "OBSERVATION", 540, 548], ["commensal", "OBSERVATION_MODIFIER", 612, 621], ["bacteria", "OBSERVATION", 622, 630], ["highly", "OBSERVATION_MODIFIER", 635, 641], ["diverse", "OBSERVATION_MODIFIER", 642, 649], ["various", "OBSERVATION_MODIFIER", 666, 673], ["surfaces", "OBSERVATION_MODIFIER", 674, 682], ["mouth", "ANATOMY", 690, 695]]], ["Their ability to form biofilms on hard and soft oral tissues makes them important in periodontal disease34.", [["soft oral tissues", "ANATOMY", 43, 60], ["periodontal disease34", "ANATOMY", 85, 106], ["soft oral tissues", "TISSUE", 43, 60], ["periodontal disease34", "CANCER", 85, 106], ["hard and soft oral tissues", "PROBLEM", 34, 60]]], ["Our 50-pathogen HTR Connectivity Map includes one oral commensal species S. gordonii and two opportunistic oral commensal species, Aggregatibacter actinomycetemcomitans and Fusobacterium nucleatum.", [["oral", "ANATOMY", 50, 54], ["oral", "ANATOMY", 107, 111], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["S. gordonii", "ORGANISM", 73, 84], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["Aggregatibacter actinomycetemcomitans", "ORGANISM", 131, 168], ["Fusobacterium nucleatum", "GENE_OR_GENE_PRODUCT", 173, 196], ["S. gordonii", "SPECIES", 73, 84], ["Aggregatibacter actinomycetemcomitans", "SPECIES", 131, 168], ["Fusobacterium nucleatum", "SPECIES", 173, 196], ["S. gordonii", "SPECIES", 73, 84], ["Aggregatibacter actinomycetemcomitans", "SPECIES", 131, 168], ["Fusobacterium nucleatum", "SPECIES", 173, 196], ["Connectivity Map", "TEST", 20, 36], ["one oral commensal species S. gordonii", "PROBLEM", 46, 84], ["two opportunistic oral commensal species", "PROBLEM", 89, 129], ["Aggregatibacter actinomycetemcomitans", "PROBLEM", 131, 168], ["Fusobacterium nucleatum", "PROBLEM", 173, 196], ["opportunistic", "OBSERVATION_MODIFIER", 93, 106], ["commensal species", "OBSERVATION", 112, 129]]], ["Intriguingly, these three species showed significant HTR similarities (Fig. 3).", [["these three species", "TEST", 14, 33], ["significant HTR similarities", "PROBLEM", 41, 69], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["HTR", "OBSERVATION", 53, 56]]], ["Of note, the oral commensal bacterium characteristic is also an enriched infection attribute for bacteria in HTR Community 8.Oral commensal bacteria ::: Associations among HTR community pathogens ::: ResultsSurprisingly however, Porphyromonas gingivalis, a periodontal pathogen found in the mouth, upper gastrointestinal tract, respiratory tract, and colon, did not positively associate with these three oral (opportunistic) commensal bacteria, but rather was classified into HTR Community 6, which is enriched with pathogenic respiratory flora and Gram-negative rod bacteria (Fig. 3).", [["oral", "ANATOMY", 13, 17], ["mouth", "ANATOMY", 291, 296], ["upper gastrointestinal tract", "ANATOMY", 298, 326], ["respiratory tract", "ANATOMY", 328, 345], ["colon", "ANATOMY", 351, 356], ["oral", "ANATOMY", 404, 408], ["respiratory", "ANATOMY", 527, 538], ["infection", "DISEASE", 73, 82], ["Porphyromonas gingivalis", "DISEASE", 229, 253], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["Porphyromonas gingivalis", "GENE_OR_GENE_PRODUCT", 229, 253], ["mouth", "ORGANISM_SUBDIVISION", 291, 296], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 298, 320], ["tract", "ORGANISM_SUBDIVISION", 321, 326], ["respiratory tract", "ORGANISM_SUBDIVISION", 328, 345], ["colon", "ORGAN", 351, 356], ["oral", "ORGANISM_SUBDIVISION", 404, 408], ["Porphyromonas gingivalis", "SPECIES", 229, 253], ["Porphyromonas gingivalis", "SPECIES", 229, 253], ["the oral commensal bacterium", "PROBLEM", 9, 37], ["an enriched infection", "PROBLEM", 61, 82], ["bacteria", "PROBLEM", 97, 105], ["Porphyromonas gingivalis", "PROBLEM", 229, 253], ["a periodontal pathogen", "PROBLEM", 255, 277], ["respiratory tract, and colon", "PROBLEM", 328, 356], ["commensal bacteria", "PROBLEM", 425, 443], ["pathogenic respiratory flora", "PROBLEM", 516, 544], ["Gram-negative rod bacteria", "PROBLEM", 549, 575], ["enriched", "OBSERVATION_MODIFIER", 64, 72], ["infection", "OBSERVATION", 73, 82], ["bacteria", "OBSERVATION", 140, 148], ["periodontal", "ANATOMY", 257, 268], ["pathogen", "OBSERVATION", 269, 277], ["mouth", "ANATOMY", 291, 296], ["upper", "ANATOMY_MODIFIER", 298, 303], ["gastrointestinal tract", "ANATOMY", 304, 326], ["respiratory tract", "ANATOMY", 328, 345], ["colon", "ANATOMY", 351, 356], ["respiratory flora", "OBSERVATION", 527, 544], ["negative rod bacteria", "OBSERVATION", 554, 575]]], ["Further evidence from gene expression pattern analysis showed that P. gingivalis shared the GO BP of activated G protein-coupled receptor pathway with Community 6, a feature not enriched in Community 8 (Fig. 4a).Oral commensal bacteria ::: Associations among HTR community pathogens ::: ResultsTo validate the specificity of this highly oral microbiota related HTR, we selected another oral commensal bacterium, Treponema denticola, with which to query the HTR Community.", [["oral", "ANATOMY", 337, 341], ["oral", "ANATOMY", 386, 390], ["P. gingivalis", "ORGANISM", 67, 80], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 111, 137], ["oral", "ORGANISM_SUBDIVISION", 337, 341], ["oral", "ORGANISM_SUBDIVISION", 386, 390], ["Treponema denticola", "ORGANISM", 412, 431], ["BP", "PROTEIN", 95, 97], ["G protein-coupled receptor", "PROTEIN", 111, 137], ["P. gingivalis", "SPECIES", 67, 80], ["Treponema denticola", "SPECIES", 412, 431], ["P. gingivalis", "SPECIES", 67, 80], ["Treponema denticola", "SPECIES", 412, 431], ["gene expression pattern analysis", "TEST", 22, 54], ["P. gingivalis", "PROBLEM", 67, 80], ["activated G protein", "TREATMENT", 101, 120], ["HTR", "PROBLEM", 361, 364], ["another oral commensal bacterium", "PROBLEM", 378, 410], ["Treponema denticola", "PROBLEM", 412, 431], ["bacteria", "OBSERVATION", 227, 235]]], ["The only available T. denticola query signature was generated from a report documenting differentially expressed genes in a murine model of T. denticola head infection (Supplementary Signatures S9 and S10; Supplementary Table S6).", [["head", "ANATOMY", 153, 157], ["T. denticola head infection", "DISEASE", 140, 167], ["T. denticola", "ORGANISM", 19, 31], ["murine", "ORGANISM", 124, 130], ["T. denticola head", "ORGANISM", 140, 157], ["T. denticola", "SPECIES", 19, 31], ["murine", "SPECIES", 124, 130], ["T. denticola", "SPECIES", 140, 152], ["T. denticola", "SPECIES", 19, 31], ["T. denticola", "SPECIES", 140, 152], ["T. denticola head infection", "PROBLEM", 140, 167], ["head", "ANATOMY", 153, 157], ["infection", "OBSERVATION", 158, 167]]], ["The conditions used in that study differed sharply from those used to build the HTR Connectivity Map with respect to RNA source (calvarial bones and overlying soft tissues vs. cell lines) and species (mouse vs. human).", [["calvarial bones", "ANATOMY", 129, 144], ["soft tissues", "ANATOMY", 159, 171], ["cell lines", "ANATOMY", 176, 186], ["calvarial bones", "MULTI-TISSUE_STRUCTURE", 129, 144], ["overlying soft tissues", "TISSUE", 149, 171], ["cell lines", "CELL", 176, 186], ["mouse", "ORGANISM", 201, 206], ["human", "ORGANISM", 211, 216], ["cell lines", "CELL_LINE", 176, 186], ["mouse", "SPECIES", 201, 206], ["human", "SPECIES", 211, 216], ["mouse", "SPECIES", 201, 206], ["human", "SPECIES", 211, 216], ["that study", "TEST", 23, 33], ["the HTR Connectivity Map", "TEST", 76, 100], ["RNA source (calvarial bones and overlying soft tissues", "PROBLEM", 117, 171], ["cell lines", "TREATMENT", 176, 186], ["calvarial bones", "ANATOMY", 129, 144], ["overlying", "ANATOMY_MODIFIER", 149, 158], ["soft tissues", "ANATOMY", 159, 171]]], ["Nonetheless, HTR community analysis yielded the strongest positive association with HTR Community 8 for the T. denticola query signature derived from calvarial overlying soft tissues, but not those from calvarial bones (Fig. 7b,c).", [["calvarial overlying soft tissues", "ANATOMY", 150, 182], ["calvarial bones", "ANATOMY", 203, 218], ["calvarial", "TISSUE", 150, 159], ["overlying soft tissues", "TISSUE", 160, 182], ["calvarial bones", "MULTI-TISSUE_STRUCTURE", 203, 218], ["T. denticola", "SPECIES", 108, 120], ["T. denticola", "SPECIES", 108, 120], ["HTR community analysis", "TEST", 13, 35], ["the T. denticola query signature", "TEST", 104, 136], ["calvarial overlying soft tissues", "PROBLEM", 150, 182], ["calvarial", "ANATOMY", 150, 159], ["overlying", "ANATOMY_MODIFIER", 160, 169], ["soft tissues", "ANATOMY", 170, 182], ["calvarial bones", "ANATOMY", 203, 218]]], ["This dissociation is likely due to the fact that the three reference profiles in the HTR Connectivity Map were not derived from calvarial bones (Supplementary Table S1), whose expressed transcripts are generally not shared with other cell or tissue types.", [["calvarial bones", "ANATOMY", 128, 143], ["cell", "ANATOMY", 234, 238], ["tissue", "ANATOMY", 242, 248], ["calvarial bones", "MULTI-TISSUE_STRUCTURE", 128, 143], ["cell", "CELL", 234, 238], ["tissue", "TISSUE", 242, 248], ["HTR Connectivity Map", "DNA", 85, 105], ["This dissociation", "PROBLEM", 0, 17], ["the HTR Connectivity Map", "TEST", 81, 105], ["likely due to", "UNCERTAINTY", 21, 34], ["calvarial bones", "ANATOMY", 128, 143]]], ["These findings demonstrated again that human microbiota with distinguishable host gene expression patterns can be identified by HTR community analysis.Respiratory viruses ::: Associations among HTR community pathogens ::: ResultsFinally, we sought to use the HTR community method to generate hypotheses about a unique HTR characteristic within a group of pathogens whose infections have indistinguishable local and systemic manifestations, but differing prognoses.", [["Respiratory viruses", "DISEASE", 151, 170], ["infections", "DISEASE", 371, 381], ["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["HTR community analysis", "TEST", 128, 150], ["the HTR community method", "TREATMENT", 255, 279], ["a unique HTR characteristic", "PROBLEM", 309, 336], ["pathogens whose infections", "PROBLEM", 355, 381], ["systemic manifestations", "PROBLEM", 415, 438], ["viruses", "OBSERVATION", 163, 170], ["systemic manifestations", "OBSERVATION", 415, 438]]], ["For this purpose, the respiratory viruses fall in our focus.Respiratory viruses ::: Associations among HTR community pathogens ::: ResultsHTR Connectivity Map included five respiratory viruses from four distinct families, namely influenza A virus (IAV) and Dhori virus in the family Orthomyxoviridae, human respiratory syncytial virus (RSV) in the family Paramyxoviridae, Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) in the family Coronaviridae, and human rhinovirus (HRV) in the family Picornaviridae.", [["respiratory viruses", "DISEASE", 22, 41], ["Respiratory viruses", "DISEASE", 60, 79], ["respiratory viruses", "DISEASE", 173, 192], ["influenza A virus", "DISEASE", 229, 246], ["respiratory syncytial virus", "DISEASE", 307, 334], ["Acute Respiratory Syndrome-associated coronavirus", "DISEASE", 379, 428], ["SARS-CoV)", "DISEASE", 430, 439], ["human rhinovirus (HRV)", "DISEASE", 473, 495], ["influenza A virus", "ORGANISM", 229, 246], ["IAV", "ORGANISM", 248, 251], ["Dhori virus", "ORGANISM", 257, 268], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 283, 299], ["human respiratory syncytial virus", "ORGANISM", 301, 334], ["RSV", "ORGANISM", 336, 339], ["Severe Acute Respiratory Syndrome-associated coronavirus", "ORGANISM", 372, 428], ["SARS-CoV", "ORGANISM", 430, 438], ["human rhinovirus", "ORGANISM", 473, 489], ["influenza A virus", "SPECIES", 229, 246], ["Dhori virus", "SPECIES", 257, 268], ["human", "SPECIES", 301, 306], ["respiratory syncytial virus", "SPECIES", 307, 334], ["RSV", "SPECIES", 336, 339], ["human", "SPECIES", 473, 478], ["rhinovirus", "SPECIES", 479, 489], ["influenza A virus", "SPECIES", 229, 246], ["IAV", "SPECIES", 248, 251], ["Dhori virus", "SPECIES", 257, 268], ["human respiratory syncytial virus", "SPECIES", 301, 334], ["RSV", "SPECIES", 336, 339], ["Severe Acute Respiratory Syndrome-associated coronavirus", "SPECIES", 372, 428], ["SARS-CoV", "SPECIES", 430, 438], ["human rhinovirus", "SPECIES", 473, 489], ["HRV", "SPECIES", 491, 494], ["the respiratory viruses fall", "PROBLEM", 18, 46], ["Connectivity Map", "TEST", 142, 158], ["five respiratory viruses", "PROBLEM", 168, 192], ["influenza A virus", "PROBLEM", 229, 246], ["Dhori virus", "PROBLEM", 257, 268], ["Orthomyxoviridae", "TREATMENT", 283, 299], ["human respiratory syncytial virus", "PROBLEM", 301, 334], ["Severe Acute Respiratory Syndrome", "PROBLEM", 372, 405], ["coronavirus", "PROBLEM", 417, 428], ["Coronaviridae", "TREATMENT", 454, 467], ["human rhinovirus", "PROBLEM", 473, 489], ["Picornaviridae", "TREATMENT", 510, 524], ["respiratory", "ANATOMY", 22, 33], ["viruses", "OBSERVATION", 34, 41], ["viruses", "OBSERVATION", 72, 79], ["respiratory viruses", "OBSERVATION", 173, 192], ["respiratory syncytial", "ANATOMY", 307, 328], ["Severe", "OBSERVATION_MODIFIER", 372, 378], ["Acute", "OBSERVATION_MODIFIER", 379, 384], ["Respiratory Syndrome", "OBSERVATION", 385, 405]]], ["All five viruses are associated with high morbidity and their infections cause similar minor (e.g., coughing, sore throat, runny nose, and fever) and severe symptoms (e.g., severe breathing problems, bronchiolitis, bronchitis, and pneumonia) in humans3536.", [["infections", "DISEASE", 62, 72], ["coughing", "DISEASE", 100, 108], ["sore throat", "DISEASE", 110, 121], ["runny nose", "DISEASE", 123, 133], ["fever", "DISEASE", 139, 144], ["breathing problems", "DISEASE", 180, 198], ["bronchiolitis", "DISEASE", 200, 213], ["bronchitis", "DISEASE", 215, 225], ["pneumonia", "DISEASE", 231, 240], ["humans", "ORGANISM", 245, 251], ["humans", "SPECIES", 245, 251], ["humans", "SPECIES", 245, 251], ["All five viruses", "PROBLEM", 0, 16], ["high morbidity", "PROBLEM", 37, 51], ["their infections", "PROBLEM", 56, 72], ["similar minor (e.g.", "PROBLEM", 79, 98], ["coughing", "PROBLEM", 100, 108], ["sore throat", "PROBLEM", 110, 121], ["runny nose", "PROBLEM", 123, 133], ["fever", "PROBLEM", 139, 144], ["severe symptoms", "PROBLEM", 150, 165], ["severe breathing problems", "PROBLEM", 173, 198], ["bronchiolitis", "PROBLEM", 200, 213], ["bronchitis", "PROBLEM", 215, 225], ["pneumonia", "PROBLEM", 231, 240], ["viruses", "OBSERVATION", 9, 16], ["high", "OBSERVATION_MODIFIER", 37, 41], ["morbidity", "OBSERVATION", 42, 51], ["infections", "OBSERVATION", 62, 72], ["runny nose", "ANATOMY", 123, 133], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["bronchiolitis", "OBSERVATION", 200, 213], ["bronchitis", "OBSERVATION", 215, 225], ["pneumonia", "OBSERVATION", 231, 240]]], ["To our surprise, these five viruses were classified into three different HTR Communities (Fig. 3): HRV was classified into HTR Community 6 (enriched with pathogenic respiratory flora), IAV into Community 3 (enriched with pathogens with oncogenic potential after chronic/persistent infection), and Dhori virus, SARS-CoV, and RSV into Community 2 (enriched with Mononegavirales order pathogens).Respiratory viruses ::: Associations among HTR community pathogens ::: ResultsTo validate the unique HTR to IAV, we first employed four IAV query signatures from a recent report in which human lung epithelial cells were infected with a novel avian-origin H7N9 strain, two highly pathogenic avian-origin H5N1 and H7N7 strains, and a human seasonal H3N2 strain (Supplementary Signatures S11\u201314 and Supplementary Table S6).", [["lung epithelial cells", "ANATOMY", 586, 607], ["strain", "ANATOMY", 653, 659], ["chronic/persistent infection", "DISEASE", 262, 290], ["SARS", "DISEASE", 310, 314], ["Respiratory viruses", "DISEASE", 393, 412], ["Dhori virus", "ORGANISM", 297, 308], ["SARS-CoV", "ORGANISM", 310, 318], ["RSV", "ORGANISM", 324, 327], ["human", "ORGANISM", 580, 585], ["lung epithelial cells", "CELL", 586, 607], ["avian-origin H7N9 strain", "ORGANISM", 635, 659], ["avian-origin H5N1", "ORGANISM", 683, 700], ["human", "ORGANISM", 725, 730], ["human lung epithelial cells", "CELL_TYPE", 580, 607], ["human", "SPECIES", 580, 585], ["avian-origin H5N1", "SPECIES", 683, 700], ["human", "SPECIES", 725, 730], ["seasonal H3N2", "SPECIES", 731, 744], ["Dhori virus", "SPECIES", 297, 308], ["SARS-CoV", "SPECIES", 310, 318], ["RSV", "SPECIES", 324, 327], ["human", "SPECIES", 580, 585], ["H7N7", "SPECIES", 705, 709], ["human seasonal H3N2 strain", "SPECIES", 725, 751], ["HRV", "PROBLEM", 99, 102], ["pathogenic respiratory flora", "PROBLEM", 154, 182], ["chronic/persistent infection", "PROBLEM", 262, 290], ["Dhori virus", "PROBLEM", 297, 308], ["SARS", "PROBLEM", 310, 314], ["RSV", "PROBLEM", 324, 327], ["Mononegavirales order pathogens", "TREATMENT", 360, 391], ["human lung epithelial cells", "PROBLEM", 580, 607], ["H7N9 strain", "PROBLEM", 648, 659], ["H5N1", "PROBLEM", 696, 700], ["H7N7 strains", "PROBLEM", 705, 717], ["a human seasonal H3N2 strain", "PROBLEM", 723, 751], ["respiratory flora", "ANATOMY", 165, 182], ["persistent", "OBSERVATION_MODIFIER", 270, 280], ["infection", "OBSERVATION", 281, 290], ["viruses", "OBSERVATION", 405, 412], ["lung", "ANATOMY", 586, 590], ["epithelial cells", "OBSERVATION", 591, 607], ["H7N7 strains", "OBSERVATION", 705, 717]]], ["For all four external IAV strains, the HTR community analysis yielded consistently strong positive associations with Community 3 (permutation P < 0.001) (Fig. 8a,d).Respiratory viruses ::: Associations among HTR community pathogens ::: ResultsWe then proceeded to investigate the HTR associations of two other clinical important respiratory viruses in the Paramyxoviridae family that were not included in the HTR Connectivity Map, namely human metapneumovirus (hMPV) and human parainfluenza virus (hPIV).", [["Respiratory viruses", "DISEASE", 165, 184], ["human metapneumovirus (hMPV) and human parainfluenza virus", "DISEASE", 438, 496], ["human", "ORGANISM", 438, 443], ["metapneumovirus", "ORGANISM", 444, 459], ["hMPV", "ORGANISM", 461, 465], ["human", "ORGANISM", 471, 476], ["parainfluenza virus", "ORGANISM", 477, 496], ["hPIV", "CANCER", 498, 502], ["human", "SPECIES", 438, 443], ["metapneumovirus", "SPECIES", 444, 459], ["hMPV", "SPECIES", 461, 465], ["human", "SPECIES", 471, 476], ["parainfluenza virus", "SPECIES", 477, 496], ["human metapneumovirus", "SPECIES", 438, 459], ["hMPV", "SPECIES", 461, 465], ["human parainfluenza virus", "SPECIES", 471, 496], ["hPIV", "SPECIES", 498, 502], ["all four external IAV strains", "PROBLEM", 4, 33], ["the HTR community analysis", "TEST", 35, 61], ["Community 3 (permutation P", "TREATMENT", 117, 143], ["two other clinical important respiratory viruses", "PROBLEM", 300, 348], ["the HTR Connectivity Map", "TEST", 405, 429], ["human metapneumovirus (hMPV", "PROBLEM", 438, 465], ["human parainfluenza virus (hPIV)", "TREATMENT", 471, 503], ["IAV strains", "OBSERVATION", 22, 33], ["viruses", "OBSERVATION", 177, 184], ["respiratory viruses", "OBSERVATION", 329, 348]]], ["Both query signatures were generated from expression profiles of human lung epithelial cells after time-course infections (Supplementary Signatures S15 and S16; Supplementary Table S6).", [["lung epithelial cells", "ANATOMY", 71, 92], ["infections", "DISEASE", 111, 121], ["human", "ORGANISM", 65, 70], ["lung epithelial cells", "CELL", 71, 92], ["human lung epithelial cells", "CELL_TYPE", 65, 92], ["S6", "PROTEIN", 181, 183], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["human lung epithelial cells", "PROBLEM", 65, 92], ["infections", "PROBLEM", 111, 121], ["lung", "ANATOMY", 71, 75], ["epithelial cells", "OBSERVATION", 76, 92]]], ["HTR community analysis yielded the strongest positive associations for hMPV and wild-type hPIV-1 with Community 6 (permutation P < 10\u22124 and =0.0062, respectively) (Fig. 8b,d), despite that they also showed positive associations with Community 3 (permutation P = 0.0236 and =0.0018, respectively) (Fig. 8c,d).Respiratory viruses ::: Associations among HTR community pathogens ::: ResultsAltogether, these results indicated that respiratory infections with indistinguishable clinical manifestations may differ greatly in HTRs.", [["respiratory", "ANATOMY", 427, 438], ["Respiratory viruses", "DISEASE", 308, 327], ["respiratory infections", "DISEASE", 427, 449], ["hMPV", "ORGANISM", 71, 75], ["hMPV", "SPECIES", 71, 75], ["HTR community analysis", "TEST", 0, 22], ["hMPV", "PROBLEM", 71, 75], ["type hPIV", "TEST", 85, 94], ["permutation P", "TEST", 115, 128], ["permutation P", "TEST", 246, 259], ["respiratory infections", "PROBLEM", 427, 449], ["indistinguishable clinical manifestations", "PROBLEM", 455, 496], ["viruses", "OBSERVATION", 320, 327], ["respiratory", "ANATOMY", 427, 438], ["infections", "OBSERVATION", 439, 449]]], ["This makes delicate HTR classification of individual infection type, especially the newly emerged viral strain(s), constantly needed to better understand the common and specific HTR features.", [["infection", "DISEASE", 53, 62], ["individual infection type", "PROBLEM", 42, 67], ["the newly emerged viral strain", "PROBLEM", 80, 110], ["individual", "OBSERVATION_MODIFIER", 42, 52], ["infection", "OBSERVATION", 53, 62]]], ["Although in a preliminary stage, the findings about known respiratory viruses and especially IAV, which is uniquely responsible for the highly contagious influenza outbreaks, underscore the necessity for specific host-directed antiviral strategies in epidemic control.DiscussionResource projects such as the Connectivity Map10 and the subsequent Library of Integrated Network-based Cellular Signatures37, which provide an expansive library of post-drug treatment gene expression profiles, are of high operability.", [["respiratory viruses", "DISEASE", 58, 77], ["influenza", "DISEASE", 154, 163], ["Connectivity Map10", "DNA", 308, 326], ["IAV", "SPECIES", 93, 96], ["known respiratory viruses", "PROBLEM", 52, 77], ["IAV", "PROBLEM", 93, 96], ["the highly contagious influenza outbreaks", "PROBLEM", 132, 173], ["specific host", "TREATMENT", 204, 217], ["antiviral strategies", "TREATMENT", 227, 247], ["epidemic control", "TREATMENT", 251, 267], ["post-drug treatment", "TREATMENT", 443, 462], ["respiratory viruses", "OBSERVATION", 58, 77], ["highly", "OBSERVATION_MODIFIER", 136, 142], ["contagious", "OBSERVATION_MODIFIER", 143, 153], ["influenza", "OBSERVATION", 154, 163], ["expansive", "OBSERVATION_MODIFIER", 422, 431]]], ["Development of a similar platform cataloguing gene expression profiles characterizing HTRs to particular pathogenic infections is needed.", [["infections", "DISEASE", 116, 126], ["HTRs", "GENE_OR_GENE_PRODUCT", 86, 90], ["a similar platform cataloguing gene expression profiles", "PROBLEM", 15, 70], ["particular pathogenic infections", "PROBLEM", 94, 126], ["pathogenic", "OBSERVATION_MODIFIER", 105, 115], ["infections", "OBSERVATION", 116, 126]]], ["The present work represents a pilot venture toward fulfilling that need.DiscussionAn essential advantage of using transcriptional bioinformatics in drug discovery and repositioning lies in the fact that plentiful information\u2014including chemical, pharmacological and pharmaceutical data, with comprehensive information about drug targeting (i.e. sequence, structure, and pathway)38 and adverse secondary effects39\u2014has been curated for small-molecule drugs.", [["a pilot venture", "TREATMENT", 28, 43], ["repositioning", "TREATMENT", 167, 180], ["small-molecule drugs", "TREATMENT", 433, 453]]], ["This plentiful information has served as an excellent annotation resource and facilitated the elucidation of drug mechanisms, as well as the identification of new drug targets and new indications for old drugs404142.DiscussionThe HTR Connectivity Map scheme developed here was limited to publically accessible expression profiling data, therefore, our data collection was unavoidably at risk of bias.", [["new drug targets", "PROBLEM", 159, 175], ["old drugs", "TREATMENT", 200, 209], ["The HTR Connectivity Map scheme", "TEST", 226, 257], ["our data collection", "TEST", 348, 367]]], ["Recognizing the limited cell type diversity among our samples in our systematic assessment of HTR similarities, we combined PRLs of a specific pathogen computationally to represent the integral feature of HTRs to that pathogen.", [["cell", "ANATOMY", 24, 28], ["samples", "ANATOMY", 54, 61], ["cell", "CELL", 24, 28], ["HTRs", "GENE_OR_GENE_PRODUCT", 205, 209], ["HTRs", "PROTEIN", 205, 209], ["our systematic assessment", "TEST", 65, 90], ["HTR similarities", "PROBLEM", 94, 110], ["a specific pathogen", "PROBLEM", 132, 151], ["HTRs", "PROBLEM", 205, 209]]], ["Through further clustering, we identified eight pathogen groups, that is, HTR Communities, with a discernible consensus of internal HTR similarities.", [["internal HTR similarities", "PROBLEM", 123, 148], ["internal HTR", "OBSERVATION", 123, 135]]], ["The methodologies used in this study, including gene expression profile merging, comparison, and clustering, were first introduced by Iorio et al.12 and Subramanian et al.11 Previously, these methods performed very well in characterizing and predicting similarities in drug effect and mode of action across cell lines and dosages, and further in partitioning drugs into communities (i.e., compounds with similar modes of action).", [["cell lines", "ANATOMY", 307, 317], ["cell lines", "CELL", 307, 317], ["cell lines", "CELL_LINE", 307, 317], ["this study", "TEST", 26, 36], ["these methods", "TEST", 186, 199], ["drug effect", "PROBLEM", 269, 280], ["action across cell lines", "TREATMENT", 293, 317], ["drug effect", "OBSERVATION", 269, 280], ["cell lines", "OBSERVATION", 307, 317]]], ["Moreover, it was our aim to complement this HTR Community as a resource and elucidate the HTR associations established among the 50 pathogens.", [["the HTR associations", "PROBLEM", 86, 106]]], ["To this end, we collected laboratory and clinical infection characteristics for individual pathogens, and then identified computationally HTR-related infection attributes, as well as differential gene expression patterns, for each HTR community.", [["infection", "DISEASE", 50, 59], ["infection", "DISEASE", 150, 159], ["individual pathogens", "PROBLEM", 80, 100], ["computationally HTR", "PROBLEM", 122, 141], ["related infection", "PROBLEM", 142, 159], ["infection", "OBSERVATION", 150, 159]]], ["These annotations greatly facilitated the understanding of correlations between pathogen types and significant HTR similarities, as well as the underlying infection mechanisms.DiscussionOverall, the associations established in our pilot 50-pathogen HTR Community are biologically revealing.", [["infection", "DISEASE", 155, 164], ["significant HTR similarities", "PROBLEM", 99, 127], ["the underlying infection mechanisms", "PROBLEM", 140, 175], ["infection", "OBSERVATION", 155, 164]]], ["We demonstrated that the HTR landscape of pathogenic infections is complex but composed of delimited and differential patterns.", [["infections", "DISEASE", 53, 63], ["pathogenic infections", "PROBLEM", 42, 63], ["HTR", "OBSERVATION_MODIFIER", 25, 28], ["landscape", "OBSERVATION_MODIFIER", 29, 38], ["pathogenic", "OBSERVATION_MODIFIER", 42, 52], ["infections", "OBSERVATION", 53, 63]]], ["Using four cases, we illustrated that such resource and analysis provide for the first time: (1) the correspondence of pathogen taxonomy with HTR classifications, which makes external/new pathogen(s) and specific infection feature(s) identifiable upon signature querying of the reference profiles in HTR Communities (e.g., the proteobacteria and oral commensal bacteria cases); (2) the common and specific HTR community gene expression patterns, which empower the elucidation on shared and distinct molecular mechanisms of host cells in confrontation with individual pathogen types (e.g., the Streptococcus case); (3) HTR categorization and differentiation of clinically related pathogens, which generate new biological hypotheses, and inform experimental validation and host-directed anti-infection therapies (e.g., the respiratory viruses case).", [["oral", "ANATOMY", 346, 350], ["cells", "ANATOMY", 528, 533], ["infection", "DISEASE", 213, 222], ["respiratory viruses", "DISEASE", 821, 840], ["oral", "ORGANISM_SUBDIVISION", 346, 350], ["host cells", "CELL", 523, 533], ["host cells", "CELL_TYPE", 523, 533], ["HTR classifications", "PROBLEM", 142, 161], ["external/new pathogen", "PROBLEM", 175, 196], ["specific infection feature", "PROBLEM", 204, 230], ["the proteobacteria", "PROBLEM", 323, 341], ["oral commensal bacteria cases", "PROBLEM", 346, 375], ["individual pathogen types", "PROBLEM", 556, 581], ["HTR categorization", "TEST", 618, 636], ["clinically related pathogens", "PROBLEM", 660, 688], ["experimental validation", "TEST", 743, 766], ["host-directed anti-infection therapies", "TREATMENT", 771, 809], ["infection", "OBSERVATION", 213, 222], ["host cells", "OBSERVATION", 523, 533]]], ["Importantly, we employed as many query signatures of HTRs to external pathogens as possible to challenge the proposed associations, and the positive results provided strong evidence confirming the robustness of the HTR community constitution and the reliability of our findings.DiscussionNevertheless, due to limitations in pathogen type coverage, it was still challenging to accurately categorize HTRs to taxonomical class with our first-generation HTR community.", [["HTRs", "GENE_OR_GENE_PRODUCT", 53, 57], ["pathogen type coverage", "TREATMENT", 324, 346]]], ["For example, in the Streptococcus case, the internal species S. Suis was classified into HTR Community 5 rather than Community 8, where other alpha-hemolyte bacterial species reside (Fig. 3).", [["S. Suis", "SPECIES", 61, 68], ["other alpha-hemolyte bacterial species", "PROBLEM", 136, 174], ["bacterial species", "OBSERVATION", 157, 174]]], ["This dissociation is likely related to the fact that S. Suis is primarily a commensal and opportunistic swine/pig pathogen, with human infections being infrequent but grave when an outbreak does occur43.", [["opportunistic swine/pig pathogen", "DISEASE", 90, 122], ["infections", "DISEASE", 135, 145], ["S. Suis", "ORGANISM", 53, 60], ["swine", "ORGANISM", 104, 109], ["pig", "ORGANISM", 110, 113], ["human", "ORGANISM", 129, 134], ["swine", "SPECIES", 104, 109], ["pig", "SPECIES", 110, 113], ["human", "SPECIES", 129, 134], ["S. Suis", "SPECIES", 53, 60], ["swine", "SPECIES", 104, 109], ["pig", "SPECIES", 110, 113], ["human", "SPECIES", 129, 134], ["This dissociation", "PROBLEM", 0, 17], ["pig pathogen", "PROBLEM", 110, 122], ["human infections", "PROBLEM", 129, 145], ["likely related to", "UNCERTAINTY", 21, 38], ["infections", "OBSERVATION", 135, 145]]], ["Besides, the enriched GO BPs obtained for HTRs to S. Suis were divergent from those of the other four pathogens in HTR Community 5, which are DNA tumor viruses (Fig. 3).DiscussionAlso in the proteobacteria case, the internal protebacteria A. actinomycetemcomitans showed negative associations with two of the nine other proteobacteria, i.e., Helicobacter pylori and Neisseria meningitidis (Supplementary Figure S9 and Supplementary Data S7).", [["tumor", "ANATOMY", 146, 151], ["tumor", "DISEASE", 146, 151], ["Helicobacter pylori", "DISEASE", 342, 361], ["HTRs", "GENE_OR_GENE_PRODUCT", 42, 46], ["S. Suis", "ORGANISM", 50, 57], ["DNA tumor", "CANCER", 142, 151], ["protebacteria A. actinomycetemcomitans", "ORGANISM", 225, 263], ["Helicobacter pylori", "ORGANISM", 342, 361], ["Neisseria meningitidis", "ORGANISM", 366, 388], ["S. Suis", "SPECIES", 50, 57], ["A. actinomycetemcomitans", "SPECIES", 239, 263], ["Helicobacter pylori", "SPECIES", 342, 361], ["Neisseria meningitidis", "SPECIES", 366, 388], ["S. Suis", "SPECIES", 50, 57], ["A. actinomycetemcomitans", "SPECIES", 239, 263], ["Helicobacter pylori", "SPECIES", 342, 361], ["Neisseria meningitidis", "SPECIES", 366, 388], ["the enriched GO BPs", "TEST", 9, 28], ["HTRs", "PROBLEM", 42, 46], ["S. Suis", "PROBLEM", 50, 57], ["DNA tumor viruses", "PROBLEM", 142, 159], ["the internal protebacteria A. actinomycetemcomitans", "TEST", 212, 263], ["the nine other proteobacteria", "PROBLEM", 305, 334], ["Helicobacter pylori", "PROBLEM", 342, 361], ["Neisseria meningitidis", "PROBLEM", 366, 388], ["pathogens", "OBSERVATION", 102, 111], ["tumor viruses", "OBSERVATION", 146, 159], ["Helicobacter pylori", "OBSERVATION", 342, 361]]], ["Besides, it was categorized in HTR Community 8 as an oral commensal bacterium, rather than as a member of HTR Community 6 or 7, where the other examined proteobacteria were classified.", [["oral", "ANATOMY", 53, 57], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["an oral commensal bacterium", "PROBLEM", 50, 77], ["proteobacteria", "PROBLEM", 153, 167]]], ["We then found by the gene expression pattern analysis that HTR to A. actinomycetemcomitans infection was unusual among proteobacteria in that it did not include up regulated G protein coupled receptor protein signaling (Fig. 4a).", [["infection", "DISEASE", 91, 100], ["A. actinomycetemcomitans", "ORGANISM", 66, 90], ["G protein coupled receptor protein", "GENE_OR_GENE_PRODUCT", 174, 208], ["G protein coupled receptor protein", "PROTEIN", 174, 208], ["A. actinomycetemcomitans", "SPECIES", 66, 90], ["A. actinomycetemcomitans", "SPECIES", 66, 90], ["HTR", "PROBLEM", 59, 62], ["A. actinomycetemcomitans infection", "PROBLEM", 66, 100], ["proteobacteria", "PROBLEM", 119, 133]]], ["This highly indicated that for pathogen type assigned with multiple enriched attributes, combined results from gene expression pattern analysis should be used to elucidate the essential and differential characteristics of host-pathogen interaction.DiscussionAnother problem in full discovering HTR associations using the first-generation HTR Community lies in the fact that the host cell type diversity is limited, i.e., mostly blood cells, epithelial cells, and cancer cell lines.", [["cell", "ANATOMY", 383, 387], ["blood cells", "ANATOMY", 428, 439], ["epithelial cells", "ANATOMY", 441, 457], ["cancer cell lines", "ANATOMY", 463, 480], ["cancer", "DISEASE", 463, 469], ["HTR", "CANCER", 294, 297], ["cell type", "CELL", 383, 392], ["blood cells", "CELL", 428, 439], ["epithelial cells", "CELL", 441, 457], ["cancer cell lines", "CELL", 463, 480], ["blood cells", "CELL_TYPE", 428, 439], ["epithelial cells", "CELL_TYPE", 441, 457], ["cancer cell lines", "CELL_LINE", 463, 480], ["pathogen type", "PROBLEM", 31, 44], ["gene expression pattern analysis", "PROBLEM", 111, 143], ["mostly blood cells", "PROBLEM", 421, 439], ["epithelial cells", "PROBLEM", 441, 457], ["cancer cell lines", "PROBLEM", 463, 480], ["host cell", "OBSERVATION", 378, 387], ["epithelial cells", "OBSERVATION", 441, 457], ["cancer cell lines", "OBSERVATION", 463, 480]]], ["It compromises the ability of HTR community, as a resource of reference profiles, to find reliable associations with other diverse cell types (e.g., bone cells).", [["cell", "ANATOMY", 131, 135], ["bone cells", "ANATOMY", 149, 159], ["cell", "CELL", 131, 135], ["bone cells", "CELL", 149, 159], ["bone cells", "CELL_TYPE", 149, 159], ["other diverse cell types (e.g., bone cells", "PROBLEM", 117, 159], ["diverse cell types", "OBSERVATION", 123, 141], ["bone", "ANATOMY", 149, 153]]], ["This was exactly the case for querying T. denticola with internal oral commensal bacteria, in which we failed to observe positive associations for query signatures derived from calvarial bones (Fig. 7c).", [["oral", "ANATOMY", 66, 70], ["calvarial bones", "ANATOMY", 177, 192], ["T. denticola", "ORGANISM", 39, 51], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["calvarial bones", "MULTI-TISSUE_STRUCTURE", 177, 192], ["T. denticola", "SPECIES", 39, 51], ["T. denticola", "SPECIES", 39, 51], ["querying T. denticola", "PROBLEM", 30, 51], ["internal oral commensal bacteria", "PROBLEM", 57, 89], ["query signatures derived from calvarial bones", "PROBLEM", 147, 192], ["calvarial bones", "ANATOMY", 177, 192]]], ["As suggested in cMap10, this particular event reminds again that, to maximize HTR community sensitivity in signature-based discovery of functional associations, reference profiles should be collected in as many cells/tissues as possible to assure appropriate, systemic exhibition of normal and extreme physiological contexts.DiscussionIn addition, interpretation of HTR community results depends on the ability to identify associations with higher confidence, including deciphering the meaning of dual associations.", [["cells", "ANATOMY", 211, 216], ["tissues", "ANATOMY", 217, 224], ["cMap10", "GENE_OR_GENE_PRODUCT", 16, 22], ["cells", "CELL", 211, 216], ["tissues", "TISSUE", 217, 224], ["cMap10", "PROTEIN", 16, 22], ["normal", "OBSERVATION", 283, 289]]], ["In the respiratory viruses case, dual associations were observed for query signatures of hMPV and wild-type hPIV-1, raising questions about the reliability of pathogen-to-community associations.", [["hMPV", "ORGANISM", 89, 93], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 108, 114], ["hMPV", "PROBLEM", 89, 93], ["pathogen", "PROBLEM", 159, 167], ["respiratory", "ANATOMY", 7, 18], ["viruses", "OBSERVATION", 19, 26], ["hMPV", "OBSERVATION", 89, 93]]], ["However, we learned from the literature that\u2014similar to IAV\u2014hPIV and hMPV also have hemagglutinin-neuraminidase and functionally similar proteins (e.g., fusion protein F) on their surfaces that serve as antigenic and virulent markers4445.", [["IAV\u2014hPIV", "GENE_OR_GENE_PRODUCT", 56, 64], ["hMPV", "ORGANISM", 69, 73], ["hemagglutinin-neuraminidase", "GENE_OR_GENE_PRODUCT", 84, 111], ["fusion protein F", "GENE_OR_GENE_PRODUCT", 153, 169], ["hemagglutinin", "PROTEIN", 84, 97], ["neuraminidase", "PROTEIN", 98, 111], ["fusion protein F", "PROTEIN", 153, 169], ["hMPV", "SPECIES", 69, 73], ["IAV\u2014hPIV", "TREATMENT", 56, 64], ["hMPV", "PROBLEM", 69, 73], ["hemagglutinin", "TREATMENT", 84, 97], ["neuraminidase", "PROBLEM", 98, 111], ["functionally similar proteins", "PROBLEM", 116, 145], ["fusion protein F", "PROBLEM", 153, 169]]], ["Specifically, HTRs to pathogens in Community 3 showed enrichment in positive regulation of NF-kappaB signaling and immune responses, as well as negative regulation of apoptosis, whereas HTRs to pathogens in Community 6 showed enrichment in decreasing host cell mitotic activity (Fig. 4).", [["cell", "ANATOMY", 256, 260], ["HTRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 91, 100], ["HTRs", "GENE_OR_GENE_PRODUCT", 186, 190], ["host cell", "CELL", 251, 260], ["HTRs", "PROTEIN", 14, 18], ["NF-kappaB", "PROTEIN", 91, 100], ["HTRs", "PROTEIN", 186, 190], ["pathogens", "PROBLEM", 22, 31], ["apoptosis", "PROBLEM", 167, 176], ["enrichment", "PROBLEM", 226, 236], ["positive regulation", "OBSERVATION", 68, 87], ["apoptosis", "OBSERVATION", 167, 176], ["decreasing", "OBSERVATION_MODIFIER", 240, 250], ["host cell mitotic activity", "OBSERVATION", 251, 277]]], ["Consistent with these findings, NF-kappaB signaling is induced strongly by hMPV and hPIV infection464748 and decreased cell mitotic activity has been reported to occur following hPIV infection49.", [["cell", "ANATOMY", 119, 123], ["infection", "DISEASE", 89, 98], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 32, 41], ["hMPV", "ORGANISM", 75, 79], ["hPIV", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell", "CELL", 119, 123], ["NF-kappaB", "PROTEIN", 32, 41], ["hMPV", "SPECIES", 75, 79], ["hPIV", "SPECIES", 84, 88], ["hPIV", "SPECIES", 178, 182], ["hMPV", "PROBLEM", 75, 79], ["hPIV infection", "PROBLEM", 84, 98], ["decreased cell mitotic activity", "PROBLEM", 109, 140], ["hPIV infection49", "PROBLEM", 178, 194], ["hMPV", "OBSERVATION", 75, 79], ["decreased cell", "OBSERVATION", 109, 123], ["mitotic activity", "OBSERVATION", 124, 140]]], ["These findings highlight the necessity to increase the specificity of annotated HTR community enriched infection attributes and gene-expression patterns.DiscussionOn the basis of the results of this pilot study, we propose that a sensible next step would be the generation of an expanded HTR Connectivity Map to be used as a public resource.", [["infection", "DISEASE", 103, 112], ["annotated HTR community enriched infection", "PROBLEM", 70, 112], ["this pilot study", "TEST", 194, 210], ["an expanded HTR Connectivity Map", "TREATMENT", 276, 308], ["a public resource", "TREATMENT", 323, 340], ["HTR", "OBSERVATION_MODIFIER", 80, 83], ["community", "OBSERVATION_MODIFIER", 84, 93], ["enriched", "OBSERVATION_MODIFIER", 94, 102], ["infection", "OBSERVATION", 103, 112]]], ["Additional reference profiles incorporating a broader taxonomic representation of pathogens and cell-type diversity, together with in vivo data, should be incorporated into the expandable HTR Connectivity Map to improve community characterization and feature identification.", [["cell", "ANATOMY", 96, 100], ["cell", "CELL", 96, 100], ["pathogens", "PROBLEM", 82, 91], ["the expandable HTR Connectivity Map", "TREATMENT", 173, 208], ["community characterization", "TEST", 220, 246], ["feature identification", "TEST", 251, 273], ["pathogens", "OBSERVATION_MODIFIER", 82, 91]]], ["More rigorous methods for determining statistical significance should improve annotation trustworthiness and strengthen the reliability of inter-pathogen HTR associations, especially as the size of the reference profile database grows.DiscussionA larger scale HTR community resource will enable HTRs to diverse pathogens to be analyzed with higher accuracy, sensitivity, and reliability.", [["inter-pathogen HTR associations", "PROBLEM", 139, 170], ["diverse pathogens", "TREATMENT", 303, 320], ["sensitivity", "TEST", 358, 369]]], ["Moreover, researchers studying HTRs to an individual pathogenic species or a group of genetically-related or clinically-associated pathogens could compare target species signatures to reference profiles, This could lead to unexpected connections and biological hypotheses for in-depth experimental validations.", [["HTRs", "GENE_OR_GENE_PRODUCT", 31, 35], ["an individual pathogenic species", "PROBLEM", 39, 71], ["clinically-associated pathogens", "PROBLEM", 109, 140]]], ["Ultimately, the advanced HTR Connectivity Map will improve our understanding of pathogens of interest when their community affiliations are defined, and with the addition of further experimental evidence, propel discovery of molecular mechanisms mediated by multiple cell types in a coordinated response to infections, as well as the development of host-directed antimicrobials.Reference profile collection ::: MethodsResources containing expression profiles of host cellular responses to pathogenic infections were collected by manual searching and expert reviewing of dataset descriptions in the Gene Expression Omnibus database.", [["cell", "ANATOMY", 267, 271], ["cellular", "ANATOMY", 467, 475], ["infections", "DISEASE", 307, 317], ["pathogenic infections", "DISEASE", 489, 510], ["cell", "CELL", 267, 271], ["cellular", "CELL", 467, 475], ["the advanced HTR Connectivity Map", "TREATMENT", 12, 45], ["molecular mechanisms", "PROBLEM", 225, 245], ["multiple cell types", "PROBLEM", 258, 277], ["infections", "PROBLEM", 307, 317], ["host-directed antimicrobials", "TREATMENT", 349, 377], ["MethodsResources", "TREATMENT", 411, 427], ["pathogenic infections", "PROBLEM", 489, 510], ["dataset descriptions", "TEST", 570, 590], ["multiple cell types", "OBSERVATION", 258, 277], ["infections", "OBSERVATION", 307, 317], ["host cellular", "OBSERVATION_MODIFIER", 462, 475], ["pathogenic", "OBSERVATION_MODIFIER", 489, 499], ["infections", "OBSERVATION", 500, 510]]], ["To limit our analysis to genome-wide gene expression changes, the gene expression profile data were produced with only Affymetrix Human Genome U133A Array and U133 Plus 2.0 Array platforms.", [["Human", "ORGANISM", 130, 135], ["Human", "SPECIES", 130, 135], ["Human", "SPECIES", 130, 135], ["our analysis", "TEST", 9, 21], ["wide gene expression changes", "PROBLEM", 32, 60], ["the gene expression profile data", "TEST", 62, 94]]], ["Our criteria for project inclusion were threefold: (1) at least one sample of untreated specific pathogen infection with infectious disease state or in vitro infection for at least 1 h; (2) at least one control sample (e.g. uninfected, mock-infected, healthy control or other blank control); (3) data processing methodology clearly defined in series matrix file, data values in series matrix file distributed in a regular fashion (e.g., log-scale distribution for count values processed with MAS5; approximate normal distribution for log-transferred values processed with RMA), and no more than 1% of data values missing.", [["infection", "DISEASE", 106, 115], ["infectious disease", "DISEASE", 121, 139], ["infection", "DISEASE", 158, 167], ["untreated specific pathogen infection", "PROBLEM", 78, 115], ["infectious disease state", "PROBLEM", 121, 145], ["vitro infection", "PROBLEM", 152, 167], ["other blank control", "TREATMENT", 270, 289], ["data values", "TEST", 363, 374], ["count values", "TEST", 464, 476], ["MAS5", "TEST", 492, 496], ["pathogen", "OBSERVATION_MODIFIER", 97, 105], ["infection", "OBSERVATION", 106, 115], ["infectious", "OBSERVATION_MODIFIER", 121, 131], ["infection", "OBSERVATION", 158, 167]]], ["And the original data collected were provided in our lab website(http://biotech.bmi.ac.cn/papers/2015/luhan.html).Generating PRLs ::: MethodsEach pair of samples containing one infection sample and one corresponding control sample was considered an instance.", [["samples", "ANATOMY", 154, 161], ["sample", "ANATOMY", 187, 193], ["infection", "DISEASE", 177, 186], ["PRLs", "PROTEIN", 125, 129], ["the original data", "TEST", 4, 21], ["one infection sample", "PROBLEM", 173, 193], ["infection", "OBSERVATION", 177, 186]]], ["We paired infection samples and control samples in accordance with five principles:Very early infection sample measurements (<1 h) were not taken.Pathogen infection samples were paired with control samples such that experiment conditions (i.e. cell type and culture time) were identical.Samples measured before infection or at infection time 0 were treated as controls if there were no control samples measured after time 0.If the number of control samples exceeded the number of infection samples, the excess control samples were omitted.If the number of infection samples exceeded the number of control samples, the excess infection samples were omitted unless they were designated as simple repeated measurements or replications of the same experimental condition.", [["samples", "ANATOMY", 20, 27], ["samples", "ANATOMY", 40, 47], ["sample", "ANATOMY", 104, 110], ["samples", "ANATOMY", 165, 172], ["samples", "ANATOMY", 198, 205], ["cell", "ANATOMY", 244, 248], ["Samples", "ANATOMY", 287, 294], ["samples", "ANATOMY", 394, 401], ["samples", "ANATOMY", 449, 456], ["samples", "ANATOMY", 490, 497], ["samples", "ANATOMY", 518, 525], ["samples", "ANATOMY", 566, 573], ["samples", "ANATOMY", 605, 612], ["samples", "ANATOMY", 635, 642], ["infection", "DISEASE", 10, 19], ["infection", "DISEASE", 94, 103], ["Pathogen infection", "DISEASE", 146, 164], ["infection", "DISEASE", 311, 320], ["infection", "DISEASE", 327, 336], ["infection", "DISEASE", 480, 489], ["infection", "DISEASE", 556, 565], ["infection", "DISEASE", 625, 634], ["cell", "CELL", 244, 248], ["samples", "CANCER", 449, 456], ["samples", "CANCER", 566, 573], ["paired infection samples", "PROBLEM", 3, 27], ["Very early infection", "PROBLEM", 83, 103], ["Pathogen infection samples", "PROBLEM", 146, 172], ["experiment conditions", "PROBLEM", 216, 237], ["cell type", "TEST", 244, 253], ["culture time", "TEST", 258, 270], ["Samples", "TEST", 287, 294], ["infection", "PROBLEM", 311, 320], ["control samples", "PROBLEM", 386, 401], ["infection samples", "PROBLEM", 480, 497], ["the excess control samples", "PROBLEM", 499, 525], ["infection samples", "PROBLEM", 556, 573], ["the excess infection samples", "PROBLEM", 614, 642], ["simple repeated measurements", "TEST", 687, 715], ["infection", "OBSERVATION", 10, 19], ["early", "OBSERVATION_MODIFIER", 88, 93], ["infection", "OBSERVATION", 94, 103], ["infection", "OBSERVATION", 155, 164], ["infection", "OBSERVATION", 311, 320], ["infection", "OBSERVATION", 556, 565]]], ["In such cases, the excess infection samples were paired with used control samples in a revolving fashion.", [["samples", "ANATOMY", 36, 43], ["infection", "DISEASE", 26, 35], ["the excess infection samples", "PROBLEM", 15, 43], ["infection", "OBSERVATION", 26, 35]]], ["For example, if there were two control samples c1 and c2 and five infection samples i1 to i5, then i1, i3, and i5 would be paired with c1, while i2 and i4 were paired with c2.Generating PRLs ::: MethodsThe intersection of probes for each dataset was generated to obtain the final probes shared by all datasets.", [["infection", "DISEASE", 66, 75], ["i2", "GENE_OR_GENE_PRODUCT", 145, 147], ["c1", "DNA", 47, 49], ["i5", "DNA", 90, 92], ["i3", "DNA", 103, 105], ["i5", "DNA", 111, 113], ["c1", "DNA", 135, 137], ["i2", "DNA", 145, 147], ["i4", "DNA", 152, 154], ["c2", "DNA", 172, 174], ["PRLs", "PROTEIN", 186, 190], ["two control samples c1 and c2 and five infection samples", "PROBLEM", 27, 83], ["Methods", "TREATMENT", 195, 202], ["c2", "ANATOMY", 54, 56], ["infection", "OBSERVATION", 66, 75]]], ["Sample data values from series matrix files were transformed into count values if they had been log transformed.", [["Sample data values", "TEST", 0, 18], ["series matrix files", "TEST", 24, 43], ["count values", "TEST", 66, 78]]], ["The probes were ranked according to the expression change produced by comparing corresponding infection and control samples.", [["samples", "ANATOMY", 116, 123], ["infection", "DISEASE", 94, 103], ["The probes", "TREATMENT", 0, 10], ["corresponding infection and control samples", "PROBLEM", 80, 123], ["infection", "OBSERVATION", 94, 103]]], ["First, sub threshold instance values were set to a threshold value.", [["a threshold value", "TEST", 49, 66]]], ["Next, probe sets were ranked in descending order of the corresponding perturbation-to-control value ratios.", [["probe sets", "TREATMENT", 6, 16]]], ["Finally, the probe sets were subsorted in descending order of the new ratio calculated.", [["the probe sets", "TEST", 9, 23], ["descending", "ANATOMY_MODIFIER", 42, 52]]], ["The sorted probe lists constituted PRLs and represented regulation level that considered both fold-changes in expression and expression values.", [["PRLs", "GENE_OR_GENE_PRODUCT", 35, 39], ["PRLs", "DNA", 35, 39], ["expression values", "TEST", 125, 142]]], ["The probes with the most up- (or down-) regulated genes had top (or bottom) PRL rankings.", [["PRL", "GENE_OR_GENE_PRODUCT", 76, 79], ["regulated genes", "DNA", 40, 55], ["PRL", "PROTEIN", 76, 79], ["The probes", "TREATMENT", 0, 10]]], ["A total of 893 PRLs, denoting infection by 50 pathogens across different cell lines and from different laboratories, were obtained.Merging PRLs for an individual pathogen ::: MethodsSpearman\u2019s Foot rule was used to measure inter-PRL distances.", [["PRLs", "ANATOMY", 15, 19], ["cell lines", "ANATOMY", 73, 83], ["infection", "DISEASE", 30, 39], ["PRLs", "CANCER", 15, 19], ["cell lines", "CELL", 73, 83], ["PRLs", "GENE_OR_GENE_PRODUCT", 139, 143], ["PRL", "GENE_OR_GENE_PRODUCT", 229, 232], ["cell lines", "CELL_LINE", 73, 83], ["PRLs", "PROTEIN", 139, 143], ["PRL", "PROTEIN", 229, 232], ["denoting infection", "PROBLEM", 21, 39], ["infection", "OBSERVATION", 30, 39], ["cell lines", "OBSERVATION", 73, 83], ["Foot", "ANATOMY", 193, 197]]], ["For given PRLs A and B, the ranking of probe identifiers P1, P2, P3,\u2026, Pm (m = 22, 160 in our study) in PRL A and B are represented by A1, A2, A3,\u2026, Am and B1, B2, B3,\u2026, Bm, respectively.", [["PRL A", "GENE_OR_GENE_PRODUCT", 104, 109], ["B", "GENE_OR_GENE_PRODUCT", 114, 115], ["A1", "GENE_OR_GENE_PRODUCT", 135, 137], ["A2", "GENE_OR_GENE_PRODUCT", 139, 141], ["B3", "ORGANISM", 164, 166], ["PRLs", "PROTEIN", 10, 14], ["P1", "DNA", 57, 59], ["P2", "DNA", 61, 63], ["P3", "DNA", 65, 67], ["Pm", "DNA", 71, 73], ["PRL A", "DNA", 104, 109], ["A1", "DNA", 135, 137], ["A2", "DNA", 139, 141], ["A3", "DNA", 143, 145], ["Am", "DNA", 149, 151], ["B1", "DNA", 156, 158], ["B2", "DNA", 160, 162], ["B3", "DNA", 164, 166], ["\u2026", "DNA", 167, 168], ["Bm", "DNA", 170, 172], ["P2", "TEST", 61, 63], ["P3", "TEST", 65, 67], ["our study", "TEST", 90, 99], ["A2", "TEST", 139, 141], ["A3", "TEST", 143, 145], ["\u2026", "TEST", 146, 147], ["B1", "TEST", 156, 158], ["B2", "TEST", 160, 162], ["A1", "ANATOMY_MODIFIER", 135, 137], ["A2", "ANATOMY", 139, 141], ["A3", "ANATOMY_MODIFIER", 143, 145], ["B1", "ANATOMY", 156, 158], ["B2", "ANATOMY_MODIFIER", 160, 162], ["B3", "ANATOMY_MODIFIER", 164, 166], ["Bm", "ANATOMY", 170, 172]]], ["Spearman\u2019s Foot rule correlations between PRL A and B were computed with the following formula:Merging PRLs for an individual pathogen ::: Methods", [["PRL A", "GENE_OR_GENE_PRODUCT", 42, 47], ["B", "GENE_OR_GENE_PRODUCT", 52, 53], ["PRL", "PROTEIN", 42, 45], ["Methods", "TREATMENT", 139, 146], ["Foot", "ANATOMY", 11, 15]]]], "PMC7391019": [["Plain Language SummaryThis ecological analysis examined the correlations between number of dialysis stations, a proxy of end-stage renal disease (ESRD) prevalence, race, poverty, and number of positive tests for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within a ZIP code in the greater Chicagoland area.", [["renal", "ANATOMY", 131, 136], ["end-stage renal disease", "DISEASE", 121, 144], ["ESRD", "DISEASE", 146, 150], ["acute respiratory syndrome coronavirus", "DISEASE", 229, 267], ["renal", "ORGAN", 131, 136], ["severe acute respiratory syndrome coronavirus", "SPECIES", 222, 267], ["SARS-CoV-2", "SPECIES", 271, 281], ["This ecological analysis", "TEST", 22, 46], ["dialysis stations", "TREATMENT", 91, 108], ["end-stage renal disease", "PROBLEM", 121, 144], ["positive tests", "PROBLEM", 193, 207], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 212, 267], ["SARS-CoV", "TEST", 271, 279], ["a ZIP code", "TREATMENT", 290, 300], ["stage", "OBSERVATION_MODIFIER", 125, 130], ["renal", "ANATOMY", 131, 136], ["disease", "OBSERVATION", 137, 144], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["acute", "OBSERVATION_MODIFIER", 229, 234], ["respiratory syndrome", "OBSERVATION", 235, 255], ["greater", "OBSERVATION_MODIFIER", 308, 315]]], ["Data on SARS-CoV-2 testing was obtained from the Illinois Department of Health and demographic information at the ZIP code level was obtained from the U.S. Census Bureau.", [["SARS-CoV", "SPECIES", 8, 16], ["SARS", "TEST", 8, 12], ["CoV-2 testing", "TEST", 13, 26]]], ["SARS-CoV-2 positive tests per capita correlated significantly with number of dialysis stations, with percentage of households living in poverty, and with percentage of residents reporting Black race and Hispanic ethnicity within a ZIP Code.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS", "TEST", 0, 4]]], ["These findings highlight the SARS-CoV-2 exposure risk that persons living in poor urban areas face, including those with ESRD.IntroductionThe coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and can lead to severe acute respiratory distress requiring hospitalization and even death.", [["respiratory", "ANATOMY", 290, 301], ["ESRD", "DISEASE", 121, 125], ["coronavirus disease", "DISEASE", 142, 161], ["COVID-19", "CHEMICAL", 168, 176], ["acute respiratory syndrome coronavirus", "DISEASE", 206, 244], ["respiratory distress", "DISEASE", 290, 310], ["death", "DISEASE", 346, 351], ["persons", "ORGANISM", 59, 66], ["coronavirus", "ORGANISM", 142, 153], ["COVID-19", "ORGANISM", 168, 176], ["SARS-CoV-2", "ORGANISM", 248, 258], ["persons", "SPECIES", 59, 66], ["coronavirus disease 2019 (COVID-19", "SPECIES", 142, 176], ["severe acute respiratory syndrome coronavirus", "SPECIES", 199, 244], ["SARS-CoV-2", "SPECIES", 248, 258], ["the SARS", "PROBLEM", 25, 33], ["ESRD", "PROBLEM", 121, 125], ["The coronavirus disease", "PROBLEM", 138, 161], ["COVID", "TEST", 168, 173], ["a novel severe acute respiratory syndrome coronavirus", "PROBLEM", 191, 244], ["SARS-CoV", "TEST", 248, 256], ["severe acute respiratory distress", "PROBLEM", 277, 310], ["coronavirus disease", "OBSERVATION", 142, 161], ["severe", "OBSERVATION_MODIFIER", 199, 205], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["respiratory syndrome", "OBSERVATION", 212, 232], ["severe", "OBSERVATION_MODIFIER", 277, 283], ["acute", "OBSERVATION_MODIFIER", 284, 289], ["respiratory distress", "OBSERVATION", 290, 310]]], ["On January 21st, the first case of COVID-19 was identified in Washington State followed just three days later by a COVID-19 diagnosis in a woman returning to Chicago, Illinois directly from Wuhan.", [["woman", "ORGANISM", 139, 144], ["COVID-19", "DNA", 35, 43], ["woman", "SPECIES", 139, 144], ["COVID", "TEST", 35, 40]]], ["On January 30, the husband of this second U.S. case also developed COVID-19 and was identified as the first U.S. case of person to person transmission of SARS-CoV-2.1,2 Illinois currently has one of the highest reported rates of COVID-19 cases within the U.S. despite having high testing rates.", [["SARS", "DISEASE", 154, 158], ["SARS-CoV", "ORGANISM", 154, 162], ["person", "SPECIES", 121, 127], ["person", "SPECIES", 131, 137], ["SARS-CoV", "SPECIES", 154, 162], ["COVID", "TEST", 229, 234], ["high testing rates", "TEST", 275, 293]]], ["As of June 15, 2020, 1,228,341 tests have been completed in Illinois; 133,639 positive cases and 6398 deaths.1", [["deaths", "DISEASE", 102, 108], ["tests", "TEST", 31, 36]]]], "e2cef67ca136f4b301736031caac1aa1085abcb6": [["IntroductionCanine malignancy rates are similar to those of humans, however, canine cancer patients can have limited therapeutic options due to financial access or safety barriers.", [["cancer", "ANATOMY", 84, 90], ["malignancy", "DISEASE", 19, 29], ["canine cancer", "DISEASE", 77, 90], ["Canine", "ORGANISM", 12, 18], ["humans", "ORGANISM", 60, 66], ["canine", "ORGANISM", 77, 83], ["cancer", "CANCER", 84, 90], ["patients", "ORGANISM", 91, 99], ["humans", "SPECIES", 60, 66], ["canine", "SPECIES", 77, 83], ["patients", "SPECIES", 91, 99], ["humans", "SPECIES", 60, 66], ["canine", "SPECIES", 77, 83], ["IntroductionCanine malignancy rates", "PROBLEM", 0, 35], ["financial access", "TREATMENT", 144, 160], ["safety barriers", "TREATMENT", 164, 179], ["malignancy", "OBSERVATION", 19, 29], ["cancer", "OBSERVATION", 84, 90]]], ["Cancer immunotherapy is a rapidly growing area of human oncology [1] , which may also have benefits for canine cancer patients.", [["Cancer", "ANATOMY", 0, 6], ["cancer", "ANATOMY", 111, 117], ["Cancer", "DISEASE", 0, 6], ["canine cancer", "DISEASE", 104, 117], ["Cancer", "CANCER", 0, 6], ["human", "ORGANISM", 50, 55], ["canine", "ORGANISM", 104, 110], ["cancer", "CANCER", 111, 117], ["patients", "ORGANISM", 118, 126], ["human", "SPECIES", 50, 55], ["canine", "SPECIES", 104, 110], ["patients", "SPECIES", 118, 126], ["human", "SPECIES", 50, 55], ["canine", "SPECIES", 104, 110], ["Cancer immunotherapy", "TREATMENT", 0, 20], ["canine cancer", "PROBLEM", 104, 117], ["cancer", "OBSERVATION", 111, 117]]], ["Furthermore, recent One Health initiatives have highlighted the use of pet dogs with spontaneous cancer as translational models for the development of human cancer therapies [2] [3] [4] .", [["cancer", "ANATOMY", 97, 103], ["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 97, 103], ["cancer", "DISEASE", 157, 163], ["dogs", "ORGANISM", 75, 79], ["cancer", "CANCER", 97, 103], ["human", "ORGANISM", 151, 156], ["cancer", "CANCER", 157, 163], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 174, 185], ["dogs", "SPECIES", 75, 79], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["pet dogs", "TREATMENT", 71, 79], ["spontaneous cancer", "PROBLEM", 85, 103], ["translational models", "TREATMENT", 107, 127], ["human cancer therapies", "TREATMENT", 151, 173], ["cancer", "OBSERVATION", 97, 103], ["cancer", "OBSERVATION", 157, 163]]], ["While rodent models provide a rapid and relatively inexpensive approach to studying cancer progression and new therapies, they have significant limitations [2, 4] .", [["cancer", "ANATOMY", 84, 90], ["cancer", "DISEASE", 84, 90], ["cancer", "CANCER", 84, 90], ["cancer progression", "PROBLEM", 84, 102], ["new therapies", "TREATMENT", 107, 120]]], ["Rodent oncology models are typically induced with the potential to create significant divergence in the immune profile of the tumor microenvironment from the spontaneous cancers seen in dogs and humans.", [["tumor", "ANATOMY", 126, 131], ["cancers", "ANATOMY", 170, 177], ["tumor", "DISEASE", 126, 131], ["cancers", "DISEASE", 170, 177], ["tumor", "CANCER", 126, 131], ["cancers", "CANCER", 170, 177], ["dogs", "ORGANISM", 186, 190], ["humans", "ORGANISM", 195, 201], ["dogs", "SPECIES", 186, 190], ["humans", "SPECIES", 195, 201], ["humans", "SPECIES", 195, 201], ["significant divergence", "PROBLEM", 74, 96], ["the tumor microenvironment", "PROBLEM", 122, 148], ["the spontaneous cancers", "PROBLEM", 154, 177], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["divergence", "OBSERVATION", 86, 96], ["tumor", "OBSERVATION", 126, 131], ["spontaneous", "OBSERVATION_MODIFIER", 158, 169], ["cancers", "OBSERVATION", 170, 177]]], ["Further, human and canine cancers are polygenic, but rodent models are usually driven by select causal genetic mutations [2] .", [["canine cancers", "ANATOMY", 19, 33], ["canine cancers", "DISEASE", 19, 33], ["human", "ORGANISM", 9, 14], ["canine cancers", "CANCER", 19, 33], ["human", "SPECIES", 9, 14], ["canine", "SPECIES", 19, 25], ["human", "SPECIES", 9, 14], ["canine", "SPECIES", 19, 25], ["human and canine cancers", "PROBLEM", 9, 33], ["polygenic", "PROBLEM", 38, 47], ["cancers", "OBSERVATION", 26, 33]]], ["Using canine patients for testing of potential immunotherapies has other key advantages such as accessibility, shared environmental exposure of humans, phenotypic diversity, similar patient size and closer genetic similarity to humans [5] .", [["canine", "ORGANISM", 6, 12], ["patients", "ORGANISM", 13, 21], ["humans", "ORGANISM", 144, 150], ["patient", "ORGANISM", 182, 189], ["humans", "ORGANISM", 228, 234], ["canine", "SPECIES", 6, 12], ["patients", "SPECIES", 13, 21], ["humans", "SPECIES", 144, 150], ["patient", "SPECIES", 182, 189], ["humans", "SPECIES", 228, 234], ["canine", "SPECIES", 6, 12], ["humans", "SPECIES", 144, 150], ["humans", "SPECIES", 228, 234], ["testing", "TEST", 26, 33], ["potential immunotherapies", "TREATMENT", 37, 62], ["phenotypic diversity", "PROBLEM", 152, 172], ["size", "OBSERVATION_MODIFIER", 190, 194]]], ["Spontaneous canine cancers reflect the phenotypic and genetic diversity of the approximately 400 breeds, thereby having similarities to an outbred human population [6] .", [["canine cancers", "ANATOMY", 12, 26], ["canine cancers", "DISEASE", 12, 26], ["canine cancers", "CANCER", 12, 26], ["human", "ORGANISM", 147, 152], ["canine", "SPECIES", 12, 18], ["human", "SPECIES", 147, 152], ["canine", "SPECIES", 12, 18], ["human", "SPECIES", 147, 152], ["Spontaneous canine cancers", "PROBLEM", 0, 26], ["canine", "OBSERVATION_MODIFIER", 12, 18], ["cancers", "OBSERVATION", 19, 26]]], ["The strong breed association of certain cancers makes diagnosis and prediction of the clinical course of canine cancer easier in these cases, with extensive published data on expected survival times relative to the grading and staging of various cancers [7] Like humans, dogs tend to develop cancer from middle age, with the majority of dogs presenting at >6 years of age, equivalent of 60-95 human years, which is when most malignancies present in humans [8] .", [["cancers", "ANATOMY", 40, 47], ["canine cancer", "ANATOMY", 105, 118], ["cancers", "ANATOMY", 246, 253], ["cancer", "ANATOMY", 292, 298], ["malignancies", "ANATOMY", 425, 437], ["cancers", "DISEASE", 40, 47], ["canine cancer", "DISEASE", 105, 118], ["cancers", "DISEASE", 246, 253], ["cancer", "DISEASE", 292, 298], ["malignancies", "DISEASE", 425, 437], ["cancers", "CANCER", 40, 47], ["canine cancer", "CANCER", 105, 118], ["cancers", "CANCER", 246, 253], ["humans", "ORGANISM", 263, 269], ["dogs", "ORGANISM", 271, 275], ["cancer", "CANCER", 292, 298], ["dogs", "ORGANISM", 337, 341], ["human", "ORGANISM", 393, 398], ["malignancies", "CANCER", 425, 437], ["humans", "ORGANISM", 449, 455], ["humans", "SPECIES", 263, 269], ["dogs", "SPECIES", 271, 275], ["dogs", "SPECIES", 337, 341], ["human", "SPECIES", 393, 398], ["humans", "SPECIES", 449, 455], ["canine", "SPECIES", 105, 111], ["humans", "SPECIES", 263, 269], ["human", "SPECIES", 393, 398], ["humans", "SPECIES", 449, 455], ["certain cancers", "PROBLEM", 32, 47], ["canine cancer", "PROBLEM", 105, 118], ["the grading", "TEST", 211, 222], ["various cancers", "PROBLEM", 238, 253], ["cancers", "OBSERVATION", 40, 47], ["cancer", "OBSERVATION", 112, 118], ["cancers", "OBSERVATION", 246, 253], ["cancer", "OBSERVATION", 292, 298]]], ["Further, greater than 50% of dogs over 10 years of age will develop cancer [2] .", [["cancer", "ANATOMY", 68, 74], ["cancer", "DISEASE", 68, 74], ["dogs", "ORGANISM", 29, 33], ["cancer", "CANCER", 68, 74], ["dogs", "SPECIES", 29, 33], ["cancer", "PROBLEM", 68, 74], ["cancer", "OBSERVATION", 68, 74]]], ["Therefore, with large populations in developed countries, pet dogs represent a substantial translational resource for cancer therapy development [2] .", [["cancer", "ANATOMY", 118, 124], ["cancer", "DISEASE", 118, 124], ["pet dogs", "ORGANISM", 58, 66], ["cancer", "CANCER", 118, 124], ["dogs", "SPECIES", 62, 66], ["pet dogs", "TREATMENT", 58, 66], ["a substantial translational resource", "TREATMENT", 77, 113], ["cancer therapy development", "TREATMENT", 118, 144], ["large", "OBSERVATION_MODIFIER", 16, 21], ["populations", "OBSERVATION_MODIFIER", 22, 33]]], ["Differences lie in canine patients generally presenting with more advanced disease than human cancers, and minimal current access to antibody-based immunotherapies due to species differences.", [["cancers", "ANATOMY", 94, 101], ["cancers", "DISEASE", 94, 101], ["canine", "ORGANISM", 19, 25], ["patients", "ORGANISM", 26, 34], ["human", "ORGANISM", 88, 93], ["cancers", "CANCER", 94, 101], ["canine", "SPECIES", 19, 25], ["patients", "SPECIES", 26, 34], ["human", "SPECIES", 88, 93], ["canine", "SPECIES", 19, 25], ["human", "SPECIES", 88, 93], ["more advanced disease", "PROBLEM", 61, 82], ["human cancers", "PROBLEM", 88, 101], ["antibody-based immunotherapies", "TREATMENT", 133, 163], ["species differences", "PROBLEM", 171, 190], ["cancers", "OBSERVATION", 94, 101]]], ["Depending on the owner's wishes and budget, treatment options include palliation, surgery, chemotherapy, radiotherapy or a combination.", [["treatment options", "TREATMENT", 44, 61], ["palliation", "TREATMENT", 70, 80], ["surgery", "TREATMENT", 82, 89], ["chemotherapy", "TREATMENT", 91, 103], ["radiotherapy", "TREATMENT", 105, 117]]], ["Overall, canine patients tend not to be treated as aggressively or consistently as humans, and euthanasia of patients is used extensively in veterinary medicine, leading to shorter survival times.", [["canine", "ORGANISM", 9, 15], ["patients", "ORGANISM", 16, 24], ["humans", "ORGANISM", 83, 89], ["patients", "ORGANISM", 109, 117], ["canine", "SPECIES", 9, 15], ["patients", "SPECIES", 16, 24], ["humans", "SPECIES", 83, 89], ["patients", "SPECIES", 109, 117], ["canine", "SPECIES", 9, 15], ["humans", "SPECIES", 83, 89]]], ["As canine cancer progression tends to be more rapid than in people, this can lead to significantly shorter duration of canine cancer trials.", [["canine cancer", "ANATOMY", 3, 16], ["cancer", "ANATOMY", 126, 132], ["canine cancer", "DISEASE", 3, 16], ["cancer", "DISEASE", 126, 132], ["canine cancer", "CANCER", 3, 16], ["people", "ORGANISM", 60, 66], ["canine", "ORGANISM", 119, 125], ["cancer", "CANCER", 126, 132], ["people", "SPECIES", 60, 66], ["canine", "SPECIES", 3, 9], ["canine", "SPECIES", 119, 125], ["canine cancer progression", "PROBLEM", 3, 28], ["canine cancer trials", "TREATMENT", 119, 139], ["cancer", "OBSERVATION", 10, 16], ["cancer", "OBSERVATION", 126, 132]]], ["This combined with the strong parallels between humans and dog cancers is a major advantage as it allows for new cancer therapies to be assessed rapidly in dogs and then translated to the clinic for the benefit of both humans and dogs.", [["cancers", "ANATOMY", 63, 70], ["cancer", "ANATOMY", 113, 119], ["dog cancers", "DISEASE", 59, 70], ["cancer", "DISEASE", 113, 119], ["humans", "ORGANISM", 48, 54], ["dog", "ORGANISM", 59, 62], ["cancers", "CANCER", 63, 70], ["cancer", "CANCER", 113, 119], ["dogs", "ORGANISM", 156, 160], ["humans", "ORGANISM", 219, 225], ["dogs", "ORGANISM", 230, 234], ["humans", "SPECIES", 48, 54], ["dog", "SPECIES", 59, 62], ["dogs", "SPECIES", 156, 160], ["humans", "SPECIES", 219, 225], ["dogs", "SPECIES", 230, 234], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 219, 225], ["dog cancers", "PROBLEM", 59, 70], ["new cancer therapies", "TREATMENT", 109, 129], ["cancer", "OBSERVATION", 113, 119]]], ["Stimulating a patient's own immune system to target and attack the neoplastic cells has become a new weapon in the fight against cancer, as with humans, canine cancers contain a unique set of mutated tumor proteins enabling a patient's own cancer-derived proteins to be used to produce a vaccine [9] .", [["neoplastic cells", "ANATOMY", 67, 83], ["cancer", "ANATOMY", 129, 135], ["cancers", "ANATOMY", 160, 167], ["tumor", "ANATOMY", 200, 205], ["cancer", "ANATOMY", 240, 246], ["cancer", "DISEASE", 129, 135], ["canine cancers", "DISEASE", 153, 167], ["tumor", "DISEASE", 200, 205], ["cancer", "DISEASE", 240, 246], ["patient", "ORGANISM", 14, 21], ["neoplastic cells", "CELL", 67, 83], ["cancer", "CANCER", 129, 135], ["humans", "ORGANISM", 145, 151], ["canine cancers", "CANCER", 153, 167], ["tumor", "CANCER", 200, 205], ["patient", "ORGANISM", 226, 233], ["cancer", "CANCER", 240, 246], ["neoplastic cells", "CELL_TYPE", 67, 83], ["mutated tumor proteins", "PROTEIN", 192, 214], ["patient", "SPECIES", 14, 21], ["humans", "SPECIES", 145, 151], ["canine", "SPECIES", 153, 159], ["patient", "SPECIES", 226, 233], ["humans", "SPECIES", 145, 151], ["canine", "SPECIES", 153, 159], ["the neoplastic cells", "PROBLEM", 63, 83], ["cancer", "PROBLEM", 129, 135], ["canine cancers", "PROBLEM", 153, 167], ["mutated tumor proteins", "PROBLEM", 192, 214], ["a patient's own cancer", "PROBLEM", 224, 246], ["a vaccine", "TREATMENT", 286, 295], ["neoplastic cells", "OBSERVATION", 67, 83], ["new", "OBSERVATION_MODIFIER", 97, 100], ["cancer", "OBSERVATION", 129, 135], ["tumor", "OBSERVATION", 200, 205]]], ["The advantage of an autologous vaccine is that MHC molecules as well as tumor-associated antigens are patient specific [10] .", [["tumor", "ANATOMY", 72, 77], ["tumor", "DISEASE", 72, 77], ["tumor", "CANCER", 72, 77], ["patient", "ORGANISM", 102, 109], ["MHC molecules", "PROTEIN", 47, 60], ["tumor-associated antigens", "PROTEIN", 72, 97], ["patient", "SPECIES", 102, 109], ["an autologous vaccine", "TREATMENT", 17, 38], ["MHC molecules", "PROBLEM", 47, 60], ["tumor", "PROBLEM", 72, 77]]], ["However, depending on the cancer type, tumor-specific antigens may have a low level of immunogenicity, or the tumor may have a low percentage of unique mutated proteins [11] .", [["cancer", "ANATOMY", 26, 32], ["tumor", "ANATOMY", 39, 44], ["tumor", "ANATOMY", 110, 115], ["cancer", "DISEASE", 26, 32], ["tumor", "DISEASE", 39, 44], ["tumor", "DISEASE", 110, 115], ["cancer", "CANCER", 26, 32], ["tumor", "CANCER", 39, 44], ["tumor", "CANCER", 110, 115], ["tumor-specific antigens", "PROTEIN", 39, 62], ["mutated proteins", "PROTEIN", 152, 168], ["the cancer type", "PROBLEM", 22, 37], ["tumor", "PROBLEM", 39, 44], ["a low level of immunogenicity", "PROBLEM", 72, 101], ["the tumor", "PROBLEM", 106, 115], ["cancer", "OBSERVATION", 26, 32], ["tumor", "OBSERVATION", 39, 44], ["low level", "OBSERVATION_MODIFIER", 74, 83], ["tumor", "OBSERVATION", 110, 115], ["low percentage", "OBSERVATION_MODIFIER", 127, 141]]], ["Bacterial products can be used to increase the level of immunogenicity to tumor antigens, for example, immune stimulants such as Bacillus Calmette-Guerin (BCG) have been used with irradiated autologous tumor cells in bladder cancer and other tumor types [12, 13] .IntroductionSeveral autologous cancer vaccines that showed promise in early phase studies have failed to deliver survival benefits for patients with advanced disease, showing benefits only for early stage disease [14, 15] .", [["tumor", "ANATOMY", 74, 79], ["tumor cells", "ANATOMY", 202, 213], ["bladder cancer", "ANATOMY", 217, 231], ["tumor", "ANATOMY", 242, 247], ["cancer", "ANATOMY", 295, 301], ["tumor", "DISEASE", 74, 79], ["Bacillus Calmette-Guerin", "CHEMICAL", 129, 153], ["tumor", "DISEASE", 202, 207], ["bladder cancer", "DISEASE", 217, 231], ["tumor", "DISEASE", 242, 247], ["cancer", "DISEASE", 295, 301], ["tumor", "CANCER", 74, 79], ["Bacillus Calmette-Guerin", "ORGANISM", 129, 153], ["BCG", "ORGANISM", 155, 158], ["tumor cells", "CELL", 202, 213], ["bladder cancer", "CANCER", 217, 231], ["tumor", "CANCER", 242, 247], ["cancer", "CANCER", 295, 301], ["patients", "ORGANISM", 399, 407], ["tumor antigens", "PROTEIN", 74, 88], ["irradiated autologous tumor cells", "CELL_TYPE", 180, 213], ["Bacillus Calmette", "SPECIES", 129, 146], ["patients", "SPECIES", 399, 407], ["Bacillus Calmette-Guerin", "SPECIES", 129, 153], ["Bacterial products", "TREATMENT", 0, 18], ["tumor antigens", "PROBLEM", 74, 88], ["immune stimulants", "TREATMENT", 103, 120], ["Bacillus Calmette", "TREATMENT", 129, 146], ["Guerin (BCG", "TREATMENT", 147, 158], ["irradiated autologous tumor cells", "TREATMENT", 180, 213], ["bladder cancer", "PROBLEM", 217, 231], ["other tumor types", "PROBLEM", 236, 253], ["Several autologous cancer vaccines", "TREATMENT", 276, 310], ["early phase studies", "TEST", 334, 353], ["advanced disease", "PROBLEM", 413, 429], ["early stage disease", "PROBLEM", 457, 476], ["tumor cells", "OBSERVATION", 202, 213], ["bladder", "ANATOMY", 217, 224], ["cancer", "OBSERVATION", 225, 231], ["tumor", "OBSERVATION", 242, 247], ["autologous cancer", "OBSERVATION", 284, 301]]], ["With the advent of immune checkpoint inhibitors (CPI) which overcome tumor immune suppression in certain cancer types [16] , the concept of combining CPI with autologous tumor vaccines to improve efficacy is now being explored using a variety of vaccine preparations [17, 18] .", [["tumor", "ANATOMY", 69, 74], ["cancer", "ANATOMY", 105, 111], ["tumor", "ANATOMY", 170, 175], ["tumor", "DISEASE", 69, 74], ["cancer", "DISEASE", 105, 111], ["tumor", "DISEASE", 170, 175], ["tumor", "CANCER", 69, 74], ["cancer", "CANCER", 105, 111], ["tumor", "CANCER", 170, 175], ["immune checkpoint inhibitors", "TREATMENT", 19, 47], ["CPI)", "TREATMENT", 49, 53], ["tumor immune suppression", "PROBLEM", 69, 93], ["combining CPI", "TREATMENT", 140, 153], ["autologous tumor vaccines", "TREATMENT", 159, 184], ["a variety of vaccine preparations", "TREATMENT", 233, 266], ["tumor", "OBSERVATION", 170, 175]]], ["One downside to the use of bacterial immune stimulants such as BCG or Freund's adjuvant in cancer therapy is their inflammation-associated side effects, with inflammation in turn upregulating immune checkpoint receptors such as PD-1 on T cells, resulting in immune suppression [19] .", [["cancer", "ANATOMY", 91, 97], ["T cells", "ANATOMY", 236, 243], ["cancer", "DISEASE", 91, 97], ["inflammation", "DISEASE", 115, 127], ["inflammation", "DISEASE", 158, 170], ["BCG", "SIMPLE_CHEMICAL", 63, 66], ["Freund", "ORGANISM", 70, 76], ["cancer", "CANCER", 91, 97], ["PD-1", "GENE_OR_GENE_PRODUCT", 228, 232], ["T cells", "CELL", 236, 243], ["immune checkpoint receptors", "PROTEIN", 192, 219], ["PD-1", "PROTEIN", 228, 232], ["T cells", "CELL_TYPE", 236, 243], ["bacterial immune stimulants", "TREATMENT", 27, 54], ["BCG", "TREATMENT", 63, 66], ["Freund's adjuvant", "TREATMENT", 70, 87], ["cancer therapy", "TREATMENT", 91, 105], ["their inflammation", "PROBLEM", 109, 127], ["side effects", "PROBLEM", 139, 151], ["inflammation", "PROBLEM", 158, 170], ["upregulating immune checkpoint receptors", "TREATMENT", 179, 219], ["PD", "TEST", 228, 230], ["T cells", "PROBLEM", 236, 243], ["immune suppression", "PROBLEM", 258, 276], ["side effects", "OBSERVATION_MODIFIER", 139, 151], ["inflammation", "OBSERVATION", 158, 170], ["immune suppression", "OBSERVATION", 258, 276]]], ["Hence, we hypothesized that the use of a non-inflammatory adjuvant may provide an enhanced safety profile but also avoid induction of regulatory T cells that suppress anti-tumor responses.", [["regulatory T cells", "ANATOMY", 134, 152], ["anti-tumor", "ANATOMY", 167, 177], ["T cells", "CELL", 145, 152], ["anti-tumor", "CANCER", 167, 177], ["regulatory T cells", "CELL_TYPE", 134, 152], ["a non-inflammatory adjuvant", "TREATMENT", 39, 66], ["regulatory T cells", "TREATMENT", 134, 152]]], ["Advax\u2122 is a unique non-inflammatory adjuvant produced from delta isoform of inulin, a natural plant polysaccharide.", [["Advax\u2122", "CHEMICAL", 0, 6], ["inulin", "CHEMICAL", 76, 82], ["Advax\u2122", "SIMPLE_CHEMICAL", 0, 6], ["inulin", "SIMPLE_CHEMICAL", 76, 82], ["delta isoform", "PROTEIN", 59, 72], ["Advax\u2122", "TREATMENT", 0, 6], ["a unique non-inflammatory adjuvant", "TREATMENT", 10, 44], ["delta isoform of inulin", "TREATMENT", 59, 82], ["a natural plant polysaccharide", "TREATMENT", 84, 114], ["polysaccharide", "OBSERVATION_MODIFIER", 100, 114]]], ["Delta inulin adjuvants have been shown to induce balanced immune responses encompassing both humoral and cellular immunity [20] .", [["cellular", "ANATOMY", 105, 113], ["inulin", "CHEMICAL", 6, 12], ["Delta inulin", "GENE_OR_GENE_PRODUCT", 0, 12], ["cellular", "CELL", 105, 113], ["Delta inulin adjuvants", "TREATMENT", 0, 22]]], ["This has been shown to translate to enhanced vaccine protection against a broad range of pathogens including Japanese encephalitis virus [21, 22] , West Nile virus [23] , hepatitis B virus [24] , influenza [25] , HIV [26] , SARS [27] , coronavirus [27] , Listeria monocytogenes [28] and Bacillus anthracis [29] , as well as non-infectious diseases such as Alzheimer's disease [30] .", [["Japanese encephalitis", "DISEASE", 109, 130], ["hepatitis B", "DISEASE", 171, 182], ["influenza", "DISEASE", 196, 205], ["SARS", "DISEASE", 224, 228], ["non-infectious diseases", "DISEASE", 324, 347], ["Alzheimer's disease", "DISEASE", 356, 375], ["Japanese encephalitis virus", "ORGANISM", 109, 136], ["West Nile virus", "ORGANISM", 148, 163], ["hepatitis B virus", "ORGANISM", 171, 188], ["influenza", "ORGANISM", 196, 205], ["HIV", "ORGANISM", 213, 216], ["SARS [27", "ORGANISM", 224, 232], ["coronavirus", "ORGANISM", 236, 247], ["Listeria monocytogenes", "ORGANISM", 255, 277], ["Bacillus anthracis", "ORGANISM", 287, 305], ["Japanese encephalitis virus", "SPECIES", 109, 136], ["West Nile virus", "SPECIES", 148, 163], ["hepatitis B virus", "SPECIES", 171, 188], ["HIV", "SPECIES", 213, 216], ["coronavirus", "SPECIES", 236, 247], ["Listeria monocytogenes", "SPECIES", 255, 277], ["Bacillus anthracis", "SPECIES", 287, 305], ["Japanese encephalitis virus", "SPECIES", 109, 136], ["West Nile virus", "SPECIES", 148, 163], ["hepatitis B virus", "SPECIES", 171, 188], ["HIV", "SPECIES", 213, 216], ["Listeria monocytogenes", "SPECIES", 255, 277], ["Bacillus anthracis", "SPECIES", 287, 305], ["enhanced vaccine protection", "TREATMENT", 36, 63], ["a broad range of pathogens", "PROBLEM", 72, 98], ["Japanese encephalitis virus", "PROBLEM", 109, 136], ["West Nile virus", "TEST", 148, 163], ["hepatitis B virus", "PROBLEM", 171, 188], ["influenza", "PROBLEM", 196, 205], ["HIV", "TEST", 213, 216], ["SARS", "PROBLEM", 224, 228], ["coronavirus", "PROBLEM", 236, 247], ["Listeria monocytogenes", "PROBLEM", 255, 277], ["Bacillus anthracis", "PROBLEM", 287, 305], ["non-infectious diseases", "PROBLEM", 324, 347], ["Alzheimer's disease", "PROBLEM", 356, 375]]], ["Advax\u2122 induces minimal inflammation even when compared to alum adjuvant formulations [31] and has been shown to be safe and effective in human trials of vaccines against influenza [32] hepatitis B [31] and allergy [33] .", [["Advax\u2122", "CHEMICAL", 0, 6], ["inflammation", "DISEASE", 23, 35], ["influenza [32] hepatitis B", "DISEASE", 170, 196], ["allergy", "DISEASE", 206, 213], ["alum", "CHEMICAL", 58, 62], ["Advax\u2122", "SIMPLE_CHEMICAL", 0, 6], ["alum", "SIMPLE_CHEMICAL", 58, 62], ["human", "ORGANISM", 137, 142], ["influenza [32] hepatitis B", "ORGANISM", 170, 196], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["Advax\u2122", "TREATMENT", 0, 6], ["minimal inflammation", "PROBLEM", 15, 35], ["alum adjuvant formulations", "TREATMENT", 58, 84], ["vaccines", "TREATMENT", 153, 161], ["influenza", "PROBLEM", 170, 179], ["hepatitis B", "PROBLEM", 185, 196], ["allergy", "PROBLEM", 206, 213], ["minimal", "OBSERVATION_MODIFIER", 15, 22], ["inflammation", "OBSERVATION", 23, 35]]], ["Therefore, we sought to conduct a Phase 1 safety trial in canine cancer patients of our autologous cancer vaccine containing Advax\u2122 adjuvant with or without an additional bacterial protein immune stimulant rhizavidin [34] to generate safety and proof of concept data for this novel oncology approach.", [["cancer", "ANATOMY", 65, 71], ["cancer", "ANATOMY", 99, 105], ["cancer", "DISEASE", 65, 71], ["cancer", "DISEASE", 99, 105], ["Advax\u2122", "CHEMICAL", 125, 131], ["rhizavidin", "CHEMICAL", 206, 216], ["rhizavidin", "CHEMICAL", 206, 216], ["canine", "ORGANISM", 58, 64], ["cancer", "CANCER", 65, 71], ["patients", "ORGANISM", 72, 80], ["cancer", "CANCER", 99, 105], ["Advax\u2122", "SIMPLE_CHEMICAL", 125, 131], ["patients", "SPECIES", 72, 80], ["canine", "SPECIES", 58, 64], ["a Phase 1 safety trial in canine cancer", "TREATMENT", 32, 71], ["our autologous cancer vaccine", "TREATMENT", 84, 113], ["Advax\u2122 adjuvant", "TREATMENT", 125, 140], ["an additional bacterial protein immune stimulant rhizavidin", "TREATMENT", 157, 216], ["this novel oncology approach", "TREATMENT", 271, 299]]], ["We hypothesized based on our own previous cancer vaccine development work [35] , that using streptavidin as an immune stimulant with the addition of a similar foreign bacterial protein such as rhizavidin may improve the immune response to vaccination.Study Outline and AimsThe aims of this study were to assess the safety of the autologous vaccine approach.", [["cancer", "ANATOMY", 42, 48], ["cancer", "DISEASE", 42, 48], ["rhizavidin", "CHEMICAL", 193, 203], ["rhizavidin", "CHEMICAL", 193, 203], ["cancer", "CANCER", 42, 48], ["streptavidin", "GENE_OR_GENE_PRODUCT", 92, 104], ["rhizavidin", "SIMPLE_CHEMICAL", 193, 203], ["foreign bacterial protein", "PROTEIN", 159, 184], ["streptavidin", "TREATMENT", 92, 104], ["an immune stimulant", "TREATMENT", 108, 127], ["a similar foreign bacterial protein", "TREATMENT", 149, 184], ["rhizavidin", "TREATMENT", 193, 203], ["this study", "TEST", 285, 295], ["the autologous vaccine approach", "TREATMENT", 325, 356], ["cancer", "OBSERVATION", 42, 48]]], ["Secondary aims were to assess for subjective responses and decide what tumour types the vaccine might best be targeted at in future studies.", [["tumour", "ANATOMY", 71, 77], ["tumour", "DISEASE", 71, 77], ["tumour", "CANCER", 71, 77], ["subjective responses", "PROBLEM", 34, 54], ["the vaccine", "TREATMENT", 84, 95]]], ["We also wished to establish whether the addition of rhizavidin as an additional immune stimulant to the vaccine was safe.", [["rhizavidin", "CHEMICAL", 52, 62], ["rhizavidin", "CHEMICAL", 52, 62], ["rhizavidin", "SIMPLE_CHEMICAL", 52, 62], ["rhizavidin", "TREATMENT", 52, 62], ["an additional immune stimulant", "TREATMENT", 66, 96], ["the vaccine", "TREATMENT", 100, 111]]], ["Alternations to dosing frequency and timing were explored during the study, as ongoing murine studies revealed greater efficacy of more frequent vaccine dosing.", [["murine", "ORGANISM", 87, 93], ["murine", "SPECIES", 87, 93], ["the study", "TEST", 65, 74], ["ongoing murine studies", "TEST", 79, 101], ["frequent vaccine dosing", "TREATMENT", 136, 159]]], ["Nevertheless, timing of vaccine doses was frequently dictated by the ability of owners to bring animals to the vet clinics.Study Outline and AimsApproval was obtained from the Animal Care and Ethics Committee of the University of Queensland; (certificates ANRFA/SVS/346/15; SVS/328/14/JMKT) to undertake a Phase 1 safety trial of the autologous vaccine approach in dogs presenting with various cancers.", [["cancers", "ANATOMY", 394, 401], ["cancers", "DISEASE", 394, 401], ["dogs", "ORGANISM", 365, 369], ["cancers", "CANCER", 394, 401], ["dogs", "SPECIES", 365, 369], ["vaccine doses", "TREATMENT", 24, 37], ["ANRFA", "TEST", 256, 261], ["SVS", "TEST", 262, 265], ["SVS", "TEST", 274, 277], ["the autologous vaccine approach", "TREATMENT", 330, 361], ["various cancers", "PROBLEM", 386, 401], ["cancers", "OBSERVATION", 394, 401]]], ["Following the provision of vaccine information, owners gave informed written consent to include their dog in the study.", [["dog", "ORGANISM", 102, 105], ["the study", "TEST", 109, 118]]], ["Participation was irrespective of tumor type, prior cancer treatment or age of the dog.", [["tumor", "ANATOMY", 34, 39], ["cancer", "ANATOMY", 52, 58], ["tumor", "DISEASE", 34, 39], ["cancer", "DISEASE", 52, 58], ["tumor", "CANCER", 34, 39], ["cancer", "CANCER", 52, 58], ["dog", "ORGANISM", 83, 86], ["dog", "SPECIES", 83, 86], ["tumor type", "PROBLEM", 34, 44], ["prior cancer treatment", "TREATMENT", 46, 68], ["tumor", "OBSERVATION", 34, 39], ["cancer", "OBSERVATION", 52, 58]]], ["Inclusion criteria included an animal with a tumor that could be sampled or removed to provide enough material for a vaccine to be produced and where the owners were prepared to give consent or participate in the study.", [["tumor", "ANATOMY", 45, 50], ["tumor", "DISEASE", 45, 50], ["tumor", "CANCER", 45, 50], ["a tumor", "PROBLEM", 43, 50], ["a vaccine", "TREATMENT", 115, 124], ["the study", "TEST", 209, 218], ["tumor", "OBSERVATION", 45, 50]]], ["Exclusion criteria included a tumor that could not be sampled; the patient had systemic illness that could impact vaccine response (such as marked fever, immune suppression, organ failure) or were not expected to live long enough for the patient to benefit from the vaccination (<1 month).", [["tumor", "ANATOMY", 30, 35], ["organ", "ANATOMY", 174, 179], ["tumor", "DISEASE", 30, 35], ["fever", "DISEASE", 147, 152], ["organ failure", "DISEASE", 174, 187], ["tumor", "CANCER", 30, 35], ["patient", "ORGANISM", 67, 74], ["organ", "ORGAN", 174, 179], ["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 67, 74], ["patient", "SPECIES", 238, 245], ["a tumor", "PROBLEM", 28, 35], ["systemic illness", "PROBLEM", 79, 95], ["marked fever", "PROBLEM", 140, 152], ["immune suppression", "PROBLEM", 154, 172], ["organ failure", "PROBLEM", 174, 187], ["tumor", "OBSERVATION", 30, 35], ["could not be", "UNCERTAINTY", 41, 53]]], ["The trial cessation criteria were any significant side effects requiring hospitalization (anaphylactic reaction, moderate to severe gastroenteritis, other systemic inflammatory reactions) in up to three animals or vaccination causing death in any animal.Study Outline and AimsAdditional patients at three Sydney (Australia) veterinarian practices were treated on compassionate grounds after owners gave informed consent.", [["anaphylactic reaction", "DISEASE", 90, 111], ["gastroenteritis", "DISEASE", 132, 147], ["death", "DISEASE", 234, 239], ["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["any significant side effects", "PROBLEM", 34, 62], ["anaphylactic reaction", "PROBLEM", 90, 111], ["moderate to severe gastroenteritis", "PROBLEM", 113, 147], ["other systemic inflammatory reactions", "PROBLEM", 149, 186], ["vaccination", "TREATMENT", 214, 225], ["death", "PROBLEM", 234, 239], ["moderate", "OBSERVATION_MODIFIER", 113, 121], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["gastroenteritis", "OBSERVATION", 132, 147], ["systemic", "OBSERVATION_MODIFIER", 155, 163], ["inflammatory", "OBSERVATION", 164, 176]]], ["All vaccines were provided at no cost to the owners.", [["All vaccines", "TREATMENT", 0, 12]]], ["Figure 1 demonstrates the vaccine production process.Vaccine ProductionThis autologous vaccine production protocol was tested and found to be safe in murine cancer models prior to starting this trial.", [["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["murine", "ORGANISM", 150, 156], ["cancer", "CANCER", 157, 163], ["murine", "SPECIES", 150, 156], ["the vaccine production process", "PROBLEM", 22, 52], ["Vaccine Production", "TREATMENT", 53, 71], ["This autologous vaccine production protocol", "TREATMENT", 71, 114], ["this trial", "TREATMENT", 189, 199], ["cancer", "OBSERVATION", 157, 163]]], ["Biopsied, resected or debulked tumor samples obtained from each individual patient were processed fresh or stored frozen at \u221220 \u00b0C until processed at laboratories at the University of Queensland or the University of Sydney.", [["tumor samples", "ANATOMY", 31, 44], ["tumor", "DISEASE", 31, 36], ["tumor samples", "CANCER", 31, 44], ["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["resected or debulked tumor samples", "PROBLEM", 10, 44], ["resected", "OBSERVATION", 10, 18], ["debulked", "OBSERVATION_MODIFIER", 22, 30], ["tumor", "OBSERVATION", 31, 36]]], ["A minimum of 0.1 g sample was required and each sample was processed into the vaccine which produces four doses via the following method.", [["sample", "ANATOMY", 48, 54], ["the vaccine", "TREATMENT", 74, 85]]], ["For each 0.1 g of tumor, 1 mL of tumor buffer (50 mM Hepes, 0.15 M NaCl, 0.01% SDS pH 7.2) was added.", [["tumor", "ANATOMY", 18, 23], ["tumor", "ANATOMY", 33, 38], ["tumor", "DISEASE", 18, 23], ["tumor", "DISEASE", 33, 38], ["NaCl", "CHEMICAL", 67, 71], ["NaCl", "CHEMICAL", 67, 71], ["tumor", "CANCER", 18, 23], ["tumor", "CANCER", 33, 38], ["tumor", "PROBLEM", 18, 23], ["tumor buffer", "TREATMENT", 33, 45], ["Hepes", "TEST", 53, 58], ["NaCl", "TREATMENT", 67, 71], ["% SDS pH", "TEST", 77, 85], ["tumor", "OBSERVATION", 18, 23]]], ["The Tumor sample was then homogenized (Ultraturrax) to obtain a uniform suspension with no fragments of tumour remaining and then spun at 15,000 rpm for 5 min and the soluble lysate was collected.", [["Tumor sample", "ANATOMY", 4, 16], ["fragments", "ANATOMY", 91, 100], ["tumour", "ANATOMY", 104, 110], ["lysate", "ANATOMY", 175, 181], ["tumour", "DISEASE", 104, 110], ["Tumor", "CANCER", 4, 9], ["tumour", "CANCER", 104, 110], ["a uniform suspension", "TREATMENT", 62, 82], ["fragments of tumour", "PROBLEM", 91, 110], ["the soluble lysate", "TREATMENT", 163, 181], ["Tumor", "OBSERVATION", 4, 9], ["no", "UNCERTAINTY", 88, 90], ["fragments", "OBSERVATION_MODIFIER", 91, 100], ["tumour", "OBSERVATION", 104, 110]]], ["Soluble lysate contained between 5 to 30 mg of material per mL depending on the tumour type and origin.", [["lysate", "ANATOMY", 8, 14], ["tumour", "ANATOMY", 80, 86], ["tumour", "DISEASE", 80, 86], ["tumour", "CANCER", 80, 86], ["Soluble lysate", "TREATMENT", 0, 14], ["tumour type", "OBSERVATION", 80, 91], ["origin", "ANATOMY_MODIFIER", 96, 102]]], ["Dithiothreitol (DTT) was then added to a final concentration of 0.1 mM and 10 mg Advax\u2122 was added per dose.", [["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Advax\u2122", "CHEMICAL", 81, 87], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Advax\u2122", "CHEMICAL", 81, 87], ["Dithiothreitol", "SIMPLE_CHEMICAL", 0, 14], ["DTT", "SIMPLE_CHEMICAL", 16, 19], ["Advax\u2122", "SIMPLE_CHEMICAL", 81, 87], ["Dithiothreitol (DTT)", "TREATMENT", 0, 20], ["Advax\u2122", "TREATMENT", 81, 87]]], ["Each final vaccine dose contained 0.2 mL Advax\u2122 at 50 mg/mL with 0.2 mL of tumour lysate with or without 25 \u00b5g of rhizavidin and 0.01 mg/mL Thiomersal as a preservative.", [["tumour lysate", "ANATOMY", 75, 88], ["Advax\u2122", "CHEMICAL", 41, 47], ["tumour", "DISEASE", 75, 81], ["rhizavidin", "CHEMICAL", 114, 124], ["Thiomersal", "CHEMICAL", 140, 150], ["rhizavidin", "CHEMICAL", 114, 124], ["Advax\u2122", "SIMPLE_CHEMICAL", 41, 47], ["tumour", "CANCER", 75, 81], ["rhizavidin", "SIMPLE_CHEMICAL", 114, 124], ["Thiomersal", "SIMPLE_CHEMICAL", 140, 150], ["Each final vaccine dose", "TREATMENT", 0, 23], ["Advax\u2122", "TREATMENT", 41, 47], ["tumour lysate", "TREATMENT", 75, 88], ["rhizavidin", "TREATMENT", 114, 124]]], ["Murine studies later demonstrated no additional efficacy from the addition of the immune stimulant rhizavidin.", [["rhizavidin", "CHEMICAL", 99, 109], ["rhizavidin", "CHEMICAL", 99, 109], ["Murine", "ORGANISM", 0, 6], ["rhizavidin", "SIMPLE_CHEMICAL", 99, 109], ["Murine studies", "TEST", 0, 14], ["the immune stimulant rhizavidin", "TREATMENT", 78, 109], ["no", "UNCERTAINTY", 34, 36]]], ["To test if this was also the case for spontaneous canine tumors, approximately 50% of dogs received rhizavidin in their vaccine to compare safety and preliminary clinical outcomes.", [["canine tumors", "ANATOMY", 50, 63], ["canine tumors", "DISEASE", 50, 63], ["rhizavidin", "CHEMICAL", 100, 110], ["rhizavidin", "CHEMICAL", 100, 110], ["canine", "ORGANISM", 50, 56], ["tumors", "CANCER", 57, 63], ["dogs", "ORGANISM", 86, 90], ["rhizavidin", "SIMPLE_CHEMICAL", 100, 110], ["dogs", "SPECIES", 86, 90], ["canine", "SPECIES", 50, 56], ["spontaneous canine tumors", "PROBLEM", 38, 63], ["rhizavidin", "TREATMENT", 100, 110], ["their vaccine", "TREATMENT", 114, 127], ["tumors", "OBSERVATION", 57, 63]]], ["The rhizavidin used in this study was donated by Dr George Anderson (Naval Research Laboratory, Washington, DC, USA) and had an endotoxin level of less than 0.1 EU/mg.Vaccine AdministrationAutologous vaccine was injected intramuscularly (I.M) at a volume of 0.4 mL at rotating sites as distal to the original tumor location as possible.", [["intramuscularly", "ANATOMY", 221, 236], ["sites", "ANATOMY", 277, 282], ["tumor", "ANATOMY", 309, 314], ["rhizavidin", "CHEMICAL", 4, 14], ["tumor", "DISEASE", 309, 314], ["rhizavidin", "CHEMICAL", 4, 14], ["rhizavidin", "SIMPLE_CHEMICAL", 4, 14], ["tumor", "CANCER", 309, 314], ["The rhizavidin", "TREATMENT", 0, 14], ["an endotoxin level", "TEST", 125, 143], ["Vaccine AdministrationAutologous vaccine", "TREATMENT", 167, 207], ["tumor", "OBSERVATION", 309, 314]]], ["Initially, patients received two doses of vaccine 2 weeks apart but as more preclinical safety and efficacy data were generated, the regimen was switched to an induction phase of four vaccine doses at weekly internals and then monthly boosts thereafter.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["vaccine", "TREATMENT", 42, 49], ["efficacy data", "TEST", 99, 112], ["the regimen", "TREATMENT", 129, 140], ["an induction phase", "TREATMENT", 157, 175], ["four vaccine doses", "TREATMENT", 179, 197]]], ["Some animals received (Table 1 ) a more intense weekly or monthly protocol based on the aggressiveness of the cancer and the availability of owners to come to the clinic.Vaccine ProductionThis autologous vaccine production protocol was tested and found to be safe in murine cancer models prior to starting this trial.", [["cancer", "ANATOMY", 110, 116], ["cancer", "ANATOMY", 274, 280], ["aggressiveness", "DISEASE", 88, 102], ["cancer", "DISEASE", 110, 116], ["cancer", "DISEASE", 274, 280], ["cancer", "CANCER", 110, 116], ["murine", "ORGANISM", 267, 273], ["cancer", "CANCER", 274, 280], ["murine", "SPECIES", 267, 273], ["monthly protocol", "TREATMENT", 58, 74], ["the cancer", "PROBLEM", 106, 116], ["Vaccine Production", "TREATMENT", 170, 188], ["This autologous vaccine production protocol", "TREATMENT", 188, 231], ["this trial", "TREATMENT", 306, 316], ["cancer", "OBSERVATION", 110, 116], ["cancer", "OBSERVATION", 274, 280]]], ["Biopsied, resected or debulked tumor samples obtained from each individual patient were processed fresh or stored frozen at \u221220 \u2022 C until processed at laboratories at the University of Queensland or the University of Sydney.", [["tumor samples", "ANATOMY", 31, 44], ["tumor", "DISEASE", 31, 36], ["tumor samples", "CANCER", 31, 44], ["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["resected or debulked tumor samples", "PROBLEM", 10, 44], ["resected", "OBSERVATION", 10, 18], ["debulked", "OBSERVATION_MODIFIER", 22, 30], ["tumor", "OBSERVATION", 31, 36]]], ["A minimum of 0.1 g sample was required and each sample was processed into the vaccine which produces four doses via the following method.", [["sample", "ANATOMY", 48, 54], ["the vaccine", "TREATMENT", 74, 85]]], ["For each 0.1 g of tumor, 1 mL of tumor buffer (50 mM Hepes, 0.15 M NaCl, 0.01% SDS pH 7.2) was added.", [["tumor", "ANATOMY", 18, 23], ["tumor", "ANATOMY", 33, 38], ["tumor", "DISEASE", 18, 23], ["tumor", "DISEASE", 33, 38], ["NaCl", "CHEMICAL", 67, 71], ["NaCl", "CHEMICAL", 67, 71], ["tumor", "CANCER", 18, 23], ["tumor", "CANCER", 33, 38], ["tumor", "PROBLEM", 18, 23], ["tumor buffer", "TREATMENT", 33, 45], ["Hepes", "TEST", 53, 58], ["NaCl", "TREATMENT", 67, 71], ["% SDS pH", "TEST", 77, 85], ["tumor", "OBSERVATION", 18, 23]]], ["The Tumor sample was then homogenized (Ultraturrax) to obtain a uniform suspension with no fragments of tumour remaining and then spun at 15,000 rpm for 5 min and the soluble lysate was collected.", [["Tumor sample", "ANATOMY", 4, 16], ["fragments", "ANATOMY", 91, 100], ["tumour", "ANATOMY", 104, 110], ["lysate", "ANATOMY", 175, 181], ["tumour", "DISEASE", 104, 110], ["Tumor", "CANCER", 4, 9], ["tumour", "CANCER", 104, 110], ["a uniform suspension", "TREATMENT", 62, 82], ["fragments of tumour", "PROBLEM", 91, 110], ["the soluble lysate", "TREATMENT", 163, 181], ["Tumor", "OBSERVATION", 4, 9], ["no", "UNCERTAINTY", 88, 90], ["fragments", "OBSERVATION_MODIFIER", 91, 100], ["tumour", "OBSERVATION", 104, 110]]], ["Soluble lysate contained between 5 to 30 mg of material per mL depending on the tumour type and origin.", [["lysate", "ANATOMY", 8, 14], ["tumour", "ANATOMY", 80, 86], ["tumour", "DISEASE", 80, 86], ["tumour", "CANCER", 80, 86], ["Soluble lysate", "TREATMENT", 0, 14], ["tumour type", "OBSERVATION", 80, 91], ["origin", "ANATOMY_MODIFIER", 96, 102]]], ["Dithiothreitol (DTT) was then added to a final concentration of 0.1 mM and 10 mg Advax\u2122 was added per dose.", [["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Advax\u2122", "CHEMICAL", 81, 87], ["Dithiothreitol", "CHEMICAL", 0, 14], ["DTT", "CHEMICAL", 16, 19], ["Advax\u2122", "CHEMICAL", 81, 87], ["Dithiothreitol", "SIMPLE_CHEMICAL", 0, 14], ["DTT", "SIMPLE_CHEMICAL", 16, 19], ["Advax\u2122", "SIMPLE_CHEMICAL", 81, 87], ["Dithiothreitol (DTT)", "TREATMENT", 0, 20], ["Advax\u2122", "TREATMENT", 81, 87]]], ["Each final vaccine dose contained 0.2 mL Advax\u2122 at 50 mg/mL with 0.2 mL of tumour lysate with or without 25 \u00b5g of rhizavidin and 0.01 mg/mL Thiomersal as a preservative.", [["tumour lysate", "ANATOMY", 75, 88], ["Advax\u2122", "CHEMICAL", 41, 47], ["tumour", "DISEASE", 75, 81], ["rhizavidin", "CHEMICAL", 114, 124], ["Thiomersal", "CHEMICAL", 140, 150], ["rhizavidin", "CHEMICAL", 114, 124], ["Advax\u2122", "SIMPLE_CHEMICAL", 41, 47], ["tumour", "CANCER", 75, 81], ["rhizavidin", "SIMPLE_CHEMICAL", 114, 124], ["Thiomersal", "SIMPLE_CHEMICAL", 140, 150], ["Each final vaccine dose", "TREATMENT", 0, 23], ["Advax\u2122", "TREATMENT", 41, 47], ["tumour lysate", "TREATMENT", 75, 88], ["rhizavidin", "TREATMENT", 114, 124]]], ["Murine studies later demonstrated no additional efficacy from the addition of the immune stimulant rhizavidin.", [["rhizavidin", "CHEMICAL", 99, 109], ["rhizavidin", "CHEMICAL", 99, 109], ["Murine", "ORGANISM", 0, 6], ["rhizavidin", "SIMPLE_CHEMICAL", 99, 109], ["Murine studies", "TEST", 0, 14], ["the immune stimulant rhizavidin", "TREATMENT", 78, 109], ["no", "UNCERTAINTY", 34, 36]]], ["To test if this was also the case for spontaneous canine tumors, approximately 50% of dogs received rhizavidin in their vaccine to compare safety and preliminary clinical outcomes.", [["canine tumors", "ANATOMY", 50, 63], ["canine tumors", "DISEASE", 50, 63], ["rhizavidin", "CHEMICAL", 100, 110], ["rhizavidin", "CHEMICAL", 100, 110], ["canine", "ORGANISM", 50, 56], ["tumors", "CANCER", 57, 63], ["dogs", "ORGANISM", 86, 90], ["rhizavidin", "SIMPLE_CHEMICAL", 100, 110], ["dogs", "SPECIES", 86, 90], ["canine", "SPECIES", 50, 56], ["spontaneous canine tumors", "PROBLEM", 38, 63], ["rhizavidin", "TREATMENT", 100, 110], ["their vaccine", "TREATMENT", 114, 127], ["tumors", "OBSERVATION", 57, 63]]], ["The rhizavidin used in this study was donated by Dr George Anderson (Naval Research Laboratory, Washington, DC, USA) and had an endotoxin level of less than 0.1 EU/mg.Vaccine AdministrationAutologous vaccine was injected intramuscularly (I.M) at a volume of 0.4 mL at rotating sites as distal to the original tumor location as possible.", [["intramuscularly", "ANATOMY", 221, 236], ["sites", "ANATOMY", 277, 282], ["tumor", "ANATOMY", 309, 314], ["rhizavidin", "CHEMICAL", 4, 14], ["tumor", "DISEASE", 309, 314], ["rhizavidin", "CHEMICAL", 4, 14], ["rhizavidin", "SIMPLE_CHEMICAL", 4, 14], ["tumor", "CANCER", 309, 314], ["The rhizavidin", "TREATMENT", 0, 14], ["an endotoxin level", "TEST", 125, 143], ["Vaccine AdministrationAutologous vaccine", "TREATMENT", 167, 207], ["tumor", "OBSERVATION", 309, 314]]], ["Initially, patients received two doses of vaccine 2 weeks apart but as more preclinical safety and efficacy data were generated, the regimen was switched to an induction phase of four vaccine doses at weekly internals and then monthly boosts thereafter.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["vaccine", "TREATMENT", 42, 49], ["efficacy data", "TEST", 99, 112], ["the regimen", "TREATMENT", 129, 140], ["an induction phase", "TREATMENT", 157, 175], ["four vaccine doses", "TREATMENT", 179, 197]]], ["Some animals received (Table 1 ) a more intense weekly or monthly protocol based on the aggressiveness of the cancer and the availability of owners to come to the clinic.Histopathology and Tumor GradingFor inclusion into the study, owners were requested to have histopathology and any applicable tumor grading performed on their dog's tumor.", [["cancer", "ANATOMY", 110, 116], ["Tumor", "ANATOMY", 189, 194], ["tumor", "ANATOMY", 296, 301], ["tumor", "ANATOMY", 335, 340], ["aggressiveness", "DISEASE", 88, 102], ["cancer", "DISEASE", 110, 116], ["tumor", "DISEASE", 296, 301], ["tumor", "DISEASE", 335, 340], ["cancer", "CANCER", 110, 116], ["Tumor", "CANCER", 189, 194], ["tumor", "CANCER", 296, 301], ["dog", "ORGANISM", 329, 332], ["tumor", "CANCER", 335, 340], ["dog", "SPECIES", 329, 332], ["monthly protocol", "TREATMENT", 58, 74], ["the cancer", "PROBLEM", 106, 116], ["Histopathology", "TEST", 170, 184], ["Tumor Grading", "TEST", 189, 202], ["the study", "TEST", 221, 230], ["histopathology", "TEST", 262, 276], ["any applicable tumor grading", "PROBLEM", 281, 309], ["cancer", "OBSERVATION", 110, 116], ["Tumor", "OBSERVATION", 189, 194], ["tumor", "OBSERVATION", 296, 301], ["tumor", "OBSERVATION", 335, 340]]], ["Standard four, micron paraffin-embedded formalin fixed sections stained with Haematoxylin and Eosin were assessed.", [["sections", "ANATOMY", 55, 63], ["paraffin", "CHEMICAL", 22, 30], ["formalin", "CHEMICAL", 40, 48], ["Haematoxylin", "CHEMICAL", 77, 89], ["Eosin", "CHEMICAL", 94, 99], ["Haematoxylin", "SIMPLE_CHEMICAL", 77, 89], ["Eosin", "SIMPLE_CHEMICAL", 94, 99], ["Standard four, micron paraffin-embedded formalin fixed sections", "TREATMENT", 0, 63], ["Haematoxylin and Eosin", "TREATMENT", 77, 99]]], ["When applicable, Toluidine Blue was used to identify mast cells, and Masson's Trichrome to examine connective tissues.", [["mast cells", "ANATOMY", 53, 63], ["connective tissues", "ANATOMY", 99, 117], ["Toluidine Blue", "CHEMICAL", 17, 31], ["Toluidine Blue", "CHEMICAL", 17, 31], ["Toluidine Blue", "SIMPLE_CHEMICAL", 17, 31], ["mast cells", "CELL", 53, 63], ["connective tissues", "TISSUE", 99, 117], ["mast cells", "CELL_TYPE", 53, 63], ["Toluidine Blue", "TREATMENT", 17, 31], ["mast cells", "PROBLEM", 53, 63], ["mast cells", "OBSERVATION", 53, 63], ["connective tissues", "ANATOMY", 99, 117]]], ["Immunohistochemistry for T-and B-cells was performed on all canine lymphoma samples to allow for subtyping the lymphoma using the WHO classification system [36] .", [["T-and B-cells", "ANATOMY", 25, 38], ["lymphoma samples", "ANATOMY", 67, 83], ["lymphoma", "ANATOMY", 111, 119], ["canine lymphoma", "DISEASE", 60, 75], ["lymphoma", "DISEASE", 111, 119], ["T-", "CELL", 25, 27], ["B-cells", "CELL", 31, 38], ["canine", "ORGANISM", 60, 66], ["lymphoma samples", "CANCER", 67, 83], ["lymphoma", "CANCER", 111, 119], ["T-and B-cells", "CELL_TYPE", 25, 38], ["canine", "SPECIES", 60, 66], ["Immunohistochemistry", "TEST", 0, 20], ["T", "TEST", 25, 26], ["all canine lymphoma samples", "TREATMENT", 56, 83], ["the lymphoma", "PROBLEM", 107, 119], ["lymphoma", "OBSERVATION", 111, 119]]], ["Canine mast cell tumors were graded as high or low according to guidelines of Kiupel et al. (2011) [37] .", [["mast cell tumors", "ANATOMY", 7, 23], ["mast cell tumors", "DISEASE", 7, 23], ["Canine", "ORGANISM", 0, 6], ["mast cell tumors", "CANCER", 7, 23], ["Canine", "SPECIES", 0, 6], ["Canine", "SPECIES", 0, 6], ["Canine mast cell tumors", "PROBLEM", 0, 23], ["mast cell tumors", "OBSERVATION", 7, 23]]], ["Canine mammary tumors were classified according to Goldschmidt et al. (2011) [38] .Patient StatusAt each clinical review, the dogs involved in the trial received a complete physical examination, and tumor measurement, shape and appearance were recorded in the patient's clinical record and were documented by digital photography.", [["mammary tumors", "ANATOMY", 7, 21], ["tumor", "ANATOMY", 199, 204], ["Canine mammary tumors", "DISEASE", 0, 21], ["tumor", "DISEASE", 199, 204], ["Canine", "ORGANISM", 0, 6], ["mammary tumors", "CANCER", 7, 21], ["dogs", "ORGANISM", 126, 130], ["tumor", "CANCER", 199, 204], ["patient", "ORGANISM", 260, 267], ["Canine", "SPECIES", 0, 6], ["Patient", "SPECIES", 83, 90], ["dogs", "SPECIES", 126, 130], ["patient", "SPECIES", 260, 267], ["Canine", "SPECIES", 0, 6], ["Canine mammary tumors", "PROBLEM", 0, 21], ["a complete physical examination", "TEST", 162, 193], ["tumor measurement", "TEST", 199, 216], ["digital photography", "TEST", 309, 328], ["mammary", "ANATOMY", 7, 14], ["tumors", "OBSERVATION", 15, 21], ["tumor", "OBSERVATION", 199, 204], ["shape", "OBSERVATION_MODIFIER", 218, 223]]], ["Patients with measurable residual disease had their clinical responses recorded according to the Veterinary Cooperative Oncology Group consensus document for solid tumors [39] .", [["solid tumors", "ANATOMY", 158, 170], ["tumors", "DISEASE", 164, 170], ["Patients", "ORGANISM", 0, 8], ["solid tumors", "CANCER", 158, 170], ["Patients", "SPECIES", 0, 8], ["measurable residual disease", "PROBLEM", 14, 41], ["solid tumors", "PROBLEM", 158, 170], ["measurable", "OBSERVATION_MODIFIER", 14, 24], ["residual", "OBSERVATION_MODIFIER", 25, 33], ["disease", "OBSERVATION", 34, 41]]], ["The following classification was used to characterize clinical response: Complete Response (CR) for the disappearance of all target lesions; Partial Response (PR) for at least 30% reduction in the sum of diameters of target lesions; Progressive Disease (PD) for either the appearance of one or more new lesions or at least a 20% increase in the sum of diameters of target lesions; Stable Disease (SD) for less than 30% reduction (PR) or 20% increase (PD) in the sum of diameters of target lesions.", [["lesions", "ANATOMY", 132, 139], ["lesions", "ANATOMY", 224, 231], ["lesions", "ANATOMY", 303, 310], ["lesions", "ANATOMY", 372, 379], ["lesions", "ANATOMY", 489, 496], ["PD", "DISEASE", 254, 256], ["SD", "DISEASE", 397, 399], ["lesions", "PATHOLOGICAL_FORMATION", 132, 139], ["lesions", "PATHOLOGICAL_FORMATION", 224, 231], ["lesions", "PATHOLOGICAL_FORMATION", 303, 310], ["lesions", "PATHOLOGICAL_FORMATION", 372, 379], ["lesions", "PATHOLOGICAL_FORMATION", 489, 496], ["PR", "PROTEIN", 430, 432], ["CR", "TEST", 92, 94], ["all target lesions", "PROBLEM", 121, 139], ["target lesions", "PROBLEM", 217, 231], ["Progressive Disease (PD)", "PROBLEM", 233, 257], ["more new lesions", "PROBLEM", 294, 310], ["target lesions", "PROBLEM", 365, 379], ["Stable Disease", "PROBLEM", 381, 395], ["PR", "TEST", 430, 432], ["20% increase (PD)", "PROBLEM", 437, 454], ["target lesions", "PROBLEM", 482, 496], ["target", "OBSERVATION_MODIFIER", 125, 131], ["lesions", "OBSERVATION", 132, 139], ["reduction", "OBSERVATION_MODIFIER", 180, 189], ["diameters", "OBSERVATION_MODIFIER", 204, 213], ["target", "OBSERVATION_MODIFIER", 217, 223], ["lesions", "OBSERVATION", 224, 231], ["Progressive", "OBSERVATION_MODIFIER", 233, 244], ["Disease", "OBSERVATION", 245, 252], ["more", "OBSERVATION_MODIFIER", 294, 298], ["new", "OBSERVATION_MODIFIER", 299, 302], ["lesions", "OBSERVATION", 303, 310], ["at least", "OBSERVATION_MODIFIER", 314, 322], ["20%", "OBSERVATION_MODIFIER", 325, 328], ["increase", "OBSERVATION_MODIFIER", 329, 337], ["diameters", "OBSERVATION_MODIFIER", 352, 361], ["target", "OBSERVATION_MODIFIER", 365, 371], ["lesions", "OBSERVATION", 372, 379], ["Stable", "OBSERVATION_MODIFIER", 381, 387], ["Disease", "OBSERVATION", 388, 395], ["increase", "OBSERVATION_MODIFIER", 441, 449], ["diameters", "OBSERVATION_MODIFIER", 469, 478], ["target", "OBSERVATION_MODIFIER", 482, 488], ["lesions", "OBSERVATION", 489, 496]]], ["All palpable lymph nodes were measured and recorded, and if >10 mm in size, a fine needle aspirate was performed to evaluate for metastatic disease in the enlarged node.Patient StatusAt the initial visit, whenever possible, the dogs received complete staging of their disease, including a complete blood count, a complete biochemistry panel, urinalysis, and diagnostic imaging to determine the presence of metastases.", [["palpable lymph nodes", "ANATOMY", 4, 24], ["node", "ANATOMY", 164, 168], ["blood", "ANATOMY", 298, 303], ["metastases", "ANATOMY", 406, 416], ["metastases", "DISEASE", 406, 416], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 13, 24], ["node", "MULTI-TISSUE_STRUCTURE", 164, 168], ["dogs", "ORGANISM", 228, 232], ["blood", "ORGANISM_SUBSTANCE", 298, 303], ["Patient", "SPECIES", 169, 176], ["dogs", "SPECIES", 228, 232], ["All palpable lymph nodes", "TEST", 0, 24], ["a fine needle aspirate", "TEST", 76, 98], ["metastatic disease in the enlarged node", "PROBLEM", 129, 168], ["their disease", "PROBLEM", 262, 275], ["a complete blood count", "TEST", 287, 309], ["a complete biochemistry panel", "TEST", 311, 340], ["urinalysis", "TEST", 342, 352], ["diagnostic imaging", "TEST", 358, 376], ["metastases", "PROBLEM", 406, 416], ["palpable", "OBSERVATION_MODIFIER", 4, 12], ["lymph nodes", "OBSERVATION", 13, 24], [">10 mm", "OBSERVATION_MODIFIER", 60, 66], ["size", "OBSERVATION_MODIFIER", 70, 74], ["metastatic", "OBSERVATION", 129, 139], ["enlarged", "OBSERVATION_MODIFIER", 155, 163], ["node", "OBSERVATION", 164, 168], ["disease", "OBSERVATION", 268, 275], ["metastases", "OBSERVATION", 406, 416]]], ["The amount of staging performed depended on the veterinary facility the dog was presented to, cost associated with testing, and the cancer type.", [["cancer", "ANATOMY", 132, 138], ["cancer", "DISEASE", 132, 138], ["dog", "ORGANISM", 72, 75], ["cancer", "CANCER", 132, 138], ["staging", "TEST", 14, 21], ["testing", "TEST", 115, 122], ["the cancer type", "PROBLEM", 128, 143], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["staging", "OBSERVATION", 14, 21], ["cancer", "OBSERVATION", 132, 138]]], ["For example, dogs that presented with mast cell tumors had abdominal ultrasounds performed whenever possible, and dogs that presented with carcinomas or sarcomas had thoracic radiography performed, as these locations represent the metastatic pattern for that particular cancer.", [["mast cell tumors", "ANATOMY", 38, 54], ["abdominal", "ANATOMY", 59, 68], ["carcinomas", "ANATOMY", 139, 149], ["sarcomas", "ANATOMY", 153, 161], ["thoracic", "ANATOMY", 166, 174], ["cancer", "ANATOMY", 270, 276], ["mast cell tumors", "DISEASE", 38, 54], ["carcinomas", "DISEASE", 139, 149], ["sarcomas", "DISEASE", 153, 161], ["cancer", "DISEASE", 270, 276], ["dogs", "ORGANISM", 13, 17], ["mast cell tumors", "CANCER", 38, 54], ["abdominal", "ORGAN", 59, 68], ["dogs", "ORGANISM", 114, 118], ["carcinomas", "CANCER", 139, 149], ["sarcomas", "CANCER", 153, 161], ["thoracic", "ORGAN", 166, 174], ["cancer", "CANCER", 270, 276], ["dogs", "SPECIES", 13, 17], ["dogs", "SPECIES", 114, 118], ["dogs", "PROBLEM", 13, 17], ["mast cell tumors", "PROBLEM", 38, 54], ["abdominal ultrasounds", "TEST", 59, 80], ["dogs", "PROBLEM", 114, 118], ["carcinomas", "PROBLEM", 139, 149], ["sarcomas", "PROBLEM", 153, 161], ["thoracic radiography", "TEST", 166, 186], ["the metastatic pattern", "PROBLEM", 227, 249], ["particular cancer", "PROBLEM", 259, 276], ["mast cell tumors", "OBSERVATION", 38, 54], ["abdominal", "ANATOMY", 59, 68], ["carcinomas", "OBSERVATION", 139, 149], ["sarcomas", "OBSERVATION", 153, 161], ["thoracic", "ANATOMY", 166, 174], ["metastatic", "OBSERVATION", 231, 241], ["cancer", "OBSERVATION", 270, 276]]], ["The cancers were staged using the information received from these tests.Patient StatusDuring the vaccination appointments, in addition to a physical examinations, dogs were monitored for any adverse events post IM injection.", [["cancers", "ANATOMY", 4, 11], ["cancers", "DISEASE", 4, 11], ["cancers", "CANCER", 4, 11], ["dogs", "ORGANISM", 163, 167], ["Patient", "SPECIES", 72, 79], ["dogs", "SPECIES", 163, 167], ["The cancers", "PROBLEM", 0, 11], ["these tests", "TEST", 60, 71], ["a physical examinations", "TEST", 138, 161], ["any adverse events", "PROBLEM", 187, 205], ["IM injection", "TREATMENT", 211, 223], ["cancers", "OBSERVATION", 4, 11]]], ["Heart rate, respiratory rate, and temperature were monitored and recorded for a 2-h period post vaccination.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart rate", "TEST", 0, 10], ["respiratory rate", "TEST", 12, 28], ["temperature", "TEST", 34, 45], ["rate", "OBSERVATION_MODIFIER", 6, 10], ["respiratory rate", "OBSERVATION", 12, 28]]], ["The vaccine injection site was observed for any signs of swelling, redness, or ulceration.", [["swelling", "DISEASE", 57, 65], ["redness", "DISEASE", 67, 74], ["ulceration", "DISEASE", 79, 89], ["ulceration", "PATHOLOGICAL_FORMATION", 79, 89], ["The vaccine injection", "TREATMENT", 0, 21], ["swelling", "PROBLEM", 57, 65], ["redness", "PROBLEM", 67, 74], ["ulceration", "PROBLEM", 79, 89], ["swelling", "OBSERVATION", 57, 65], ["redness", "OBSERVATION", 67, 74], ["ulceration", "OBSERVATION", 79, 89]]], ["Any adverse events observed were reported according to the Veterinary Cooperative Oncology Group-Common Criteria for Adverse Events (VCOG-CTCAE) [40] .Treatment of Advanced Cancers with Autologous Tumor VaccineTwenty-seven pet dogs (19 male and 8 female) of a variety of pure and mixed breeds presented with 11 different types of cancer.", [["Cancers", "ANATOMY", 173, 180], ["cancer", "ANATOMY", 330, 336], ["Cancers", "DISEASE", 173, 180], ["cancer", "DISEASE", 330, 336], ["Cancers", "CANCER", 173, 180], ["Tumor", "CANCER", 197, 202], ["dogs", "ORGANISM", 227, 231], ["cancer", "CANCER", 330, 336], ["dogs", "SPECIES", 227, 231], ["Any adverse events", "PROBLEM", 0, 18], ["Adverse Events", "PROBLEM", 117, 131], ["Advanced Cancers", "PROBLEM", 164, 180], ["Autologous Tumor VaccineTwenty", "TREATMENT", 186, 216], ["cancer", "PROBLEM", 330, 336], ["Advanced", "OBSERVATION_MODIFIER", 164, 172], ["Cancers", "OBSERVATION", 173, 180], ["Autologous Tumor", "OBSERVATION", 186, 202], ["mixed breeds", "OBSERVATION", 280, 292], ["11 different", "OBSERVATION_MODIFIER", 308, 320], ["cancer", "OBSERVATION", 330, 336]]], ["They were all treated with vaccines prepared from their own tumor as part of this pilot Phase 1 safety study.Treatment of Advanced Cancers with Autologous Tumor VaccineOf dogs included in the intervention arm of the study, the majority had a significant burden of disease at vaccination.", [["tumor", "ANATOMY", 60, 65], ["Cancers", "ANATOMY", 131, 138], ["Tumor", "ANATOMY", 155, 160], ["tumor", "DISEASE", 60, 65], ["Cancers", "DISEASE", 131, 138], ["tumor", "CANCER", 60, 65], ["Cancers", "CANCER", 131, 138], ["Tumor", "CANCER", 155, 160], ["dogs", "ORGANISM", 171, 175], ["dogs", "SPECIES", 171, 175], ["vaccines", "TREATMENT", 27, 35], ["this pilot Phase", "TEST", 77, 93], ["safety study", "TEST", 96, 108], ["Advanced Cancers", "PROBLEM", 122, 138], ["Autologous Tumor VaccineOf dogs", "TREATMENT", 144, 175], ["the study", "TEST", 212, 221], ["a significant burden of disease at vaccination", "PROBLEM", 240, 286], ["tumor", "OBSERVATION", 60, 65], ["Advanced", "OBSERVATION_MODIFIER", 122, 130], ["Cancers", "OBSERVATION", 131, 138], ["Autologous Tumor", "OBSERVATION", 144, 160], ["significant", "OBSERVATION_MODIFIER", 242, 253], ["burden", "OBSERVATION", 254, 260], ["disease", "OBSERVATION", 264, 271]]], ["This included inoperable tumors, relapse following other therapies, metastases or residual tumor remaining after surgery.", [["inoperable tumors", "ANATOMY", 14, 31], ["metastases", "ANATOMY", 68, 78], ["tumor", "ANATOMY", 91, 96], ["tumors", "DISEASE", 25, 31], ["metastases", "DISEASE", 68, 78], ["tumor", "DISEASE", 91, 96], ["tumors", "CANCER", 25, 31], ["tumor", "CANCER", 91, 96], ["inoperable tumors", "PROBLEM", 14, 31], ["other therapies", "TREATMENT", 51, 66], ["metastases", "PROBLEM", 68, 78], ["residual tumor", "PROBLEM", 82, 96], ["surgery", "TREATMENT", 113, 120], ["inoperable", "OBSERVATION_MODIFIER", 14, 24], ["tumors", "OBSERVATION", 25, 31], ["metastases", "OBSERVATION", 68, 78], ["residual", "OBSERVATION_MODIFIER", 82, 90], ["tumor", "OBSERVATION", 91, 96]]], ["All 27 dogs enrolled in the active study were followed up at the census date (June 2018) and the following assessments were given: Dead/euthanased, Stable disease (SD), Complete Remission (CR), New Cancer (NC: new cancer of different histiogenesis from primary treated cancer).", [["Cancer", "ANATOMY", 198, 204], ["cancer", "ANATOMY", 214, 220], ["cancer", "ANATOMY", 269, 275], ["Stable disease", "DISEASE", 148, 162], ["SD", "DISEASE", 164, 166], ["Cancer", "DISEASE", 198, 204], ["NC", "DISEASE", 206, 208], ["cancer", "DISEASE", 214, 220], ["histiogenesis", "DISEASE", 234, 247], ["primary treated cancer", "DISEASE", 253, 275], ["dogs", "ORGANISM", 7, 11], ["Cancer", "CANCER", 198, 204], ["cancer", "CANCER", 214, 220], ["cancer", "CANCER", 269, 275], ["dogs", "SPECIES", 7, 11], ["the active study", "TEST", 24, 40], ["New Cancer", "PROBLEM", 194, 204], ["new cancer", "PROBLEM", 210, 220], ["different histiogenesis", "PROBLEM", 224, 247], ["primary treated cancer", "PROBLEM", 253, 275], ["Stable", "OBSERVATION_MODIFIER", 148, 154], ["disease", "OBSERVATION", 155, 162], ["New", "OBSERVATION_MODIFIER", 194, 197], ["Cancer", "OBSERVATION", 198, 204], ["new", "OBSERVATION_MODIFIER", 210, 213], ["cancer", "OBSERVATION", 214, 220], ["cancer", "OBSERVATION", 269, 275]]], ["Two of the 27 patients were lost to follow up (LTFU) due to owners moving.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Table 1 outlines the clinical features of the 27 dogs enrolled in the study.Vaccine SafetyWith over 150 vaccine doses administered, there were no major adverse events recorded.", [["dogs", "ORGANISM", 49, 53], ["dogs", "SPECIES", 49, 53], ["the study", "TEST", 66, 75], ["Vaccine SafetyWith", "TREATMENT", 76, 94], ["major adverse events", "PROBLEM", 146, 166], ["no", "UNCERTAINTY", 143, 145]]], ["There was no evidence of local injection site reactions (swelling, erythema, nodules, ulcers), or systemic reactions (fever, lethargy) in response to the vaccine.", [["site", "ANATOMY", 41, 45], ["nodules", "ANATOMY", 77, 84], ["ulcers", "ANATOMY", 86, 92], ["swelling", "DISEASE", 57, 65], ["erythema", "DISEASE", 67, 75], ["ulcers", "DISEASE", 86, 92], ["fever", "DISEASE", 118, 123], ["lethargy", "DISEASE", 125, 133], ["erythema", "PATHOLOGICAL_FORMATION", 67, 75], ["nodules", "PATHOLOGICAL_FORMATION", 77, 84], ["ulcers", "PATHOLOGICAL_FORMATION", 86, 92], ["local injection site reactions", "PROBLEM", 25, 55], ["swelling", "PROBLEM", 57, 65], ["erythema", "PROBLEM", 67, 75], ["nodules", "PROBLEM", 77, 84], ["ulcers", "PROBLEM", 86, 92], ["systemic reactions", "PROBLEM", 98, 116], ["fever", "PROBLEM", 118, 123], ["lethargy", "PROBLEM", 125, 133], ["the vaccine", "TREATMENT", 150, 161], ["no evidence of", "UNCERTAINTY", 10, 24], ["local", "OBSERVATION_MODIFIER", 25, 30], ["injection", "OBSERVATION", 31, 40], ["swelling", "OBSERVATION_MODIFIER", 57, 65], ["erythema", "OBSERVATION_MODIFIER", 67, 75], ["nodules", "OBSERVATION", 77, 84], ["ulcers", "OBSERVATION", 86, 92], ["systemic", "OBSERVATION_MODIFIER", 98, 106], ["reactions", "OBSERVATION", 107, 116]]], ["No cases of anaphylaxis were recorded.", [["anaphylaxis", "DISEASE", 12, 23], ["anaphylaxis", "PROBLEM", 12, 23], ["anaphylaxis", "OBSERVATION", 12, 23]]], ["Only two grade 1 reactions were observed, as classified by the VCOG-CTCAE.", [["CTCAE", "DISEASE", 68, 73], ["two grade 1 reactions", "PROBLEM", 5, 26], ["two", "OBSERVATION_MODIFIER", 5, 8], ["grade 1", "OBSERVATION_MODIFIER", 9, 16], ["reactions", "OBSERVATION", 17, 26]]], ["These two grade 1 events were in dogs already suffering from osteoarthritis that were reported by their owners to be more lame in the 24 h period post vaccination.", [["osteoarthritis", "DISEASE", 61, 75], ["dogs", "ORGANISM", 33, 37], ["dogs", "SPECIES", 33, 37], ["These two grade 1 events", "PROBLEM", 0, 24], ["osteoarthritis", "PROBLEM", 61, 75], ["osteoarthritis", "OBSERVATION", 61, 75]]], ["Rhizavidin, which in preclinical trials was shown to be safe but did not increase efficacy (unpublished data), was incorporated into the vaccine for some patients (n = 13) as an additional immune stimulant.", [["Rhizavidin", "CHEMICAL", 0, 10], ["Rhizavidin", "CHEMICAL", 0, 10], ["Rhizavidin", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["Rhizavidin", "TREATMENT", 0, 10], ["the vaccine", "TREATMENT", 133, 144], ["an additional immune stimulant", "TREATMENT", 175, 205]]], ["A similar number of patients (n = 12) received vaccine without rhizavidin to provide a comparison.", [["rhizavidin", "CHEMICAL", 63, 73], ["rhizavidin", "CHEMICAL", 63, 73], ["patients", "ORGANISM", 20, 28], ["rhizavidin", "SIMPLE_CHEMICAL", 63, 73], ["patients", "SPECIES", 20, 28], ["vaccine", "TREATMENT", 47, 54], ["rhizavidin", "TREATMENT", 63, 73], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["No significant adverse events were recorded in dogs receiving vaccine with or without rhizavidin, matching preclinical findings.", [["rhizavidin", "CHEMICAL", 86, 96], ["rhizavidin", "CHEMICAL", 86, 96], ["dogs", "ORGANISM", 47, 51], ["rhizavidin", "SIMPLE_CHEMICAL", 86, 96], ["dogs", "SPECIES", 47, 51], ["significant adverse events", "PROBLEM", 3, 29], ["vaccine", "TREATMENT", 62, 69], ["rhizavidin", "TREATMENT", 86, 96], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["adverse", "OBSERVATION", 15, 22]]], ["Increasing dosing schedule and frequency did not result in any dosing-related adverse events.Vaccine EfficacyMany of the dogs enrolled in this Phase 1 trial were also receiving or had received other cancer therapies, and this plus the diversity of tumors and breeds of dogs, meant that any additional impact of the vaccine on the natural history of their cancers cannot be determined from this safety trial.", [["cancer", "ANATOMY", 199, 205], ["tumors", "ANATOMY", 248, 254], ["cancers", "ANATOMY", 355, 362], ["cancer", "DISEASE", 199, 205], ["tumors", "DISEASE", 248, 254], ["cancers", "DISEASE", 355, 362], ["dogs", "ORGANISM", 121, 125], ["cancer", "CANCER", 199, 205], ["tumors", "CANCER", 248, 254], ["dogs", "ORGANISM", 269, 273], ["cancers", "CANCER", 355, 362], ["dogs", "SPECIES", 121, 125], ["dogs", "SPECIES", 269, 273], ["Increasing dosing schedule", "TREATMENT", 0, 26], ["adverse events", "PROBLEM", 78, 92], ["Vaccine", "TREATMENT", 93, 100], ["the dogs", "PROBLEM", 117, 125], ["other cancer therapies", "TREATMENT", 193, 215], ["tumors", "PROBLEM", 248, 254], ["the vaccine", "TREATMENT", 311, 322], ["their cancers", "PROBLEM", 349, 362], ["cancer", "OBSERVATION", 199, 205], ["tumors", "OBSERVATION", 248, 254], ["cancers", "OBSERVATION", 355, 362]]], ["However, 11 dogs had no progression of their tumor (Stable Disease), and one dog went into complete remission (CR) after treatment with the vaccine alone.", [["tumor", "ANATOMY", 45, 50], ["tumor", "DISEASE", 45, 50], ["Stable Disease", "DISEASE", 52, 66], ["dogs", "ORGANISM", 12, 16], ["tumor", "CANCER", 45, 50], ["dog", "ORGANISM", 77, 80], ["dogs", "SPECIES", 12, 16], ["their tumor", "PROBLEM", 39, 50], ["treatment", "TREATMENT", 121, 130], ["the vaccine", "TREATMENT", 136, 147], ["progression", "OBSERVATION_MODIFIER", 24, 35], ["tumor", "OBSERVATION", 45, 50], ["Stable", "OBSERVATION_MODIFIER", 52, 58], ["Disease", "OBSERVATION", 59, 66]]], ["Two dogs diagnosed with a high grade mast cell tumor exceeded their expected survival by more than 5 months at the consensus date (9 month survival at census, versus 4 months expected [41]).", [["high grade mast cell tumor", "ANATOMY", 26, 52], ["mast cell tumor", "DISEASE", 37, 52], ["dogs", "ORGANISM", 4, 8], ["mast cell tumor", "CANCER", 37, 52], ["dogs", "SPECIES", 4, 8], ["a high grade mast cell tumor", "PROBLEM", 24, 52], ["high grade", "OBSERVATION_MODIFIER", 26, 36], ["mast cell tumor", "OBSERVATION", 37, 52]]], ["The one dog with complete remission had a diagnosis of non-epitheliotrophic T-cell lymphoma, with resolution of the 13 lesions present at the time of initial enrollment in the trial.", [["non-epitheliotrophic T-cell lymphoma", "ANATOMY", 55, 91], ["lesions", "ANATOMY", 119, 126], ["non-epitheliotrophic T-cell lymphoma", "DISEASE", 55, 91], ["dog", "ORGANISM", 8, 11], ["non-epitheliotrophic T-cell lymphoma", "CANCER", 55, 91], ["lesions", "PATHOLOGICAL_FORMATION", 119, 126], ["non-epitheliotrophic T-cell lymphoma", "PROBLEM", 55, 91], ["the 13 lesions", "PROBLEM", 112, 126], ["non-epitheliotrophic T-cell lymphoma", "OBSERVATION", 55, 91], ["resolution", "OBSERVATION_MODIFIER", 98, 108], ["lesions", "OBSERVATION", 119, 126]]], ["The data suggested better than expected outcomes in some immunized patients although the study was not designed for analysis of efficacy.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["The data", "TEST", 0, 8], ["the study", "TEST", 85, 94]]], ["This suggestion of clinical benefit, particularly in those dogs receiving the Advax\u2122 vaccine without addition of rhizavidin on a weekly induction schedule followed by monthly boosters, supports further testing in placebo-controlled clinical trials.Vaccine CompositionSome versions of the vaccine included rhizavidin as an additional immune stimulant in combination with tumor protein and Advax\u2122 adjuvant.", [["tumor", "ANATOMY", 370, 375], ["Advax\u2122", "CHEMICAL", 78, 84], ["rhizavidin", "CHEMICAL", 113, 123], ["rhizavidin", "CHEMICAL", 305, 315], ["tumor", "DISEASE", 370, 375], ["Advax\u2122", "CHEMICAL", 388, 394], ["rhizavidin", "CHEMICAL", 113, 123], ["rhizavidin", "CHEMICAL", 305, 315], ["dogs", "ORGANISM", 59, 63], ["rhizavidin", "SIMPLE_CHEMICAL", 113, 123], ["rhizavidin", "SIMPLE_CHEMICAL", 305, 315], ["tumor", "CANCER", 370, 375], ["Advax\u2122", "SIMPLE_CHEMICAL", 388, 394], ["tumor protein", "PROTEIN", 370, 383], ["dogs", "SPECIES", 59, 63], ["the Advax\u2122 vaccine", "TREATMENT", 74, 92], ["rhizavidin", "TREATMENT", 113, 123], ["a weekly induction schedule", "TREATMENT", 127, 154], ["further testing", "TEST", 194, 209], ["placebo", "TREATMENT", 213, 220], ["Vaccine", "TREATMENT", 248, 255], ["the vaccine", "TREATMENT", 284, 295], ["rhizavidin", "TREATMENT", 305, 315], ["an additional immune stimulant", "TREATMENT", 319, 349], ["tumor protein", "TREATMENT", 370, 383], ["Advax\u2122 adjuvant", "TREATMENT", 388, 403]]], ["These dogs were vaccinated with tumor protein plus rhizavidin (25 \u00b5g) and Advax\u2122 (10 mg) to a total volume of 0.4 mL (n = 13).", [["tumor", "ANATOMY", 32, 37], ["tumor", "DISEASE", 32, 37], ["rhizavidin", "CHEMICAL", 51, 61], ["Advax\u2122", "CHEMICAL", 74, 80], ["rhizavidin", "CHEMICAL", 51, 61], ["Advax\u2122", "CHEMICAL", 74, 80], ["dogs", "ORGANISM", 6, 10], ["tumor", "CANCER", 32, 37], ["rhizavidin", "SIMPLE_CHEMICAL", 51, 61], ["Advax\u2122", "SIMPLE_CHEMICAL", 74, 80], ["tumor protein", "PROTEIN", 32, 45], ["dogs", "SPECIES", 6, 10], ["tumor protein", "TREATMENT", 32, 45], ["rhizavidin", "TREATMENT", 51, 61], ["Advax\u2122", "TREATMENT", 74, 80]]], ["Subsequently, as no benefit was demonstrated in mouse models from the addition of rhizavidin, patients entering the study in Sydney received vaccine formulations without rhizavidin.", [["rhizavidin", "CHEMICAL", 82, 92], ["rhizavidin", "CHEMICAL", 170, 180], ["rhizavidin", "CHEMICAL", 82, 92], ["rhizavidin", "CHEMICAL", 170, 180], ["mouse", "ORGANISM", 48, 53], ["rhizavidin", "SIMPLE_CHEMICAL", 82, 92], ["patients", "ORGANISM", 94, 102], ["rhizavidin", "SIMPLE_CHEMICAL", 170, 180], ["mouse", "SPECIES", 48, 53], ["patients", "SPECIES", 94, 102], ["mouse", "SPECIES", 48, 53], ["rhizavidin", "TREATMENT", 82, 92], ["the study", "TEST", 112, 121], ["vaccine formulations", "TREATMENT", 141, 161], ["rhizavidin", "TREATMENT", 170, 180]]], ["At the time of the census cutoff, the current status and survival period post-vaccination of each patient receiving vaccinations with or without rhizavidin were recorded (Figure 2 ).", [["rhizavidin", "CHEMICAL", 145, 155], ["rhizavidin", "CHEMICAL", 145, 155], ["patient", "ORGANISM", 98, 105], ["rhizavidin", "SIMPLE_CHEMICAL", 145, 155], ["patient", "SPECIES", 98, 105], ["vaccinations", "TREATMENT", 116, 128], ["rhizavidin", "TREATMENT", 145, 155]]], ["While not statistically significant, a higher proportion of dogs were alive at the census in patients that received vaccine without (75%), compared to with (51%) rhizavidin as no benefit was demonstrated in mouse models from the addition of rhizavidin, patients entering the study in Sydney received vaccine formulations without rhizavidin.", [["rhizavidin", "CHEMICAL", 162, 172], ["rhizavidin", "CHEMICAL", 241, 251], ["rhizavidin", "CHEMICAL", 329, 339], ["rhizavidin", "CHEMICAL", 162, 172], ["rhizavidin", "CHEMICAL", 241, 251], ["rhizavidin", "CHEMICAL", 329, 339], ["dogs", "ORGANISM", 60, 64], ["patients", "ORGANISM", 93, 101], ["rhizavidin", "SIMPLE_CHEMICAL", 162, 172], ["mouse", "ORGANISM", 207, 212], ["rhizavidin", "SIMPLE_CHEMICAL", 241, 251], ["patients", "ORGANISM", 253, 261], ["rhizavidin", "SIMPLE_CHEMICAL", 329, 339], ["dogs", "SPECIES", 60, 64], ["patients", "SPECIES", 93, 101], ["mouse", "SPECIES", 207, 212], ["patients", "SPECIES", 253, 261], ["mouse", "SPECIES", 207, 212], ["vaccine", "TREATMENT", 116, 123], ["rhizavidin", "TREATMENT", 162, 172], ["rhizavidin", "TREATMENT", 241, 251], ["the study", "TEST", 271, 280], ["vaccine formulations", "TREATMENT", 300, 320], ["rhizavidin", "TREATMENT", 329, 339], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["At the time of the census cutoff, the current status and survival period post-vaccination of each patient receiving vaccinations with or without rhizavidin were recorded (Figure 2 ).", [["rhizavidin", "CHEMICAL", 145, 155], ["rhizavidin", "CHEMICAL", 145, 155], ["patient", "ORGANISM", 98, 105], ["rhizavidin", "SIMPLE_CHEMICAL", 145, 155], ["patient", "SPECIES", 98, 105], ["vaccinations", "TREATMENT", 116, 128], ["rhizavidin", "TREATMENT", 145, 155]]], ["While not statistically significant, a higher proportion of dogs were alive at the census in patients that received vaccine without (75%), compared to with (51%) rhizavidinDose ScheduleOne of the challenges of translating from preclinical rodent models of cancer to treating canine patients is establishing the most effective dosing schedule.", [["cancer", "ANATOMY", 256, 262], ["rhizavidin", "CHEMICAL", 162, 172], ["cancer", "DISEASE", 256, 262], ["rhizavidin", "CHEMICAL", 162, 172], ["dogs", "ORGANISM", 60, 64], ["patients", "ORGANISM", 93, 101], ["rhizavidin", "SIMPLE_CHEMICAL", 162, 172], ["cancer", "CANCER", 256, 262], ["canine", "ORGANISM", 275, 281], ["patients", "ORGANISM", 282, 290], ["dogs", "SPECIES", 60, 64], ["patients", "SPECIES", 93, 101], ["canine", "SPECIES", 275, 281], ["patients", "SPECIES", 282, 290], ["canine", "SPECIES", 275, 281], ["vaccine", "TREATMENT", 116, 123], ["rhizavidin", "TREATMENT", 162, 172], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["higher", "OBSERVATION_MODIFIER", 39, 45], ["cancer", "OBSERVATION", 256, 262]]], ["Regimens of two doses 2 or 4 weeks apart were effective in two murine models of cancer, so initially dogs were treated using this same schedule followed by monthly boosts.", [["cancer", "ANATOMY", 80, 86], ["cancer", "DISEASE", 80, 86], ["murine", "ORGANISM", 63, 69], ["cancer", "CANCER", 80, 86], ["dogs", "ORGANISM", 101, 105], ["murine", "SPECIES", 63, 69], ["dogs", "SPECIES", 101, 105], ["cancer", "PROBLEM", 80, 86], ["this same schedule", "TREATMENT", 125, 143], ["two murine", "OBSERVATION_MODIFIER", 59, 69], ["cancer", "OBSERVATION", 80, 86]]], ["After seeing no adverse events in initial subjects and with new preclinical data confirming better efficacy with weekly vaccinations in murine models, this schedule was adopted for subsequent canine patients.", [["murine", "ORGANISM", 136, 142], ["canine", "ORGANISM", 192, 198], ["patients", "ORGANISM", 199, 207], ["murine", "SPECIES", 136, 142], ["patients", "SPECIES", 199, 207], ["canine", "SPECIES", 192, 198], ["adverse events", "PROBLEM", 16, 30], ["new preclinical data", "TEST", 60, 80]]], ["Figure 3 shows the outcome of patients receiving different vaccine schedules regardless of tumor type.Dose ScheduleOne of the challenges of translating from preclinical rodent models of cancer to treating canine patients is establishing the most effective dosing schedule.", [["tumor", "ANATOMY", 91, 96], ["cancer", "ANATOMY", 186, 192], ["tumor", "DISEASE", 91, 96], ["cancer", "DISEASE", 186, 192], ["patients", "ORGANISM", 30, 38], ["tumor", "CANCER", 91, 96], ["cancer", "CANCER", 186, 192], ["canine", "ORGANISM", 205, 211], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 30, 38], ["canine", "SPECIES", 205, 211], ["patients", "SPECIES", 212, 220], ["canine", "SPECIES", 205, 211], ["different vaccine schedules", "TREATMENT", 49, 76], ["tumor type", "PROBLEM", 91, 101], ["tumor", "OBSERVATION", 91, 96], ["cancer", "OBSERVATION", 186, 192]]], ["Regimens of two doses 2 or 4 weeks apart were effective in two murine models of cancer, so initially dogs were treated using this same schedule followed by monthly boosts.", [["cancer", "ANATOMY", 80, 86], ["cancer", "DISEASE", 80, 86], ["murine", "ORGANISM", 63, 69], ["cancer", "CANCER", 80, 86], ["dogs", "ORGANISM", 101, 105], ["murine", "SPECIES", 63, 69], ["dogs", "SPECIES", 101, 105], ["cancer", "PROBLEM", 80, 86], ["this same schedule", "TREATMENT", 125, 143], ["two murine", "OBSERVATION_MODIFIER", 59, 69], ["cancer", "OBSERVATION", 80, 86]]], ["After seeing no adverse events in initial subjects and with new preclinical data confirming better efficacy with weekly vaccinations in murine models, this schedule was adopted for subsequent canine patients.", [["murine", "ORGANISM", 136, 142], ["canine", "ORGANISM", 192, 198], ["patients", "ORGANISM", 199, 207], ["murine", "SPECIES", 136, 142], ["patients", "SPECIES", 199, 207], ["canine", "SPECIES", 192, 198], ["adverse events", "PROBLEM", 16, 30], ["new preclinical data", "TEST", 60, 80]]], ["Figure 3 shows the outcome of patients receiving different vaccine schedules regardless of tumor type.Dose ScheduleVet.", [["tumor", "ANATOMY", 91, 96], ["tumor", "DISEASE", 91, 96], ["patients", "ORGANISM", 30, 38], ["tumor", "CANCER", 91, 96], ["patients", "SPECIES", 30, 38], ["different vaccine schedules", "TREATMENT", 49, 76], ["tumor type", "PROBLEM", 91, 101], ["Dose ScheduleVet", "TREATMENT", 102, 118], ["tumor", "OBSERVATION", 91, 96]]], ["Survival comparison and outcome of different vaccine dosing schedules.", [["Survival comparison", "TEST", 0, 19], ["different vaccine dosing schedules", "TREATMENT", 35, 69]]], ["No significant difference was seen between groups receiving either the weekly 4\u00d7 with monthly boosts (n = 12) and monthly interval (n = 5) groups with 83% and 60% of patients being alive, respectively, at the time of the census.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["This compares to 50% in the second weekly group and 0% in groups that received a single dose (indicative of end stage terminal disease).Surgery and ResponsePatients enrolled in this study had tumor tissue harvested via complete or incomplete resection, debulking of primary tumor, biopsy or in the case of two dogs with osteosarcoma, amputation and sample collection.", [["tumor tissue", "ANATOMY", 192, 204], ["primary tumor", "ANATOMY", 266, 279], ["osteosarcoma", "ANATOMY", 320, 332], ["sample", "ANATOMY", 349, 355], ["tumor", "DISEASE", 192, 197], ["primary tumor", "DISEASE", 266, 279], ["osteosarcoma", "DISEASE", 320, 332], ["amputation", "DISEASE", 334, 344], ["tumor tissue", "TISSUE", 192, 204], ["tumor", "CANCER", 274, 279], ["dogs", "ORGANISM", 310, 314], ["osteosarcoma", "CANCER", 320, 332], ["dogs", "SPECIES", 310, 314], ["end stage terminal disease)", "PROBLEM", 108, 135], ["Surgery", "TREATMENT", 136, 143], ["this study", "TEST", 177, 187], ["tumor tissue", "PROBLEM", 192, 204], ["incomplete resection", "TREATMENT", 231, 251], ["debulking", "TREATMENT", 253, 262], ["primary tumor", "PROBLEM", 266, 279], ["biopsy", "TEST", 281, 287], ["osteosarcoma", "PROBLEM", 320, 332], ["amputation", "TREATMENT", 334, 344], ["sample collection", "TEST", 349, 366], ["end stage", "OBSERVATION_MODIFIER", 108, 117], ["terminal", "OBSERVATION_MODIFIER", 118, 126], ["disease", "OBSERVATION", 127, 134], ["resection", "OBSERVATION", 242, 251], ["primary", "OBSERVATION_MODIFIER", 266, 273], ["tumor", "OBSERVATION", 274, 279], ["osteosarcoma", "OBSERVATION", 320, 332], ["amputation", "OBSERVATION", 334, 344]]], ["Figure 4 shows the survival curves of the four different types of sample collection. .", [["sample", "ANATOMY", 66, 72], ["the survival curves", "PROBLEM", 15, 34], ["sample collection", "PROBLEM", 66, 83], ["four different", "OBSERVATION_MODIFIER", 42, 56], ["sample", "OBSERVATION_MODIFIER", 66, 72], ["collection", "OBSERVATION", 73, 83]]], ["Survival comparison and outcome of different vaccine dosing schedules.", [["Survival comparison", "TEST", 0, 19], ["different vaccine dosing schedules", "TREATMENT", 35, 69]]], ["No significant difference was seen between groups receiving either the weekly 4\u00d7 with monthly boosts (n = 12) and monthly interval (n = 5) groups with 83% and 60% of patients being alive, respectively, at the time of the census.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["This compares to 50% in the second weekly group and 0% in groups that received a single dose (indicative of end stage terminal disease).Surgery and ResponsePatients enrolled in this study had tumor tissue harvested via complete or incomplete resection, debulking of primary tumor, biopsy or in the case of two dogs with osteosarcoma, amputation and sample collection.", [["tumor tissue", "ANATOMY", 192, 204], ["primary tumor", "ANATOMY", 266, 279], ["osteosarcoma", "ANATOMY", 320, 332], ["sample", "ANATOMY", 349, 355], ["tumor", "DISEASE", 192, 197], ["primary tumor", "DISEASE", 266, 279], ["osteosarcoma", "DISEASE", 320, 332], ["amputation", "DISEASE", 334, 344], ["tumor tissue", "TISSUE", 192, 204], ["tumor", "CANCER", 274, 279], ["dogs", "ORGANISM", 310, 314], ["osteosarcoma", "CANCER", 320, 332], ["dogs", "SPECIES", 310, 314], ["end stage terminal disease)", "PROBLEM", 108, 135], ["Surgery", "TREATMENT", 136, 143], ["this study", "TEST", 177, 187], ["tumor tissue", "PROBLEM", 192, 204], ["incomplete resection", "TREATMENT", 231, 251], ["debulking", "TREATMENT", 253, 262], ["primary tumor", "PROBLEM", 266, 279], ["biopsy", "TEST", 281, 287], ["osteosarcoma", "PROBLEM", 320, 332], ["amputation", "TREATMENT", 334, 344], ["sample collection", "TEST", 349, 366], ["end stage", "OBSERVATION_MODIFIER", 108, 117], ["terminal", "OBSERVATION_MODIFIER", 118, 126], ["disease", "OBSERVATION", 127, 134], ["resection", "OBSERVATION", 242, 251], ["primary", "OBSERVATION_MODIFIER", 266, 273], ["tumor", "OBSERVATION", 274, 279], ["osteosarcoma", "OBSERVATION", 320, 332], ["amputation", "OBSERVATION", 334, 344]]], ["Figure 4 shows the survival curves of the four different types of sample collection.", [["sample", "ANATOMY", 66, 72], ["the survival curves", "PROBLEM", 15, 34], ["sample collection", "PROBLEM", 66, 83], ["four different", "OBSERVATION_MODIFIER", 42, 56], ["sample", "OBSERVATION_MODIFIER", 66, 72], ["collection", "OBSERVATION", 73, 83]]], ["Resectable tumors (n = 7) had the highest rate of survival (86%) at the time of the census compared to debulking (n = 4) 75%, amputation (n = 2) 50% and biopsy (n = 12).", [["tumors", "ANATOMY", 11, 17], ["tumors", "DISEASE", 11, 17], ["tumors", "CANCER", 11, 17], ["Resectable tumors", "PROBLEM", 0, 17], ["debulking", "TREATMENT", 103, 112], ["amputation", "TEST", 126, 136], ["biopsy", "TEST", 153, 159], ["tumors", "OBSERVATION", 11, 17]]], ["Survival comparison and outcome of different vaccine dosing schedules.", [["Survival comparison", "TEST", 0, 19], ["different vaccine dosing schedules", "TREATMENT", 35, 69]]], ["No significant difference was seen between groups receiving either the weekly 4\u00d7 with monthly boosts (n = 12) and monthly interval (n = 5) groups with 83% and 60% of patients being alive, respectively, at the time of the census.", [["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["This compares to 50% in the second weekly group and 0% in groups that received a single dose (indicative of end stage terminal disease).Surgery and ResponsePatients enrolled in this study had tumor tissue harvested via complete or incomplete resection, debulking of primary tumor, biopsy or in the case of two dogs with osteosarcoma, amputation and sample collection.", [["tumor tissue", "ANATOMY", 192, 204], ["primary tumor", "ANATOMY", 266, 279], ["osteosarcoma", "ANATOMY", 320, 332], ["sample", "ANATOMY", 349, 355], ["tumor", "DISEASE", 192, 197], ["primary tumor", "DISEASE", 266, 279], ["osteosarcoma", "DISEASE", 320, 332], ["amputation", "DISEASE", 334, 344], ["tumor tissue", "TISSUE", 192, 204], ["tumor", "CANCER", 274, 279], ["dogs", "ORGANISM", 310, 314], ["osteosarcoma", "CANCER", 320, 332], ["dogs", "SPECIES", 310, 314], ["end stage terminal disease)", "PROBLEM", 108, 135], ["Surgery", "TREATMENT", 136, 143], ["this study", "TEST", 177, 187], ["tumor tissue", "PROBLEM", 192, 204], ["incomplete resection", "TREATMENT", 231, 251], ["debulking", "TREATMENT", 253, 262], ["primary tumor", "PROBLEM", 266, 279], ["biopsy", "TEST", 281, 287], ["osteosarcoma", "PROBLEM", 320, 332], ["amputation", "TREATMENT", 334, 344], ["sample collection", "TEST", 349, 366], ["end stage", "OBSERVATION_MODIFIER", 108, 117], ["terminal", "OBSERVATION_MODIFIER", 118, 126], ["disease", "OBSERVATION", 127, 134], ["resection", "OBSERVATION", 242, 251], ["primary", "OBSERVATION_MODIFIER", 266, 273], ["tumor", "OBSERVATION", 274, 279], ["osteosarcoma", "OBSERVATION", 320, 332], ["amputation", "OBSERVATION", 334, 344]]], ["Figure 4 shows the survival curves of the four different types of sample collection.", [["sample", "ANATOMY", 66, 72], ["the survival curves", "PROBLEM", 15, 34], ["sample collection", "PROBLEM", 66, 83], ["four different", "OBSERVATION_MODIFIER", 42, 56], ["sample", "OBSERVATION_MODIFIER", 66, 72], ["collection", "OBSERVATION", 73, 83]]], ["Resectable tumors (n = 7) had the highest rate of survival (86%) at the time of the census compared to debulking (n = 4) 75%, amputation (n = 2) 50% and biopsy (n = 12). .", [["tumors", "ANATOMY", 11, 17], ["tumors", "DISEASE", 11, 17], ["tumors", "CANCER", 11, 17], ["Resectable tumors", "PROBLEM", 0, 17], ["debulking", "TREATMENT", 103, 112], ["amputation", "TEST", 126, 136], ["biopsy", "TEST", 153, 159], ["tumors", "OBSERVATION", 11, 17]]], ["Survival curves of patients receiving biopsy, resection, debulking or amputation to collect sample.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["Survival curves", "TEST", 0, 15], ["biopsy", "TEST", 38, 44], ["resection", "TREATMENT", 46, 55], ["debulking", "TREATMENT", 57, 66], ["amputation", "TREATMENT", 70, 80], ["collect sample", "TEST", 84, 98], ["resection", "OBSERVATION", 46, 55], ["debulking", "OBSERVATION", 57, 66], ["amputation", "OBSERVATION", 70, 80]]], ["No significant difference was seen between groups, however, survival rates were 50% for amputation, 49% for biopsy, 75% for debulking and 86% for resectable tumors at the time of the census.", [["resectable tumors", "ANATOMY", 146, 163], ["tumors", "DISEASE", 157, 163], ["tumors", "CANCER", 157, 163], ["survival rates", "TEST", 60, 74], ["amputation", "TEST", 88, 98], ["biopsy", "TEST", 108, 114], ["debulking", "TREATMENT", 124, 133], ["resectable tumors", "PROBLEM", 146, 163], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["resectable", "OBSERVATION_MODIFIER", 146, 156], ["tumors", "OBSERVATION", 157, 163]]], ["Survival curves of patients receiving biopsy, resection, debulking or amputation to collect sample.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["Survival curves", "TEST", 0, 15], ["biopsy", "TEST", 38, 44], ["resection", "TREATMENT", 46, 55], ["debulking", "TREATMENT", 57, 66], ["amputation", "TREATMENT", 70, 80], ["collect sample", "TEST", 84, 98], ["resection", "OBSERVATION", 46, 55], ["debulking", "OBSERVATION", 57, 66], ["amputation", "OBSERVATION", 70, 80]]], ["No significant difference was seen between groups, however, survival rates were 50% for amputation, 49% for biopsy, 75% for debulking and 86% for resectable tumors at the time of the census.Response in Different Tumor TypesWhile this study was primarily designed to demonstrate the safety of the autologous vaccine formulated with Advax\u2122 adjuvant, the data might provide initial insights into which tumor types may respond best to this vaccine approach.", [["resectable tumors", "ANATOMY", 146, 163], ["Tumor", "ANATOMY", 212, 217], ["tumor", "ANATOMY", 399, 404], ["tumors", "DISEASE", 157, 163], ["Advax\u2122", "CHEMICAL", 331, 337], ["tumor", "DISEASE", 399, 404], ["tumors", "CANCER", 157, 163], ["Tumor", "CANCER", 212, 217], ["Advax\u2122", "SIMPLE_CHEMICAL", 331, 337], ["tumor", "CANCER", 399, 404], ["survival rates", "TEST", 60, 74], ["amputation", "TEST", 88, 98], ["biopsy", "TEST", 108, 114], ["debulking", "TREATMENT", 124, 133], ["resectable tumors", "PROBLEM", 146, 163], ["this study", "TEST", 229, 239], ["the autologous vaccine", "TREATMENT", 292, 314], ["Advax\u2122 adjuvant", "TREATMENT", 331, 346], ["this vaccine approach", "TREATMENT", 431, 452], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["resectable", "OBSERVATION_MODIFIER", 146, 156], ["tumors", "OBSERVATION", 157, 163], ["Different", "OBSERVATION_MODIFIER", 202, 211], ["Tumor", "OBSERVATION", 212, 217], ["tumor", "OBSERVATION", 399, 404]]], ["A variety of both solid and blood tumors were treated.", [["solid", "ANATOMY", 18, 23], ["blood tumors", "ANATOMY", 28, 40], ["blood tumors", "DISEASE", 28, 40], ["solid", "CANCER", 18, 23], ["blood tumors", "CANCER", 28, 40], ["both solid and blood tumors", "PROBLEM", 13, 40], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["both", "OBSERVATION_MODIFIER", 13, 17], ["solid", "OBSERVATION_MODIFIER", 18, 23], ["blood tumors", "OBSERVATION", 28, 40]]], ["Figure 5 shows the survival times and disease/patient status for the different tumor types.Response in Different Tumor TypesWhile this study was primarily designed to demonstrate the safety of the autologous vaccine formulated with Advax\u2122 adjuvant, the data might provide initial insights into which tumor types may respond best to this vaccine approach.", [["tumor", "ANATOMY", 79, 84], ["Tumor", "ANATOMY", 113, 118], ["tumor", "ANATOMY", 300, 305], ["tumor", "DISEASE", 79, 84], ["Advax\u2122", "CHEMICAL", 232, 238], ["tumor", "DISEASE", 300, 305], ["patient", "ORGANISM", 46, 53], ["tumor", "CANCER", 79, 84], ["Tumor", "CANCER", 113, 118], ["Advax\u2122", "SIMPLE_CHEMICAL", 232, 238], ["tumor", "CANCER", 300, 305], ["patient", "SPECIES", 46, 53], ["disease", "PROBLEM", 38, 45], ["the different tumor types", "PROBLEM", 65, 90], ["this study", "TEST", 130, 140], ["the autologous vaccine", "TREATMENT", 193, 215], ["Advax\u2122 adjuvant", "TREATMENT", 232, 247], ["this vaccine approach", "TREATMENT", 332, 353], ["tumor", "OBSERVATION", 79, 84], ["Different", "OBSERVATION_MODIFIER", 103, 112], ["Tumor", "OBSERVATION", 113, 118], ["tumor", "OBSERVATION", 300, 305]]], ["A variety of both solid and blood tumors were treated.", [["solid", "ANATOMY", 18, 23], ["blood tumors", "ANATOMY", 28, 40], ["blood tumors", "DISEASE", 28, 40], ["solid", "CANCER", 18, 23], ["blood tumors", "CANCER", 28, 40], ["both solid and blood tumors", "PROBLEM", 13, 40], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["both", "OBSERVATION_MODIFIER", 13, 17], ["solid", "OBSERVATION_MODIFIER", 18, 23], ["blood tumors", "OBSERVATION", 28, 40]]], ["Figure 5 shows the survival times and disease/patient status for the different tumor types.DiscussionWhile traditional laboratory rodent models of cancer are useful for the initial evaluation of vaccine preparations, dogs provide a clinical presentation and scenario better matching that of human patients [2] [3] [4] .", [["tumor", "ANATOMY", 79, 84], ["cancer", "ANATOMY", 147, 153], ["tumor", "DISEASE", 79, 84], ["cancer", "DISEASE", 147, 153], ["patient", "ORGANISM", 46, 53], ["tumor", "CANCER", 79, 84], ["cancer", "CANCER", 147, 153], ["dogs", "ORGANISM", 217, 221], ["human", "ORGANISM", 291, 296], ["patients", "ORGANISM", 297, 305], ["patient", "SPECIES", 46, 53], ["human", "SPECIES", 291, 296], ["patients", "SPECIES", 297, 305], ["human", "SPECIES", 291, 296], ["disease", "PROBLEM", 38, 45], ["the different tumor types", "PROBLEM", 65, 90], ["cancer", "PROBLEM", 147, 153], ["the initial evaluation", "TEST", 169, 191], ["vaccine preparations", "TREATMENT", 195, 215], ["tumor", "OBSERVATION", 79, 84], ["cancer", "OBSERVATION", 147, 153]]], ["Dogs naturally develop similar cancers to humans, with correlating histopathological appearance, metastatic pattern, and response to therapy [42] .", [["cancers", "ANATOMY", 31, 38], ["cancers", "DISEASE", 31, 38], ["Dogs", "ORGANISM", 0, 4], ["cancers", "CANCER", 31, 38], ["humans", "ORGANISM", 42, 48], ["humans", "SPECIES", 42, 48], ["humans", "SPECIES", 42, 48], ["similar cancers to humans", "PROBLEM", 23, 48], ["metastatic pattern", "PROBLEM", 97, 115], ["therapy", "TREATMENT", 133, 140], ["similar", "OBSERVATION_MODIFIER", 23, 30], ["cancers", "OBSERVATION", 31, 38], ["metastatic", "OBSERVATION", 97, 107]]], ["In addition, equivalent cancers are associated with similar genetic mutations in dogs and humans [42] .DiscussionWhile traditional laboratory rodent models of cancer are useful for the initial evaluation of vaccine preparations, dogs provide a clinical presentation and scenario better matching that of human patients [2] [3] [4] .", [["cancers", "ANATOMY", 24, 31], ["cancer", "ANATOMY", 159, 165], ["cancers", "DISEASE", 24, 31], ["cancer", "DISEASE", 159, 165], ["cancers", "CANCER", 24, 31], ["dogs", "ORGANISM", 81, 85], ["humans", "ORGANISM", 90, 96], ["cancer", "CANCER", 159, 165], ["dogs", "ORGANISM", 229, 233], ["human", "ORGANISM", 303, 308], ["patients", "ORGANISM", 309, 317], ["dogs", "SPECIES", 81, 85], ["humans", "SPECIES", 90, 96], ["human", "SPECIES", 303, 308], ["patients", "SPECIES", 309, 317], ["humans", "SPECIES", 90, 96], ["human", "SPECIES", 303, 308], ["equivalent cancers", "PROBLEM", 13, 31], ["cancer", "PROBLEM", 159, 165], ["the initial evaluation", "TEST", 181, 203], ["vaccine preparations", "TREATMENT", 207, 227], ["equivalent", "OBSERVATION_MODIFIER", 13, 23], ["cancers", "OBSERVATION", 24, 31], ["cancer", "OBSERVATION", 159, 165]]], ["Dogs naturally develop similar cancers to humans, with correlating histopathological appearance, metastatic pattern, and response to therapy [42] .", [["cancers", "ANATOMY", 31, 38], ["cancers", "DISEASE", 31, 38], ["Dogs", "ORGANISM", 0, 4], ["cancers", "CANCER", 31, 38], ["humans", "ORGANISM", 42, 48], ["humans", "SPECIES", 42, 48], ["humans", "SPECIES", 42, 48], ["similar cancers to humans", "PROBLEM", 23, 48], ["metastatic pattern", "PROBLEM", 97, 115], ["therapy", "TREATMENT", 133, 140], ["similar", "OBSERVATION_MODIFIER", 23, 30], ["cancers", "OBSERVATION", 31, 38], ["metastatic", "OBSERVATION", 97, 107]]], ["In addition, equivalent cancers are associated with similar genetic mutations in dogs and humans [42] .DiscussionIn this Phase I safety trial, no adverse reactions were observed when the autologous cancer vaccine containing Advax\u2122 was administered alone or in combination with a variety of other cancer treatments.", [["cancers", "ANATOMY", 24, 31], ["cancer", "ANATOMY", 198, 204], ["cancer", "ANATOMY", 296, 302], ["cancers", "DISEASE", 24, 31], ["cancer", "DISEASE", 198, 204], ["Advax\u2122", "CHEMICAL", 224, 230], ["cancer", "DISEASE", 296, 302], ["cancers", "CANCER", 24, 31], ["dogs", "ORGANISM", 81, 85], ["humans", "ORGANISM", 90, 96], ["cancer", "CANCER", 198, 204], ["Advax\u2122", "SIMPLE_CHEMICAL", 224, 230], ["cancer", "CANCER", 296, 302], ["dogs", "SPECIES", 81, 85], ["humans", "SPECIES", 90, 96], ["humans", "SPECIES", 90, 96], ["equivalent cancers", "PROBLEM", 13, 31], ["adverse reactions", "PROBLEM", 146, 163], ["the autologous cancer vaccine", "TREATMENT", 183, 212], ["Advax\u2122", "TREATMENT", 224, 230], ["other cancer treatments", "TREATMENT", 290, 313], ["equivalent", "OBSERVATION_MODIFIER", 13, 23], ["cancers", "OBSERVATION", 24, 31], ["cancer", "OBSERVATION", 296, 302]]], ["These results confirm the safety of this autologous vaccine approach for the treatment of canine cancers.", [["canine cancers", "ANATOMY", 90, 104], ["canine cancers", "DISEASE", 90, 104], ["canine", "ORGANISM", 90, 96], ["cancers", "CANCER", 97, 104], ["canine", "SPECIES", 90, 96], ["this autologous vaccine approach", "TREATMENT", 36, 68], ["canine cancers", "PROBLEM", 90, 104], ["cancers", "OBSERVATION", 97, 104]]], ["Neither the vaccine when given alone or when combined with standard of care (SOC) therapy was associated with any pattern of adverse events, suggesting the vaccine is safe to use as a stand-alone therapy or combined with SOC.DiscussionWhile only designed to assess safety across a wide range of tumour types, some anecdotal suggestions of possible efficacy in some subjects were reported by treating clinicians, despite the canine patients presenting in various stages of disease (curable via surgical excision versus end-stage metastatic disease) and a variety of tumor types.", [["tumour", "ANATOMY", 295, 301], ["tumor", "ANATOMY", 565, 570], ["tumour", "DISEASE", 295, 301], ["tumor", "DISEASE", 565, 570], ["tumour", "CANCER", 295, 301], ["canine", "ORGANISM", 424, 430], ["patients", "ORGANISM", 431, 439], ["tumor", "CANCER", 565, 570], ["patients", "SPECIES", 431, 439], ["canine", "SPECIES", 424, 430], ["the vaccine", "TREATMENT", 8, 19], ["therapy", "TREATMENT", 82, 89], ["adverse events", "PROBLEM", 125, 139], ["the vaccine", "TREATMENT", 152, 163], ["a stand-alone therapy", "TREATMENT", 182, 203], ["disease", "PROBLEM", 472, 479], ["surgical excision", "TREATMENT", 493, 510], ["end-stage metastatic disease)", "PROBLEM", 518, 547], ["tumor types", "PROBLEM", 565, 576], ["tumour", "OBSERVATION", 295, 301], ["possible", "UNCERTAINTY", 339, 347], ["disease", "OBSERVATION", 472, 479], ["stage", "OBSERVATION_MODIFIER", 522, 527], ["metastatic", "OBSERVATION", 528, 538], ["variety", "OBSERVATION_MODIFIER", 554, 561], ["tumor", "OBSERVATION", 565, 570]]], ["Vaccinated dogs with residual or metastatic disease often survived longer than published predicted survival times, suggesting the vaccine had a positive clinical benefit, but more patients are needed to allow for assessment of statistical significance.", [["metastatic disease", "ANATOMY", 33, 51], ["dogs", "ORGANISM", 11, 15], ["patients", "ORGANISM", 180, 188], ["dogs", "SPECIES", 11, 15], ["patients", "SPECIES", 180, 188], ["Vaccinated dogs", "PROBLEM", 0, 15], ["residual or metastatic disease", "PROBLEM", 21, 51], ["the vaccine", "TREATMENT", 126, 137], ["assessment", "TEST", 213, 223], ["residual", "OBSERVATION_MODIFIER", 21, 29], ["metastatic", "OBSERVATION", 33, 43]]], ["Vaccination also appeared anecdotally to stop or at least slow the reoccurrence of tumors after resection, especially in patients with mast cell tumors.", [["tumors", "ANATOMY", 83, 89], ["mast cell tumors", "ANATOMY", 135, 151], ["tumors", "DISEASE", 83, 89], ["mast cell tumors", "DISEASE", 135, 151], ["tumors", "CANCER", 83, 89], ["patients", "ORGANISM", 121, 129], ["mast cell tumors", "CANCER", 135, 151], ["patients", "SPECIES", 121, 129], ["Vaccination", "TREATMENT", 0, 11], ["tumors", "PROBLEM", 83, 89], ["resection", "TREATMENT", 96, 105], ["mast cell tumors", "PROBLEM", 135, 151], ["tumors", "OBSERVATION", 83, 89], ["resection", "OBSERVATION", 96, 105], ["mast cell tumors", "OBSERVATION", 135, 151]]], ["At the time of writing, one dog with non-epitheliotrophic T-cell lymphoma was in complete remission, with the disappearance of all lesions recorded pre-vaccination.", [["non-epitheliotrophic T-cell lymphoma", "ANATOMY", 37, 73], ["lesions", "ANATOMY", 131, 138], ["non-epitheliotrophic T-cell lymphoma", "DISEASE", 37, 73], ["dog", "ORGANISM", 28, 31], ["non-epitheliotrophic T-cell lymphoma", "CANCER", 37, 73], ["lesions", "PATHOLOGICAL_FORMATION", 131, 138], ["dog", "SPECIES", 28, 31], ["non-epitheliotrophic T-cell lymphoma", "PROBLEM", 37, 73], ["all lesions", "PROBLEM", 127, 138], ["cell lymphoma", "OBSERVATION", 60, 73], ["all", "OBSERVATION_MODIFIER", 127, 130], ["lesions", "OBSERVATION", 131, 138]]], ["This dog received no other treatments in conjunction to the autologous vaccine, and at the census date had no visible lesions.", [["lesions", "ANATOMY", 118, 125], ["dog", "ORGANISM", 5, 8], ["lesions", "PATHOLOGICAL_FORMATION", 118, 125], ["other treatments", "TREATMENT", 21, 37], ["the autologous vaccine", "TREATMENT", 56, 78], ["visible lesions", "PROBLEM", 110, 125], ["no", "UNCERTAINTY", 107, 109], ["visible", "OBSERVATION_MODIFIER", 110, 117], ["lesions", "OBSERVATION", 118, 125]]], ["Although the efficacy data provided is preliminary, the autologous vaccine produced positive clinical benefits including remissions, static disease and amelioration of cancer-associated symptoms, with some animals exceeding the predicted survival times for their tumor and stage.DiscussionThe ability to produce an autologous vaccine with a lag time of only a few hours between surgery and treatment, highlights its applicability to clinical situations.", [["cancer", "ANATOMY", 168, 174], ["tumor", "ANATOMY", 263, 268], ["cancer", "DISEASE", 168, 174], ["tumor", "DISEASE", 263, 268], ["cancer", "CANCER", 168, 174], ["tumor", "CANCER", 263, 268], ["the autologous vaccine", "TREATMENT", 52, 74], ["remissions", "PROBLEM", 121, 131], ["static disease", "PROBLEM", 133, 147], ["cancer", "PROBLEM", 168, 174], ["associated symptoms", "PROBLEM", 175, 194], ["their tumor", "PROBLEM", 257, 268], ["an autologous vaccine", "TREATMENT", 312, 333], ["surgery", "TREATMENT", 378, 385], ["treatment", "TREATMENT", 390, 399], ["cancer", "OBSERVATION", 168, 174], ["tumor", "OBSERVATION", 263, 268]]], ["Furthermore, fresh tumor samples once frozen can be stored indefinitely until the vaccine is required if using in an adjunct setting.", [["tumor samples", "ANATOMY", 19, 32], ["tumor", "DISEASE", 19, 24], ["tumor samples", "CANCER", 19, 32], ["fresh tumor samples", "TREATMENT", 13, 32], ["the vaccine", "TREATMENT", 78, 89], ["tumor", "OBSERVATION", 19, 24]]], ["Further, many dog owners do not pursue current best practice cancer therapies such as radiotherapy or chemotherapy for their pets due to financial considerations.", [["cancer", "ANATOMY", 61, 67], ["cancer", "DISEASE", 61, 67], ["dog", "ORGANISM", 14, 17], ["cancer", "CANCER", 61, 67], ["practice cancer therapies", "TREATMENT", 52, 77], ["radiotherapy", "TREATMENT", 86, 98], ["chemotherapy", "TREATMENT", 102, 114]]], ["Likewise, many owners are very concerned about cytotoxic urine and faeces near or around their home associated with chemotherapy, and dog owners with young families often cite this as a reason for declining chemotherapy.", [["urine", "ANATOMY", 57, 62], ["faeces", "ANATOMY", 67, 73], ["urine", "ORGANISM_SUBSTANCE", 57, 62], ["faeces", "ORGANISM_SUBSTANCE", 67, 73], ["cytotoxic urine and faeces", "PROBLEM", 47, 73], ["chemotherapy", "TREATMENT", 116, 128], ["declining chemotherapy", "TREATMENT", 197, 219]]], ["Immunotherapy or immunization has no such associated hazards.DiscussionAt the time of census, survival rates of 50% for amputation, 49% for biopsy, 75% for debulking and 86% for resectable tumors were observed.", [["resectable tumors", "ANATOMY", 178, 195], ["amputation", "DISEASE", 120, 130], ["tumors", "DISEASE", 189, 195], ["tumors", "CANCER", 189, 195], ["Immunotherapy", "TREATMENT", 0, 13], ["immunization", "TREATMENT", 17, 29], ["survival rates", "TEST", 94, 108], ["amputation", "TEST", 120, 130], ["biopsy", "TEST", 140, 146], ["debulking", "TREATMENT", 156, 165], ["resectable tumors", "PROBLEM", 178, 195], ["tumors", "OBSERVATION", 189, 195]]], ["The results indicate complete resection or debulking of tumor likely improves outcome as less residual disease will be present and this gives more time for vaccinations to stimulate the immune system.", [["tumor", "ANATOMY", 56, 61], ["immune system", "ANATOMY", 186, 199], ["tumor", "DISEASE", 56, 61], ["tumor", "CANCER", 56, 61], ["complete resection", "TREATMENT", 21, 39], ["debulking", "TREATMENT", 43, 52], ["tumor", "PROBLEM", 56, 61], ["less residual disease", "PROBLEM", 89, 110], ["vaccinations", "TREATMENT", 156, 168], ["complete", "OBSERVATION_MODIFIER", 21, 29], ["resection", "OBSERVATION", 30, 39], ["debulking", "OBSERVATION", 43, 52], ["tumor", "OBSERVATION", 56, 61]]], ["Further, with complete resection, surgical cure may have been achieved by the surgery alone.", [["complete resection", "TREATMENT", 14, 32], ["surgical cure", "TREATMENT", 34, 47], ["the surgery", "TREATMENT", 74, 85], ["resection", "OBSERVATION", 23, 32]]], ["While biopsied subjects had a reduced response rate, this is most likely due to higher residual disease burden; although some longer term survivors (n = 3) with stable disease indicate biopsy samples and vaccination as an approach still demonstrated a positive clinical benefit.DiscussionWhile there was no significant difference in survival between dose schedules at the time of the census, of patients receiving four weekly doses, then monthly boosters 83% were still alive compared to 60% survival in those dosed at monthly intervals and 50% in those with fortnightly dosing \u00b1 monthly boosts.", [["biopsy samples", "ANATOMY", 185, 199], ["biopsy samples", "CANCER", 185, 199], ["patients", "ORGANISM", 395, 403], ["patients", "SPECIES", 395, 403], ["a reduced response rate", "PROBLEM", 28, 51], ["higher residual disease burden", "PROBLEM", 80, 110], ["some longer term survivors", "PROBLEM", 121, 147], ["stable disease", "PROBLEM", 161, 175], ["biopsy samples", "TEST", 185, 199], ["vaccination", "TREATMENT", 204, 215], ["an approach", "TEST", 219, 230], ["dose schedules", "TREATMENT", 350, 364], ["most likely due to", "UNCERTAINTY", 61, 79], ["higher", "OBSERVATION_MODIFIER", 80, 86], ["residual", "OBSERVATION_MODIFIER", 87, 95], ["disease", "OBSERVATION", 96, 103], ["stable", "OBSERVATION_MODIFIER", 161, 167], ["disease", "OBSERVATION", 168, 175], ["no", "UNCERTAINTY", 304, 306], ["significant", "OBSERVATION_MODIFIER", 307, 318], ["difference", "OBSERVATION_MODIFIER", 319, 329]]], ["The 0% survival rate of dogs receiving one dose or less represents the late stage cancers in these patients on enrollment in the trial.", [["cancers", "ANATOMY", 82, 89], ["cancers", "DISEASE", 82, 89], ["dogs", "ORGANISM", 24, 28], ["cancers", "CANCER", 82, 89], ["patients", "ORGANISM", 99, 107], ["dogs", "SPECIES", 24, 28], ["patients", "SPECIES", 99, 107], ["The 0% survival rate of dogs", "TREATMENT", 0, 28], ["the late stage cancers", "PROBLEM", 67, 89], ["late stage", "OBSERVATION_MODIFIER", 71, 81], ["cancers", "OBSERVATION", 82, 89]]], ["The results indicate that a more intense weekly vaccination schedule for four doses up front may improve response rates and outcomes.DiscussionThe wide range of cancers treated by autologous vaccine varied from blood cancers (lymphoma) to various solid tumor types (mast cell tumor, osteosarcoma etc.).", [["cancers", "ANATOMY", 161, 168], ["blood cancers", "ANATOMY", 211, 224], ["lymphoma", "ANATOMY", 226, 234], ["solid tumor", "ANATOMY", 247, 258], ["mast cell tumor", "ANATOMY", 266, 281], ["osteosarcoma", "ANATOMY", 283, 295], ["cancers", "DISEASE", 161, 168], ["blood cancers", "DISEASE", 211, 224], ["lymphoma", "DISEASE", 226, 234], ["tumor", "DISEASE", 253, 258], ["mast cell tumor", "DISEASE", 266, 281], ["osteosarcoma", "DISEASE", 283, 295], ["cancers", "CANCER", 161, 168], ["blood cancers", "CANCER", 211, 224], ["lymphoma", "CANCER", 226, 234], ["solid tumor", "CANCER", 247, 258], ["mast cell tumor", "CANCER", 266, 281], ["osteosarcoma", "CANCER", 283, 295], ["a more intense weekly vaccination schedule", "TREATMENT", 26, 68], ["cancers", "PROBLEM", 161, 168], ["autologous vaccine", "TREATMENT", 180, 198], ["blood cancers", "PROBLEM", 211, 224], ["lymphoma", "PROBLEM", 226, 234], ["various solid tumor types", "PROBLEM", 239, 264], ["mast cell tumor", "PROBLEM", 266, 281], ["osteosarcoma", "PROBLEM", 283, 295], ["cancers", "OBSERVATION", 161, 168], ["blood", "ANATOMY", 211, 216], ["cancers", "OBSERVATION", 217, 224], ["lymphoma", "OBSERVATION", 226, 234], ["solid", "OBSERVATION_MODIFIER", 247, 252], ["tumor", "OBSERVATION", 253, 258], ["mast cell tumor", "OBSERVATION", 266, 281], ["osteosarcoma", "OBSERVATION", 283, 295]]], ["Although not a controlled study, suggestion of a possible positive effect of vaccination was seen for carcinomas, sarcomas and mast cell tumors.", [["carcinomas", "ANATOMY", 102, 112], ["sarcomas", "ANATOMY", 114, 122], ["mast cell tumors", "ANATOMY", 127, 143], ["carcinomas", "DISEASE", 102, 112], ["sarcomas", "DISEASE", 114, 122], ["mast cell tumors", "DISEASE", 127, 143], ["carcinomas", "CANCER", 102, 112], ["sarcomas", "CANCER", 114, 122], ["mast cell tumors", "CANCER", 127, 143], ["a controlled study", "TEST", 13, 31], ["positive effect of vaccination", "PROBLEM", 58, 88], ["carcinomas", "PROBLEM", 102, 112], ["sarcomas", "PROBLEM", 114, 122], ["mast cell tumors", "PROBLEM", 127, 143], ["sarcomas", "OBSERVATION", 114, 122], ["mast cell tumors", "OBSERVATION", 127, 143]]], ["Interestingly, 4/5 subjects with B cell lymphomas that survived less than 3 months were all treated with a vaccine containing rhizavidin, whereas the other case with the stable disease at 9 months received only tumor lysate and Advax\u2122.", [["B cell lymphomas", "ANATOMY", 33, 49], ["tumor lysate", "ANATOMY", 211, 223], ["B cell lymphomas", "DISEASE", 33, 49], ["rhizavidin", "CHEMICAL", 126, 136], ["tumor", "DISEASE", 211, 216], ["rhizavidin", "CHEMICAL", 126, 136], ["B cell lymphomas", "CANCER", 33, 49], ["rhizavidin", "SIMPLE_CHEMICAL", 126, 136], ["tumor", "CANCER", 211, 216], ["Advax\u2122", "SIMPLE_CHEMICAL", 228, 234], ["B cell lymphomas", "PROBLEM", 33, 49], ["a vaccine containing rhizavidin", "TREATMENT", 105, 136], ["the stable disease", "PROBLEM", 166, 184], ["tumor lysate", "TREATMENT", 211, 223], ["Advax\u2122", "TREATMENT", 228, 234], ["cell lymphomas", "OBSERVATION", 35, 49], ["stable", "OBSERVATION_MODIFIER", 170, 176], ["disease", "OBSERVATION", 177, 184], ["tumor lysate", "OBSERVATION", 211, 223]]], ["Given the overall negative trend in patients receiving rhizavidin in their vaccine formulation, it has been excluded from future studies.", [["rhizavidin", "CHEMICAL", 55, 65], ["rhizavidin", "CHEMICAL", 55, 65], ["patients", "ORGANISM", 36, 44], ["rhizavidin", "SIMPLE_CHEMICAL", 55, 65], ["patients", "SPECIES", 36, 44], ["rhizavidin", "TREATMENT", 55, 65], ["their vaccine formulation", "TREATMENT", 69, 94], ["future studies", "TEST", 122, 136]]], ["This highlights the value of treating canine patients with spontaneous tumors in a clinical setting before translating to human therapy.DiscussionThe autologous vaccine containing Advax\u2122 adjuvant proved to be a safe alternative with significant clinical benefits due to ease of administration.", [["tumors", "ANATOMY", 71, 77], ["tumors", "DISEASE", 71, 77], ["Advax\u2122", "CHEMICAL", 180, 186], ["canine", "ORGANISM", 38, 44], ["patients", "ORGANISM", 45, 53], ["tumors", "CANCER", 71, 77], ["human", "ORGANISM", 122, 127], ["Advax\u2122", "SIMPLE_CHEMICAL", 180, 186], ["canine", "SPECIES", 38, 44], ["patients", "SPECIES", 45, 53], ["human", "SPECIES", 122, 127], ["canine", "SPECIES", 38, 44], ["human", "SPECIES", 122, 127], ["spontaneous tumors", "PROBLEM", 59, 77], ["human therapy", "TREATMENT", 122, 135], ["The autologous vaccine", "TREATMENT", 146, 168], ["Advax\u2122 adjuvant", "TREATMENT", 180, 195], ["tumors", "OBSERVATION", 71, 77]]], ["The vaccination schedule was well accepted by dog owners, and well tolerated by dogs with minimal side effects.", [["dog", "ORGANISM", 46, 49], ["dogs", "ORGANISM", 80, 84], ["dogs", "SPECIES", 80, 84], ["The vaccination schedule", "TREATMENT", 0, 24], ["minimal side effects", "PROBLEM", 90, 110]]], ["Sedation or general anaesthesia was not required to administer the vaccine, and the pet could be returned to the owner quickly, which contrasts with chemotherapy and some radiation therapies where animal contact with the family must be restricted during the metabolism and excretion of the drug.DiscussionLastly, the turn-around-time of several hours from tumor resection or biopsy to vaccine manufacture and subsequent administration significantly expedites treatment compared to other immunotherapy approaches.ConclusionsIn conclusion, these results demonstrate the feasibility of using Advax\u2122-based autologous vaccines for the treatment of several types of naturally occurring canine cancers.", [["tumor", "ANATOMY", 356, 361], ["canine cancers", "ANATOMY", 680, 694], ["tumor", "DISEASE", 356, 361], ["Advax\u2122", "CHEMICAL", 589, 595], ["canine cancers", "DISEASE", 680, 694], ["tumor", "CANCER", 356, 361], ["Advax\u2122", "SIMPLE_CHEMICAL", 589, 595], ["canine", "ORGANISM", 680, 686], ["cancers", "CANCER", 687, 694], ["canine", "SPECIES", 680, 686], ["Sedation", "TREATMENT", 0, 8], ["general anaesthesia", "TREATMENT", 12, 31], ["the vaccine", "TREATMENT", 63, 74], ["chemotherapy", "TREATMENT", 149, 161], ["some radiation therapies", "TREATMENT", 166, 190], ["the drug", "TREATMENT", 286, 294], ["tumor resection", "TREATMENT", 356, 371], ["biopsy", "TREATMENT", 375, 381], ["vaccine manufacture", "TREATMENT", 385, 404], ["subsequent administration significantly expedites treatment", "TREATMENT", 409, 468], ["other immunotherapy approaches", "TREATMENT", 481, 511], ["Advax\u2122", "TREATMENT", 589, 595], ["based autologous vaccines", "TREATMENT", 596, 621], ["the treatment", "TREATMENT", 626, 639], ["naturally occurring canine cancers", "PROBLEM", 660, 694], ["resection", "OBSERVATION", 362, 371], ["canine cancers", "OBSERVATION", 680, 694]]], ["The trial demonstrated safety and proof of concept, achieving positive clinical benefits in some patients including remission, static disease, and extended survival times in a clinical setting.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["static disease", "PROBLEM", 127, 141]]], ["Future controlled clinical trials with increased numbers of canine patients will be required to define clinical benefit.PatentsAdvax\u2122 adjuvants are covered by patents owned by Vaxine Pty Ltd.PatentsAuthor Contributions: C.W. was a lead investigator in this study and developed the methodology to make the vaccine.", [["canine", "ORGANISM", 60, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["canine", "SPECIES", 60, 66], ["PatentsAdvax\u2122 adjuvants", "TREATMENT", 120, 143], ["this study", "TEST", 252, 262], ["the vaccine", "TREATMENT", 301, 312]]], ["He was involved in the original draft preparation and data curation and analysis.", [["data curation", "TEST", 54, 67], ["analysis", "TEST", 72, 80]]], ["A.O. was a principal investigator involved in data curation, treating canine patients and writing, reviewing and editing.", [["canine", "ORGANISM", 70, 76], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["canine", "SPECIES", 70, 76]]], ["J.M. treated patients in the study and helped collate data.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["M.A. treated patients in the study.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["N.K. treated patients in the study.", [["N.K.", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["Z.W.-W. treated patients in the study.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["the study", "TEST", 28, 37]]], ["F.T. treated patients in the study.", [["F.T.", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["P.M.-W. treated patients in the study.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["the study", "TEST", 28, 37]]], ["H.R. treated patients in the study.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["R.N. treated patients in the study.", [["R.N.", "CHEMICAL", 0, 4], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the study", "TEST", 25, 34]]], ["K.C. was an investigator on the study.", [["the study", "TEST", 28, 37]]], ["N.P. provided resources for the study and helped with manuscript review and editing and data analysis.", [["the study", "TEST", 28, 37], ["editing and data analysis", "TEST", 76, 101]]]], "PMC3147166": [["IntroductionIn order to discuss the ways in which viruses exploit the host Ub machinery, we must first provide a general outline of that machinery.", [["Ub", "GENE_OR_GENE_PRODUCT", 75, 77], ["Ub", "PROTEIN", 75, 77]]], ["Prior to its conjugation to targeted proteins, Ub is first activated via an ATP-dependent thioester linkage to an E1 enzyme (reviewed in Schulman and Harper, 2009).", [["ATP", "CHEMICAL", 76, 79], ["ATP", "CHEMICAL", 76, 79], ["thioester", "CHEMICAL", 90, 99], ["Ub", "GENE_OR_GENE_PRODUCT", 47, 49], ["ATP", "SIMPLE_CHEMICAL", 76, 79], ["targeted proteins", "PROTEIN", 28, 45], ["Ub", "PROTEIN", 47, 49], ["E1 enzyme", "PROTEIN", 114, 123], ["an ATP-dependent thioester linkage", "TREATMENT", 73, 107], ["an E1 enzyme", "TEST", 111, 123]]], ["Once activated, the energy in that unstable bond is then used to couple the Ub moiety\u2019s C-terminal residue to the catalytic Cys residue of an E2 Ub conjugating enzyme (reviewed in Pickart, 2001).", [["E2", "CHEMICAL", 142, 144], ["Cys", "CHEMICAL", 124, 127], ["Ub", "GENE_OR_GENE_PRODUCT", 76, 78], ["E2 Ub", "GENE_OR_GENE_PRODUCT", 142, 147], ["Ub moiety", "PROTEIN", 76, 85], ["E2 Ub conjugating enzyme", "PROTEIN", 142, 166], ["the Ub moiety", "TREATMENT", 72, 85], ["C-terminal residue", "PROBLEM", 88, 106], ["an E2 Ub conjugating enzyme", "TEST", 139, 166], ["unstable", "OBSERVATION", 35, 43]]], ["Ub-loaded E2 enzymes are then ready to form conjugates between the Ub C-terminal glycine and either Lys, Ser, Thr, Cys, or N-terminal-MET residues within proteins to be ubiquitinated (Breitschopf et al., 1998; Cadwell and Coscoy, 2005; Wang et al., 2007; Williams et al., 2007).", [["E2", "CHEMICAL", 10, 12], ["glycine", "CHEMICAL", 81, 88], ["C", "CHEMICAL", 70, 71], ["glycine", "CHEMICAL", 81, 88], ["Lys", "CHEMICAL", 100, 103], ["Ser", "CHEMICAL", 105, 108], ["Thr", "CHEMICAL", 110, 113], ["Cys", "CHEMICAL", 115, 118], ["N-", "CHEMICAL", 123, 125], ["Ub", "GENE_OR_GENE_PRODUCT", 0, 2], ["E2", "GENE_OR_GENE_PRODUCT", 10, 12], ["Ub", "GENE_OR_GENE_PRODUCT", 67, 69], ["glycine", "AMINO_ACID", 81, 88], ["Lys", "AMINO_ACID", 100, 103], ["Ser,", "AMINO_ACID", 105, 109], ["Thr,", "AMINO_ACID", 110, 114], ["Cys", "AMINO_ACID", 115, 118], ["Ub", "PROTEIN", 0, 2], ["E2 enzymes", "PROTEIN", 10, 20], ["Ub C-terminal glycine", "PROTEIN", 67, 88], ["N-terminal-MET residues", "PROTEIN", 123, 146], ["Ub", "TEST", 0, 2], ["E2 enzymes", "TREATMENT", 10, 20], ["conjugates", "TEST", 44, 54], ["terminal glycine", "TREATMENT", 72, 88], ["Cys", "TEST", 115, 118], ["N-terminal-MET residues", "PROBLEM", 123, 146]]], ["The specificity of that conjugation process is conferred by the over 600 E3 Ub ligases encoded by the human genome (Li et al., 2008).", [["Ub", "GENE_OR_GENE_PRODUCT", 76, 78], ["human", "ORGANISM", 102, 107], ["E3 Ub ligases", "PROTEIN", 73, 86], ["human genome", "DNA", 102, 114], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107]]], ["Thus far, four primary types of E3 ligases have been described, and their sub-categorization is based on common structural features.", [["E3", "GENE_OR_GENE_PRODUCT", 32, 34], ["E3 ligases", "PROTEIN", 32, 42], ["E3 ligases", "PROBLEM", 32, 42], ["E3 ligases", "OBSERVATION", 32, 42]]], ["The RING (really interesting new gene, reviewed in Deshaies and Joazeiro, 2009) ligases, which are by far the most commonly occurring E3s, serve as docking complexes that bring E2 and target proteins within close proximity, whereupon the E2 catalyzes the transfer of Ub to the substrate protein.", [["E2", "CHEMICAL", 177, 179], ["E2", "CHEMICAL", 238, 240], ["RING", "GENE_OR_GENE_PRODUCT", 4, 8], ["E3s", "GENE_OR_GENE_PRODUCT", 134, 137], ["E2", "GENE_OR_GENE_PRODUCT", 177, 179], ["E2", "GENE_OR_GENE_PRODUCT", 238, 240], ["Ub", "GENE_OR_GENE_PRODUCT", 267, 269], ["RING", "PROTEIN", 4, 8], ["E3s", "PROTEIN", 134, 137], ["docking complexes", "PROTEIN", 148, 165], ["E2", "PROTEIN", 177, 179], ["E2", "PROTEIN", 238, 240], ["Ub", "PROTEIN", 267, 269], ["substrate protein", "PROTEIN", 277, 294], ["RING", "OBSERVATION_MODIFIER", 4, 8]]], ["The primary identifying feature of a RING domain is a conserved (Cys)3-His-(Cys)4 sequence that coordinates a pair of zinc atoms to maintain its structure.", [["zinc", "CHEMICAL", 118, 122], ["Cys", "CHEMICAL", 65, 68], ["His", "CHEMICAL", 71, 74], ["Cys", "CHEMICAL", 76, 79], ["zinc", "CHEMICAL", 118, 122], ["zinc atoms", "SIMPLE_CHEMICAL", 118, 128], ["RING domain", "PROTEIN", 37, 48], ["a RING domain", "PROBLEM", 35, 48], ["His-(Cys)", "TREATMENT", 71, 80], ["a pair of zinc atoms", "TREATMENT", 108, 128], ["RING domain", "OBSERVATION", 37, 48]]], ["The plant homeodomain (PHD) ligases are structurally related to the RING ligases and use what appears to be a reversed set of residues [(Cys)4-His-(Cys)3] to coordinate a pair of zinc atoms (reviewed in Bienz, 2006).", [["zinc", "CHEMICAL", 179, 183], ["[(Cys)4-His-(Cys)3", "CHEMICAL", 135, 153], ["zinc", "CHEMICAL", 179, 183], ["PHD", "GENE_OR_GENE_PRODUCT", 23, 26], ["zinc atoms", "SIMPLE_CHEMICAL", 179, 189], ["plant homeodomain (PHD) ligases", "PROTEIN", 4, 35], ["RING ligases", "PROTEIN", 68, 80], ["The plant homeodomain (PHD) ligases", "TREATMENT", 0, 35], ["the RING ligases", "TREATMENT", 64, 80], ["a reversed set of residues [(Cys)", "TREATMENT", 108, 141], ["His-(Cys)", "TREATMENT", 143, 152], ["plant homeodomain", "OBSERVATION", 4, 21]]], ["PHD domains are found in many chromatin-binding proteins, and once their similarity to RING domains was noted, it was expected that at least a subset of these would also function as E3s.", [["chromatin", "ANATOMY", 30, 39], ["PHD", "GENE_OR_GENE_PRODUCT", 0, 3], ["chromatin", "CELLULAR_COMPONENT", 30, 39], ["RING", "GENE_OR_GENE_PRODUCT", 87, 91], ["E3s", "GENE_OR_GENE_PRODUCT", 182, 185], ["PHD domains", "PROTEIN", 0, 11], ["chromatin", "DNA", 30, 39], ["binding proteins", "PROTEIN", 40, 56], ["RING domains", "PROTEIN", 87, 99], ["E3s", "PROTEIN", 182, 185], ["PHD domains", "PROBLEM", 0, 11], ["many", "OBSERVATION_MODIFIER", 25, 29], ["chromatin", "OBSERVATION", 30, 39], ["binding proteins", "OBSERVATION", 40, 56]]], ["However, thus far, only two examples of PHD proteins with E3 activity have surfaced (Dul and Walworth, 2007; Ivanov et al., 2007).", [["PHD", "GENE_OR_GENE_PRODUCT", 40, 43], ["E3", "GENE_OR_GENE_PRODUCT", 58, 60], ["PHD proteins", "PROTEIN", 40, 52], ["E3", "PROTEIN", 58, 60], ["PHD proteins", "PROBLEM", 40, 52]]], ["The U-box (ubiquitin fusion degradation, UFD2-homology domain) ligases were first identified in yeast (Koegl et al., 1999), and seven human genes encoding such ligases have been identified (reviewed in Marin, 2010).", [["U-box", "GENE_OR_GENE_PRODUCT", 4, 9], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 11, 20], ["UFD2", "GENE_OR_GENE_PRODUCT", 41, 45], ["human", "ORGANISM", 134, 139], ["U-box", "DNA", 4, 9], ["ubiquitin fusion degradation, UFD2-homology domain) ligases", "PROTEIN", 11, 70], ["human genes", "DNA", 134, 145], ["ligases", "PROTEIN", 160, 167], ["yeast", "SPECIES", 96, 101], ["human", "SPECIES", 134, 139], ["yeast", "SPECIES", 96, 101], ["human", "SPECIES", 134, 139], ["The U-box (ubiquitin fusion degradation", "TREATMENT", 0, 39], ["ligases", "TEST", 63, 70]]], ["A subset of this family are referred to as E4 ligases, which are distinguished from E3 ligases by virtue of their specific targeting of substrates that have already been modified with 1\u20133 ubiquitin residues (Hoppe, 2005).", [["E4", "GENE_OR_GENE_PRODUCT", 43, 45], ["E3", "GENE_OR_GENE_PRODUCT", 84, 86], ["E4 ligases", "PROTEIN", 43, 53], ["E3 ligases", "PROTEIN", 84, 94], ["1\u20133 ubiquitin residues", "PROTEIN", 184, 206]]], ["Interestingly, U-box ligases are structurally related to RING fingers, but this structure is maintained in the absence of zinc-chelating residues (Aravind and Koonin, 2000; Ohi et al., 2003).", [["zinc", "CHEMICAL", 122, 126], ["zinc", "CHEMICAL", 122, 126], ["U-box ligases", "GENE_OR_GENE_PRODUCT", 15, 28], ["RING", "GENE_OR_GENE_PRODUCT", 57, 61], ["zinc-chelating residues", "SIMPLE_CHEMICAL", 122, 145], ["U-box ligases", "PROTEIN", 15, 28], ["RING fingers", "PROTEIN", 57, 69], ["box ligases", "TEST", 17, 28], ["RING fingers", "PROBLEM", 57, 69], ["RING fingers", "OBSERVATION", 57, 69], ["maintained", "OBSERVATION_MODIFIER", 93, 103], ["chelating residues", "OBSERVATION", 127, 145]]], ["Therefore, based on structural features alone, the RING, PHD, and U-box ligases can all be viewed as RING-like variants.", [["RING", "GENE_OR_GENE_PRODUCT", 51, 55], ["PHD", "GENE_OR_GENE_PRODUCT", 57, 60], ["U-box ligases", "GENE_OR_GENE_PRODUCT", 66, 79], ["RING", "GENE_OR_GENE_PRODUCT", 101, 105], ["RING", "PROTEIN", 51, 55], ["PHD", "PROTEIN", 57, 60], ["U-box ligases", "PROTEIN", 66, 79], ["RING", "PROTEIN", 101, 105], ["U-box ligases", "TREATMENT", 66, 79]]], ["Finally, the HECT (homologous to E6-associated protein C-terminus, reviewed in Rotin and Kumar, 2009) ligases harbor their own catalytic cysteine residues to which Ub is first transferred from an E2 enzyme.", [["E2", "CHEMICAL", 196, 198], ["cysteine", "CHEMICAL", 137, 145], ["HECT", "GENE_OR_GENE_PRODUCT", 13, 17], ["E6", "GENE_OR_GENE_PRODUCT", 33, 35], ["Ub", "GENE_OR_GENE_PRODUCT", 164, 166], ["E2", "GENE_OR_GENE_PRODUCT", 196, 198], ["HECT", "PROTEIN", 13, 17], ["E6", "PROTEIN", 33, 35], ["associated protein C-terminus", "PROTEIN", 36, 65], ["Rotin and Kumar, 2009) ligases", "PROTEIN", 79, 109], ["Ub", "PROTEIN", 164, 166], ["E2 enzyme", "PROTEIN", 196, 205], ["the HECT", "TEST", 9, 17], ["E6", "TEST", 33, 35], ["catalytic cysteine residues", "TREATMENT", 127, 154], ["an E2 enzyme", "TEST", 193, 205], ["cysteine residues", "OBSERVATION", 137, 154]]], ["Once loaded, the HECT ligases themselves catalyze target ubiquitination.IntroductionAs initially described, lysines were the residues most frequently modified via ubiquitination, and it was found that K48-linked polyubiquitin chains were attached to proteins destined for degradation via the 26S proteasome (reviewed in Hershko and Ciechanover, 1998; Mayer, 2000).", [["lysines", "CHEMICAL", 108, 115], ["K48", "CHEMICAL", 201, 204], ["HECT", "GENE_OR_GENE_PRODUCT", 17, 21], ["K48", "SIMPLE_CHEMICAL", 201, 204], ["26S", "GENE_OR_GENE_PRODUCT", 292, 295], ["HECT ligases", "PROTEIN", 17, 29], ["K48", "PROTEIN", 201, 204], ["polyubiquitin chains", "PROTEIN", 212, 232], ["26S proteasome", "PROTEIN", 292, 306], ["the HECT ligases", "TREATMENT", 13, 29], ["IntroductionAs", "TREATMENT", 72, 86], ["K48-linked polyubiquitin chains", "PROBLEM", 201, 232], ["polyubiquitin chains", "OBSERVATION", 212, 232]]], ["Since that time, it is now appreciated that all seven Lys residues within Ub can be used to build chains (Xu et al., 2009), and that this leads to Ub polymers with extremely diverse topologies (reviewed in Komander, 2009), further adding to ubiquitin\u2019s flexibility as a post-translational modification.", [["Lys", "CHEMICAL", 54, 57], ["Ub", "GENE_OR_GENE_PRODUCT", 74, 76], ["Ub", "GENE_OR_GENE_PRODUCT", 147, 149], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 241, 250], ["Ub", "PROTEIN", 74, 76], ["ubiquitin", "PROTEIN", 241, 250], ["Ub polymers", "TREATMENT", 147, 158], ["ubiquitin\u2019s flexibility", "TREATMENT", 241, 264], ["a post-translational modification", "TREATMENT", 268, 301]]], ["It is important to note that ubiquitination can be reversed by de-ubiquitinating (DUB) proteases, so, like other post-translational modifications, Ub signals can be precisely controlled.", [["DUB", "GENE_OR_GENE_PRODUCT", 82, 85], ["Ub", "GENE_OR_GENE_PRODUCT", 147, 149], ["de-ubiquitinating (DUB) proteases", "PROTEIN", 63, 96], ["Ub", "PROTEIN", 147, 149]]], ["There are also examples of proteins that harbor Ub-binding motifs, which, in combination with Ub ligases and DUBs, enable Ub to serve as a reversible protein-binding surface that allows for regulated generation and subsequent disassembly of protein complexes (reviewed in Hicke et al., 2005; Dikic et al., 2009).", [["Ub", "GENE_OR_GENE_PRODUCT", 48, 50], ["Ub", "GENE_OR_GENE_PRODUCT", 94, 96], ["DUBs", "GENE_OR_GENE_PRODUCT", 109, 113], ["Ub", "GENE_OR_GENE_PRODUCT", 122, 124], ["surface", "CELLULAR_COMPONENT", 166, 173], ["Ub", "PROTEIN", 48, 50], ["Ub ligases", "PROTEIN", 94, 104], ["DUBs", "PROTEIN", 109, 113], ["Ub", "PROTEIN", 122, 124], ["protein complexes", "PROTEIN", 241, 258], ["binding motifs", "PROBLEM", 51, 65], ["Ub ligases", "PROBLEM", 94, 104], ["DUBs", "PROBLEM", 109, 113], ["a reversible protein-binding surface", "PROBLEM", 137, 173], ["binding motifs", "OBSERVATION_MODIFIER", 51, 65], ["ligases", "OBSERVATION", 97, 104]]], ["Finally, the ubiquitin domain has been found to be encoded within the linear sequence of larger proteins.", [["ubiquitin domain", "PROTEIN", 13, 29], ["the ubiquitin domain", "PROBLEM", 9, 29], ["larger", "OBSERVATION_MODIFIER", 89, 95], ["proteins", "OBSERVATION", 96, 104]]], ["While several such ubiquitin-like domain (ULD) proteins have been shown to be involved with protein degradation and proteasome function, others participate in functions ranging from metabolism to signal transduction, in both prokaryotes and eukaryotes (reviewed in Burroughs et al., 2007; Grabbe and Dikic, 2009).", [["ULD", "GENE_OR_GENE_PRODUCT", 42, 45], ["ubiquitin-like domain (ULD) proteins", "PROTEIN", 19, 55], ["proteasome", "PROTEIN", 116, 126], ["several such ubiquitin-like domain (ULD) proteins", "PROBLEM", 6, 55], ["protein degradation and proteasome function", "PROBLEM", 92, 135], ["signal transduction", "TEST", 196, 215]]], ["Thus, the small ubiquitin domain and its cognate ubiquitin-binding domains represent a pair of complimentary structural features that have seen a great deal of use, reuse, and reassortment during evolution.IntroductionThere are of course many examples in which the host itself uses Ub to limit viral production, particularly via the activation of NF-\u03baB (reviewed in Skaug et al., 2009).", [["Ub", "GENE_OR_GENE_PRODUCT", 282, 284], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 347, 352], ["small ubiquitin domain", "PROTEIN", 10, 32], ["cognate ubiquitin-binding domains", "PROTEIN", 41, 74], ["Ub", "PROTEIN", 282, 284], ["NF-\u03baB", "PROTEIN", 347, 352], ["the small ubiquitin domain", "PROBLEM", 6, 32], ["complimentary structural features", "PROBLEM", 95, 128], ["small", "OBSERVATION_MODIFIER", 10, 15], ["ubiquitin domain", "OBSERVATION", 16, 32]]], ["Likewise, in addition to Ub, there are other Ub-like (UBL) proteins that are used to modify and control cellular processes (reviewed in Hochstrasser, 2009).", [["cellular", "ANATOMY", 104, 112], ["Ub", "GENE_OR_GENE_PRODUCT", 25, 27], ["Ub", "GENE_OR_GENE_PRODUCT", 45, 47], ["UBL", "GENE_OR_GENE_PRODUCT", 54, 57], ["cellular", "CELL", 104, 112], ["Ub", "PROTEIN", 25, 27], ["Ub-like (UBL) proteins", "PROTEIN", 45, 67], ["other Ub-like (UBL) proteins", "PROBLEM", 39, 67]]], ["However, because it is the most extensively characterized of the Ub-like proteins, we have chosen to focus upon Ub itself and the ways in which viruses exploit this small protein at each stage of the lifecycle.", [["Ub", "GENE_OR_GENE_PRODUCT", 65, 67], ["Ub", "GENE_OR_GENE_PRODUCT", 112, 114], ["Ub", "PROTEIN", 65, 67], ["Ub", "PROTEIN", 112, 114], ["the Ub-like proteins", "PROBLEM", 61, 81], ["this small protein", "PROBLEM", 160, 178]]], ["At the end of the review, we have provided a figure that integrates many of the examples discussed herein.Proteasome inhibitors in vivo ::: Viral Entry and Nucleocapsid TransportBecause numerous in vitro studies have shown that multiple points in the viral life cycle can be blocked with proteasome inhibitors, their potential use as anti-viral agents has been an enthusiastic topic of discussion.", [["Proteasome", "GENE_OR_GENE_PRODUCT", 106, 116], ["Proteasome inhibitors", "TREATMENT", 106, 127], ["Viral Entry", "PROBLEM", 140, 151], ["vitro studies", "TEST", 198, 211], ["the viral life cycle", "TREATMENT", 247, 267], ["proteasome inhibitors", "TREATMENT", 288, 309], ["anti-viral agents", "TREATMENT", 334, 351], ["multiple", "OBSERVATION_MODIFIER", 228, 236]]], ["However, recent in vivo studies suggest no clear consensus for the efficacy of these inhibitors.", [["vivo studies", "TEST", 19, 31], ["these inhibitors", "TREATMENT", 79, 95], ["no", "UNCERTAINTY", 40, 42]]], ["Several mouse studies evaluating the proteasome inhibitor bortezomib, which is clinically approved for multiple myeloma, found that lymphocytic choriomeningitis virus (LCMV; Basler et al., 2009), mouse hepatitis virus (MHV; Raaben et al., 2010a), and human respiratory syncytial virus (HRSV; Lupfer et al., 2010) each replicated better in the presence of bortezomib, so much so that MHV and HRSV hastened the mortality of infected mice.", [["myeloma", "ANATOMY", 112, 119], ["bortezomib", "CHEMICAL", 58, 68], ["multiple myeloma", "DISEASE", 103, 119], ["lymphocytic choriomeningitis virus", "DISEASE", 132, 166], ["mouse hepatitis virus", "DISEASE", 196, 217], ["respiratory syncytial virus", "DISEASE", 257, 284], ["bortezomib", "CHEMICAL", 355, 365], ["bortezomib", "CHEMICAL", 58, 68], ["bortezomib", "CHEMICAL", 355, 365], ["mouse", "ORGANISM", 8, 13], ["bortezomib", "SIMPLE_CHEMICAL", 58, 68], ["myeloma", "CANCER", 112, 119], ["lymphocytic choriomeningitis virus", "ORGANISM", 132, 166], ["LCMV", "ORGANISM", 168, 172], ["mouse hepatitis virus", "ORGANISM", 196, 217], ["MHV", "ORGANISM", 219, 222], ["human", "ORGANISM", 251, 256], ["respiratory syncytial virus", "ORGANISM", 257, 284], ["HRSV", "ORGANISM", 286, 290], ["bortezomib", "SIMPLE_CHEMICAL", 355, 365], ["MHV", "ORGANISM", 383, 386], ["HRSV", "ORGANISM", 391, 395], ["mice", "ORGANISM", 431, 435], ["mouse", "SPECIES", 8, 13], ["lymphocytic choriomeningitis virus", "SPECIES", 132, 166], ["mouse", "SPECIES", 196, 201], ["hepatitis virus", "SPECIES", 202, 217], ["human", "SPECIES", 251, 256], ["respiratory syncytial virus", "SPECIES", 257, 284], ["mice", "SPECIES", 431, 435], ["mouse", "SPECIES", 8, 13], ["lymphocytic choriomeningitis virus", "SPECIES", 132, 166], ["LCMV", "SPECIES", 168, 172], ["mouse hepatitis virus", "SPECIES", 196, 217], ["MHV", "SPECIES", 219, 222], ["human respiratory syncytial virus", "SPECIES", 251, 284], ["HRSV", "SPECIES", 286, 290], ["MHV", "SPECIES", 383, 386], ["HRSV", "SPECIES", 391, 395], ["mice", "SPECIES", 431, 435], ["Several mouse studies", "TEST", 0, 21], ["the proteasome inhibitor bortezomib", "TREATMENT", 33, 68], ["multiple myeloma", "PROBLEM", 103, 119], ["lymphocytic choriomeningitis virus", "PROBLEM", 132, 166], ["mouse hepatitis virus", "PROBLEM", 196, 217], ["human respiratory syncytial virus", "PROBLEM", 251, 284], ["HRSV", "PROBLEM", 286, 290], ["bortezomib", "TREATMENT", 355, 365], ["MHV", "TREATMENT", 383, 386], ["HRSV", "PROBLEM", 391, 395], ["myeloma", "OBSERVATION", 112, 119], ["lymphocytic choriomeningitis", "OBSERVATION", 132, 160], ["respiratory syncytial", "ANATOMY", 257, 278]]], ["In contrast, Ma et al. (2010) showed that treatment of MHV-infected mice (pneumonitis model) with three different proteasome inhibitors (including bortezomib) resulted in reduced viral replication and a 40% survival rate.", [["MHV-infected", "DISEASE", 55, 67], ["pneumonitis", "DISEASE", 74, 85], ["bortezomib", "CHEMICAL", 147, 157], ["bortezomib", "CHEMICAL", 147, 157], ["MHV", "ORGANISM", 55, 58], ["mice", "ORGANISM", 68, 72], ["bortezomib", "SIMPLE_CHEMICAL", 147, 157], ["mice", "SPECIES", 68, 72], ["MHV", "SPECIES", 55, 58], ["mice", "SPECIES", 68, 72], ["MHV", "PROBLEM", 55, 58], ["infected mice (pneumonitis model", "PROBLEM", 59, 91], ["three different proteasome inhibitors", "TREATMENT", 98, 135], ["bortezomib", "TREATMENT", 147, 157], ["reduced viral replication", "TREATMENT", 171, 196], ["a 40% survival rate", "TREATMENT", 201, 220], ["MHV", "OBSERVATION", 55, 58], ["infected mice", "OBSERVATION", 59, 72], ["pneumonitis", "OBSERVATION", 74, 85], ["reduced", "OBSERVATION_MODIFIER", 171, 178], ["viral replication", "OBSERVATION", 179, 196]]], ["While these studies are not directly comparable due to the variety of viruses and mouse models employed, they suggest that much more research is necessary before these inhibitors can be approved for the treatment of viral infections.Viral TranscriptionThere are relatively few examples in which viral transcription is enhanced by manipulation of the UPS.", [["viral infections", "DISEASE", 216, 232], ["mouse", "ORGANISM", 82, 87], ["UPS", "GENE_OR_GENE_PRODUCT", 350, 353], ["UPS", "PROTEIN", 350, 353], ["mouse", "SPECIES", 82, 87], ["mouse", "SPECIES", 82, 87], ["these studies", "TEST", 6, 19], ["these inhibitors", "TREATMENT", 162, 178], ["viral infections", "PROBLEM", 216, 232], ["Viral Transcription", "TREATMENT", 233, 252], ["viral transcription", "TREATMENT", 295, 314], ["viruses", "OBSERVATION", 70, 77], ["viral", "OBSERVATION_MODIFIER", 216, 221], ["infections", "OBSERVATION", 222, 232], ["relatively", "OBSERVATION_MODIFIER", 262, 272], ["few", "OBSERVATION_MODIFIER", 273, 276], ["viral transcription", "OBSERVATION", 295, 314], ["enhanced", "OBSERVATION_MODIFIER", 318, 326]]], ["The transactivator proteins encoded by Epstein\u2013Barr virus (EBV), HIV, and human T-lymphotropic virus (HTLV) each appear to interact with the UPS, and this results in the enhancement of transactivator function.", [["Epstein\u2013Barr virus", "ORGANISM", 39, 57], ["EBV", "ORGANISM", 59, 62], ["HIV", "ORGANISM", 65, 68], ["human T-lymphotropic virus", "ORGANISM", 74, 100], ["HTLV", "ORGANISM", 102, 106], ["UPS", "GENE_OR_GENE_PRODUCT", 141, 144], ["transactivator proteins", "PROTEIN", 4, 27], ["UPS", "PROTEIN", 141, 144], ["Epstein\u2013Barr virus", "SPECIES", 39, 57], ["HIV", "SPECIES", 65, 68], ["human", "SPECIES", 74, 79], ["T-lymphotropic virus", "SPECIES", 80, 100], ["Epstein\u2013Barr virus", "SPECIES", 39, 57], ["EBV", "SPECIES", 59, 62], ["HIV", "SPECIES", 65, 68], ["human T-lymphotropic virus", "SPECIES", 74, 100], ["HTLV", "SPECIES", 102, 106], ["The transactivator proteins", "TEST", 0, 27], ["Epstein\u2013Barr virus", "PROBLEM", 39, 57], ["HIV", "PROBLEM", 65, 68], ["human T-lymphotropic virus", "PROBLEM", 74, 100]]], ["The EBV transactivator EBNA1 binds the Ub-specific-processing protease 7 (USP7), a cellular DUB, and this augments binding of EBNA1 to the viral oriP site.", [["cellular", "ANATOMY", 83, 91], ["EBV", "ORGANISM", 4, 7], ["EBNA1", "GENE_OR_GENE_PRODUCT", 23, 28], ["Ub-specific-processing protease 7", "GENE_OR_GENE_PRODUCT", 39, 72], ["USP7", "GENE_OR_GENE_PRODUCT", 74, 78], ["cellular", "CELL", 83, 91], ["EBNA1", "GENE_OR_GENE_PRODUCT", 126, 131], ["EBV transactivator", "PROTEIN", 4, 22], ["EBNA1", "PROTEIN", 23, 28], ["Ub-specific-processing protease 7", "PROTEIN", 39, 72], ["USP7", "PROTEIN", 74, 78], ["cellular DUB", "PROTEIN", 83, 95], ["EBNA1", "PROTEIN", 126, 131], ["viral oriP site", "DNA", 139, 154], ["The EBV transactivator EBNA1", "TEST", 0, 28], ["the Ub", "TEST", 35, 41], ["a cellular DUB", "PROBLEM", 81, 95], ["this augments binding of EBNA1", "TREATMENT", 101, 131], ["cellular DUB", "OBSERVATION", 83, 95], ["viral oriP", "OBSERVATION", 139, 149]]], ["This interaction also results in the deubiquitination of histone 2A at the oriP site (Sarkari et al., 2009), although the relevance of this histone modification to viral transactivation has not been evaluated.", [["histone 2A", "GENE_OR_GENE_PRODUCT", 57, 67], ["histone", "GENE_OR_GENE_PRODUCT", 140, 147], ["histone 2A", "PROTEIN", 57, 67], ["oriP site", "DNA", 75, 84], ["histone", "PROTEIN", 140, 147], ["the deubiquitination of histone 2A", "PROBLEM", 33, 67], ["this histone modification", "TREATMENT", 135, 160], ["viral transactivation", "PROBLEM", 164, 185], ["histone 2A", "OBSERVATION", 57, 67], ["viral transactivation", "OBSERVATION", 164, 185]]], ["The HIV-1 transactivator Tat was shown to be ubiquitinated by Hdm2, which did not result in degradation of Tat, but instead enhanced viral transcription from the LTR (Bres et al., 2003).", [["LTR", "ANATOMY", 162, 165], ["HIV-1", "ORGANISM", 4, 9], ["Tat", "GENE_OR_GENE_PRODUCT", 25, 28], ["Hdm2", "GENE_OR_GENE_PRODUCT", 62, 66], ["Tat", "GENE_OR_GENE_PRODUCT", 107, 110], ["LTR", "CELLULAR_COMPONENT", 162, 165], ["HIV-1 transactivator", "PROTEIN", 4, 24], ["Tat", "PROTEIN", 25, 28], ["Hdm2", "PROTEIN", 62, 66], ["Tat", "PROTEIN", 107, 110], ["LTR", "DNA", 162, 165], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["The HIV", "TEST", 0, 7], ["transactivator Tat", "TEST", 10, 28], ["Tat", "PROBLEM", 107, 110], ["Hdm2", "OBSERVATION", 62, 66]]], ["A more recent paper found that basal (Tat-independent) transcription from the HIV LTR requires Ski-interacting protein (SKIP) recruitment by the histone H2B ring finger protein 20 (RNF20) Ub ligase (Bres et al., 2009).", [["LTR", "ANATOMY", 82, 85], ["Tat", "GENE_OR_GENE_PRODUCT", 38, 41], ["Ski-interacting protein", "GENE_OR_GENE_PRODUCT", 95, 118], ["SKIP", "GENE_OR_GENE_PRODUCT", 120, 124], ["histone H2B ring finger protein 20", "GENE_OR_GENE_PRODUCT", 145, 179], ["RNF20", "GENE_OR_GENE_PRODUCT", 181, 186], ["Ub", "GENE_OR_GENE_PRODUCT", 188, 190], ["Tat", "PROTEIN", 38, 41], ["HIV LTR", "DNA", 78, 85], ["Ski-interacting protein", "PROTEIN", 95, 118], ["SKIP", "PROTEIN", 120, 124], ["histone H2B ring finger protein 20 (RNF20) Ub ligase", "PROTEIN", 145, 197], ["HIV", "SPECIES", 78, 81], ["basal (Tat-independent) transcription", "PROBLEM", 31, 68], ["the HIV LTR", "TREATMENT", 74, 85], ["Ski-interacting protein", "TREATMENT", 95, 118], ["the histone H2B ring", "TREATMENT", 141, 161], ["finger protein", "TEST", 162, 176]]], ["Similar to Tat, the HTLV-1 transactivator Tax is also monoubiquitinated (Chiari et al., 2004) and sumoylated (Nasr et al., 2006).", [["Tat", "GENE_OR_GENE_PRODUCT", 11, 14], ["HTLV-1", "ORGANISM", 20, 26], ["Tax", "GENE_OR_GENE_PRODUCT", 42, 45], ["Tat", "PROTEIN", 11, 14], ["HTLV-1 transactivator", "PROTEIN", 20, 41], ["Tax", "PROTEIN", 42, 45], ["HTLV-1", "SPECIES", 20, 26], ["Tat", "TEST", 11, 14], ["the HTLV", "TEST", 16, 24]]], ["These modifications appear to enhance Tax\u2019s ability to activate NF-\u03baB, which in turn is necessary for viral transactivation and is also responsible for the oncogenic properties of the virus (Nasr et al., 2006; Harhaj et al., 2007).", [["Tax", "GENE_OR_GENE_PRODUCT", 38, 41], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 64, 69], ["Tax", "PROTEIN", 38, 41], ["NF-\u03baB", "PROTEIN", 64, 69], ["viral transactivation", "PROBLEM", 102, 123]]], ["Ubiquitination of Tax C-terminal lysine residues is necessary for its role in binding and relocalizing I\u03baB kinase (IKK) from the cytoplasm to perinuclear regions, which in turn modulates NF-\u03baB activation.", [["cytoplasm", "ANATOMY", 129, 138], ["perinuclear regions", "ANATOMY", 142, 161], ["C", "CHEMICAL", 22, 23], ["lysine", "CHEMICAL", 33, 39], ["Tax", "GENE_OR_GENE_PRODUCT", 18, 21], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 103, 113], ["IKK", "GENE_OR_GENE_PRODUCT", 115, 118], ["cytoplasm", "ORGANISM_SUBSTANCE", 129, 138], ["perinuclear regions", "CELLULAR_COMPONENT", 142, 161], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 187, 192], ["Tax C", "PROTEIN", 18, 23], ["I\u03baB kinase", "PROTEIN", 103, 113], ["IKK", "PROTEIN", 115, 118], ["perinuclear regions", "PROTEIN", 142, 161], ["NF-\u03baB", "PROTEIN", 187, 192], ["Tax C-terminal lysine residues", "TREATMENT", 18, 48], ["lysine residues", "OBSERVATION", 33, 48], ["perinuclear", "ANATOMY_MODIFIER", 142, 153]]], ["The sumoylation of Tax on overlapping lysine residues mediates both the development of Tax nuclear bodies (NB) and complete NF-\u03baB activation (Nasr et al., 2006).", [["nuclear bodies", "ANATOMY", 91, 105], ["NB", "ANATOMY", 107, 109], ["lysine", "CHEMICAL", 38, 44], ["lysine", "CHEMICAL", 38, 44], ["Tax", "GENE_OR_GENE_PRODUCT", 19, 22], ["lysine", "AMINO_ACID", 38, 44], ["Tax", "GENE_OR_GENE_PRODUCT", 87, 90], ["NB", "CANCER", 107, 109], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 124, 129], ["Tax", "PROTEIN", 19, 22], ["Tax", "PROTEIN", 87, 90], ["NF-\u03baB", "PROTEIN", 124, 129], ["overlapping lysine residues", "TREATMENT", 26, 53], ["lysine residues", "OBSERVATION", 38, 53], ["Tax nuclear bodies", "OBSERVATION", 87, 105]]], ["This same group later found that a single Tax molecule can be both ubiquitinated and sumoylated, and that this differential modification is responsible for shuttling Tax and IKK between the cytoplasm, NB, and the centrosome (Kfoury et al., 2010).", [["cytoplasm", "ANATOMY", 190, 199], ["NB", "ANATOMY", 201, 203], ["centrosome", "ANATOMY", 213, 223], ["Tax", "GENE_OR_GENE_PRODUCT", 42, 45], ["Tax", "GENE_OR_GENE_PRODUCT", 166, 169], ["IKK", "GENE_OR_GENE_PRODUCT", 174, 177], ["cytoplasm", "ORGANISM_SUBSTANCE", 190, 199], ["NB", "CANCER", 201, 203], ["centrosome", "CELLULAR_COMPONENT", 213, 223], ["Tax molecule", "PROTEIN", 42, 54], ["Tax", "PROTEIN", 166, 169], ["IKK", "PROTEIN", 174, 177], ["ubiquitinated", "OBSERVATION_MODIFIER", 67, 80]]], ["The UPS has also been implicated in human cytomegalovirus (HCMV) viral transcription.", [["UPS", "GENE_OR_GENE_PRODUCT", 4, 7], ["human cytomegalovirus", "ORGANISM", 36, 57], ["HCMV", "ORGANISM", 59, 63], ["UPS", "PROTEIN", 4, 7], ["human", "SPECIES", 36, 41], ["human cytomegalovirus", "SPECIES", 36, 57], ["HCMV", "SPECIES", 59, 63], ["human cytomegalovirus", "PROBLEM", 36, 57], ["viral transcription", "TREATMENT", 65, 84], ["cytomegalovirus", "OBSERVATION", 42, 57]]], ["A delay in both early and late viral gene expression was observed in the presence of proteasome inhibitors, which was likely due to a block in viral RNA transcription.", [["proteasome", "PROTEIN", 85, 95], ["viral RNA", "RNA", 143, 152], ["A delay in both early and late viral gene expression", "PROBLEM", 0, 52], ["proteasome inhibitors", "TREATMENT", 85, 106], ["a block in viral RNA transcription", "PROBLEM", 132, 166], ["delay", "OBSERVATION_MODIFIER", 2, 7], ["viral RNA transcription", "OBSERVATION", 143, 166]]], ["Tran et al. (2010) also observed that the 19s proteasome subunit Rpn2 relocalizes to viral replication centers in a viral DNA replication-dependent manner (Table 2).Viral lytic/latency regulation ::: Viral ReplicationAn important aspect of the herpesviral lifecycle is the regulation of lytic replication and latency.", [["Rpn2", "GENE_OR_GENE_PRODUCT", 65, 69], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["19s proteasome subunit", "PROTEIN", 42, 64], ["Rpn2", "PROTEIN", 65, 69], ["the 19s proteasome subunit Rpn2", "TREATMENT", 38, 69], ["viral replication centers", "TREATMENT", 85, 110], ["a viral DNA replication", "TREATMENT", 114, 137], ["Viral ReplicationAn", "TREATMENT", 200, 219], ["the herpesviral lifecycle", "TREATMENT", 240, 265], ["lytic replication", "TREATMENT", 287, 304], ["viral replication", "OBSERVATION", 85, 102], ["lytic", "OBSERVATION_MODIFIER", 171, 176], ["lytic", "OBSERVATION_MODIFIER", 287, 292], ["latency", "OBSERVATION_MODIFIER", 309, 316]]], ["There are now several examples of UPS involvement in various aspects of this regulation.", [["UPS", "GENE_OR_GENE_PRODUCT", 34, 37], ["UPS", "PROTEIN", 34, 37], ["UPS involvement", "PROBLEM", 34, 49]]], ["In particular, lytic reactivation of Kaposi's sarcoma herpesvirus (KSHV) from latency is regulated by at least two UPS-dependent mechanisms.", [["Kaposi's sarcoma herpesvirus", "DISEASE", 37, 65], ["Kaposi's sarcoma herpesvirus", "ORGANISM", 37, 65], ["KSHV", "ORGANISM", 67, 71], ["UPS", "GENE_OR_GENE_PRODUCT", 115, 118], ["UPS", "PROTEIN", 115, 118], ["Kaposi's sarcoma herpesvirus", "SPECIES", 37, 65], ["Kaposi's sarcoma herpesvirus", "SPECIES", 37, 65], ["KSHV", "SPECIES", 67, 71], ["lytic reactivation", "PROBLEM", 15, 33], ["Kaposi's sarcoma herpesvirus", "PROBLEM", 37, 65], ["lytic", "OBSERVATION_MODIFIER", 15, 20], ["Kaposi", "OBSERVATION_MODIFIER", 37, 43], ["sarcoma", "OBSERVATION", 46, 53]]], ["The viral replication and transcription activator (RTA) protein also acts as an E3 Ub ligase that ubiquitinates and degrades its own repressors, including KSHV-RTA binding protein (K-RBP; Yang et al., 2008) and hairy/enhancer-of-split related with YRPW motif 1 (Hey1; Gould et al., 2009), which normally limit lytic replication.", [["RTA", "GENE_OR_GENE_PRODUCT", 51, 54], ["E3", "GENE_OR_GENE_PRODUCT", 80, 82], ["KSHV-RTA binding protein", "GENE_OR_GENE_PRODUCT", 155, 179], ["K-RBP", "GENE_OR_GENE_PRODUCT", 181, 186], ["YRPW motif 1", "GENE_OR_GENE_PRODUCT", 248, 260], ["transcription activator (RTA) protein", "PROTEIN", 26, 63], ["E3 Ub ligase", "PROTEIN", 80, 92], ["KSHV-RTA binding protein", "PROTEIN", 155, 179], ["K", "PROTEIN", 181, 182], ["RBP", "PROTEIN", 183, 186], ["hairy/enhancer", "DNA", 211, 225], ["YRPW motif 1", "DNA", 248, 260], ["The viral replication", "TREATMENT", 0, 21], ["transcription activator (RTA) protein", "TREATMENT", 26, 63], ["an E3 Ub ligase", "TREATMENT", 77, 92], ["KSHV", "TEST", 155, 159], ["RTA binding protein", "TEST", 160, 179], ["K", "TEST", 181, 182], ["RBP", "TEST", 183, 186], ["hairy/enhancer", "PROBLEM", 211, 225], ["viral replication", "OBSERVATION", 4, 21], ["lytic replication", "OBSERVATION", 310, 327]]], ["Another KSHV protein required for lytic reactivation is the tegument protein ORF64, which has been identified as a viral DUB (Gonzalez et al., 2009).", [["tegument", "ANATOMY", 60, 68], ["KSHV", "ORGANISM", 8, 12], ["ORF64", "GENE_OR_GENE_PRODUCT", 77, 82], ["DUB", "GENE_OR_GENE_PRODUCT", 121, 124], ["KSHV protein", "PROTEIN", 8, 20], ["tegument protein", "PROTEIN", 60, 76], ["ORF64", "PROTEIN", 77, 82], ["viral DUB", "PROTEIN", 115, 124], ["KSHV", "SPECIES", 8, 12], ["Another KSHV protein", "TEST", 0, 20], ["lytic reactivation", "PROBLEM", 34, 52], ["the tegument protein ORF64", "TEST", 56, 82], ["viral DUB", "OBSERVATION", 115, 124]]], ["ORF64 cleaves Ub from both K48- and K63-linked chains and requires a specific cysteine for its DUB activity.", [["cysteine", "CHEMICAL", 78, 86], ["cysteine", "CHEMICAL", 78, 86], ["ORF64", "GENE_OR_GENE_PRODUCT", 0, 5], ["Ub", "GENE_OR_GENE_PRODUCT", 14, 16], ["K48", "GENE_OR_GENE_PRODUCT", 27, 30], ["cysteine", "AMINO_ACID", 78, 86], ["DUB", "GENE_OR_GENE_PRODUCT", 95, 98], ["ORF64", "PROTEIN", 0, 5], ["Ub", "PROTEIN", 14, 16], ["K48", "PROTEIN", 27, 30], ["K63", "PROTEIN", 36, 39], ["DUB", "PROTEIN", 95, 98], ["K48", "TEST", 27, 30], ["a specific cysteine", "TREATMENT", 67, 86]]], ["While knockdown of ORF64 with siRNA lowered lytic reactivation and lytic protein expression, a direct role for DUB activity in this reactivation was not shown.", [["ORF64", "GENE_OR_GENE_PRODUCT", 19, 24], ["DUB", "GENE_OR_GENE_PRODUCT", 111, 114], ["ORF64", "PROTEIN", 19, 24], ["DUB", "PROTEIN", 111, 114], ["siRNA lowered lytic reactivation", "PROBLEM", 30, 62], ["lytic protein expression", "TREATMENT", 67, 91], ["DUB activity", "PROBLEM", 111, 123], ["this reactivation", "PROBLEM", 127, 144], ["lytic", "OBSERVATION_MODIFIER", 44, 49]]], ["The murine gammaherpesvirus-68 (MHV68) ORF64 homolog has also been identified as a viral DUB.", [["murine gammaherpesvirus-68", "ORGANISM", 4, 30], ["MHV68", "GENE_OR_GENE_PRODUCT", 32, 37], ["ORF64", "GENE_OR_GENE_PRODUCT", 39, 44], ["DUB", "GENE_OR_GENE_PRODUCT", 89, 92], ["murine gammaherpesvirus-68 (MHV68) ORF64 homolog", "PROTEIN", 4, 52], ["viral DUB", "PROTEIN", 83, 92], ["murine", "SPECIES", 4, 10], ["murine gammaherpesvirus-68", "SPECIES", 4, 30], ["MHV68", "SPECIES", 32, 37], ["The murine gammaherpesvirus", "TEST", 0, 27], ["a viral DUB", "PROBLEM", 81, 92], ["murine gammaherpesvirus", "OBSERVATION", 4, 27], ["viral DUB", "OBSERVATION", 83, 92]]], ["Gredmark-Russ et al. (2009) found that a virus expressing an ORF64 with an alanine substitution for the critical active site cysteine was more rapidly cleared than the wildtype virus in an in vivo mouse model.", [["alanine", "CHEMICAL", 75, 82], ["alanine", "CHEMICAL", 75, 82], ["cysteine", "CHEMICAL", 125, 133], ["ORF64", "GENE_OR_GENE_PRODUCT", 61, 66], ["alanine", "AMINO_ACID", 75, 82], ["cysteine", "AMINO_ACID", 125, 133], ["wildtype virus", "ORGANISM", 168, 182], ["mouse", "ORGANISM", 197, 202], ["ORF64", "PROTEIN", 61, 66], ["mouse", "SPECIES", 197, 202], ["mouse", "SPECIES", 197, 202], ["a virus", "PROBLEM", 39, 46], ["an alanine substitution", "TREATMENT", 72, 95], ["the critical active site cysteine", "PROBLEM", 100, 133], ["the wildtype virus", "PROBLEM", 164, 182], ["active", "OBSERVATION_MODIFIER", 113, 119], ["site cysteine", "OBSERVATION", 120, 133]]], ["This suggested an important role for DUB activity in viral replication and possibly persistence, although they observed no differences in viral genome copy numbers (Gredmark-Russ et al., 2009).", [["DUB", "GENE_OR_GENE_PRODUCT", 37, 40], ["DUB", "PROTEIN", 37, 40], ["DUB activity", "PROBLEM", 37, 49], ["viral replication", "TREATMENT", 53, 70], ["viral replication", "OBSERVATION", 53, 70], ["possibly", "UNCERTAINTY", 75, 83], ["persistence", "OBSERVATION_MODIFIER", 84, 95]]], ["Another MHV68 protein involved in viral persistence is ORF73.", [["MHV68", "GENE_OR_GENE_PRODUCT", 8, 13], ["ORF73", "GENE_OR_GENE_PRODUCT", 55, 60], ["MHV68 protein", "PROTEIN", 8, 21], ["ORF73", "PROTEIN", 55, 60], ["Another MHV68 protein", "TEST", 0, 21], ["viral persistence", "OBSERVATION", 34, 51]]], ["Recent evidence suggests that ORF73\u2019s abilities to both assemble with an ElonginC/Cul5/suppressor of cytokine signaling (SOCS)-like complex and effect the ubiquitination and degradation of RelA/NF-\u03baB may be responsible for maintaining viral infection.", [["viral infection", "DISEASE", 235, 250], ["ORF73", "GENE_OR_GENE_PRODUCT", 30, 35], ["ElonginC", "GENE_OR_GENE_PRODUCT", 73, 81], ["Cul5", "GENE_OR_GENE_PRODUCT", 82, 86], ["suppressor of cytokine signaling", "GENE_OR_GENE_PRODUCT", 87, 119], ["SOCS", "GENE_OR_GENE_PRODUCT", 121, 125], ["RelA", "GENE_OR_GENE_PRODUCT", 189, 193], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 194, 199], ["ORF73", "PROTEIN", 30, 35], ["ElonginC", "PROTEIN", 73, 81], ["Cul5", "PROTEIN", 82, 86], ["cytokine signaling (SOCS)-like complex", "PROTEIN", 101, 139], ["RelA", "PROTEIN", 189, 193], ["NF-\u03baB", "PROTEIN", 194, 199], ["an ElonginC/Cul5/suppressor", "TREATMENT", 70, 97], ["cytokine signaling", "PROBLEM", 101, 119], ["the ubiquitination", "PROBLEM", 151, 169], ["RelA/NF", "TREATMENT", 189, 196], ["viral infection", "PROBLEM", 235, 250], ["viral", "OBSERVATION_MODIFIER", 235, 240], ["infection", "OBSERVATION", 241, 250]]], ["In an in vivo mouse model, an MHV68 virus with a mutation of the ORF73 SOCS-box motif was unable to induce B-cell proliferation or set up a persistent infection, suggesting that NF-\u03baB plays a role in these processes (Rodrigues et al., 2009).", [["B-cell", "ANATOMY", 107, 113], ["infection", "DISEASE", 151, 160], ["mouse", "ORGANISM", 14, 19], ["MHV68 virus", "ORGANISM", 30, 41], ["ORF73", "GENE_OR_GENE_PRODUCT", 65, 70], ["B-cell", "CELL", 107, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 178, 183], ["ORF73 SOCS-box motif", "DNA", 65, 85], ["NF-\u03baB", "PROTEIN", 178, 183], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["MHV68 virus", "SPECIES", 30, 41], ["an MHV68 virus", "PROBLEM", 27, 41], ["box motif", "PROBLEM", 76, 85], ["B-cell proliferation", "PROBLEM", 107, 127], ["a persistent infection", "PROBLEM", 138, 160], ["cell proliferation", "OBSERVATION", 109, 127], ["persistent", "OBSERVATION_MODIFIER", 140, 150], ["infection", "OBSERVATION", 151, 160]]], ["However, while the degradation of NF-\u03baB also has the potential to impact interferon (IFN) induction (see below), this was not investigated.Viral lytic/latency regulation ::: Viral ReplicationAn interesting twist on the role of the UPS in the regulation of viral latency is provided by the herpesvirus EBV.", [["NF-\u03baB", "CHEMICAL", 34, 39], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["interferon", "GENE_OR_GENE_PRODUCT", 73, 83], ["IFN", "GENE_OR_GENE_PRODUCT", 85, 88], ["UPS", "GENE_OR_GENE_PRODUCT", 231, 234], ["herpesvirus EBV", "ORGANISM", 289, 304], ["NF-\u03baB", "PROTEIN", 34, 39], ["interferon", "PROTEIN", 73, 83], ["IFN", "PROTEIN", 85, 88], ["UPS", "PROTEIN", 231, 234], ["interferon (IFN) induction", "TREATMENT", 73, 99], ["viral latency", "PROBLEM", 256, 269], ["lytic", "OBSERVATION_MODIFIER", 145, 150], ["viral latency", "OBSERVATION", 256, 269], ["herpesvirus EBV", "OBSERVATION", 289, 304]]], ["The viral latent membrane protein 2A (LMP2A) has been implicated in the regulation of both EBV latency and oncogenesis through its action as a B-cell receptor (BCR) mimic that constitutively activates the Lyn and Syk protein tyrosine kinases (reviewed in Portis et al., 2004).", [["B-cell", "ANATOMY", 143, 149], ["tyrosine", "CHEMICAL", 225, 233], ["tyrosine", "CHEMICAL", 225, 233], ["latent membrane protein 2A", "GENE_OR_GENE_PRODUCT", 10, 36], ["LMP2A", "GENE_OR_GENE_PRODUCT", 38, 43], ["EBV", "ORGANISM", 91, 94], ["B-cell receptor", "GENE_OR_GENE_PRODUCT", 143, 158], ["BCR", "GENE_OR_GENE_PRODUCT", 160, 163], ["Lyn", "GENE_OR_GENE_PRODUCT", 205, 208], ["Syk protein tyrosine kinases", "GENE_OR_GENE_PRODUCT", 213, 241], ["viral latent membrane protein 2A", "PROTEIN", 4, 36], ["LMP2A", "PROTEIN", 38, 43], ["B-cell receptor", "PROTEIN", 143, 158], ["BCR", "PROTEIN", 160, 163], ["Lyn", "PROTEIN", 205, 208], ["Syk protein tyrosine kinases", "PROTEIN", 213, 241], ["The viral latent membrane protein", "TEST", 0, 33], ["both EBV latency", "PROBLEM", 86, 102], ["a B-cell receptor (BCR", "TREATMENT", 141, 163], ["Syk protein tyrosine kinases", "TREATMENT", 213, 241], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["latent", "OBSERVATION_MODIFIER", 10, 16], ["membrane protein 2A", "OBSERVATION", 17, 36], ["EBV latency", "OBSERVATION", 91, 102]]], ["To determine if LMP2A is regulated similarly to BCR, Ikeda and Longnecker (2009) investigated the role that c-Cbl, an E3 Ub ligase that negatively regulates B-cell signaling, might play in LMP2A regulation.", [["B-cell", "ANATOMY", 157, 163], ["LMP2A", "GENE_OR_GENE_PRODUCT", 16, 21], ["BCR", "GENE_OR_GENE_PRODUCT", 48, 51], ["c-Cbl", "GENE_OR_GENE_PRODUCT", 108, 113], ["E3", "GENE_OR_GENE_PRODUCT", 118, 120], ["B-cell", "CELL", 157, 163], ["LMP2A", "GENE_OR_GENE_PRODUCT", 189, 194], ["LMP2A", "PROTEIN", 16, 21], ["BCR", "PROTEIN", 48, 51], ["Cbl", "PROTEIN", 110, 113], ["E3 Ub ligase", "PROTEIN", 118, 130], ["LMP2A", "PROTEIN", 189, 194], ["LMP2A", "PROBLEM", 16, 21], ["an E3 Ub ligase", "TEST", 115, 130], ["LMP2A regulation", "TREATMENT", 189, 205]]], ["They discovered that LMP2A is ubiquitinated and degraded in a c-Cbl-dependent manner and that the Syk kinase is also degraded by c-Cbl in the presence of LMP2A.", [["LMP2A", "GENE_OR_GENE_PRODUCT", 21, 26], ["c-Cbl", "GENE_OR_GENE_PRODUCT", 62, 67], ["Syk", "GENE_OR_GENE_PRODUCT", 98, 101], ["c-Cbl", "GENE_OR_GENE_PRODUCT", 129, 134], ["LMP2A", "GENE_OR_GENE_PRODUCT", 154, 159], ["LMP2A", "PROTEIN", 21, 26], ["Cbl", "PROTEIN", 64, 67], ["Syk kinase", "PROTEIN", 98, 108], ["c", "PROTEIN", 129, 130], ["Cbl", "PROTEIN", 131, 134], ["LMP2A", "PROTEIN", 154, 159], ["LMP2A", "PROBLEM", 21, 26], ["the Syk kinase", "TEST", 94, 108], ["LMP2A", "PROBLEM", 154, 159], ["LMP2A", "OBSERVATION", 21, 26], ["ubiquitinated", "OBSERVATION_MODIFIER", 30, 43], ["Syk kinase", "OBSERVATION", 98, 108], ["LMP2A", "OBSERVATION", 154, 159]]], ["In addition, when c-Cbl was knocked down with shRNA, LMP2A induced lytic gene expression.", [["c-Cbl", "GENE_OR_GENE_PRODUCT", 18, 23], ["LMP2A", "GENE_OR_GENE_PRODUCT", 53, 58], ["c", "PROTEIN", 18, 19], ["Cbl", "PROTEIN", 20, 23], ["LMP2A", "PROTEIN", 53, 58], ["c-Cbl", "TEST", 18, 23], ["shRNA", "PROBLEM", 46, 51], ["LMP2A induced lytic gene expression", "PROBLEM", 53, 88], ["lytic", "OBSERVATION_MODIFIER", 67, 72]]], ["Together with previous data showing that LMP2A contains two PPXY motifs and recruits Nedd4 Ub ligase to degrade Lyn kinase (Ikeda et al., 2001), these findings suggest that the cellular UPS is an important factor in the maintenance of EBV latency.", [["cellular", "ANATOMY", 177, 185], ["LMP2A", "GENE_OR_GENE_PRODUCT", 41, 46], ["PPXY", "GENE_OR_GENE_PRODUCT", 60, 64], ["Nedd4", "GENE_OR_GENE_PRODUCT", 85, 90], ["Lyn", "GENE_OR_GENE_PRODUCT", 112, 115], ["cellular", "CELL", 177, 185], ["EBV", "ORGANISM", 235, 238], ["LMP2A", "PROTEIN", 41, 46], ["PPXY motifs", "PROTEIN", 60, 71], ["Nedd4 Ub ligase", "PROTEIN", 85, 100], ["Lyn kinase", "PROTEIN", 112, 122], ["UPS", "PROTEIN", 186, 189], ["previous data", "TEST", 14, 27], ["LMP2A", "PROBLEM", 41, 46], ["two PPXY motifs", "TREATMENT", 56, 71], ["Nedd4 Ub ligase", "TEST", 85, 100], ["Lyn kinase", "TEST", 112, 122], ["the cellular UPS", "PROBLEM", 173, 189], ["EBV latency", "PROBLEM", 235, 246], ["LMP2A", "OBSERVATION", 41, 46], ["Lyn kinase", "OBSERVATION", 112, 122], ["EBV latency", "OBSERVATION", 235, 246]]], ["In a similar story, the EBV LMP1 protein also appears to modulate latency through its interaction with the UPS.", [["EBV", "ORGANISM", 24, 27], ["LMP1", "GENE_OR_GENE_PRODUCT", 28, 32], ["UPS", "GENE_OR_GENE_PRODUCT", 107, 110], ["EBV LMP1 protein", "PROTEIN", 24, 40], ["UPS", "PROTEIN", 107, 110], ["EBV", "SPECIES", 24, 27], ["the EBV LMP1 protein", "TEST", 20, 40], ["modulate latency", "PROBLEM", 57, 73]]], ["LMP1 stimulates the TNF receptor associated factor 6 (TRAF6) E3 ligase-dependent ubiquitination of IFN response factor (IRF) 7, and this modification is required for the subsequent phosphorylation of IRF7 by RIP1 kinase (Ning et al., 2008).", [["LMP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNF receptor associated factor 6", "GENE_OR_GENE_PRODUCT", 20, 52], ["TRAF6", "GENE_OR_GENE_PRODUCT", 54, 59], ["E3", "GENE_OR_GENE_PRODUCT", 61, 63], ["IFN response factor (IRF) 7", "GENE_OR_GENE_PRODUCT", 99, 126], ["IRF7", "GENE_OR_GENE_PRODUCT", 200, 204], ["RIP1", "GENE_OR_GENE_PRODUCT", 208, 212], ["LMP1", "PROTEIN", 0, 4], ["TNF receptor associated factor 6 (TRAF6) E3 ligase", "PROTEIN", 20, 70], ["IFN response factor (IRF) 7", "PROTEIN", 99, 126], ["IRF7", "PROTEIN", 200, 204], ["RIP1 kinase", "PROTEIN", 208, 219], ["LMP1 stimulates", "TEST", 0, 15], ["the TNF receptor", "TEST", 16, 32], ["factor", "TEST", 44, 50], ["TRAF6", "TEST", 54, 59], ["E3 ligase", "TEST", 61, 70], ["IFN response factor (IRF)", "PROBLEM", 99, 124], ["the subsequent phosphorylation of IRF7", "TREATMENT", 166, 204], ["dependent ubiquitination", "OBSERVATION_MODIFIER", 71, 95]]], ["If left unchecked, this would lead to activation of lytic replication and IFN induction.", [["IFN", "GENE_OR_GENE_PRODUCT", 74, 77], ["IFN", "PROTEIN", 74, 77], ["lytic replication", "TREATMENT", 52, 69], ["IFN induction", "TREATMENT", 74, 87], ["lytic", "OBSERVATION_MODIFIER", 52, 57]]], ["However, LMP1 was also recently shown to induce the cellular DUB A20, which inactivates IRF7 via deubiquitination (Ning and Pagano, 2010).", [["cellular", "ANATOMY", 52, 60], ["LMP1", "GENE_OR_GENE_PRODUCT", 9, 13], ["cellular", "CELL", 52, 60], ["A20", "GENE_OR_GENE_PRODUCT", 65, 68], ["IRF7", "GENE_OR_GENE_PRODUCT", 88, 92], ["LMP1", "PROTEIN", 9, 13], ["DUB A20", "PROTEIN", 61, 68], ["IRF7", "PROTEIN", 88, 92], ["LMP1", "PROBLEM", 9, 13], ["the cellular DUB A20", "PROBLEM", 48, 68], ["LMP1", "OBSERVATION", 9, 13], ["cellular DUB A20", "OBSERVATION", 52, 68]]], ["Whether these intricate regulatory mechanisms are more advantageous for the cell or virus remains to be determined.Human papillomaviruses E6 ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationHuman papillomaviruses E6 can function as an adaptor to redirect the cellular E6-associated protein (E6AP) HECT ligase to target a number of cellular proteins for proteasome-dependent degradation (see Table 3).", [["cell", "ANATOMY", 76, 80], ["Cell", "ANATOMY", 145, 149], ["cellular", "ANATOMY", 287, 295], ["cellular", "ANATOMY", 359, 367], ["cell", "CELL", 76, 80], ["Human", "ORGANISM", 115, 120], ["papillomaviruses", "ORGANISM", 121, 137], ["E6", "ORGANISM", 138, 140], ["Cell", "CELL", 145, 149], ["Cellular ProliferationHuman papillomaviruses E6", "ORGANISM", 196, 243], ["cellular E6-associated protein", "GENE_OR_GENE_PRODUCT", 287, 317], ["E6AP", "GENE_OR_GENE_PRODUCT", 319, 323], ["cellular", "CELL", 359, 367], ["E6", "PROTEIN", 138, 140], ["E6", "PROTEIN", 241, 243], ["cellular E6-associated protein (E6AP) HECT ligase", "PROTEIN", 287, 336], ["cellular proteins", "PROTEIN", 359, 376], ["proteasome", "PROTEIN", 381, 391], ["Human", "SPECIES", 115, 120], ["Human papillomaviruses E6", "SPECIES", 115, 140], ["ProliferationHuman papillomaviruses E6", "SPECIES", 205, 243], ["the cell or virus", "PROBLEM", 72, 89], ["Cell Cycle Regulation", "TREATMENT", 145, 166], ["Apoptosis", "PROBLEM", 182, 191], ["Cellular ProliferationHuman papillomaviruses E6", "TREATMENT", 196, 243], ["an adaptor", "TEST", 260, 270], ["the cellular E6", "TEST", 283, 298], ["associated protein (E6AP) HECT ligase", "PROBLEM", 299, 336], ["proteasome-dependent degradation", "PROBLEM", 381, 413]]], ["Chief among these is p53, which appears to be upregulated by the activities of HPV E7 (Demers et al., 1994, and see below).", [["p53", "GENE_OR_GENE_PRODUCT", 21, 24], ["HPV E7", "ORGANISM", 79, 85], ["p53", "PROTEIN", 21, 24], ["HPV E7", "PROTEIN", 79, 85]]], ["E6 can also target a number of PDZ [post synaptic density protein (PSD95), Drosophila disk large tumor suppressor (DlgA), and zonula occludens-1 protein (zo-1)]-domain proteins for degradation independently of E6AP, including human disks large (hDlg), membrane-associated guanylate kinase with inverted orientation 1, 2, and 3 (MAGI), and hScrib (Mammas et al., 2008).", [["tumor", "ANATOMY", 97, 102], ["membrane", "ANATOMY", 252, 260], ["tumor", "DISEASE", 97, 102], ["guanylate", "CHEMICAL", 272, 281], ["E6", "GENE_OR_GENE_PRODUCT", 0, 2], ["PDZ", "GENE_OR_GENE_PRODUCT", 31, 34], ["post synaptic density protein", "GENE_OR_GENE_PRODUCT", 36, 65], ["PSD95", "GENE_OR_GENE_PRODUCT", 67, 72], ["Drosophila disk large tumor suppressor", "GENE_OR_GENE_PRODUCT", 75, 113], ["DlgA", "GENE_OR_GENE_PRODUCT", 115, 119], ["zonula occludens-1", "GENE_OR_GENE_PRODUCT", 126, 144], ["zo-1", "GENE_OR_GENE_PRODUCT", 154, 158], ["E6AP", "GENE_OR_GENE_PRODUCT", 210, 214], ["human", "ORGANISM", 226, 231], ["disks large (hDlg)", "GENE_OR_GENE_PRODUCT", 232, 250], ["membrane", "CELLULAR_COMPONENT", 252, 260], ["guanylate kinase with inverted orientation 1", "GENE_OR_GENE_PRODUCT", 272, 316], ["2", "GENE_OR_GENE_PRODUCT", 318, 319], ["3", "GENE_OR_GENE_PRODUCT", 325, 326], ["MAGI", "GENE_OR_GENE_PRODUCT", 328, 332], ["hScrib", "GENE_OR_GENE_PRODUCT", 339, 345], ["E6", "PROTEIN", 0, 2], ["PDZ", "PROTEIN", 31, 34], ["post synaptic density protein", "PROTEIN", 36, 65], ["PSD95", "PROTEIN", 67, 72], ["Drosophila disk large tumor suppressor", "PROTEIN", 75, 113], ["DlgA", "PROTEIN", 115, 119], ["zonula occludens-1 protein (zo-1)]-domain proteins", "PROTEIN", 126, 176], ["E6AP", "PROTEIN", 210, 214], ["hDlg", "PROTEIN", 245, 249], ["membrane-associated guanylate kinase", "PROTEIN", 252, 288], ["Drosophila", "SPECIES", 75, 85], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["synaptic density protein (PSD95)", "TREATMENT", 41, 73], ["Drosophila disk large tumor suppressor", "PROBLEM", 75, 113], ["zonula occludens", "TEST", 126, 142], ["zo", "TEST", 154, 156], ["E6AP", "TEST", 210, 214], ["human disks", "TEST", 226, 237], ["membrane-associated guanylate kinase", "PROBLEM", 252, 288], ["disk", "OBSERVATION_MODIFIER", 86, 90], ["large", "OBSERVATION_MODIFIER", 91, 96], ["tumor suppressor", "OBSERVATION", 97, 113], ["zonula", "ANATOMY", 126, 132]]], ["More E6 targets continue to be discovered.", [["E6", "GENE_OR_GENE_PRODUCT", 5, 7], ["E6", "PROTEIN", 5, 7]]], ["For example, E6 has recently been found to augment Wnt signaling in an E6AP-dependent manner, suggesting that Wnts may play a role in HPV carcinogenesis (Lichtig et al., 2010).", [["HPV carcinogenesis", "DISEASE", 134, 152], ["E6", "GENE_OR_GENE_PRODUCT", 13, 15], ["Wnt", "GENE_OR_GENE_PRODUCT", 51, 54], ["E6AP", "GENE_OR_GENE_PRODUCT", 71, 75], ["Wnts", "GENE_OR_GENE_PRODUCT", 110, 114], ["HPV", "ORGANISM", 134, 137], ["E6", "PROTEIN", 13, 15], ["E6AP", "PROTEIN", 71, 75], ["Wnts", "PROTEIN", 110, 114], ["HPV", "SPECIES", 134, 137], ["E6AP-dependent", "OBSERVATION_MODIFIER", 71, 85]]], ["In a search for the cellular proteins targeted by E6 to stimulate Wnt signals, Rampias et al. (2010) found that the cellular E3 ligase seven in absentia homolog (Siah-1), which is known to promote beta-catenin degradation via the UPS, is inhibited by the combination of HPV E6 and E7.", [["cellular", "ANATOMY", 20, 28], ["cellular", "ANATOMY", 116, 124], ["cellular", "CELL", 20, 28], ["E6", "GENE_OR_GENE_PRODUCT", 50, 52], ["Wnt", "GENE_OR_GENE_PRODUCT", 66, 69], ["cellular", "CELL", 116, 124], ["absentia homolog", "GENE_OR_GENE_PRODUCT", 144, 160], ["Siah-1", "GENE_OR_GENE_PRODUCT", 162, 168], ["beta-catenin", "GENE_OR_GENE_PRODUCT", 197, 209], ["UPS", "GENE_OR_GENE_PRODUCT", 230, 233], ["HPV E6", "ORGANISM", 270, 276], ["E7", "GENE_OR_GENE_PRODUCT", 281, 283], ["cellular proteins", "PROTEIN", 20, 37], ["E6", "PROTEIN", 50, 52], ["cellular E3 ligase", "PROTEIN", 116, 134], ["absentia homolog", "PROTEIN", 144, 160], ["Siah", "PROTEIN", 162, 166], ["beta-catenin", "PROTEIN", 197, 209], ["UPS", "PROTEIN", 230, 233], ["HPV E6", "PROTEIN", 270, 276], ["E7", "PROTEIN", 281, 283], ["the cellular proteins", "TEST", 16, 37], ["the cellular E3 ligase", "TEST", 112, 134], ["beta-catenin degradation", "PROBLEM", 197, 221], ["HPV E6 and E7", "TREATMENT", 270, 283], ["beta-catenin degradation", "OBSERVATION", 197, 221]]], ["This provides evidence for what may be an interesting example of a virus redirecting a cellular E3 ligase (E6AP) to target another cellular E3 ligase (Siah-1).", [["cellular", "ANATOMY", 87, 95], ["cellular", "ANATOMY", 131, 139], ["cellular E3", "GENE_OR_GENE_PRODUCT", 87, 98], ["E6AP", "GENE_OR_GENE_PRODUCT", 107, 111], ["cellular", "CELL", 131, 139], ["Siah-1", "GENE_OR_GENE_PRODUCT", 151, 157], ["cellular E3 ligase", "PROTEIN", 87, 105], ["E6AP", "PROTEIN", 107, 111], ["cellular E3 ligase", "PROTEIN", 131, 149], ["Siah-1", "PROTEIN", 151, 157], ["a virus", "PROBLEM", 65, 72]]], ["Yet another player in the p53 pathway, the tumor suppressor Tat-interacting protein 60 kDa (TIP60), is targeted for proteasome-dependent degradation by E6, although this does not require E6AP (Jha et al., 2010).", [["tumor", "ANATOMY", 43, 48], ["tumor", "DISEASE", 43, 48], ["p53", "GENE_OR_GENE_PRODUCT", 26, 29], ["tumor", "CANCER", 43, 48], ["Tat-interacting protein 60 kDa", "GENE_OR_GENE_PRODUCT", 60, 90], ["TIP60", "GENE_OR_GENE_PRODUCT", 92, 97], ["E6", "GENE_OR_GENE_PRODUCT", 152, 154], ["p53", "PROTEIN", 26, 29], ["tumor suppressor Tat-interacting protein 60 kDa", "PROTEIN", 43, 90], ["TIP60", "PROTEIN", 92, 97], ["proteasome", "PROTEIN", 116, 126], ["E6", "PROTEIN", 152, 154], ["the tumor suppressor Tat", "TREATMENT", 39, 63], ["proteasome-dependent degradation", "PROBLEM", 116, 148]]], ["TIP60 was found to bind to the HPV major early promoter, recruiting a cellular repressor of E6 expression in the process.", [["cellular", "ANATOMY", 70, 78], ["TIP60", "CHEMICAL", 0, 5], ["TIP60", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 70, 78], ["E6", "GENE_OR_GENE_PRODUCT", 92, 94], ["TIP60", "PROTEIN", 0, 5], ["HPV major early promoter", "DNA", 31, 55], ["E6", "PROTEIN", 92, 94], ["TIP60", "TREATMENT", 0, 5], ["a cellular repressor", "TREATMENT", 68, 88], ["E6 expression", "OBSERVATION", 92, 105]]], ["Therefore, degradation of TIP60 serves to derepress both E6 expression as well as cellular genes whose products limit p53-dependent apoptosis.", [["cellular", "ANATOMY", 82, 90], ["TIP60", "CHEMICAL", 26, 31], ["TIP60", "GENE_OR_GENE_PRODUCT", 26, 31], ["E6", "GENE_OR_GENE_PRODUCT", 57, 59], ["cellular", "CELL", 82, 90], ["p53", "GENE_OR_GENE_PRODUCT", 118, 121], ["TIP60", "PROTEIN", 26, 31], ["E6", "PROTEIN", 57, 59], ["cellular genes", "DNA", 82, 96], ["p53", "PROTEIN", 118, 121], ["TIP60 serves", "TREATMENT", 26, 38], ["dependent apoptosis", "PROBLEM", 122, 141], ["dependent", "OBSERVATION_MODIFIER", 122, 131], ["apoptosis", "OBSERVATION", 132, 141]]], ["As mentioned above, the cellular E6AP HECT ligase is variably required for E6 phenotypes.", [["cellular", "ANATOMY", 24, 32], ["cellular", "CELL", 24, 32], ["HECT", "GENE_OR_GENE_PRODUCT", 38, 42], ["E6", "GENE_OR_GENE_PRODUCT", 75, 77], ["cellular E6AP HECT ligase", "PROTEIN", 24, 49], ["E6", "PROTEIN", 75, 77], ["the cellular E6AP HECT ligase", "TEST", 20, 49], ["E6 phenotypes", "PROBLEM", 75, 88]]], ["A recent study examined the requirement for E6AP in clinical HPV outcomes (Shai et al., 2010).", [["E6AP", "GENE_OR_GENE_PRODUCT", 44, 48], ["HPV", "ORGANISM", 61, 64], ["E6AP", "PROTEIN", 44, 48], ["A recent study", "TEST", 0, 14]]], ["Using a transgenic mouse model of HPV oncogenic phenotypes, they found that while E6AP is dispensable for epithelial hyperplasia and the limitation of DNA damage responses, E6AP is absolutely required for cervical carcinomas.", [["epithelial hyperplasia", "ANATOMY", 106, 128], ["cervical carcinomas", "ANATOMY", 205, 224], ["epithelial hyperplasia", "DISEASE", 106, 128], ["cervical carcinomas", "DISEASE", 205, 224], ["mouse", "ORGANISM", 19, 24], ["HPV", "ORGANISM", 34, 37], ["E6AP", "GENE_OR_GENE_PRODUCT", 82, 86], ["epithelial", "TISSUE", 106, 116], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["cervical carcinomas", "CANCER", 205, 224], ["E6AP", "PROTEIN", 82, 86], ["E6AP", "PROTEIN", 173, 177], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["HPV", "SPECIES", 34, 37], ["HPV oncogenic phenotypes", "PROBLEM", 34, 58], ["epithelial hyperplasia", "PROBLEM", 106, 128], ["DNA damage responses", "PROBLEM", 151, 171], ["cervical carcinomas", "PROBLEM", 205, 224], ["oncogenic phenotypes", "OBSERVATION", 38, 58], ["dispensable for", "UNCERTAINTY", 90, 105], ["epithelial", "ANATOMY_MODIFIER", 106, 116], ["hyperplasia", "OBSERVATION", 117, 128], ["cervical", "ANATOMY", 205, 213], ["carcinomas", "OBSERVATION", 214, 224]]], ["Therefore, while this cellular E3 ligase may not be necessary for all E6 functions, it still has an impact upon the most serious consequence of HPV infection.Human papillomaviruses E7 ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationE7 is the other primary contributor to HPV-mediated transformation.", [["cellular", "ANATOMY", 22, 30], ["Cell", "ANATOMY", 188, 192], ["HPV infection", "DISEASE", 144, 157], ["Human papillomaviruses", "DISEASE", 158, 180], ["cellular", "CELL", 22, 30], ["E6", "GENE_OR_GENE_PRODUCT", 70, 72], ["HPV", "ORGANISM", 144, 147], ["Human", "ORGANISM", 158, 163], ["papillomaviruses", "ORGANISM", 164, 180], ["E7", "ORGANISM", 181, 183], ["Cell", "CELL", 188, 192], ["HPV", "ORGANISM", 300, 303], ["cellular E3 ligase", "PROTEIN", 22, 40], ["E6", "PROTEIN", 70, 72], ["E7", "PROTEIN", 181, 183], ["Human", "SPECIES", 158, 163], ["HPV", "SPECIES", 144, 147], ["Human papillomaviruses", "SPECIES", 158, 180], ["this cellular E3 ligase", "TEST", 17, 40], ["all E6 functions", "PROBLEM", 66, 82], ["HPV infection", "PROBLEM", 144, 157], ["Cell Cycle Regulation", "TEST", 188, 209], ["Apoptosis", "PROBLEM", 225, 234], ["Cellular ProliferationE7", "TREATMENT", 239, 263], ["HPV-mediated transformation", "PROBLEM", 300, 327], ["most serious", "OBSERVATION_MODIFIER", 116, 128], ["infection", "OBSERVATION", 148, 157], ["Apoptosis", "OBSERVATION_MODIFIER", 225, 234], ["Cellular ProliferationE7", "OBSERVATION", 239, 263], ["transformation", "OBSERVATION", 313, 327]]], ["Members of the cellular pRb/pocket protein family normally function to control G1/S-phase progression by inhibiting the E2F family of transcriptional activators, which in turn control the transcription of S-phase promoters (Moody and Laimins, 2010).", [["cellular", "ANATOMY", 15, 23], ["cellular", "CELL", 15, 23], ["pRb", "GENE_OR_GENE_PRODUCT", 24, 27], ["E2F", "GENE_OR_GENE_PRODUCT", 120, 123], ["cellular pRb/pocket protein family", "PROTEIN", 15, 49], ["E2F family", "PROTEIN", 120, 130], ["transcriptional activators", "PROTEIN", 134, 160], ["S-phase promoters", "DNA", 205, 222], ["transcriptional activators", "TREATMENT", 134, 160]]], ["The most well-characterized E7 function is to target pRb family members for UPS-dependent degradation, thereby derepressing E2F-dependent promoters (Boyer et al., 1996).", [["E7", "GENE_OR_GENE_PRODUCT", 28, 30], ["pRb", "GENE_OR_GENE_PRODUCT", 53, 56], ["UPS", "GENE_OR_GENE_PRODUCT", 76, 79], ["E2F", "GENE_OR_GENE_PRODUCT", 124, 127], ["E7", "PROTEIN", 28, 30], ["pRb family members", "PROTEIN", 53, 71], ["UPS", "PROTEIN", 76, 79], ["E2F-dependent promoters", "DNA", 124, 147], ["dependent degradation", "PROBLEM", 80, 101]]], ["At the same time, E7 is a relatively unstable protein (Selvey et al., 1994) that has been found to be ubiquitinated on its N-terminal residue and then destroyed by the proteasome (Reinstein et al., 2000; Wang et al., 2001).", [["N", "CHEMICAL", 123, 124], ["E7", "GENE_OR_GENE_PRODUCT", 18, 20], ["E7", "PROTEIN", 18, 20], ["N-terminal residue", "PROTEIN", 123, 141], ["proteasome", "PROTEIN", 168, 178], ["terminal residue", "PROBLEM", 125, 141], ["ubiquitinated", "OBSERVATION_MODIFIER", 102, 115], ["terminal residue", "OBSERVATION", 125, 141]]], ["While E7 has been detected in complexes with several E3 ligases (Kamio et al., 2004; Oh et al., 2004), of those, the only E3 complex also shown to contain pRb is Cul2/ElonginBC/Rbx1 (Huh et al., 2007), suggesting that this is the Ub ligase responsible for pRb degradation.", [["E7", "GENE_OR_GENE_PRODUCT", 6, 8], ["E3", "GENE_OR_GENE_PRODUCT", 53, 55], ["E3", "GENE_OR_GENE_PRODUCT", 122, 124], ["pRb", "GENE_OR_GENE_PRODUCT", 155, 158], ["Cul2", "GENE_OR_GENE_PRODUCT", 162, 166], ["ElonginBC", "GENE_OR_GENE_PRODUCT", 167, 176], ["Ub", "GENE_OR_GENE_PRODUCT", 230, 232], ["pRb", "GENE_OR_GENE_PRODUCT", 256, 259], ["E7", "PROTEIN", 6, 8], ["E3 ligases", "PROTEIN", 53, 63], ["E3 complex", "PROTEIN", 122, 132], ["pRb", "PROTEIN", 155, 158], ["Cul2", "PROTEIN", 162, 166], ["ElonginBC", "PROTEIN", 167, 176], ["Rbx1", "PROTEIN", 177, 181], ["Ub ligase", "PROTEIN", 230, 239], ["pRb", "PROTEIN", 256, 259], ["Cul2", "TEST", 162, 166], ["the Ub ligase", "PROBLEM", 226, 239], ["pRb degradation", "PROBLEM", 256, 271], ["ligase", "OBSERVATION", 233, 239]]], ["Lastly, in what is perhaps an attempt to counter the host\u2019s efforts to destroy it, E7 also interacts with the cellular DUB USP11, which leads to the stabilization of E7 (Lin et al., 2008).", [["cellular", "ANATOMY", 110, 118], ["E7", "GENE_OR_GENE_PRODUCT", 83, 85], ["cellular", "CELL", 110, 118], ["USP11", "GENE_OR_GENE_PRODUCT", 123, 128], ["E7", "GENE_OR_GENE_PRODUCT", 166, 168], ["E7", "PROTEIN", 83, 85], ["cellular DUB USP11", "PROTEIN", 110, 128], ["E7", "PROTEIN", 166, 168]]], ["While E7 interacts with many cellular proteins to dysregulate the host cell cycle, aside from pRb, few others have been shown to be targeted for degradation.", [["cellular", "ANATOMY", 29, 37], ["cell", "ANATOMY", 71, 75], ["E7", "GENE_OR_GENE_PRODUCT", 6, 8], ["cellular", "CELL", 29, 37], ["cell", "CELL", 71, 75], ["pRb", "GENE_OR_GENE_PRODUCT", 94, 97], ["E7", "PROTEIN", 6, 8], ["cellular proteins", "PROTEIN", 29, 46], ["pRb", "PROTEIN", 94, 97], ["many cellular proteins", "PROBLEM", 24, 46], ["pRb", "TREATMENT", 94, 97], ["host cell cycle", "OBSERVATION", 66, 81]]], ["Chang et al. (2010) have recently added to this list the transforming growth factor-beta inducible early gene-1 (TIEG1), a transcription factor that can induce apoptosis in carcinoma cell lines.", [["carcinoma cell lines", "ANATOMY", 173, 193], ["carcinoma", "DISEASE", 173, 182], ["transforming growth factor-beta inducible early gene-1", "GENE_OR_GENE_PRODUCT", 57, 111], ["TIEG1", "GENE_OR_GENE_PRODUCT", 113, 118], ["carcinoma cell lines", "CELL", 173, 193], ["transforming growth factor-beta inducible early gene-1", "DNA", 57, 111], ["TIEG1", "DNA", 113, 118], ["transcription factor", "PROTEIN", 123, 143], ["carcinoma cell lines", "CELL_LINE", 173, 193], ["the transforming growth factor", "TEST", 53, 83], ["a transcription factor", "PROBLEM", 121, 143], ["apoptosis in carcinoma cell lines", "PROBLEM", 160, 193], ["carcinoma cell lines", "OBSERVATION", 173, 193]]], ["E7 binds directly to TIEG1, and TIEG1 is subsequently ubiquitinated and degraded via the proteasome, further contributing to E7-induced cellular transformation.Human papillomaviruses E2 ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationThe HPV protein E2 is a DNA-binding protein that can both activate and repress the transcription of viral promoters (reviewed in Lagunas-Martinez et al., 2010).", [["cellular", "ANATOMY", 136, 144], ["Cell", "ANATOMY", 190, 194], ["Cellular", "ANATOMY", 241, 249], ["E2", "CHEMICAL", 183, 185], ["E2", "CHEMICAL", 279, 281], ["E7", "GENE_OR_GENE_PRODUCT", 0, 2], ["TIEG1", "GENE_OR_GENE_PRODUCT", 21, 26], ["TIEG1", "GENE_OR_GENE_PRODUCT", 32, 37], ["E7", "GENE_OR_GENE_PRODUCT", 125, 127], ["cellular", "CELL", 136, 144], ["Human", "ORGANISM", 160, 165], ["papillomaviruses", "ORGANISM", 166, 182], ["Cell", "CELL", 190, 194], ["HPV", "ORGANISM", 267, 270], ["E2", "GENE_OR_GENE_PRODUCT", 279, 281], ["DNA", "CELLULAR_COMPONENT", 287, 290], ["E7", "PROTEIN", 0, 2], ["TIEG1", "PROTEIN", 21, 26], ["TIEG1", "PROTEIN", 32, 37], ["proteasome", "PROTEIN", 89, 99], ["E7", "PROTEIN", 125, 127], ["HPV protein E2", "PROTEIN", 267, 281], ["DNA-binding protein", "PROTEIN", 287, 306], ["viral promoters", "DNA", 363, 378], ["Human", "SPECIES", 160, 165], ["Human papillomaviruses", "SPECIES", 160, 182], ["the proteasome", "TREATMENT", 85, 99], ["E7-induced cellular transformation", "PROBLEM", 125, 159], ["Cell Cycle Regulation", "TEST", 190, 211], ["Apoptosis", "PROBLEM", 227, 236], ["Cellular Proliferation", "TEST", 241, 263], ["The HPV protein E2", "TEST", 263, 281], ["a DNA-binding protein", "PROBLEM", 285, 306], ["viral promoters", "TREATMENT", 363, 378], ["cellular transformation", "OBSERVATION", 136, 159], ["Apoptosis", "OBSERVATION_MODIFIER", 227, 236], ["Cellular Proliferation", "OBSERVATION", 241, 263]]], ["Interestingly, HPV E2 normally represses the transcription of the genes encoding E6/E7.", [["E2", "CHEMICAL", 19, 21], ["HPV E2", "ORGANISM", 15, 21], ["E6", "GENE_OR_GENE_PRODUCT", 81, 83], ["E7", "GENE_OR_GENE_PRODUCT", 84, 86], ["E6", "PROTEIN", 81, 83], ["E7", "PROTEIN", 84, 86], ["HPV", "SPECIES", 15, 18]]], ["However, in cells infected with high risk HPV\u2019s, the viral genome frequently integrates into that of the host, and HPV E2 is inactivated in the process.", [["cells", "ANATOMY", 12, 17], ["E2", "CHEMICAL", 119, 121], ["cells", "CELL", 12, 17], ["HPV", "ORGANISM", 42, 45], ["HPV E2", "ORGANISM", 115, 121], ["viral genome", "DNA", 53, 65], ["HPV", "SPECIES", 42, 45], ["HPV", "SPECIES", 115, 118], ["high risk HPV\u2019s", "PROBLEM", 32, 47], ["the viral genome", "PROBLEM", 49, 65], ["HPV E2", "TREATMENT", 115, 121], ["viral genome", "OBSERVATION", 53, 65]]], ["HPV E2 has also been shown to interfere with cellular pathways in a Ub-dependent manner.", [["cellular", "ANATOMY", 45, 53], ["E2", "CHEMICAL", 4, 6], ["HPV E2", "ORGANISM", 0, 6], ["cellular", "CELL", 45, 53], ["Ub", "GENE_OR_GENE_PRODUCT", 68, 70], ["Ub", "PROTEIN", 68, 70], ["HPV", "SPECIES", 0, 3]]], ["For example, HPV E2 interacts with the Cdc20 and Cdh1 substrate-specificity subunits of the anaphase promoting complex (APC) E3 ligase.", [["E2", "CHEMICAL", 17, 19], ["HPV E2", "ORGANISM", 13, 19], ["Cdc20", "GENE_OR_GENE_PRODUCT", 39, 44], ["Cdh1", "GENE_OR_GENE_PRODUCT", 49, 53], ["anaphase promoting complex", "GENE_OR_GENE_PRODUCT", 92, 118], ["APC", "GENE_OR_GENE_PRODUCT", 120, 123], ["E3", "GENE_OR_GENE_PRODUCT", 125, 127], ["HPV E2", "PROTEIN", 13, 19], ["Cdc20", "PROTEIN", 39, 44], ["Cdh1 substrate-specificity subunits", "PROTEIN", 49, 84], ["anaphase promoting complex (APC) E3 ligase", "PROTEIN", 92, 134], ["HPV", "SPECIES", 13, 16], ["the Cdc20", "TEST", 35, 44], ["Cdh1 substrate", "TEST", 49, 63]]], ["This inhibits normal APC-dependent Cyclin B degradation, thereby leading to G2/M arrest (Bellanger et al., 2005).", [["APC", "GENE_OR_GENE_PRODUCT", 21, 24], ["Cyclin B", "GENE_OR_GENE_PRODUCT", 35, 43], ["APC", "CELL_TYPE", 21, 24], ["Cyclin B", "PROTEIN", 35, 43], ["dependent Cyclin B degradation", "PROBLEM", 25, 55], ["G2/M arrest", "PROBLEM", 76, 87], ["normal APC", "OBSERVATION", 14, 24], ["dependent", "OBSERVATION_MODIFIER", 25, 34], ["Cyclin B degradation", "OBSERVATION", 35, 55]]], ["It has recently been shown that HPV E2 binds to Skp2, an F-box protein that serves as a specificity determinant for the SCF complex.", [["E2", "CHEMICAL", 36, 38], ["HPV E2", "ORGANISM", 32, 38], ["Skp2", "GENE_OR_GENE_PRODUCT", 48, 52], ["SCF", "GENE_OR_GENE_PRODUCT", 120, 123], ["Skp2", "PROTEIN", 48, 52], ["F-box protein", "PROTEIN", 57, 70], ["SCF complex", "PROTEIN", 120, 131], ["HPV", "SPECIES", 32, 35], ["HPV E2 binds", "PROBLEM", 32, 44], ["an F-box protein", "TEST", 54, 70]]], ["In this way, HPV E2 is targeted for ubiquitination and subsequent proteasomal degradation.", [["proteasomal", "ANATOMY", 66, 77], ["E2", "CHEMICAL", 17, 19], ["HPV E2", "ORGANISM", 13, 19], ["HPV", "SPECIES", 13, 16], ["HPV E2", "TREATMENT", 13, 19], ["ubiquitination", "PROBLEM", 36, 50], ["subsequent proteasomal degradation", "PROBLEM", 55, 89], ["proteasomal degradation", "OBSERVATION", 66, 89]]], ["However, Skp2 is itself a known APC target, and APC-dependent Skp2 degradation is required to maintain cells in G1.", [["cells", "ANATOMY", 103, 108], ["Skp2", "GENE_OR_GENE_PRODUCT", 9, 13], ["APC", "GENE_OR_GENE_PRODUCT", 32, 35], ["APC", "GENE_OR_GENE_PRODUCT", 48, 51], ["Skp2", "GENE_OR_GENE_PRODUCT", 62, 66], ["cells", "CELL", 103, 108], ["Skp2", "PROTEIN", 9, 13], ["APC", "PROTEIN", 48, 51], ["Skp2", "PROTEIN", 62, 66], ["a known APC target", "PROBLEM", 24, 42], ["APC-dependent Skp2 degradation", "PROBLEM", 48, 78]]], ["Because HPV E2 interferes with APC (see above), this suggests a criss-crossing autoregulatory loop in which HPV E2 interferes with APC, thus stabilizing Skp2 and promoting G1/S progression.", [["E2", "CHEMICAL", 12, 14], ["E2", "CHEMICAL", 112, 114], ["HPV E2", "ORGANISM", 8, 14], ["APC", "GENE_OR_GENE_PRODUCT", 31, 34], ["HPV E2", "ORGANISM", 108, 114], ["APC", "GENE_OR_GENE_PRODUCT", 131, 134], ["Skp2", "GENE_OR_GENE_PRODUCT", 153, 157], ["APC", "CELL_TYPE", 31, 34], ["APC", "CELL_TYPE", 131, 134], ["Skp2", "PROTEIN", 153, 157], ["HPV", "SPECIES", 8, 11], ["HPV", "SPECIES", 108, 111], ["APC", "PROBLEM", 31, 34], ["a criss", "PROBLEM", 62, 69], ["crossing autoregulatory loop", "PROBLEM", 70, 98], ["APC", "PROBLEM", 131, 134], ["autoregulatory loop", "OBSERVATION", 79, 98]]], ["Once Skp2 reaches sufficient levels, Skp2/SCF ubiquitinates and degrades HPV E2, which de-represses HPV E6 and E7 expression.", [["E2", "CHEMICAL", 77, 79], ["Skp2", "GENE_OR_GENE_PRODUCT", 5, 9], ["Skp2", "GENE_OR_GENE_PRODUCT", 37, 41], ["SCF", "GENE_OR_GENE_PRODUCT", 42, 45], ["HPV E2", "GENE_OR_GENE_PRODUCT", 73, 79], ["HPV", "ORGANISM", 100, 103], ["E6", "GENE_OR_GENE_PRODUCT", 104, 106], ["E7", "GENE_OR_GENE_PRODUCT", 111, 113], ["Skp2", "PROTEIN", 5, 9], ["Skp2", "PROTEIN", 37, 41], ["SCF", "PROTEIN", 42, 45], ["E7", "PROTEIN", 111, 113], ["HPV", "SPECIES", 100, 103], ["Skp2", "TEST", 5, 9], ["Skp2/SCF ubiquitinates", "PROBLEM", 37, 59], ["SCF ubiquitinates", "OBSERVATION", 42, 59]]], ["This combination tends to push the host cell toward S-phase, and perhaps into transformation (Bellanger et al., 2010).Human papillomaviruses E5 ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationAlthough it has been shown to induce epithelial cell hyperproliferation when overexpressed in transgenic mice (Maufort et al., 2010), HPV E5 has primarily been characterized as a mere contributor to E6/E7-driven transformation (reviewed in Moody and Laimins, 2010).", [["cell", "ANATOMY", 40, 44], ["Cell", "ANATOMY", 148, 152], ["Cellular", "ANATOMY", 199, 207], ["epithelial cell", "ANATOMY", 258, 273], ["cell", "CELL", 40, 44], ["Human", "ORGANISM", 118, 123], ["papillomaviruses", "ORGANISM", 124, 140], ["Cell", "CELL", 148, 152], ["epithelial cell", "CELL", 258, 273], ["mice", "ORGANISM", 326, 330], ["HPV E5", "ORGANISM", 355, 361], ["E6", "GENE_OR_GENE_PRODUCT", 420, 422], ["E7", "GENE_OR_GENE_PRODUCT", 423, 425], ["E6", "PROTEIN", 420, 422], ["E7", "PROTEIN", 423, 425], ["Human", "SPECIES", 118, 123], ["mice", "SPECIES", 326, 330], ["Human papillomaviruses E5", "SPECIES", 118, 143], ["mice", "SPECIES", 326, 330], ["Cell Cycle Regulation", "TEST", 148, 169], ["Apoptosis", "PROBLEM", 185, 194], ["Cellular ProliferationAlthough", "PROBLEM", 199, 229], ["epithelial cell hyperproliferation", "PROBLEM", 258, 292], ["Apoptosis", "OBSERVATION_MODIFIER", 185, 194], ["Cellular ProliferationAlthough", "OBSERVATION", 199, 229], ["epithelial cell hyperproliferation", "OBSERVATION", 258, 292]]], ["Due to its ER localization and proposed inhibition of endosome acidification, it is thought that HPV E5 impacts the trafficking of proteins such as EGF-R, which enhances proliferative cell signaling (Leechanachai et al., 1992; Straight et al., 1995).", [["endosome", "ANATOMY", 54, 62], ["cell", "ANATOMY", 184, 188], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["endosome", "CELLULAR_COMPONENT", 54, 62], ["HPV E5", "ORGANISM", 97, 103], ["EGF-R", "GENE_OR_GENE_PRODUCT", 148, 153], ["cell", "CELL", 184, 188], ["ER", "PROTEIN", 11, 13], ["HPV E5", "PROTEIN", 97, 103], ["EGF-R", "PROTEIN", 148, 153], ["HPV", "SPECIES", 97, 100], ["endosome acidification", "PROBLEM", 54, 76], ["HPV E5", "PROBLEM", 97, 103], ["EGF", "TEST", 148, 151], ["endosome acidification", "OBSERVATION", 54, 76], ["proliferative cell signaling", "OBSERVATION", 170, 198]]], ["A role for Ub in this process was provided by the observation that E5 binding to EGF-R prevents the receptor from binding to the cellular E3 c-Cbl (Zhang et al., 2005), which is involved in normal EGF-R receptor downregulation.", [["cellular", "ANATOMY", 129, 137], ["Ub", "GENE_OR_GENE_PRODUCT", 11, 13], ["E5", "GENE_OR_GENE_PRODUCT", 67, 69], ["EGF-R", "GENE_OR_GENE_PRODUCT", 81, 86], ["cellular", "CELL", 129, 137], ["c-Cbl", "GENE_OR_GENE_PRODUCT", 141, 146], ["EGF-R receptor", "GENE_OR_GENE_PRODUCT", 197, 211], ["Ub", "PROTEIN", 11, 13], ["E5", "PROTEIN", 67, 69], ["EGF-R", "PROTEIN", 81, 86], ["cellular E3 c", "PROTEIN", 129, 142], ["Cbl", "PROTEIN", 143, 146], ["EGF-R receptor", "PROTEIN", 197, 211], ["EGF", "TEST", 81, 84]]], ["This stabilizes EGF-R and leads to constitutive signaling.", [["EGF-R", "GENE_OR_GENE_PRODUCT", 16, 21], ["EGF-R", "PROTEIN", 16, 21], ["constitutive signaling", "PROBLEM", 35, 57], ["constitutive signaling", "OBSERVATION", 35, 57]]], ["In what appears to be yet another Ub-dependent E5 phenotype, Oh et al. (2010) have recently shown that the HPV16 E5 contribution to cervical cancer may lie in its ability to limit Bax-dependent apoptosis of infected cells.", [["cervical cancer", "ANATOMY", 132, 147], ["cells", "ANATOMY", 216, 221], ["cervical cancer", "DISEASE", 132, 147], ["Ub", "GENE_OR_GENE_PRODUCT", 34, 36], ["E5", "GENE_OR_GENE_PRODUCT", 47, 49], ["HPV16", "ORGANISM", 107, 112], ["E5", "GENE_OR_GENE_PRODUCT", 113, 115], ["cervical cancer", "CANCER", 132, 147], ["cells", "CELL", 216, 221], ["Ub", "PROTEIN", 34, 36], ["HPV16 E5", "PROTEIN", 107, 115], ["infected cells", "CELL_TYPE", 207, 221], ["HPV16", "SPECIES", 107, 112], ["another Ub", "TEST", 26, 36], ["the HPV16", "PROBLEM", 103, 112], ["cervical cancer", "PROBLEM", 132, 147], ["Bax-dependent apoptosis of infected cells", "PROBLEM", 180, 221], ["appears to be", "UNCERTAINTY", 8, 21], ["cervical", "ANATOMY", 132, 140], ["cancer", "OBSERVATION", 141, 147], ["infected cells", "OBSERVATION", 207, 221]]], ["Expression of E5 induced the degradation of Bax in a UPS-dependent manner.", [["E5", "GENE_OR_GENE_PRODUCT", 14, 16], ["Bax", "GENE_OR_GENE_PRODUCT", 44, 47], ["UPS", "GENE_OR_GENE_PRODUCT", 53, 56], ["E5", "PROTEIN", 14, 16], ["Bax", "PROTEIN", 44, 47], ["UPS", "PROTEIN", 53, 56]]], ["E5 may therefore function as an adaptor that targets cellular proteins for ubiquitination, and this may be responsible for other established E5 activities as well.Adenovirus ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationLike the high risk HPVs, adenoviral infection can also result in host cell transformation.", [["cellular", "ANATOMY", 53, 61], ["Cell", "ANATOMY", 178, 182], ["cell", "ANATOMY", 321, 325], ["HPVs", "DISEASE", 270, 274], ["adenoviral infection", "DISEASE", 276, 296], ["E5", "GENE_OR_GENE_PRODUCT", 0, 2], ["cellular", "CELL", 53, 61], ["E5", "GENE_OR_GENE_PRODUCT", 141, 143], ["Adenovirus", "ORGANISM", 163, 173], ["Cell", "CELL", 178, 182], ["HPVs", "ORGANISM", 270, 274], ["adenoviral", "ORGANISM", 276, 286], ["host cell", "CELL", 316, 325], ["E5", "PROTEIN", 0, 2], ["cellular proteins", "PROTEIN", 53, 70], ["E5", "PROTEIN", 141, 143], ["adenoviral", "SPECIES", 276, 286], ["ubiquitination", "PROBLEM", 75, 89], ["Adenovirus", "PROBLEM", 163, 173], ["Cell Cycle Regulation", "TEST", 178, 199], ["Apoptosis", "PROBLEM", 215, 224], ["Cellular ProliferationLike the high risk HPVs", "PROBLEM", 229, 274], ["adenoviral infection", "PROBLEM", 276, 296], ["host cell transformation", "PROBLEM", 316, 340], ["Apoptosis", "OBSERVATION_MODIFIER", 215, 224], ["Cellular ProliferationLike", "OBSERVATION", 229, 255], ["infection", "OBSERVATION", 287, 296], ["host cell transformation", "OBSERVATION", 316, 340]]], ["The primary culprits here are the viral proteins E4orf6 and E1B55k, which combine to effect the UPS-dependent degradation of host proteins related to cell cycle regulation and DNA damage repair (see Table 3).", [["cell", "ANATOMY", 150, 154], ["E4orf6", "GENE_OR_GENE_PRODUCT", 49, 55], ["E1B55k", "GENE_OR_GENE_PRODUCT", 60, 66], ["UPS", "GENE_OR_GENE_PRODUCT", 96, 99], ["cell", "CELL", 150, 154], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["viral proteins", "PROTEIN", 34, 48], ["E4orf6", "PROTEIN", 49, 55], ["E1B55k", "PROTEIN", 60, 66], ["UPS", "PROTEIN", 96, 99], ["host proteins", "PROTEIN", 125, 138], ["E1B55k", "TREATMENT", 60, 66], ["the UPS", "PROBLEM", 92, 99], ["host proteins", "TREATMENT", 125, 138], ["cell cycle regulation", "TREATMENT", 150, 171], ["DNA damage repair", "TREATMENT", 176, 193]]], ["E4orf6 functions as an adaptor that links E1B55k to various Cul containing E3 complexes.", [["E4orf6", "GENE_OR_GENE_PRODUCT", 0, 6], ["E1B55k", "GENE_OR_GENE_PRODUCT", 42, 48], ["Cul", "GENE_OR_GENE_PRODUCT", 60, 63], ["E3", "GENE_OR_GENE_PRODUCT", 75, 77], ["E4orf6", "PROTEIN", 0, 6], ["E1B55k", "PROTEIN", 42, 48], ["Cul", "PROTEIN", 60, 63], ["E3 complexes", "PROTEIN", 75, 87]]], ["E1B55k then acts as a substrate recognition subunit that redirects the new E3 complex to various cellular targets.", [["cellular", "ANATOMY", 97, 105], ["E1B55k", "GENE_OR_GENE_PRODUCT", 0, 6], ["E3", "GENE_OR_GENE_PRODUCT", 75, 77], ["cellular", "CELL", 97, 105], ["E1B55k", "PROTEIN", 0, 6], ["substrate recognition subunit", "PROTEIN", 22, 51], ["E3 complex", "PROTEIN", 75, 85], ["cellular targets", "OBSERVATION", 97, 113]]], ["The prevention of apoptosis leads to the accumulation of DNA damage within infected cells.", [["cells", "ANATOMY", 84, 89], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["cells", "CELL", 84, 89], ["infected cells", "CELL_TYPE", 75, 89], ["apoptosis", "PROBLEM", 18, 27], ["DNA damage within infected cells", "PROBLEM", 57, 89], ["apoptosis", "OBSERVATION", 18, 27], ["accumulation", "OBSERVATION_MODIFIER", 41, 53], ["DNA damage", "OBSERVATION", 57, 67], ["infected cells", "OBSERVATION", 75, 89]]], ["To avoid cellular DNA damage responses, adenovirus blocks the ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related) pathways (Carson et al., 2003).", [["cellular", "ANATOMY", 9, 17], ["ataxia telangiectasia", "DISEASE", 67, 88], ["cellular", "CELL", 9, 17], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["adenovirus", "ORGANISM", 40, 50], ["ATM", "GENE_OR_GENE_PRODUCT", 62, 65], ["ataxia telangiectasia mutated", "GENE_OR_GENE_PRODUCT", 67, 96], ["ATR", "GENE_OR_GENE_PRODUCT", 102, 105], ["ATM", "GENE_OR_GENE_PRODUCT", 107, 110], ["Rad3", "GENE_OR_GENE_PRODUCT", 115, 119], ["ATM", "PROTEIN", 62, 65], ["ATR", "PROTEIN", 102, 105], ["ATM", "PROTEIN", 107, 110], ["Rad3", "PROTEIN", 115, 119], ["cellular DNA damage responses", "PROBLEM", 9, 38], ["adenovirus blocks the ATM (ataxia telangiectasia mutated)", "PROBLEM", 40, 97], ["ATR (ATM", "TREATMENT", 102, 110]]], ["Most Adenovirus serotypes, including Ad5 and Ad12, prevent the activation of the ATM pathway by inducing the degradation of the MRN (Mre11, Rad50, and Nbs1) DNA damage complex via the mechanism just described.", [["Adenovirus serotypes", "ORGANISM", 5, 25], ["Ad5", "ORGANISM", 37, 40], ["Ad12", "GENE_OR_GENE_PRODUCT", 45, 49], ["ATM", "GENE_OR_GENE_PRODUCT", 81, 84], ["MRN", "GENE_OR_GENE_PRODUCT", 128, 131], ["Mre11", "GENE_OR_GENE_PRODUCT", 133, 138], ["Rad50", "GENE_OR_GENE_PRODUCT", 140, 145], ["Nbs1", "GENE_OR_GENE_PRODUCT", 151, 155], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["damage complex", "GENE_OR_GENE_PRODUCT", 161, 175], ["ATM", "PROTEIN", 81, 84], ["MRN", "PROTEIN", 128, 131], ["Mre11", "PROTEIN", 133, 138], ["Rad50", "PROTEIN", 140, 145], ["Nbs1", "PROTEIN", 151, 155], ["DNA damage complex", "PROTEIN", 157, 175], ["Adenovirus", "SPECIES", 5, 15], ["Ad5", "SPECIES", 37, 40], ["Most Adenovirus serotypes", "PROBLEM", 0, 25], ["Ad5 and Ad12", "TREATMENT", 37, 49], ["the ATM pathway", "TREATMENT", 77, 92], ["Mre11", "TEST", 133, 138], ["Rad50", "TEST", 140, 145], ["DNA damage complex", "PROBLEM", 157, 175]]], ["However, it has recently been shown that Ad5 and Ad12 prevent the activation of the ATR pathway in different ways.", [["Ad5", "ORGANISM", 41, 44], ["Ad12", "GENE_OR_GENE_PRODUCT", 49, 53], ["ATR", "GENE_OR_GENE_PRODUCT", 84, 87], ["ATR", "PROTEIN", 84, 87], ["Ad5", "SPECIES", 41, 44], ["Ad5", "TREATMENT", 41, 44], ["Ad12", "TREATMENT", 49, 53], ["the ATR pathway", "TREATMENT", 80, 95]]], ["Prior to the E4orf6/E1B55K-dependent degradation of the MRN complex, Ad5 utilizes E4orf3 to mislocalize and immobilize the MRN complex, which prevents ATR activation (Carson et al., 2009).", [["E4orf6", "GENE_OR_GENE_PRODUCT", 13, 19], ["E1B55K", "GENE_OR_GENE_PRODUCT", 20, 26], ["MRN", "GENE_OR_GENE_PRODUCT", 56, 59], ["Ad5", "ORGANISM", 69, 72], ["E4orf3", "GENE_OR_GENE_PRODUCT", 82, 88], ["MRN", "GENE_OR_GENE_PRODUCT", 123, 126], ["ATR", "GENE_OR_GENE_PRODUCT", 151, 154], ["E4orf6", "PROTEIN", 13, 19], ["E1B55K", "PROTEIN", 20, 26], ["MRN complex", "PROTEIN", 56, 67], ["E4orf3", "PROTEIN", 82, 88], ["MRN complex", "PROTEIN", 123, 134], ["ATR", "PROTEIN", 151, 154], ["Ad5", "SPECIES", 69, 72], ["E4orf3", "TREATMENT", 82, 88]]], ["In contrast, Ad12 E4orf3 does not appear to have this function.", [["Ad12", "ORGANISM", 13, 17], ["E4orf3", "GENE_OR_GENE_PRODUCT", 18, 24], ["Ad12 E4orf3", "PROTEIN", 13, 24], ["Ad12", "SPECIES", 13, 17]]], ["Instead, Ad12 E4orf6 (without E1B55k) interacts with a Cul2/Rbx1/ElonginC ligase to promote the UPS-dependent degradation of the ATR activator protein topoisomerase-IL\u03b2-binding protein-1 (TOPBP1), thereby blocking ATR activation (Blackford et al., 2010).", [["Ad12", "ORGANISM", 9, 13], ["E4orf6", "GENE_OR_GENE_PRODUCT", 14, 20], ["E1B55k", "GENE_OR_GENE_PRODUCT", 30, 36], ["Cul2", "GENE_OR_GENE_PRODUCT", 55, 59], ["Rbx1", "GENE_OR_GENE_PRODUCT", 60, 64], ["ElonginC", "GENE_OR_GENE_PRODUCT", 65, 73], ["UPS", "GENE_OR_GENE_PRODUCT", 96, 99], ["topoisomerase-IL\u03b2-binding protein-1", "GENE_OR_GENE_PRODUCT", 151, 186], ["TOPBP1", "GENE_OR_GENE_PRODUCT", 188, 194], ["ATR", "GENE_OR_GENE_PRODUCT", 214, 217], ["Ad12 E4orf6", "PROTEIN", 9, 20], ["E1B55k", "PROTEIN", 30, 36], ["Cul2", "PROTEIN", 55, 59], ["Rbx1", "PROTEIN", 60, 64], ["ElonginC ligase", "PROTEIN", 65, 80], ["UPS", "PROTEIN", 96, 99], ["ATR activator protein topoisomerase-IL\u03b2-binding protein-1", "PROTEIN", 129, 186], ["TOPBP1", "PROTEIN", 188, 194], ["ATR", "PROTEIN", 214, 217], ["a Cul2/Rbx1", "TREATMENT", 53, 64], ["ElonginC ligase", "TREATMENT", 65, 80], ["the UPS", "TEST", 92, 99], ["dependent degradation", "PROBLEM", 100, 121], ["the ATR activator protein topoisomerase", "TEST", 125, 164], ["IL\u03b2", "TEST", 165, 168], ["binding protein", "TEST", 169, 184]]], ["This observation of differential Cul usage by adenoviruses has been extended even further.", [["Cul", "CHEMICAL", 33, 36], ["Cul", "GENE_OR_GENE_PRODUCT", 33, 36], ["adenoviruses", "ORGANISM", 46, 58], ["Cul", "DNA", 33, 36], ["adenoviruses", "PROBLEM", 46, 58]]], ["In a recent survey of all adenoviral subgroups, it was found that while all E4orf6/E1B55k pairs associate with Cul family members, the particular Cul varies.", [["adenoviral", "ORGANISM", 26, 36], ["E4orf6", "GENE_OR_GENE_PRODUCT", 76, 82], ["E1B55k", "GENE_OR_GENE_PRODUCT", 83, 89], ["Cul", "GENE_OR_GENE_PRODUCT", 111, 114], ["Cul", "GENE_OR_GENE_PRODUCT", 146, 149], ["E4orf6/E1B55k pairs", "DNA", 76, 95], ["Cul family members", "PROTEIN", 111, 129], ["Cul", "DNA", 146, 149]]], ["Among the serotypes, Cul5 is most frequently bound, but some serotypes recruit Cul2, and Ad16 E4orf6/E1B55k recruited both Cul2 and Cul5 equally well.", [["Cul5", "GENE_OR_GENE_PRODUCT", 21, 25], ["Cul2", "GENE_OR_GENE_PRODUCT", 79, 83], ["Ad16", "GENE_OR_GENE_PRODUCT", 89, 93], ["E4orf6", "GENE_OR_GENE_PRODUCT", 94, 100], ["E1B55k", "GENE_OR_GENE_PRODUCT", 101, 107], ["Cul2", "GENE_OR_GENE_PRODUCT", 123, 127], ["Cul5", "GENE_OR_GENE_PRODUCT", 132, 136], ["Cul5", "PROTEIN", 21, 25], ["Cul2", "PROTEIN", 79, 83], ["Ad16", "PROTEIN", 89, 93], ["E4orf6", "PROTEIN", 94, 100], ["E1B55k", "PROTEIN", 101, 107], ["Cul2", "PROTEIN", 123, 127], ["Cul5", "PROTEIN", 132, 136], ["the serotypes", "PROBLEM", 6, 19], ["serotypes", "OBSERVATION", 10, 19]]], ["While all serotypes degraded DNA ligase IV, complexes from some serotypes failed to degrade Mre11, p53, or integrin \u03b13, suggesting that the choice of Cullin may in part dictate which targets are destroyed (Cheng et al., 2010).Adenovirus ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationFinally, the adenoviral protein E4orf4 is known to induce cell death via a number of cell-type specific mechanisms (Robert et al., 2002).", [["Cell", "ANATOMY", 241, 245], ["cell", "ANATOMY", 372, 376], ["cell", "ANATOMY", 399, 403], ["Cullin", "CHEMICAL", 150, 156], ["death", "DISEASE", 377, 382], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["Mre11", "GENE_OR_GENE_PRODUCT", 92, 97], ["p53", "GENE_OR_GENE_PRODUCT", 99, 102], ["integrin \u03b13", "GENE_OR_GENE_PRODUCT", 107, 118], ["Cullin", "GENE_OR_GENE_PRODUCT", 150, 156], ["Adenovirus", "ORGANISM", 226, 236], ["Cell", "CELL", 241, 245], ["adenoviral", "ORGANISM", 327, 337], ["E4orf4", "GENE_OR_GENE_PRODUCT", 346, 352], ["cell", "CELL", 372, 376], ["cell", "CELL", 399, 403], ["DNA ligase IV", "PROTEIN", 29, 42], ["Mre11", "PROTEIN", 92, 97], ["p53", "PROTEIN", 99, 102], ["integrin \u03b13", "PROTEIN", 107, 118], ["Cullin", "PROTEIN", 150, 156], ["adenoviral protein", "PROTEIN", 327, 345], ["E4orf4", "PROTEIN", 346, 352], ["DNA ligase IV", "TREATMENT", 29, 42], ["some serotypes", "PROBLEM", 59, 73], ["Mre11", "TEST", 92, 97], ["p53", "TEST", 99, 102], ["Cullin", "TREATMENT", 150, 156], ["Adenovirus", "PROBLEM", 226, 236], ["Cell Cycle Regulation", "TEST", 241, 262], ["Apoptosis", "PROBLEM", 278, 287], ["Cellular ProliferationFinally", "TEST", 292, 321], ["the adenoviral protein E4orf4", "TEST", 323, 352], ["cell death", "PROBLEM", 372, 382]]], ["One commonality amongst these mechanisms is the modification of the APC E3 ligase activity, although it has been reported that E4orf4 can both reduce (Kornitzer et al., 2001) and induce (Mui et al., 2010) APC activity to achieve this end.", [["APC", "GENE_OR_GENE_PRODUCT", 68, 71], ["E4orf4", "GENE_OR_GENE_PRODUCT", 127, 133], ["APC", "GENE_OR_GENE_PRODUCT", 205, 208], ["APC E3 ligase", "PROTEIN", 68, 81], ["E4orf4", "PROTEIN", 127, 133], ["APC activity", "TREATMENT", 205, 217], ["ligase activity", "OBSERVATION", 75, 90]]], ["In the latter case, E4orf4 expression led to degradation of the APC substrate Pds1/securin, a protein that is required for the completion of mitosis.", [["E4orf4", "GENE_OR_GENE_PRODUCT", 20, 26], ["APC", "GENE_OR_GENE_PRODUCT", 64, 67], ["Pds1", "GENE_OR_GENE_PRODUCT", 78, 82], ["securin", "GENE_OR_GENE_PRODUCT", 83, 90], ["mitosis", "CELLULAR_COMPONENT", 141, 148], ["E4orf4", "PROTEIN", 20, 26], ["APC substrate", "PROTEIN", 64, 77], ["Pds1", "PROTEIN", 78, 82], ["securin", "PROTEIN", 83, 90], ["the APC substrate Pds1", "TREATMENT", 60, 82], ["securin", "TREATMENT", 83, 90], ["a protein", "TREATMENT", 92, 101], ["mitosis", "PROBLEM", 141, 148]]], ["Thus, it appears that yet another adenoviral protein can, albeit indirectly, redirect the host Ub system to target host proteins that disrupt the cell cycle.Herpesvirus ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationThe herpesviral large tegument proteins harbor a cysteine protease catalytic site that shows little homology to known DUBs, but nevertheless has been shown to display DUB activity (Kattenhorn et al., 2005).", [["cell", "ANATOMY", 146, 150], ["Cell", "ANATOMY", 173, 177], ["Cellular", "ANATOMY", 224, 232], ["cysteine", "CHEMICAL", 295, 303], ["adenoviral", "ORGANISM", 34, 44], ["Ub", "GENE_OR_GENE_PRODUCT", 95, 97], ["cell", "CELL", 146, 150], ["Herpesvirus", "ORGANISM", 157, 168], ["Cell", "CELL", 173, 177], ["herpesviral large tegument proteins", "GENE_OR_GENE_PRODUCT", 250, 285], ["DUBs", "GENE_OR_GENE_PRODUCT", 364, 368], ["DUB", "GENE_OR_GENE_PRODUCT", 413, 416], ["adenoviral protein", "PROTEIN", 34, 52], ["Ub", "PROTEIN", 95, 97], ["herpesviral large tegument proteins", "PROTEIN", 250, 285], ["cysteine protease catalytic site", "PROTEIN", 295, 327], ["DUBs", "PROTEIN", 364, 368], ["DUB", "PROTEIN", 413, 416], ["Herpesvirus", "SPECIES", 157, 168], ["Herpesvirus", "PROBLEM", 157, 168], ["Cell Cycle Regulation", "TEST", 173, 194], ["Apoptosis", "PROBLEM", 210, 219], ["Cellular Proliferation", "TREATMENT", 224, 246], ["The herpesviral large tegument proteins", "TREATMENT", 246, 285], ["a cysteine protease catalytic site", "TREATMENT", 293, 327], ["little homology to known DUBs", "PROBLEM", 339, 368], ["cell cycle", "OBSERVATION", 146, 156], ["Apoptosis", "OBSERVATION_MODIFIER", 210, 219], ["Cellular Proliferation", "OBSERVATION", 224, 246], ["DUBs", "OBSERVATION", 364, 368]]], ["As discussed above, the KSHV and MHV68 large tegument homologs (ORF64) have been implicated in the regulation of the lytic/latent balance.", [["KSHV", "ORGANISM", 24, 28], ["MHV68 large tegument homologs", "GENE_OR_GENE_PRODUCT", 33, 62], ["ORF64", "GENE_OR_GENE_PRODUCT", 64, 69], ["KSHV and MHV68 large tegument homologs", "PROTEIN", 24, 62], ["ORF64", "PROTEIN", 64, 69], ["KSHV", "SPECIES", 24, 28], ["the KSHV and MHV68 large tegument homologs", "TREATMENT", 20, 62], ["latent balance", "OBSERVATION", 123, 137]]], ["Mutation of the active site residues in the Marek\u2019s disease virus homolog lowered viral replication and reduced the number of T-cell lymphomas among infected chickens (Jarosinski et al., 2007).", [["T-cell lymphomas", "ANATOMY", 126, 142], ["Marek\u2019s disease", "DISEASE", 44, 59], ["T-cell lymphomas", "DISEASE", 126, 142], ["Marek\u2019s disease virus", "ORGANISM", 44, 65], ["T-cell lymphomas", "CANCER", 126, 142], ["chickens", "ORGANISM", 158, 166], ["chickens", "SPECIES", 158, 166], ["Marek\u2019s disease virus", "SPECIES", 44, 65], ["chickens", "SPECIES", 158, 166], ["Mutation of the active site residues", "PROBLEM", 0, 36], ["viral replication", "TREATMENT", 82, 99], ["T-cell lymphomas", "PROBLEM", 126, 142], ["active", "OBSERVATION_MODIFIER", 16, 22], ["site residues", "OBSERVATION", 23, 36], ["viral replication", "OBSERVATION", 82, 99], ["reduced", "OBSERVATION_MODIFIER", 104, 111], ["T-cell lymphomas", "OBSERVATION", 126, 142]]], ["A similar mutation introduced into Pseudorabies virus likewise impaired viral replication and lowered virulence (Bottcher et al., 2008).", [["Pseudorabies virus", "ORGANISM", 35, 53], ["Pseudorabies virus", "SPECIES", 35, 53], ["A similar mutation", "PROBLEM", 0, 18], ["Pseudorabies virus", "TREATMENT", 35, 53], ["impaired viral replication", "PROBLEM", 63, 89], ["mutation", "OBSERVATION", 10, 18], ["impaired", "OBSERVATION_MODIFIER", 63, 71], ["viral replication", "OBSERVATION", 72, 89]]], ["A bioinformatics approach was used to search the EBV genome for proteins encoding DUB activity, revealing BSLF1, BXLF1, and the EBV large tegument protein BPLF1 (Sompallae et al., 2008).", [["EBV", "ORGANISM", 49, 52], ["DUB", "GENE_OR_GENE_PRODUCT", 82, 85], ["BSLF1", "GENE_OR_GENE_PRODUCT", 106, 111], ["BXLF1", "GENE_OR_GENE_PRODUCT", 113, 118], ["EBV", "ORGANISM", 128, 131], ["EBV genome", "DNA", 49, 59], ["DUB", "PROTEIN", 82, 85], ["BSLF1", "PROTEIN", 106, 111], ["BXLF1", "PROTEIN", 113, 118], ["EBV large tegument protein", "PROTEIN", 128, 154], ["BPLF1", "PROTEIN", 155, 160], ["A bioinformatics approach", "TREATMENT", 0, 25], ["BSLF1", "TEST", 106, 111], ["BXLF1", "TEST", 113, 118], ["the EBV large tegument protein BPLF1", "PROBLEM", 124, 160], ["tegument protein", "ANATOMY", 138, 154]]], ["In a follow-up paper, the same group focused on BPLF1 and found that it functions to dysregulate the host cell cycle in an effort to promote viral DNA replication (Gastaldello et al., 2010).", [["cell", "ANATOMY", 106, 110], ["BPLF1", "GENE_OR_GENE_PRODUCT", 48, 53], ["cell", "CELL", 106, 110], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["BPLF1", "PROTEIN", 48, 53], ["the host cell cycle", "TREATMENT", 97, 116], ["viral DNA replication", "TREATMENT", 141, 162], ["host cell cycle", "OBSERVATION", 101, 116], ["viral DNA", "OBSERVATION", 141, 150]]], ["This was shown to depend on BPLF1\u2019s ability to proteolytically remove the ubiquitin-like modifier protein NEDD8 from Cul1 and Cul4a.", [["BPLF1", "GENE_OR_GENE_PRODUCT", 28, 33], ["NEDD8", "GENE_OR_GENE_PRODUCT", 106, 111], ["Cul1", "GENE_OR_GENE_PRODUCT", 117, 121], ["Cul4a", "GENE_OR_GENE_PRODUCT", 126, 131], ["BPLF1", "PROTEIN", 28, 33], ["ubiquitin-like modifier protein", "PROTEIN", 74, 105], ["NEDD8", "PROTEIN", 106, 111], ["Cul1", "PROTEIN", 117, 121], ["Cul4a", "PROTEIN", 126, 131], ["the ubiquitin", "TREATMENT", 70, 83], ["modifier protein NEDD8", "TREATMENT", 89, 111], ["Cul4a", "TEST", 126, 131]]], ["This in turn leads to the stabilization of the Cul substrate CDT1, which then pushes the host cell toward S-phase.", [["cell", "ANATOMY", 94, 98], ["Cul", "CHEMICAL", 47, 50], ["CDT1", "GENE_OR_GENE_PRODUCT", 61, 65], ["cell", "CELL", 94, 98], ["Cul substrate", "PROTEIN", 47, 60], ["CDT1", "PROTEIN", 61, 65], ["the Cul substrate CDT1", "TREATMENT", 43, 65], ["Cul substrate CDT1", "OBSERVATION", 47, 65], ["host cell", "OBSERVATION", 89, 98]]], ["The authors found a similar activity encoded by the HSV and MCMV large tegument proteins, suggesting that perhaps all herpesviruses utilize their tegument proteins in this manner.Herpesvirus ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationIn addition to BPFL1, EBV encodes numerous other proteins that contribute to cellular transformation.", [["Cell", "ANATOMY", 195, 199], ["cellular", "ANATOMY", 345, 353], ["HSV", "ORGANISM", 52, 55], ["MCMV", "ORGANISM", 60, 64], ["large tegument proteins", "GENE_OR_GENE_PRODUCT", 65, 88], ["Herpesvirus", "ORGANISM", 179, 190], ["Cell", "CELL", 195, 199], ["BPFL1", "GENE_OR_GENE_PRODUCT", 283, 288], ["EBV", "ORGANISM", 290, 293], ["cellular", "CELL", 345, 353], ["HSV and MCMV large tegument proteins", "PROTEIN", 52, 88], ["tegument proteins", "PROTEIN", 146, 163], ["BPFL1", "PROTEIN", 283, 288], ["Herpesvirus", "SPECIES", 179, 190], ["HSV", "SPECIES", 52, 55], ["MCMV", "SPECIES", 60, 64], ["the HSV", "TEST", 48, 55], ["MCMV large tegument proteins", "PROBLEM", 60, 88], ["all herpesviruses", "PROBLEM", 114, 131], ["Herpesvirus", "PROBLEM", 179, 190], ["Cell Cycle Regulation", "TEST", 195, 216], ["Apoptosis", "PROBLEM", 232, 241], ["BPFL1", "TREATMENT", 283, 288], ["EBV encodes numerous other proteins", "PROBLEM", 290, 325], ["cellular transformation", "PROBLEM", 345, 368], ["tegument proteins", "OBSERVATION", 71, 88], ["Cellular ProliferationIn", "OBSERVATION", 246, 270], ["cellular transformation", "OBSERVATION", 345, 368]]], ["Among these is EBNA3c, which is itself ubiquitinated (Knight et al., 2005b), and targets pRb and p27 for degradation by recruitment of the SCF (Skp2) E3 Ub ligase complex (Knight et al., 2005a; Saha et al., 2009).", [["EBNA3c", "GENE_OR_GENE_PRODUCT", 15, 21], ["pRb", "GENE_OR_GENE_PRODUCT", 89, 92], ["p27", "GENE_OR_GENE_PRODUCT", 97, 100], ["SCF", "GENE_OR_GENE_PRODUCT", 139, 142], ["Skp2", "GENE_OR_GENE_PRODUCT", 144, 148], ["EBNA3c", "PROTEIN", 15, 21], ["pRb", "PROTEIN", 89, 92], ["p27", "PROTEIN", 97, 100], ["SCF (Skp2) E3 Ub ligase complex", "PROTEIN", 139, 170], ["degradation", "PROBLEM", 105, 116]]], ["EBNA3c has also been shown to have a DUB activity that can remove Ub from itself.", [["EBNA3c", "CHEMICAL", 0, 6], ["EBNA3c", "GENE_OR_GENE_PRODUCT", 0, 6], ["DUB", "GENE_OR_GENE_PRODUCT", 37, 40], ["Ub", "GENE_OR_GENE_PRODUCT", 66, 68], ["EBNA3c", "PROTEIN", 0, 6], ["DUB", "PROTEIN", 37, 40], ["Ub", "PROTEIN", 66, 68], ["a DUB activity", "PROBLEM", 35, 49], ["DUB", "OBSERVATION", 37, 40]]], ["Interestingly, EBNA3c was found in complexes with both p53 and Mdm2, the cellular E3 responsible for p53 ubiquitination.", [["cellular", "ANATOMY", 73, 81], ["EBNA3c", "GENE_OR_GENE_PRODUCT", 15, 21], ["p53", "GENE_OR_GENE_PRODUCT", 55, 58], ["Mdm2", "GENE_OR_GENE_PRODUCT", 63, 67], ["cellular E3", "GENE_OR_GENE_PRODUCT", 73, 84], ["p53", "GENE_OR_GENE_PRODUCT", 101, 104], ["EBNA3c", "PROTEIN", 15, 21], ["p53", "PROTEIN", 55, 58], ["Mdm2", "PROTEIN", 63, 67], ["cellular E3", "PROTEIN", 73, 84], ["p53", "PROTEIN", 101, 104], ["EBNA3c", "TEST", 15, 21], ["Mdm2", "TEST", 63, 67], ["p53 ubiquitination", "PROBLEM", 101, 119], ["Mdm2", "OBSERVATION", 63, 67], ["p53 ubiquitination", "OBSERVATION", 101, 119]]], ["More recently EBNA3c was shown to prevent the degradation of Cyclin D1, which overrides the activity of the tumor suppressor pRb and thereby promotes G1/S-phase transition (Saha et al., 2011).", [["tumor", "ANATOMY", 108, 113], ["EBNA3c", "CHEMICAL", 14, 20], ["tumor", "DISEASE", 108, 113], ["EBNA3c", "GENE_OR_GENE_PRODUCT", 14, 20], ["Cyclin D1", "GENE_OR_GENE_PRODUCT", 61, 70], ["tumor", "CANCER", 108, 113], ["pRb", "GENE_OR_GENE_PRODUCT", 125, 128], ["EBNA3c", "PROTEIN", 14, 20], ["Cyclin D1", "PROTEIN", 61, 70], ["tumor suppressor pRb", "PROTEIN", 108, 128], ["Cyclin D1", "TREATMENT", 61, 70], ["the tumor suppressor pRb", "TREATMENT", 104, 128], ["tumor", "OBSERVATION", 108, 113]]], ["Thus, EBNA3c appears to both positively and negatively modulate the ubiquitin status of a number of proteins whose dysregulation can promote tumorigenesis.Hepadnaviruses ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationHepatitis B virus (HBV) is one of the primary causes of hepatocellular carcinoma (HCC), and the viral protein HBx has been shown to promote cell cycle progression via a number of mechanisms (reviewed in Kew, 2011).", [["Cell", "ANATOMY", 174, 178], ["hepatocellular carcinoma", "ANATOMY", 303, 327], ["HCC", "ANATOMY", 329, 332], ["cell", "ANATOMY", 387, 391], ["hepatocellular carcinoma", "DISEASE", 303, 327], ["HCC", "DISEASE", 329, 332], ["EBNA3c", "GENE_OR_GENE_PRODUCT", 6, 12], ["Cell", "CELL", 174, 178], ["Cellular ProliferationHepatitis B virus", "ORGANISM", 225, 264], ["HBV", "ORGANISM", 266, 269], ["hepatocellular carcinoma", "CANCER", 303, 327], ["HCC", "CANCER", 329, 332], ["HBx", "GENE_OR_GENE_PRODUCT", 357, 360], ["cell", "CELL", 387, 391], ["EBNA3c", "PROTEIN", 6, 12], ["viral protein", "PROTEIN", 343, 356], ["HBx", "PROTEIN", 357, 360], ["B virus", "SPECIES", 257, 264], ["ProliferationHepatitis B virus", "SPECIES", 234, 264], ["HBV", "SPECIES", 266, 269], ["Cell Cycle Regulation", "TEST", 174, 195], ["Apoptosis", "PROBLEM", 211, 220], ["Cellular ProliferationHepatitis B virus (HBV", "PROBLEM", 225, 269], ["hepatocellular carcinoma", "PROBLEM", 303, 327], ["HCC)", "PROBLEM", 329, 333], ["the viral protein HBx", "PROBLEM", 339, 360], ["Apoptosis", "OBSERVATION_MODIFIER", 211, 220], ["Cellular ProliferationHepatitis", "OBSERVATION", 225, 256], ["hepatocellular", "ANATOMY", 303, 317], ["carcinoma", "OBSERVATION", 318, 327], ["viral", "OBSERVATION_MODIFIER", 343, 348], ["protein HBx", "OBSERVATION", 349, 360], ["promote cell cycle", "OBSERVATION", 379, 397]]], ["While a role for ubiquitin was not initially appreciated, it was found that HBx binds to damage-specific DNA-binding protein 1 (DDB1; Lee et al., 1995), and that numerous HBx phenotypes depend upon this interaction (see references in Martin-Lluesma et al., 2008).", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 17, 26], ["HBx", "GENE_OR_GENE_PRODUCT", 76, 79], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["-binding protein 1", "GENE_OR_GENE_PRODUCT", 108, 126], ["DDB1", "GENE_OR_GENE_PRODUCT", 128, 132], ["HBx", "GENE_OR_GENE_PRODUCT", 171, 174], ["ubiquitin", "PROTEIN", 17, 26], ["HBx", "PROTEIN", 76, 79], ["DNA-binding protein 1", "PROTEIN", 105, 126], ["DDB1", "PROTEIN", 128, 132], ["HBx", "PROTEIN", 171, 174], ["HBx binds", "PROBLEM", 76, 85], ["specific DNA", "TEST", 96, 108], ["binding protein", "TEST", 109, 124], ["numerous HBx phenotypes", "PROBLEM", 162, 185], ["HBx", "OBSERVATION", 171, 174]]], ["The later finding that DDB1 is a part of Cul4a E3 ligase complex (Shiyanov et al., 1999) suggested that HBx functions to interfere with such complexes, resulting in many of the HBx phenotypes.", [["DDB1", "GENE_OR_GENE_PRODUCT", 23, 27], ["Cul4a E3", "GENE_OR_GENE_PRODUCT", 41, 49], ["HBx", "GENE_OR_GENE_PRODUCT", 104, 107], ["HBx", "GENE_OR_GENE_PRODUCT", 177, 180], ["DDB1", "PROTEIN", 23, 27], ["Cul4a E3 ligase complex", "PROTEIN", 41, 64], ["HBx", "PROTEIN", 104, 107], ["HBx", "PROTEIN", 177, 180], ["HBx functions", "PROBLEM", 104, 117], ["such complexes", "PROBLEM", 136, 150], ["the HBx phenotypes", "PROBLEM", 173, 191], ["DDB1", "OBSERVATION", 23, 27], ["HBx phenotypes", "OBSERVATION", 177, 191]]], ["One recent paper has shown that HBx stabilizes the proto-oncogene pituitary tumor-transforming gene 1 (PTTG1) protein, which is known to be overexpressed in HCC (Molina-Jimenez et al., 2010) and which has previously been shown to bind to and inhibit p53 (Bernal et al., 2002).", [["HCC", "ANATOMY", 157, 160], ["pituitary tumor", "DISEASE", 66, 81], ["HCC", "DISEASE", 157, 160], ["HBx", "GENE_OR_GENE_PRODUCT", 32, 35], ["pituitary tumor-transforming gene 1", "GENE_OR_GENE_PRODUCT", 66, 101], ["PTTG1", "GENE_OR_GENE_PRODUCT", 103, 108], ["HCC", "CANCER", 157, 160], ["p53", "GENE_OR_GENE_PRODUCT", 250, 253], ["HBx", "PROTEIN", 32, 35], ["proto-oncogene pituitary tumor-transforming gene 1 (PTTG1) protein", "PROTEIN", 51, 117], ["p53", "PROTEIN", 250, 253], ["HBx", "PROBLEM", 32, 35], ["the proto-oncogene pituitary tumor", "PROBLEM", 47, 81], ["PTTG1) protein", "TEST", 103, 117], ["HCC", "PROBLEM", 157, 160], ["HBx", "OBSERVATION", 32, 35], ["proto-oncogene pituitary tumor", "OBSERVATION", 51, 81], ["known to be", "UNCERTAINTY", 128, 139], ["HCC", "OBSERVATION", 157, 160]]], ["However, whether PTTG1 ubiquitination is directly or indirectly inhibited by HBx remains to be determined.Poxvirus ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationUnlike the other viruses described in this section, the members of the poxvirus family are not well known for their ability to interfere with the host cell cycle.", [["Cell", "ANATOMY", 119, 123], ["Cellular", "ANATOMY", 170, 178], ["cell", "ANATOMY", 343, 347], ["PTTG1", "GENE_OR_GENE_PRODUCT", 17, 22], ["HBx", "GENE_OR_GENE_PRODUCT", 77, 80], ["Cell", "CELL", 119, 123], ["poxvirus", "ORGANISM", 263, 271], ["cell", "CELL", 343, 347], ["PTTG1", "PROTEIN", 17, 22], ["HBx", "PROTEIN", 77, 80], ["PTTG1 ubiquitination", "PROBLEM", 17, 37], ["HBx", "PROBLEM", 77, 80], ["Cell Cycle Regulation", "TREATMENT", 119, 140], ["Apoptosis", "PROBLEM", 156, 165], ["Cellular Proliferation", "PROBLEM", 170, 192], ["the other viruses", "PROBLEM", 199, 216], ["Apoptosis", "OBSERVATION_MODIFIER", 156, 165], ["Cellular Proliferation", "OBSERVATION", 170, 192], ["viruses", "OBSERVATION", 209, 216], ["host cell cycle", "OBSERVATION", 338, 353]]], ["However, there have been several reports noted for vaccinia (Koziorowska et al., 1971; Puckett and Moss, 1983; Yoo et al., 2008).", [["vaccinia", "DISEASE", 51, 59], ["vaccinia", "ORGANISM", 51, 59], ["vaccinia", "PROBLEM", 51, 59]]], ["Poxviruses are presumed to manipulate the host ubiquitin system via (a) their ankyrin-like proteins, which have been found to interact with Cul1 ligase complexes, (b) their BTB-Kelch proteins, which interact with Cul3 ligase complexes (reviewed in Shchelkunov, 2010), and (c) their conserved p28 proteins that are E3 ligases (Huang et al., 2004).", [["Poxviruses", "GENE_OR_GENE_PRODUCT", 0, 10], ["ankyrin-like proteins", "GENE_OR_GENE_PRODUCT", 78, 99], ["Cul1", "GENE_OR_GENE_PRODUCT", 140, 144], ["BTB-Kelch proteins", "GENE_OR_GENE_PRODUCT", 173, 191], ["Cul3", "GENE_OR_GENE_PRODUCT", 213, 217], ["p28", "GENE_OR_GENE_PRODUCT", 292, 295], ["E3", "GENE_OR_GENE_PRODUCT", 314, 316], ["ankyrin-like proteins", "PROTEIN", 78, 99], ["Cul1 ligase complexes", "PROTEIN", 140, 161], ["BTB", "PROTEIN", 173, 176], ["Kelch proteins", "PROTEIN", 177, 191], ["Cul3 ligase complexes", "PROTEIN", 213, 234], ["p28 proteins", "PROTEIN", 292, 304], ["E3 ligases", "PROTEIN", 314, 324], ["Poxviruses", "TREATMENT", 0, 10], ["their ankyrin-like proteins", "PROBLEM", 72, 99], ["Kelch proteins", "PROBLEM", 177, 191]]], ["Amongst these, only the Myxoma M-T5 ankyrin repeat protein has been shown to affect the cell cycle, and it does so by overcoming the G0/G1 arrest that normally takes place in infected cells.", [["cell", "ANATOMY", 88, 92], ["cells", "ANATOMY", 184, 189], ["Myxoma M-T5 ankyrin", "GENE_OR_GENE_PRODUCT", 24, 43], ["cell", "CELL", 88, 92], ["cells", "CELL", 184, 189], ["Myxoma M-T5 ankyrin repeat protein", "PROTEIN", 24, 58], ["infected cells", "CELL_TYPE", 175, 189], ["the Myxoma M", "TEST", 20, 32], ["T5 ankyrin repeat protein", "TEST", 33, 58], ["G1 arrest", "PROBLEM", 136, 145], ["Myxoma", "OBSERVATION", 24, 30], ["G1 arrest", "OBSERVATION", 136, 145], ["infected cells", "OBSERVATION", 175, 189]]], ["However, a direct role for ubiquitin in this process has not been shown (Johnston et al., 2005).", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 27, 36], ["ubiquitin", "PROTEIN", 27, 36]]], ["Interestingly, several poxviruses were recently found to encode a RING domain protein referred to as poxvirus APC/cyclosome activator (PACR), which inhibits the function of the APC E3 ligase complex (Mo et al., 2009).", [["poxvirus APC/cyclosome activator", "GENE_OR_GENE_PRODUCT", 101, 133], ["PACR", "GENE_OR_GENE_PRODUCT", 135, 139], ["APC", "GENE_OR_GENE_PRODUCT", 177, 180], ["RING domain protein", "PROTEIN", 66, 85], ["poxvirus APC", "PROTEIN", 101, 113], ["cyclosome activator", "PROTEIN", 114, 133], ["PACR", "PROTEIN", 135, 139], ["APC E3 ligase complex", "PROTEIN", 177, 198], ["a RING domain protein", "TREATMENT", 64, 85], ["poxvirus APC/cyclosome activator", "TREATMENT", 101, 133], ["several", "OBSERVATION_MODIFIER", 15, 22], ["poxviruses", "OBSERVATION", 23, 33]]], ["PACR is homologous to the RING domain protein APC11, which is the APC subunit responsible for binding to Ub-charged E2 ligases.", [["E2", "CHEMICAL", 116, 118], ["PACR", "GENE_OR_GENE_PRODUCT", 0, 4], ["APC11", "GENE_OR_GENE_PRODUCT", 46, 51], ["APC", "GENE_OR_GENE_PRODUCT", 66, 69], ["Ub", "GENE_OR_GENE_PRODUCT", 105, 107], ["PACR", "PROTEIN", 0, 4], ["RING domain protein", "PROTEIN", 26, 45], ["APC11", "PROTEIN", 46, 51], ["APC subunit", "PROTEIN", 66, 77], ["Ub", "PROTEIN", 105, 107], ["charged E2 ligases", "PROTEIN", 108, 126], ["the APC subunit", "TREATMENT", 62, 77], ["charged E2 ligases", "TREATMENT", 108, 126]]], ["That same group\u2019s subsequent finding that PACR competes with APC11 for binding to the APC complex suggests that PACR is a dominant negative inhibitor of the APC complex (Mo et al., 2010).", [["APC11", "CHEMICAL", 61, 66], ["PACR", "GENE_OR_GENE_PRODUCT", 42, 46], ["APC11", "GENE_OR_GENE_PRODUCT", 61, 66], ["APC", "GENE_OR_GENE_PRODUCT", 86, 89], ["PACR", "GENE_OR_GENE_PRODUCT", 112, 116], ["APC", "GENE_OR_GENE_PRODUCT", 157, 160], ["PACR", "PROTEIN", 42, 46], ["APC11", "PROTEIN", 61, 66], ["APC complex", "PROTEIN", 86, 97], ["PACR", "PROTEIN", 112, 116], ["APC complex", "PROTEIN", 157, 168], ["APC11", "TREATMENT", 61, 66]]], ["Because APC normally functions to maintain cells in a quiescent state, the authors suggest that PACR-dependent inhibition of APC may promote viral DNA replication by pushing host cells toward S-phase.Human immunodeficiency virus-1 ::: Cell Cycle Regulation, Inhibition of Apoptosis and Cellular ProliferationThe small accessory proteins encoded by HIV-1 (and variably by HIV-2 and SIV) include Vif, Vpu, and Vpx/Vpr.", [["cells", "ANATOMY", 43, 48], ["cells", "ANATOMY", 179, 184], ["Cell", "ANATOMY", 235, 239], ["Cellular", "ANATOMY", 286, 294], ["Human immunodeficiency virus", "DISEASE", 200, 228], ["APC", "GENE_OR_GENE_PRODUCT", 8, 11], ["cells", "CELL", 43, 48], ["PACR", "GENE_OR_GENE_PRODUCT", 96, 100], ["APC", "GENE_OR_GENE_PRODUCT", 125, 128], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["cells", "CELL", 179, 184], ["Human immunodeficiency virus-1", "ORGANISM", 200, 230], ["Cell", "CELL", 235, 239], ["HIV-1", "ORGANISM", 348, 353], ["HIV-2", "ORGANISM", 371, 376], ["SIV", "ORGANISM", 381, 384], ["Vif", "GENE_OR_GENE_PRODUCT", 394, 397], ["Vpu", "GENE_OR_GENE_PRODUCT", 399, 402], ["Vpx", "GENE_OR_GENE_PRODUCT", 408, 411], ["Vpr", "GENE_OR_GENE_PRODUCT", 412, 415], ["APC", "CELL_TYPE", 8, 11], ["PACR", "PROTEIN", 96, 100], ["APC", "CELL_TYPE", 125, 128], ["host cells", "CELL_TYPE", 174, 184], ["small accessory proteins", "PROTEIN", 312, 336], ["Vif", "PROTEIN", 394, 397], ["Vpu", "PROTEIN", 399, 402], ["Vpx", "PROTEIN", 408, 411], ["Vpr", "PROTEIN", 412, 415], ["Human", "SPECIES", 200, 205], ["immunodeficiency virus", "SPECIES", 206, 228], ["HIV-1", "SPECIES", 348, 353], ["HIV-", "SPECIES", 371, 375], ["Human immunodeficiency virus-1", "SPECIES", 200, 230], ["HIV-1", "SPECIES", 348, 353], ["HIV-2", "SPECIES", 371, 376], ["SIV", "SPECIES", 381, 384], ["APC", "PROBLEM", 8, 11], ["PACR", "TEST", 96, 100], ["APC", "TREATMENT", 125, 128], ["viral DNA replication", "TREATMENT", 141, 162], ["Human immunodeficiency virus", "PROBLEM", 200, 228], ["Cell Cycle Regulation", "TEST", 235, 256], ["Apoptosis", "PROBLEM", 272, 281], ["Cellular Proliferation", "PROBLEM", 286, 308], ["The small accessory proteins", "PROBLEM", 308, 336], ["HIV", "TEST", 348, 351], ["HIV", "TEST", 371, 374], ["Vif", "TREATMENT", 394, 397], ["Vpu", "TREATMENT", 399, 402], ["Vpx", "TREATMENT", 408, 411], ["Vpr", "TREATMENT", 412, 415], ["Apoptosis", "OBSERVATION_MODIFIER", 272, 281], ["Cellular Proliferation", "OBSERVATION", 286, 308], ["small", "OBSERVATION_MODIFIER", 312, 317], ["accessory proteins", "OBSERVATION", 318, 336]]], ["Each of these proteins has been shown to function as adaptors for various Cul-based E3 ligase complexes, which, at least in the case of Vif and Vpu, have clear benefits for the virus with respect to replication and egress (see below).", [["Cul", "GENE_OR_GENE_PRODUCT", 74, 77], ["E3", "GENE_OR_GENE_PRODUCT", 84, 86], ["Vif", "GENE_OR_GENE_PRODUCT", 136, 139], ["Vpu", "GENE_OR_GENE_PRODUCT", 144, 147], ["Cul", "PROTEIN", 74, 77], ["E3 ligase complexes", "PROTEIN", 84, 103], ["Vif", "PROTEIN", 136, 139], ["Vpu", "PROTEIN", 144, 147], ["various Cul", "TEST", 66, 77], ["Vif and Vpu", "TREATMENT", 136, 147], ["the virus", "PROBLEM", 173, 182], ["ligase complexes", "OBSERVATION", 87, 103]]], ["Among the numerous activities attributed to Vpr, only a subset has been shown to depend upon Vpr\u2019s ability to associate with the DDB1-Cul4 associated factor 1 (DCAF1), which functions as the specificity determinant for a Cul4 E3 ligase complex (see references in Casey et al., 2010).", [["Vpr", "GENE_OR_GENE_PRODUCT", 44, 47], ["Vpr", "GENE_OR_GENE_PRODUCT", 93, 96], ["DDB1-Cul4 associated factor 1", "GENE_OR_GENE_PRODUCT", 129, 158], ["DCAF1", "GENE_OR_GENE_PRODUCT", 160, 165], ["Cul4 E3", "GENE_OR_GENE_PRODUCT", 221, 228], ["Vpr", "PROTEIN", 44, 47], ["Vpr", "PROTEIN", 93, 96], ["DDB1", "PROTEIN", 129, 133], ["Cul4 associated factor 1", "PROTEIN", 134, 158], ["DCAF1", "PROTEIN", 160, 165], ["Cul4 E3 ligase complex", "PROTEIN", 221, 243], ["Vpr", "PROBLEM", 44, 47], ["the DDB1", "TEST", 125, 133]]], ["In the mid-1990s, several laboratories observed that Vpr induces a G2 cell cycle arrest in dividing cells (Jowett et al., 1995; Rogel et al., 1995).", [["cell", "ANATOMY", 70, 74], ["cells", "ANATOMY", 100, 105], ["Vpr", "GENE_OR_GENE_PRODUCT", 53, 56], ["cell", "CELL", 70, 74], ["cells", "CELL", 100, 105], ["Vpr", "PROTEIN", 53, 56], ["dividing cells", "CELL_TYPE", 91, 105], ["several laboratories", "TEST", 18, 38], ["Vpr", "PROBLEM", 53, 56], ["a G2 cell cycle arrest", "TREATMENT", 65, 87], ["G2 cell cycle arrest", "OBSERVATION", 67, 87]]], ["While the benefit to the virus remains unclear, many other groups subsequently found that this activity is dependent upon Vpr\u2019s engagement of the DCAF1/DDB1/Cul4 Ub ligase.", [["Vpr", "GENE_OR_GENE_PRODUCT", 122, 125], ["DCAF1", "GENE_OR_GENE_PRODUCT", 146, 151], ["DDB1", "GENE_OR_GENE_PRODUCT", 152, 156], ["Cul4 Ub", "GENE_OR_GENE_PRODUCT", 157, 164], ["Vpr", "PROTEIN", 122, 125], ["DCAF1", "PROTEIN", 146, 151], ["DDB1", "PROTEIN", 152, 156], ["Cul4", "PROTEIN", 157, 161], ["Ub ligase", "PROTEIN", 162, 171], ["the virus", "PROBLEM", 21, 30], ["the DCAF1", "TEST", 142, 151]]], ["However, due to the Vpr-induced change in the levels of a large number of host proteins, which includes transcription factors, cytokines, and chemokines (see references in Casey et al., 2010), some have argued that the G2 arrest is a mere byproduct of those changes.", [["host proteins", "PROTEIN", 74, 87], ["transcription factors", "PROTEIN", 104, 125], ["cytokines", "PROTEIN", 127, 136], ["chemokines", "PROTEIN", 142, 152], ["the Vpr-induced change", "PROBLEM", 16, 38], ["host proteins", "PROBLEM", 74, 87], ["transcription factors", "PROBLEM", 104, 125], ["cytokines", "TREATMENT", 127, 136], ["the G2 arrest", "PROBLEM", 215, 228], ["large", "OBSERVATION_MODIFIER", 58, 63], ["number", "OBSERVATION_MODIFIER", 64, 70], ["host proteins", "OBSERVATION", 74, 87], ["G2 arrest", "OBSERVATION", 219, 228]]], ["In support of this notion, one group has shown that Vif can also arrest cells in G2 (DeHart et al., 2008), and others have found that DCAF1 is itself required for normal S-phase progression (McCall et al., 2008).", [["cells", "ANATOMY", 72, 77], ["Vif", "GENE_OR_GENE_PRODUCT", 52, 55], ["cells", "CELL", 72, 77], ["DCAF1", "GENE_OR_GENE_PRODUCT", 134, 139], ["Vif", "PROTEIN", 52, 55], ["DCAF1", "PROTEIN", 134, 139]]], ["These findings suggest that the titration of host Ub ligases may result in G2 arrest, and perhaps other Vpr phenotypes as well.Retroviruses ::: Viral BuddingIn an attempt to clarify the requirement for Ub in retroviral budding, Zhadina and Bieniasz (2010) have recently engineered a foamy virus Gag protein that generates VLPs when provided with a variety of L-domains.", [["Ub", "GENE_OR_GENE_PRODUCT", 50, 52], ["Vpr", "GENE_OR_GENE_PRODUCT", 104, 107], ["Retroviruses", "ORGANISM", 127, 139], ["Ub", "GENE_OR_GENE_PRODUCT", 202, 204], ["retroviral", "ORGANISM", 208, 218], ["foamy virus", "ORGANISM", 283, 294], ["Ub ligases", "PROTEIN", 50, 60], ["Vpr", "PROTEIN", 104, 107], ["Ub", "PROTEIN", 202, 204], ["foamy virus Gag protein", "PROTEIN", 283, 306], ["L-domains", "PROTEIN", 359, 368], ["foamy virus", "SPECIES", 283, 294], ["host Ub ligases", "TREATMENT", 45, 60], ["G2 arrest", "PROBLEM", 75, 84], ["other Vpr phenotypes", "PROBLEM", 98, 118], ["Viral Budding", "PROBLEM", 144, 157], ["Ub in retroviral budding", "PROBLEM", 202, 226], ["a foamy virus Gag protein", "TREATMENT", 281, 306], ["a variety of L-domains", "TREATMENT", 346, 368], ["G2 arrest", "OBSERVATION", 75, 84], ["Vpr phenotypes", "OBSERVATION", 104, 118]]], ["When Nedd4-dependent PPXY motifs were inserted, they found that budding occurred, and that Gag was not ubiquitinated in the process.", [["Nedd4", "GENE_OR_GENE_PRODUCT", 5, 10], ["PPXY", "GENE_OR_GENE_PRODUCT", 21, 25], ["Gag", "GENE_OR_GENE_PRODUCT", 91, 94], ["Nedd4", "PROTEIN", 5, 10], ["PPXY motifs", "DNA", 21, 32], ["Gag", "PROTEIN", 91, 94], ["Nedd4-dependent PPXY motifs", "TREATMENT", 5, 32], ["budding", "PROBLEM", 64, 71], ["Gag", "OBSERVATION", 91, 94]]], ["Because catalytically active Nedd4 ligases were required, their data suggests that if Gag is not ubiquitinated, a cellular protein(s) is instead targeted.", [["cellular", "ANATOMY", 114, 122], ["Nedd4", "GENE_OR_GENE_PRODUCT", 29, 34], ["Gag", "GENE_OR_GENE_PRODUCT", 86, 89], ["cellular", "CELL", 114, 122], ["Nedd4 ligases", "PROTEIN", 29, 42], ["Gag", "PROTEIN", 86, 89], ["cellular protein", "PROTEIN", 114, 130], ["catalytically active Nedd4 ligases", "PROBLEM", 8, 42], ["their data", "TEST", 58, 68], ["Gag", "PROBLEM", 86, 89], ["a cellular protein", "TEST", 112, 130], ["active", "OBSERVATION_MODIFIER", 22, 28], ["Nedd4 ligases", "OBSERVATION", 29, 42]]], ["However, when they generated Gag variants without an L-domain, but that were directly fused to Ub, budding was efficient, and depended upon an intact Vps system.", [["Gag", "GENE_OR_GENE_PRODUCT", 29, 32], ["Ub", "GENE_OR_GENE_PRODUCT", 95, 97], ["Vps", "GENE_OR_GENE_PRODUCT", 150, 153], ["Gag variants", "PROTEIN", 29, 41], ["L-domain", "PROTEIN", 53, 61], ["Ub", "PROTEIN", 95, 97], ["Vps", "PROTEIN", 150, 153], ["intact", "OBSERVATION", 143, 149], ["Vps system", "OBSERVATION", 150, 160]]], ["This somewhat perplexing result hints at the plasticity of the system, and indicates that as long as ubiquitination occurs in the vicinity of the L-domain, budding can take place.", [["L-domain", "PROTEIN", 146, 154]]], ["Similar results have also been obtained for HIV-1 by Weiss et al. (2010) who find that a number of Nedd4 ligases, including yeast Rsp5, will promote VLP formation when targeted to Gag, but that budding does not correlate with the ability of these ligases to ubiquitinate Gag.", [["HIV-1", "ORGANISM", 44, 49], ["Nedd4", "GENE_OR_GENE_PRODUCT", 99, 104], ["Rsp5", "GENE_OR_GENE_PRODUCT", 130, 134], ["VLP", "GENE_OR_GENE_PRODUCT", 149, 152], ["Gag", "GENE_OR_GENE_PRODUCT", 180, 183], ["Gag", "GENE_OR_GENE_PRODUCT", 271, 274], ["Nedd4 ligases", "PROTEIN", 99, 112], ["yeast Rsp5", "PROTEIN", 124, 134], ["Gag", "PROTEIN", 180, 183], ["Gag", "PROTEIN", 271, 274], ["yeast", "SPECIES", 124, 129], ["HIV-1", "SPECIES", 44, 49], ["yeast", "SPECIES", 124, 129], ["Nedd4 ligases", "TREATMENT", 99, 112], ["yeast Rsp5", "PROBLEM", 124, 134], ["yeast Rsp5", "OBSERVATION", 124, 134]]], ["The identity of at least one cellular ubiquitination target is perhaps suggested by Sette et al. (2010) who have recently provided evidence that ALIX binds to HIV-1 Gag, recruits Nedd4.1, and is then itself ubiquitinated by Nedd4.1 to promote egress.Filoviruses ::: Viral BuddingLike the retroviral Gag proteins, the VP40 matrix proteins encoded by both Ebola (Harty et al., 2000) and Marburg (Urata et al., 2007) viruses can form VLPs in the absence of other viral proteins.", [["cellular", "ANATOMY", 29, 37], ["cellular", "CELL", 29, 37], ["ALIX", "GENE_OR_GENE_PRODUCT", 145, 149], ["HIV-1", "ORGANISM", 159, 164], ["Gag", "GENE_OR_GENE_PRODUCT", 165, 168], ["Nedd4.1", "GENE_OR_GENE_PRODUCT", 179, 186], ["Nedd4.1", "GENE_OR_GENE_PRODUCT", 224, 231], ["retroviral", "ORGANISM", 288, 298], ["Gag", "GENE_OR_GENE_PRODUCT", 299, 302], ["VP40", "GENE_OR_GENE_PRODUCT", 317, 321], ["Ebola", "ORGANISM", 354, 359], ["VLPs", "ORGANISM", 431, 435], ["ALIX", "PROTEIN", 145, 149], ["HIV-1 Gag", "PROTEIN", 159, 168], ["Nedd4.1", "PROTEIN", 179, 186], ["Nedd4.1", "PROTEIN", 224, 231], ["Viral BuddingLike the retroviral Gag proteins", "PROTEIN", 266, 311], ["VP40 matrix proteins", "PROTEIN", 317, 337], ["viral proteins", "PROTEIN", 460, 474], ["HIV-1", "SPECIES", 159, 164], ["HIV-1", "SPECIES", 159, 164], ["ALIX binds", "PROBLEM", 145, 155], ["Viral BuddingLike the retroviral Gag proteins", "PROBLEM", 266, 311], ["the VP40 matrix proteins", "TEST", 313, 337], ["viruses", "PROBLEM", 414, 421], ["VLPs", "PROBLEM", 431, 435], ["other viral proteins", "PROBLEM", 454, 474], ["cellular", "OBSERVATION", 29, 37], ["ubiquitination target", "OBSERVATION", 38, 59], ["retroviral Gag proteins", "OBSERVATION", 288, 311], ["viral proteins", "OBSERVATION", 460, 474]]], ["Ebola VP40 harbors both PPXY and PT/SAP L-domains, and appears to engage both Nedd4 and Tsg101, respectively (Timmins et al., 2003).", [["Ebola VP40", "ORGANISM", 0, 10], ["PPXY", "GENE_OR_GENE_PRODUCT", 24, 28], ["Nedd4", "GENE_OR_GENE_PRODUCT", 78, 83], ["Tsg101", "GENE_OR_GENE_PRODUCT", 88, 94], ["Ebola VP40", "PROTEIN", 0, 10], ["PPXY", "PROTEIN", 24, 28], ["PT", "PROTEIN", 33, 35], ["SAP L-domains", "PROTEIN", 36, 49], ["Nedd4", "PROTEIN", 78, 83], ["Tsg101", "PROTEIN", 88, 94], ["Tsg", "TEST", 88, 91]]], ["On the other hand, Marburg virus encodes only a PPXY motif.", [["Marburg virus", "ORGANISM", 19, 32], ["PPXY", "GENE_OR_GENE_PRODUCT", 48, 52], ["PPXY motif", "DNA", 48, 58], ["Marburg virus", "SPECIES", 19, 32], ["Marburg virus encodes", "PROBLEM", 19, 40], ["a PPXY motif", "TREATMENT", 46, 58]]], ["Interestingly, it has been shown that while deletion of the PPXY motif severely limits Marburg VLP formation, co-expression of the viral nucleoprotein (NP), or glycoprotein (GP) with the VP40 PPXY mutant rescues budding (Urata et al., 2007).", [["PPXY", "GENE_OR_GENE_PRODUCT", 60, 64], ["Marburg VLP", "ORGANISM", 87, 98], ["viral nucleoprotein (NP)", "GENE_OR_GENE_PRODUCT", 131, 155], ["GP", "GENE_OR_GENE_PRODUCT", 174, 176], ["VP40", "GENE_OR_GENE_PRODUCT", 187, 191], ["PPXY", "GENE_OR_GENE_PRODUCT", 192, 196], ["PPXY motif", "DNA", 60, 70], ["viral nucleoprotein", "PROTEIN", 131, 150], ["NP", "PROTEIN", 152, 154], ["glycoprotein", "PROTEIN", 160, 172], ["GP", "PROTEIN", 174, 176], ["VP40 PPXY mutant", "PROTEIN", 187, 203], ["the PPXY motif", "PROBLEM", 56, 70], ["Marburg VLP formation", "PROBLEM", 87, 108], ["the viral nucleoprotein (NP)", "PROBLEM", 127, 155], ["viral nucleoprotein", "OBSERVATION", 131, 150]]], ["In that same paper it was found that Tsg101 is recruited to VP40 in a PPXY-dependent manner, providing a unique example of non-PT/SAP-dependent Tsg101 interaction.", [["Tsg101", "GENE_OR_GENE_PRODUCT", 37, 43], ["VP40", "GENE_OR_GENE_PRODUCT", 60, 64], ["PPXY", "GENE_OR_GENE_PRODUCT", 70, 74], ["non-PT", "GENE_OR_GENE_PRODUCT", 123, 129], ["SAP", "GENE_OR_GENE_PRODUCT", 130, 133], ["Tsg101", "GENE_OR_GENE_PRODUCT", 144, 150], ["Tsg101", "PROTEIN", 37, 43], ["VP40", "PROTEIN", 60, 64], ["PPXY", "PROTEIN", 70, 74], ["SAP", "PROTEIN", 130, 133], ["Tsg101", "PROTEIN", 144, 150]]], ["This same group has more recently shown that the Marburg VP40 PPXY motif also interacts with Nedd4 (Urata and Yasuda, 2010).", [["Marburg VP40", "ORGANISM", 49, 61], ["Nedd4", "GENE_OR_GENE_PRODUCT", 93, 98], ["Marburg VP40 PPXY motif", "PROTEIN", 49, 72], ["Nedd4", "PROTEIN", 93, 98]]], ["Coupled with their earlier data, this result indicates that the filoviruses require both Nedd4 and Tsg101 for VLP formation, and that at least in the case of Marburg, NP and/or GP may also play a role in recruiting those proteins.Paramyxoviruses ::: Viral BuddingThe paramyxoviruses are another group of enveloped RNA viruses, which appear less consistent in their use of L-domains and the MVB apparatus.", [["MVB", "ANATOMY", 390, 393], ["filoviruses", "GENE_OR_GENE_PRODUCT", 64, 75], ["Nedd4", "GENE_OR_GENE_PRODUCT", 89, 94], ["Tsg101", "GENE_OR_GENE_PRODUCT", 99, 105], ["VLP", "GENE_OR_GENE_PRODUCT", 110, 113], ["Marburg", "ORGANISM", 158, 165], ["NP", "GENE_OR_GENE_PRODUCT", 167, 169], ["GP", "GENE_OR_GENE_PRODUCT", 177, 179], ["L-domains", "GENE_OR_GENE_PRODUCT", 372, 381], ["MVB apparatus", "CELLULAR_COMPONENT", 390, 403], ["Nedd4", "PROTEIN", 89, 94], ["Tsg101", "PROTEIN", 99, 105], ["GP", "PROTEIN", 177, 179], ["L-domains", "PROTEIN", 372, 381], ["the filoviruses", "PROBLEM", 60, 75], ["both Nedd4", "TREATMENT", 84, 94], ["Tsg", "TEST", 99, 102], ["VLP formation", "PROBLEM", 110, 123], ["Paramyxoviruses", "PROBLEM", 230, 245], ["Viral Budding", "PROBLEM", 250, 263], ["The paramyxoviruses", "PROBLEM", 263, 282], ["enveloped RNA viruses", "PROBLEM", 304, 325], ["L-domains", "TREATMENT", 372, 381], ["paramyxoviruses", "OBSERVATION", 267, 282], ["enveloped", "OBSERVATION_MODIFIER", 304, 313], ["RNA viruses", "OBSERVATION", 314, 325], ["less", "OBSERVATION_MODIFIER", 340, 344]]], ["For example, parainfluenza virus 5 (PIV5) budding requires matrix (M), nucleocapsid (NP), and spike glycoproteins (Schmitt et al., 2002), none of which appear to encode obvious L-domain sequences.", [["parainfluenza", "DISEASE", 13, 26], ["parainfluenza virus 5", "ORGANISM", 13, 34], ["PIV5", "GENE_OR_GENE_PRODUCT", 36, 40], ["matrix", "CELLULAR_COMPONENT", 59, 65], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 71, 83], ["nucleocapsid", "PROTEIN", 71, 83], ["NP", "PROTEIN", 85, 87], ["spike glycoproteins", "PROTEIN", 94, 113], ["L-domain sequences", "DNA", 177, 195], ["parainfluenza virus", "SPECIES", 13, 32], ["parainfluenza virus", "SPECIES", 13, 32], ["parainfluenza virus", "PROBLEM", 13, 32], ["nucleocapsid (NP)", "PROBLEM", 71, 88], ["spike glycoproteins", "PROBLEM", 94, 113], ["parainfluenza virus", "OBSERVATION", 13, 32]]], ["However, PIV5 budding has been shown to depend on the host VPS machinery, as well as to be sensitive to proteasome inhibitors, suggesting commonalities between the retro- and filoviral budding pathways (Schmitt et al., 2005).", [["PIV5", "GENE_OR_GENE_PRODUCT", 9, 13], ["VPS", "GENE_OR_GENE_PRODUCT", 59, 62], ["PIV5", "PROTEIN", 9, 13], ["VPS", "PROTEIN", 59, 62], ["PIV5 budding", "PROBLEM", 9, 21], ["proteasome inhibitors", "TREATMENT", 104, 125], ["retro", "ANATOMY_MODIFIER", 164, 169]]], ["Interestingly, the PIV5 M protein was found to harbor a unique FPIV L-domain that was discovered via complementation of an HIV-1 PTAP Gag mutant (Schmitt et al., 2005).", [["PIV5 M", "GENE_OR_GENE_PRODUCT", 19, 25], ["HIV-1", "ORGANISM", 123, 128], ["PTAP", "GENE_OR_GENE_PRODUCT", 129, 133], ["PIV5 M protein", "PROTEIN", 19, 33], ["FPIV L-domain", "PROTEIN", 63, 76], ["HIV-1 PTAP Gag mutant", "PROTEIN", 123, 144], ["HIV-1", "SPECIES", 123, 128], ["HIV-1", "SPECIES", 123, 128], ["the PIV5 M protein", "TEST", 15, 33], ["an HIV", "TEST", 120, 126]]], ["Mutation of that motif in a recombinant PIV5 virus led to drops in viral titers by five orders of magnitude compared to the wildtype, demonstrating the importance of this sequence to viral production.", [["PIV5 virus", "ORGANISM", 40, 50], ["PIV5 virus", "SPECIES", 40, 50], ["Mutation of that motif", "PROBLEM", 0, 22], ["a recombinant PIV5 virus", "TREATMENT", 26, 50], ["drops in viral titers", "PROBLEM", 58, 79], ["viral production", "PROBLEM", 183, 199]]], ["However, it remains to be seen if the PIV5 FPIV motif functions as a binding site for either ESCRT components or Nedd4 ligases.", [["PIV5", "GENE_OR_GENE_PRODUCT", 38, 42], ["ESCRT", "GENE_OR_GENE_PRODUCT", 93, 98], ["Nedd4", "GENE_OR_GENE_PRODUCT", 113, 118], ["PIV5 FPIV motif", "DNA", 38, 53], ["ESCRT components", "PROTEIN", 93, 109], ["Nedd4 ligases", "PROTEIN", 113, 126], ["the PIV5 FPIV motif functions", "TREATMENT", 34, 63], ["a binding site", "PROBLEM", 67, 81], ["Nedd4 ligases", "PROBLEM", 113, 126], ["Nedd4 ligases", "OBSERVATION", 113, 126]]], ["While present in some paramyxoviruses, the FPIV motif is not observed in the M proteins from measles, Sendai, and Nipah virus, suggesting variability in paramyxoviral budding pathways.", [["measles", "DISEASE", 93, 100], ["Nipah virus", "DISEASE", 114, 125], ["FPIV", "GENE_OR_GENE_PRODUCT", 43, 47], ["measles", "ORGANISM", 93, 100], ["Sendai", "ORGANISM", 102, 108], ["Nipah virus", "ORGANISM", 114, 125], ["FPIV motif", "DNA", 43, 53], ["M proteins", "PROTEIN", 77, 87], ["Nipah virus", "SPECIES", 114, 125], ["Nipah virus", "SPECIES", 114, 125], ["some paramyxoviruses", "PROBLEM", 17, 37], ["the FPIV motif", "TEST", 39, 53], ["the M proteins", "PROBLEM", 73, 87], ["measles", "PROBLEM", 93, 100], ["Sendai", "PROBLEM", 102, 108], ["Nipah virus", "PROBLEM", 114, 125], ["variability in paramyxoviral budding pathways", "PROBLEM", 138, 183], ["paramyxoviruses", "OBSERVATION", 22, 37], ["Nipah virus", "OBSERVATION", 114, 125]]], ["Support for this notion comes from studies of Nipah virus, which encodes an M protein that is necessary and sufficient for VLP production (Ciancanelli and Basler, 2006).", [["Nipah virus", "DISEASE", 46, 57], ["Nipah virus", "ORGANISM", 46, 57], ["M protein", "PROTEIN", 76, 85], ["Nipah virus", "SPECIES", 46, 57], ["Nipah virus", "SPECIES", 46, 57], ["Nipah virus", "PROBLEM", 46, 57], ["an M protein", "TEST", 73, 85]]], ["Wang et al. (2010) have recently shown that prior to budding from the host plasma membrane, the Nipah M protein must first pass through the nucleus.", [["plasma membrane", "ANATOMY", 75, 90], ["nucleus", "ANATOMY", 140, 147], ["plasma membrane", "CELLULAR_COMPONENT", 75, 90], ["Nipah M protein", "GENE_OR_GENE_PRODUCT", 96, 111], ["nucleus", "CELLULAR_COMPONENT", 140, 147], ["Nipah M protein", "PROTEIN", 96, 111], ["the Nipah M protein", "TREATMENT", 92, 111], ["nucleus", "ANATOMY", 140, 147]]], ["Treatment of infected cells with proteasome inhibitors trapped M protein within the nucleus, and like PIV5, lowered viral titers substantially, suggesting that ubiquitination is involved in M protein trafficking.", [["cells", "ANATOMY", 22, 27], ["nucleus", "ANATOMY", 84, 91], ["cells", "CELL", 22, 27], ["M protein", "GENE_OR_GENE_PRODUCT", 63, 72], ["nucleus", "CELLULAR_COMPONENT", 84, 91], ["PIV5", "GENE_OR_GENE_PRODUCT", 102, 106], ["M protein", "GENE_OR_GENE_PRODUCT", 190, 199], ["infected cells", "CELL_TYPE", 13, 27], ["proteasome", "PROTEIN", 33, 43], ["M protein", "PROTEIN", 63, 72], ["PIV5", "PROTEIN", 102, 106], ["M protein", "PROTEIN", 190, 199], ["infected cells", "PROBLEM", 13, 27], ["proteasome inhibitors", "TREATMENT", 33, 54], ["lowered viral titers", "PROBLEM", 108, 128], ["infected cells", "OBSERVATION", 13, 27], ["nucleus", "ANATOMY", 84, 91], ["viral titers", "OBSERVATION", 116, 128], ["ubiquitination", "OBSERVATION", 160, 174]]], ["The authors went on to provide evidence that M protein is monoubiquitinated on four separate residues, including a lysine within a putative bipartite nuclear localization signal, and that this same lysine is likely to be ubiquitinated in order for M protein to be exported from the nucleus.", [["nuclear", "ANATOMY", 150, 157], ["nucleus", "ANATOMY", 282, 289], ["lysine", "CHEMICAL", 115, 121], ["lysine", "CHEMICAL", 198, 204], ["lysine", "CHEMICAL", 115, 121], ["lysine", "CHEMICAL", 198, 204], ["M protein", "GENE_OR_GENE_PRODUCT", 45, 54], ["nuclear", "CELLULAR_COMPONENT", 150, 157], ["lysine", "AMINO_ACID", 198, 204], ["M protein", "GENE_OR_GENE_PRODUCT", 248, 257], ["nucleus", "CELLULAR_COMPONENT", 282, 289], ["M protein", "PROTEIN", 45, 54], ["putative bipartite nuclear localization signal", "PROTEIN", 131, 177], ["M protein", "PROTEIN", 248, 257], ["M protein", "PROBLEM", 45, 54], ["a lysine", "TREATMENT", 113, 121], ["M protein", "PROBLEM", 248, 257], ["nucleus", "ANATOMY", 282, 289]]], ["They finished by showing that Nipah virus release was sensitive to levels of the proteasome inhibitor bortezomib that are readily achievable in human patients.", [["bortezomib", "CHEMICAL", 102, 112], ["bortezomib", "CHEMICAL", 102, 112], ["Nipah virus", "ORGANISM", 30, 41], ["bortezomib", "SIMPLE_CHEMICAL", 102, 112], ["human", "ORGANISM", 144, 149], ["patients", "ORGANISM", 150, 158], ["proteasome", "PROTEIN", 81, 91], ["human", "SPECIES", 144, 149], ["patients", "SPECIES", 150, 158], ["Nipah virus", "SPECIES", 30, 41], ["human", "SPECIES", 144, 149], ["Nipah virus release", "TREATMENT", 30, 49], ["the proteasome inhibitor bortezomib", "TREATMENT", 77, 112]]], ["While the precise mechanisms are not known, it is clear that Ub plays a role in the Nipah virus lifecycle.", [["Ub", "GENE_OR_GENE_PRODUCT", 61, 63], ["Nipah virus", "ORGANISM", 84, 95], ["Ub", "PROTEIN", 61, 63], ["Nipah virus", "SPECIES", 84, 95], ["the Nipah virus lifecycle", "TREATMENT", 80, 105]]], ["However, because proteasome inhibitors appear to block upstream events (e.g., M protein release from the nucleus), a specific role for Ub in Nipah budding is less certain.Rhabdoviruses ::: Viral BuddingSimilar to other Gag/Matrix proteins discussed above, the vesicular stomatitis virus (VSV) M protein can promote VLP formation in the absence of other viral proteins (Harty et al., 1999), and this has been shown to depend upon a PPXY motif within the M protein (Craven et al., 1999).", [["nucleus", "ANATOMY", 105, 112], ["vesicular stomatitis", "DISEASE", 260, 280], ["M protein", "GENE_OR_GENE_PRODUCT", 78, 87], ["nucleus", "CELLULAR_COMPONENT", 105, 112], ["Ub", "GENE_OR_GENE_PRODUCT", 135, 137], ["Nipah", "ORGANISM", 141, 146], ["Gag", "GENE_OR_GENE_PRODUCT", 219, 222], ["Matrix", "GENE_OR_GENE_PRODUCT", 223, 229], ["vesicular stomatitis virus", "ORGANISM", 260, 286], ["VSV", "ORGANISM", 288, 291], ["VLP", "GENE_OR_GENE_PRODUCT", 315, 318], ["PPXY", "GENE_OR_GENE_PRODUCT", 431, 435], ["Ub", "PROTEIN", 135, 137], ["Gag", "PROTEIN", 219, 222], ["Matrix proteins", "PROTEIN", 223, 238], ["vesicular stomatitis virus (VSV) M protein", "PROTEIN", 260, 302], ["viral proteins", "PROTEIN", 353, 367], ["PPXY motif", "PROTEIN", 431, 441], ["M protein", "PROTEIN", 453, 462], ["vesicular stomatitis virus", "SPECIES", 260, 286], ["stomatitis virus", "SPECIES", 270, 286], ["VSV", "SPECIES", 288, 291], ["proteasome inhibitors", "TREATMENT", 17, 38], ["block upstream events", "PROBLEM", 49, 70], ["Rhabdoviruses", "PROBLEM", 171, 184], ["Viral BuddingSimilar", "PROBLEM", 189, 209], ["other Gag/Matrix proteins", "TEST", 213, 238], ["the vesicular stomatitis virus", "PROBLEM", 256, 286], ["VLP formation", "PROBLEM", 315, 328], ["other viral proteins", "PROBLEM", 347, 367], ["nucleus", "ANATOMY", 105, 112], ["less certain", "OBSERVATION_MODIFIER", 158, 170], ["vesicular stomatitis", "ANATOMY", 260, 280], ["VLP formation", "OBSERVATION", 315, 328]]], ["As one might expect for PPXY L-domain proteins, VSV M protein was found to bind Nedd4 E3 ligases, and proteasome inhibitors limit viral release, suggesting that Ub is involved (Harty et al., 2001).", [["VSV M", "GENE_OR_GENE_PRODUCT", 48, 53], ["Nedd4", "GENE_OR_GENE_PRODUCT", 80, 85], ["Ub", "GENE_OR_GENE_PRODUCT", 161, 163], ["PPXY L-domain proteins", "PROTEIN", 24, 46], ["VSV M protein", "PROTEIN", 48, 61], ["Nedd4 E3 ligases", "PROTEIN", 80, 96], ["Ub", "PROTEIN", 161, 163], ["VSV", "SPECIES", 48, 51], ["PPXY L-domain proteins", "PROBLEM", 24, 46], ["VSV M protein", "TEST", 48, 61], ["Nedd4 E3 ligases", "TREATMENT", 80, 96], ["proteasome inhibitors", "TREATMENT", 102, 123]]], ["However, unlike other viruses that utilize PPXY L-domains, VSV budding does not appear to depend upon either Tsg101 or downstream players in the ESCRT pathway (Irie et al., 2004), indicating that the combination of an L-domain and a Ub-dependent budding mechanism is not a guarantee of dependence upon the host VPS pathway.Arenaviruses ::: Viral BuddingThe Lassa virus matrix protein (Z) alone results in the production of VLPs, and harbors both PTAP and PPXY L-domains (Perez et al., 2003; Eichler et al., 2004).", [["PPXY", "GENE_OR_GENE_PRODUCT", 43, 47], ["VSV", "ORGANISM", 59, 62], ["Tsg101", "GENE_OR_GENE_PRODUCT", 109, 115], ["ESCRT", "GENE_OR_GENE_PRODUCT", 145, 150], ["L-domain", "GENE_OR_GENE_PRODUCT", 218, 226], ["Ub", "GENE_OR_GENE_PRODUCT", 233, 235], ["VPS", "GENE_OR_GENE_PRODUCT", 311, 314], ["Lassa virus matrix protein (Z)", "GENE_OR_GENE_PRODUCT", 357, 387], ["VLPs", "GENE_OR_GENE_PRODUCT", 423, 427], ["PTAP", "GENE_OR_GENE_PRODUCT", 446, 450], ["PPXY L", "PROTEIN", 43, 49], ["Tsg101", "PROTEIN", 109, 115], ["L-domain", "PROTEIN", 218, 226], ["Ub", "PROTEIN", 233, 235], ["VPS", "PROTEIN", 311, 314], ["Lassa virus matrix protein", "PROTEIN", 357, 383], ["Z", "PROTEIN", 385, 386], ["VLPs", "PROTEIN", 423, 427], ["PTAP", "PROTEIN", 446, 450], ["PPXY L", "PROTEIN", 455, 461], ["Lassa virus", "SPECIES", 357, 368], ["VSV", "SPECIES", 59, 62], ["Lassa virus", "SPECIES", 357, 368], ["other viruses", "PROBLEM", 16, 29], ["VSV budding", "PROBLEM", 59, 70], ["Tsg", "TEST", 109, 112], ["an L-domain", "TREATMENT", 215, 226], ["a Ub-dependent budding mechanism", "PROBLEM", 231, 263], ["Viral Budding", "PROBLEM", 340, 353], ["The Lassa virus matrix protein", "TEST", 353, 383], ["VLPs", "TEST", 423, 427], ["viruses", "OBSERVATION", 22, 29], ["Lassa virus", "OBSERVATION", 357, 368]]], ["Similar to other enveloped RNA viruses, it has been demonstrated that budding of Lassa virus Z-protein VLPs is dependent upon Tsg101 and other ESCRT components (Urata et al., 2006).", [["Lassa virus", "ORGANISM", 81, 92], ["Tsg101", "GENE_OR_GENE_PRODUCT", 126, 132], ["Lassa virus Z-protein VLPs", "PROTEIN", 81, 107], ["Tsg101", "PROTEIN", 126, 132], ["ESCRT components", "PROTEIN", 143, 159], ["Lassa virus", "SPECIES", 81, 92], ["Lassa virus", "SPECIES", 81, 92], ["other enveloped RNA viruses", "PROBLEM", 11, 38], ["Lassa virus Z-protein VLPs", "TREATMENT", 81, 107], ["Tsg", "TEST", 126, 129], ["enveloped", "OBSERVATION_MODIFIER", 17, 26], ["RNA viruses", "OBSERVATION", 27, 38], ["Lassa virus", "OBSERVATION", 81, 92]]], ["However, while the New World Tacaribe virus Z protein also promotes VLP budding, it harbors no obvious L-domain sequences and is not dependent upon Tsg101 (Urata et al., 2009).", [["New World Tacaribe virus Z", "ORGANISM", 19, 45], ["VLP", "GENE_OR_GENE_PRODUCT", 68, 71], ["New World Tacaribe virus Z protein", "PROTEIN", 19, 53], ["L-domain sequences", "DNA", 103, 121], ["Tacaribe virus", "SPECIES", 29, 43], ["the New World Tacaribe virus Z protein", "TREATMENT", 15, 53], ["obvious L-domain sequences", "PROBLEM", 95, 121], ["Tsg", "TEST", 148, 151]]], ["Nevertheless, Tacaribe Z-protein budding was still shown to require downstream Vps components, and so it is likely that arenavirus budding will, in general, depend upon the host MVB pathway.DNA viruses ::: Viral BuddingWhile not all enveloped viruses bud through the plasma membrane, they are still faced with the same mechanistic problems.", [["MVB", "ANATOMY", 178, 181], ["bud", "ANATOMY", 251, 254], ["plasma membrane", "ANATOMY", 267, 282], ["Tacaribe Z-protein", "GENE_OR_GENE_PRODUCT", 14, 32], ["Vps", "GENE_OR_GENE_PRODUCT", 79, 82], ["arenavirus", "ORGANISM", 120, 130], ["MVB", "GENE_OR_GENE_PRODUCT", 178, 181], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["plasma membrane", "CELLULAR_COMPONENT", 267, 282], ["Tacaribe Z", "PROTEIN", 14, 24], ["Vps components", "PROTEIN", 79, 93], ["Tacaribe Z-protein budding", "PROBLEM", 14, 40], ["downstream Vps components", "TREATMENT", 68, 93], ["arenavirus budding", "PROBLEM", 120, 138], ["Viral Budding", "PROBLEM", 206, 219], ["is likely", "UNCERTAINTY", 105, 114], ["arenavirus", "OBSERVATION", 120, 130], ["viruses", "OBSERVATION", 194, 201], ["enveloped", "OBSERVATION_MODIFIER", 233, 242], ["viruses", "OBSERVATION", 243, 250], ["plasma membrane", "OBSERVATION", 267, 282]]], ["HBV budding can be subcategorized into the formation of either non-infectious subviral particles (SVP, composed of only the three viral envelope proteins), or fully infectious particles (recently reviewed in Patient et al., 2009), each of which appears to bud through cytoplasmic membranes.", [["bud", "ANATOMY", 256, 259], ["cytoplasmic membranes", "ANATOMY", 268, 289], ["HBV", "ORGANISM", 0, 3], ["cytoplasmic membranes", "CELLULAR_COMPONENT", 268, 289], ["viral envelope proteins", "PROTEIN", 130, 153], ["HBV", "SPECIES", 0, 3], ["HBV budding", "PROBLEM", 0, 11], ["either non-infectious subviral particles", "PROBLEM", 56, 96], ["the three viral envelope proteins", "PROBLEM", 120, 153], ["fully infectious particles", "PROBLEM", 159, 185], ["non-infectious", "OBSERVATION_MODIFIER", 63, 77], ["subviral particles", "OBSERVATION", 78, 96], ["infectious", "OBSERVATION", 165, 175], ["cytoplasmic membranes", "OBSERVATION", 268, 289]]], ["Interestingly, release of infectious HBV from cells has been shown to depend on the host VPS pathway (Kian Chua et al., 2006; Lambert et al., 2007; Watanabe et al., 2007).", [["cells", "ANATOMY", 46, 51], ["infectious HBV", "ORGANISM", 26, 40], ["cells", "CELL", 46, 51], ["VPS", "GENE_OR_GENE_PRODUCT", 89, 92], ["HBV", "SPECIES", 37, 40], ["infectious HBV from cells", "PROBLEM", 26, 51], ["infectious", "OBSERVATION", 26, 36]]], ["Moreover, the HBV core protein harbors a PPXY motif that has been shown to interact with Nedd4 (Rost et al., 2006), implicating a role for ubiquitination.", [["HBV", "ORGANISM", 14, 17], ["PPXY", "GENE_OR_GENE_PRODUCT", 41, 45], ["Nedd4", "GENE_OR_GENE_PRODUCT", 89, 94], ["HBV core protein", "PROTEIN", 14, 30], ["PPXY motif", "PROTEIN", 41, 51], ["Nedd4", "PROTEIN", 89, 94], ["HBV", "SPECIES", 14, 17]]], ["Mutation of the two Lys residues within the core protein had no effect on budding (Garcia et al., 2009), but, as described above, alternate Ub acceptor residues may instead be targeted.", [["Lys", "CHEMICAL", 20, 23], ["Ub", "GENE_OR_GENE_PRODUCT", 140, 142], ["core protein", "PROTEIN", 44, 56], ["Ub", "PROTEIN", 140, 142], ["Mutation of the two Lys residues", "PROBLEM", 0, 32], ["the core protein", "TEST", 40, 56], ["effect on budding", "PROBLEM", 64, 81], ["alternate Ub acceptor residues", "TREATMENT", 130, 160], ["no", "UNCERTAINTY", 61, 63], ["effect", "OBSERVATION_MODIFIER", 64, 70]]], ["Members of the herpesviridae appear to sequentially bud first through the inner nuclear membrane and then again through the TGN membrane (reviewed in Mettenleiter et al., 2009).", [["bud", "ANATOMY", 52, 55], ["inner nuclear membrane", "ANATOMY", 74, 96], ["TGN membrane", "ANATOMY", 124, 136], ["herpesviridae", "GENE_OR_GENE_PRODUCT", 15, 28], ["inner nuclear membrane", "CELLULAR_COMPONENT", 74, 96], ["TGN membrane", "CELLULAR_COMPONENT", 124, 136], ["herpesviridae", "PROTEIN", 15, 28], ["inner", "ANATOMY_MODIFIER", 74, 79], ["nuclear membrane", "ANATOMY", 80, 96]]], ["The release of both Herpes simplex virus 1 (HSV-1; Calistri et al., 2007; Crump et al., 2007; Pawliczek and Crump, 2009) and HCMV (Tandon et al., 2009) particles has been shown to require components of the MVB pathway, suggesting that this may be a common theme among the herpesviruses.", [["MVB", "ANATOMY", 206, 209], ["Herpes simplex virus", "DISEASE", 20, 40], ["Herpes simplex virus 1", "ORGANISM", 20, 42], ["HSV-1", "ORGANISM", 44, 49], ["HCMV", "ORGANISM", 125, 129], ["MVB", "CELLULAR_COMPONENT", 206, 209], ["herpesviruses", "ORGANISM", 272, 285], ["Herpes simplex virus 1", "SPECIES", 20, 42], ["HSV-1", "SPECIES", 44, 49], ["Herpes simplex virus 1", "SPECIES", 20, 42], ["HSV-1", "SPECIES", 44, 49], ["HCMV", "SPECIES", 125, 129], ["both Herpes simplex virus", "TEST", 15, 40], ["HSV", "TEST", 44, 47], ["the herpesviruses", "PROBLEM", 268, 285]]], ["However, the details regarding their use of Ub in these budding events awaits further experimentation.Viral ReleaseThe recent identification of Tetherin (BST-2/CD317/HM1.24) as an IFN-induced anti-viral factor that restricts the egress of HIV-1 and other enveloped viruses by tethering mature virions to the host cell surface (Neil et al., 2008; Jouvenet et al., 2009) has revealed additional viral countermeasures that require the assistance of the UPS.", [["virions", "ANATOMY", 293, 300], ["cell surface", "ANATOMY", 313, 325], ["Ub", "GENE_OR_GENE_PRODUCT", 44, 46], ["Tetherin", "GENE_OR_GENE_PRODUCT", 144, 152], ["BST-2", "GENE_OR_GENE_PRODUCT", 154, 159], ["CD317", "GENE_OR_GENE_PRODUCT", 160, 165], ["HM1.24", "GENE_OR_GENE_PRODUCT", 166, 172], ["IFN", "GENE_OR_GENE_PRODUCT", 180, 183], ["HIV-1", "ORGANISM", 239, 244], ["cell surface", "CELLULAR_COMPONENT", 313, 325], ["UPS", "GENE_OR_GENE_PRODUCT", 450, 453], ["Ub", "PROTEIN", 44, 46], ["Tetherin", "PROTEIN", 144, 152], ["BST", "PROTEIN", 154, 157], ["CD317", "PROTEIN", 160, 165], ["HM1.24", "PROTEIN", 166, 172], ["IFN", "PROTEIN", 180, 183], ["anti-viral factor", "PROTEIN", 192, 209], ["UPS", "PROTEIN", 450, 453], ["HIV-1", "SPECIES", 239, 244], ["HIV-1", "SPECIES", 239, 244], ["Tetherin", "TEST", 144, 152], ["BST", "TEST", 154, 157], ["an IFN", "TREATMENT", 177, 183], ["anti-viral factor", "PROBLEM", 192, 209], ["HIV", "PROBLEM", 239, 242], ["other enveloped viruses", "PROBLEM", 249, 272], ["additional viral countermeasures", "TREATMENT", 382, 414], ["viruses", "OBSERVATION", 265, 272], ["host cell", "OBSERVATION_MODIFIER", 308, 317], ["viral countermeasures", "OBSERVATION", 393, 414]]], ["The ability of the HIV-1 accessory protein Vpu to enhance viral release has been known for quite some time, however the mechanism for this function was not clear.", [["HIV-1", "ORGANISM", 19, 24], ["Vpu", "GENE_OR_GENE_PRODUCT", 43, 46], ["HIV-1 accessory protein", "PROTEIN", 19, 42], ["Vpu", "PROTEIN", 43, 46], ["HIV-1", "SPECIES", 19, 24], ["HIV-1", "SPECIES", 19, 24], ["the HIV", "TEST", 15, 22]]], ["Viral egress appeared to be separable from Vpu\u2019s prominent role in inducing the ER-associated proteasomal degradation of the HIV-1 receptor, CD4 (Schubert and Strebel, 1994; Schubert et al., 1996), although some viral release enhancement has been attributed to CD4 depletion (Bour et al., 1999).", [["proteasomal", "ANATOMY", 94, 105], ["Viral", "ORGANISM", 0, 5], ["Vpu", "GENE_OR_GENE_PRODUCT", 43, 46], ["ER", "GENE_OR_GENE_PRODUCT", 80, 82], ["HIV-1 receptor", "GENE_OR_GENE_PRODUCT", 125, 139], ["CD4", "GENE_OR_GENE_PRODUCT", 141, 144], ["CD4", "GENE_OR_GENE_PRODUCT", 261, 264], ["Vpu", "PROTEIN", 43, 46], ["ER", "PROTEIN", 80, 82], ["HIV-1 receptor", "PROTEIN", 125, 139], ["CD4", "PROTEIN", 141, 144], ["CD4", "PROTEIN", 261, 264], ["HIV-1", "SPECIES", 125, 130], ["HIV-1", "SPECIES", 125, 130], ["Viral egress", "PROBLEM", 0, 12], ["proteasomal degradation", "PROBLEM", 94, 117], ["the HIV", "TEST", 121, 128], ["some viral release enhancement", "PROBLEM", 207, 237], ["CD4 depletion", "PROBLEM", 261, 274], ["egress", "OBSERVATION", 6, 12], ["proteasomal degradation", "OBSERVATION", 94, 117], ["CD4 depletion", "OBSERVATION", 261, 274]]], ["However, recent evidence suggests that, similar to the situation with CD4, Vpu acts as a substrate recognition factor for an SCF Ub ligase complex to target Tetherin for downregulation (Van Damme et al., 2008; Douglas et al., 2009; Goffinet et al., 2009; Iwabu et al., 2009; Mangeat et al., 2009; Mitchell et al., 2009).", [["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["Vpu", "GENE_OR_GENE_PRODUCT", 75, 78], ["SCF", "GENE_OR_GENE_PRODUCT", 125, 128], ["Tetherin", "GENE_OR_GENE_PRODUCT", 157, 165], ["CD4", "PROTEIN", 70, 73], ["Vpu", "PROTEIN", 75, 78], ["substrate recognition factor", "PROTEIN", 89, 117], ["SCF Ub ligase complex", "PROTEIN", 125, 146], ["Tetherin", "PROTEIN", 157, 165], ["an SCF Ub ligase complex", "TREATMENT", 122, 146]]], ["Several studies by our group and others have concluded that in contrast to CD4, Vpu promotes the degradation of Tetherin within the lysosome (Douglas et al., 2009; Iwabu et al., 2009; Mitchell et al., 2009), although under certain conditions proteasomal degradation has been observed (Goffinet et al., 2009; Mangeat et al., 2009; reviewed in Douglas et al., 2010).", [["lysosome", "ANATOMY", 132, 140], ["CD4", "GENE_OR_GENE_PRODUCT", 75, 78], ["Vpu", "GENE_OR_GENE_PRODUCT", 80, 83], ["Tetherin", "GENE_OR_GENE_PRODUCT", 112, 120], ["lysosome", "CELLULAR_COMPONENT", 132, 140], ["CD4", "PROTEIN", 75, 78], ["Vpu", "PROTEIN", 80, 83], ["Tetherin", "PROTEIN", 112, 120], ["Several studies", "TEST", 0, 15]]], ["A recent paper suggests that Vpu-mediated ubiquitination of Tetherin can occur on all lysine and non-lysine Ub targets in the cytoplasmic tail (Tokarev et al., 2010).", [["cytoplasmic tail", "ANATOMY", 126, 142], ["lysine", "CHEMICAL", 86, 92], ["lysine", "CHEMICAL", 86, 92], ["Tetherin", "GENE_OR_GENE_PRODUCT", 60, 68], ["lysine", "AMINO_ACID", 86, 92], ["non-lysine Ub", "GENE_OR_GENE_PRODUCT", 97, 110], ["cytoplasmic", "ORGANISM_SUBSTANCE", 126, 137], ["Tetherin", "PROTEIN", 60, 68], ["lysine and non-lysine Ub targets", "PROTEIN", 86, 118], ["cytoplasmic tail", "PROTEIN", 126, 142], ["Vpu-mediated ubiquitination of Tetherin", "PROBLEM", 29, 68], ["all lysine", "TREATMENT", 82, 92]]], ["Before this tethering function was known, our group had identified BST-2 in a proteomics screen for targets of the viral Ub-ligase K5 of the gammaherpesvirus KSHV (Bartee et al., 2006).", [["BST-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["Ub", "GENE_OR_GENE_PRODUCT", 121, 123], ["K5", "GENE_OR_GENE_PRODUCT", 131, 133], ["gammaherpesvirus", "ORGANISM", 141, 157], ["KSHV", "ORGANISM", 158, 162], ["BST-2", "DNA", 67, 72], ["viral Ub-ligase K5", "PROTEIN", 115, 133], ["gammaherpesvirus KSHV", "SPECIES", 141, 162], ["BST", "TEST", 67, 70], ["a proteomics screen", "TEST", 76, 95], ["the viral Ub", "TEST", 111, 123], ["gammaherpesvirus KSHV", "OBSERVATION", 141, 162]]], ["Later we showed that K5 induces ubiquitination of Tetherin\u2019s cytosolic lysines, which leads to both its lysosomal degradation and the enhancement of KSHV egress (Mansouri et al., 2009).", [["cytosolic", "ANATOMY", 61, 70], ["lysosomal", "ANATOMY", 104, 113], ["lysines", "CHEMICAL", 71, 78], ["K5", "GENE_OR_GENE_PRODUCT", 21, 23], ["Tetherin", "GENE_OR_GENE_PRODUCT", 50, 58], ["lysosomal", "CELLULAR_COMPONENT", 104, 113], ["KSHV", "ORGANISM", 149, 153], ["K5", "PROTEIN", 21, 23], ["Tetherin", "PROTEIN", 50, 58], ["KSHV", "SPECIES", 149, 153], ["Tetherin\u2019s cytosolic lysines", "TREATMENT", 50, 78], ["its lysosomal degradation", "PROBLEM", 100, 125], ["Tetherin", "OBSERVATION_MODIFIER", 50, 58], ["cytosolic lysines", "OBSERVATION", 61, 78], ["lysosomal degradation", "OBSERVATION", 104, 125], ["enhancement", "OBSERVATION_MODIFIER", 134, 145], ["KSHV egress", "OBSERVATION", 149, 160]]], ["Other viruses, such as HIV-2 (Douglas et al., 2009; Le Tortorec and Neil, 2009), SIV (Jia et al., 2009; Zhang et al., 2009), and Ebola (Kaletsky et al., 2009) also express antagonists of Tetherin, but there is no evidence thus far to indicate that they utilize the UPS for this function.Viral ReleaseAs discussed previously, adenoviruses express the E4orf6 and E1B55k proteins that complex with cellular E3 Ub ligases to degrade cellular proteins involved in apoptosis and cell cycle regulation.", [["cellular", "ANATOMY", 395, 403], ["cellular", "ANATOMY", 429, 437], ["cell", "ANATOMY", 473, 477], ["Ebola", "DISEASE", 129, 134], ["HIV-2", "ORGANISM", 23, 28], ["SIV", "ORGANISM", 81, 84], ["Ebola", "ORGANISM", 129, 134], ["Tetherin", "GENE_OR_GENE_PRODUCT", 187, 195], ["UPS", "GENE_OR_GENE_PRODUCT", 265, 268], ["adenoviruses", "ORGANISM", 325, 337], ["E4orf6", "GENE_OR_GENE_PRODUCT", 350, 356], ["E1B55k", "GENE_OR_GENE_PRODUCT", 361, 367], ["cellular", "CELL", 395, 403], ["Ub", "GENE_OR_GENE_PRODUCT", 407, 409], ["cellular", "CELL", 429, 437], ["cell", "CELL", 473, 477], ["Tetherin", "PROTEIN", 187, 195], ["UPS", "PROTEIN", 265, 268], ["E4orf6", "PROTEIN", 350, 356], ["E1B55k proteins", "PROTEIN", 361, 376], ["cellular E3 Ub ligases", "PROTEIN", 395, 417], ["cellular proteins", "PROTEIN", 429, 446], ["HIV", "SPECIES", 23, 26], ["HIV-2", "SPECIES", 23, 28], ["Other viruses", "PROBLEM", 0, 13], ["Tetherin", "TREATMENT", 187, 195], ["Viral ReleaseAs", "PROBLEM", 287, 302], ["cellular E3 Ub ligases", "TREATMENT", 395, 417], ["cellular proteins", "PROBLEM", 429, 446], ["apoptosis", "PROBLEM", 459, 468], ["cell cycle regulation", "TREATMENT", 473, 494], ["viruses", "OBSERVATION", 6, 13], ["no evidence", "UNCERTAINTY", 210, 221], ["cellular proteins", "OBSERVATION", 429, 446], ["cell cycle", "OBSERVATION", 473, 483]]], ["A recent proteomics study looking for new substrates of E4orf6 and E1B55k/Cul5 found numerous host proteins that were both up- and down-regulated.", [["E4orf6", "GENE_OR_GENE_PRODUCT", 56, 62], ["E1B55k", "GENE_OR_GENE_PRODUCT", 67, 73], ["Cul5", "GENE_OR_GENE_PRODUCT", 74, 78], ["E4orf6", "PROTEIN", 56, 62], ["E1B55k", "PROTEIN", 67, 73], ["Cul5", "PROTEIN", 74, 78], ["A recent proteomics study", "TEST", 0, 25], ["new substrates of E4orf6 and E1B55k/Cul5", "TEST", 38, 78], ["numerous host proteins", "PROBLEM", 85, 107], ["host proteins", "OBSERVATION_MODIFIER", 94, 107]]], ["One of the substrates identified was \u03b13 integrin, which was degraded in the presence of the Adenoviral proteins (Dallaire et al., 2009a).", [["\u03b13 integrin", "GENE_OR_GENE_PRODUCT", 37, 48], ["Adenoviral", "ORGANISM", 92, 102], ["\u03b13 integrin", "PROTEIN", 37, 48], ["Adenoviral proteins", "PROTEIN", 92, 111], ["Adenoviral", "SPECIES", 92, 102]]], ["This same group showed that \u03b13 integrin degradation promotes cell detachment from the extracellular matrix and that this may contribute to viral release and spreading (Dallaire et al., 2009b).Retinoic acid inducible gene-I ::: Downregulation of factors leading to IFN production ::: Evading Innate Immune MechanismsIn an effort to inhibit IFN activation, influenza and HBV utilize Ub-dependent mechanisms to target RIG-I either directly or through its downstream effector the mitochondrial anti-viral signaling protein (MAVS).", [["cell", "ANATOMY", 61, 65], ["extracellular matrix", "ANATOMY", 86, 106], ["mitochondrial", "ANATOMY", 476, 489], ["Retinoic acid", "CHEMICAL", 192, 205], ["influenza", "DISEASE", 355, 364], ["Retinoic acid", "CHEMICAL", 192, 205], ["\u03b13 integrin", "GENE_OR_GENE_PRODUCT", 28, 39], ["cell", "CELL", 61, 65], ["extracellular matrix", "CELLULAR_COMPONENT", 86, 106], ["Retinoic acid inducible gene-I", "GENE_OR_GENE_PRODUCT", 192, 222], ["IFN", "GENE_OR_GENE_PRODUCT", 264, 267], ["IFN", "GENE_OR_GENE_PRODUCT", 339, 342], ["HBV", "ORGANISM", 369, 372], ["Ub", "GENE_OR_GENE_PRODUCT", 381, 383], ["RIG-I", "GENE_OR_GENE_PRODUCT", 415, 420], ["mitochondrial", "CELLULAR_COMPONENT", 476, 489], ["anti-viral signaling protein", "GENE_OR_GENE_PRODUCT", 490, 518], ["MAVS", "GENE_OR_GENE_PRODUCT", 520, 524], ["\u03b13 integrin", "PROTEIN", 28, 39], ["IFN", "PROTEIN", 264, 267], ["IFN", "PROTEIN", 339, 342], ["Ub", "PROTEIN", 381, 383], ["RIG-I", "PROTEIN", 415, 420], ["mitochondrial anti-viral signaling protein", "PROTEIN", 476, 518], ["MAVS", "PROTEIN", 520, 524], ["HBV", "SPECIES", 369, 372], ["\u03b13 integrin degradation", "PROBLEM", 28, 51], ["cell detachment", "PROBLEM", 61, 76], ["viral release", "PROBLEM", 139, 152], ["Downregulation of factors", "PROBLEM", 227, 252], ["IFN activation", "TREATMENT", 339, 353], ["influenza", "PROBLEM", 355, 364], ["HBV", "TREATMENT", 369, 372], ["dependent mechanisms", "PROBLEM", 384, 404], ["promotes cell detachment", "OBSERVATION", 52, 76], ["extracellular matrix", "OBSERVATION_MODIFIER", 86, 106], ["may contribute to", "UNCERTAINTY", 121, 138]]], ["In order to initiate the anti-viral signaling cascade, RIG-I must first be ubiquitinated by the E3 ligase tripartite motif (TRIM) protein 25.", [["RIG-I", "GENE_OR_GENE_PRODUCT", 55, 60], ["E3", "GENE_OR_GENE_PRODUCT", 96, 98], ["RIG-I", "PROTEIN", 55, 60], ["E3 ligase tripartite motif (TRIM) protein 25", "PROTEIN", 96, 140], ["the anti-viral signaling cascade", "TREATMENT", 21, 53]]], ["The influenza NS1 protein interacts with TRIM25, thereby preventing the ubiquitination of RIG-I.", [["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["TRIM25", "GENE_OR_GENE_PRODUCT", 41, 47], ["RIG-I.", "GENE_OR_GENE_PRODUCT", 90, 96], ["influenza NS1 protein", "PROTEIN", 4, 25], ["TRIM25", "PROTEIN", 41, 47], ["RIG", "PROTEIN", 90, 93], ["The influenza NS1 protein", "TREATMENT", 0, 25], ["TRIM25", "TREATMENT", 41, 47]]], ["Gack et al. (2009) suggest that NS1 works by blocking the oligomerization of TRIM25, which is critical for its E3 ligase activity.", [["NS1", "GENE_OR_GENE_PRODUCT", 32, 35], ["TRIM25", "GENE_OR_GENE_PRODUCT", 77, 83], ["E3", "GENE_OR_GENE_PRODUCT", 111, 113], ["NS1", "PROTEIN", 32, 35], ["TRIM25", "PROTEIN", 77, 83], ["E3 ligase", "PROTEIN", 111, 120], ["NS1", "TREATMENT", 32, 35], ["the oligomerization of TRIM25", "TREATMENT", 54, 83]]], ["The HBV X protein (HBx) was recently found to inhibit IFN-\u03b2 production by interacting with MAVS, leading to its ubiquitination and proteasomal degradation (Wei et al., 2010).", [["HBV X protein", "GENE_OR_GENE_PRODUCT", 4, 17], ["HBx", "GENE_OR_GENE_PRODUCT", 19, 22], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["MAVS", "GENE_OR_GENE_PRODUCT", 91, 95], ["HBV X protein", "PROTEIN", 4, 17], ["HBx", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 54, 57], ["\u03b2", "PROTEIN", 58, 59], ["MAVS", "PROTEIN", 91, 95], ["HBV", "SPECIES", 4, 7], ["The HBV X protein", "TEST", 0, 17], ["HBx", "TEST", 19, 22], ["IFN", "TEST", 54, 57], ["MAVS", "PROBLEM", 91, 95], ["its ubiquitination", "PROBLEM", 108, 126], ["proteasomal degradation", "PROBLEM", 131, 154]]], ["One particular MAVS lysine mutant exhibited increased IFN-\u03b2 activation, suggesting that this is the residue targeted for HBx-dependent ubiquitination.", [["lysine", "CHEMICAL", 20, 26], ["lysine", "CHEMICAL", 20, 26], ["MAVS", "GENE_OR_GENE_PRODUCT", 15, 19], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["HBx", "GENE_OR_GENE_PRODUCT", 121, 124], ["MAVS lysine mutant", "PROTEIN", 15, 33], ["IFN", "PROTEIN", 54, 57], ["-\u03b2", "PROTEIN", 57, 59], ["HBx", "PROTEIN", 121, 124], ["increased IFN-\u03b2 activation", "PROBLEM", 44, 70], ["the residue", "PROBLEM", 96, 107], ["HBx", "PROBLEM", 121, 124], ["dependent ubiquitination", "PROBLEM", 125, 149], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["IFN", "OBSERVATION_MODIFIER", 54, 57], ["dependent", "OBSERVATION_MODIFIER", 125, 134], ["ubiquitination", "OBSERVATION_MODIFIER", 135, 149]]], ["However, the particular E3 Ub ligase involved in this process has not been identified.IFN response factors ::: Downregulation of factors leading to IFN production ::: Evading Innate Immune MechanismsOther common viral targets degraded with the help of the UPS to limit IFN production are IRF3 and IRF7.", [["E3", "GENE_OR_GENE_PRODUCT", 24, 26], ["Ub", "GENE_OR_GENE_PRODUCT", 27, 29], ["IFN", "GENE_OR_GENE_PRODUCT", 148, 151], ["UPS", "GENE_OR_GENE_PRODUCT", 256, 259], ["IFN", "GENE_OR_GENE_PRODUCT", 269, 272], ["IRF3", "GENE_OR_GENE_PRODUCT", 288, 292], ["IRF7", "GENE_OR_GENE_PRODUCT", 297, 301], ["E3 Ub ligase", "PROTEIN", 24, 36], ["IFN response factors", "PROTEIN", 86, 106], ["IFN", "PROTEIN", 148, 151], ["UPS", "PROTEIN", 256, 259], ["IFN", "PROTEIN", 269, 272], ["IRF3", "PROTEIN", 288, 292], ["IRF7", "PROTEIN", 297, 301], ["Downregulation of factors", "PROBLEM", 111, 136], ["IRF3", "PROBLEM", 288, 292], ["ligase", "OBSERVATION", 30, 36]]], ["Examples can be found among the flaviviruses, reoviruses, and herpesviruses.", [["reoviruses", "GENE_OR_GENE_PRODUCT", 46, 56], ["herpesviruses", "ORGANISM", 62, 75], ["the flaviviruses", "PROBLEM", 28, 44], ["reoviruses", "PROBLEM", 46, 56], ["herpesviruses", "PROBLEM", 62, 75], ["flaviviruses", "OBSERVATION", 32, 44]]], ["Bovine viral diarrhea virus (BVDV) and classical swine fever virus (CSFV) are flaviviruses that encode NPro, a papain-like protease that acts as an IFN antagonist by binding and inducing the polyubiquitination and subsequent degradation of IRF3 (Hilton et al., 2006; Chen et al., 2007a).", [["Bovine viral diarrhea virus", "DISEASE", 0, 27], ["swine fever", "DISEASE", 49, 60], ["Bovine viral diarrhea virus", "ORGANISM", 0, 27], ["BVDV", "ORGANISM", 29, 33], ["classical swine fever virus", "ORGANISM", 39, 66], ["CSFV", "ORGANISM", 68, 72], ["NPro", "GENE_OR_GENE_PRODUCT", 103, 107], ["papain", "GENE_OR_GENE_PRODUCT", 111, 117], ["IRF3", "GENE_OR_GENE_PRODUCT", 240, 244], ["NPro", "PROTEIN", 103, 107], ["papain-like protease", "PROTEIN", 111, 131], ["IFN", "PROTEIN", 148, 151], ["IRF3", "PROTEIN", 240, 244], ["Bovine viral diarrhea virus", "SPECIES", 0, 27], ["BVDV", "SPECIES", 29, 33], ["swine fever virus", "SPECIES", 49, 66], ["CSFV", "SPECIES", 68, 72], ["Bovine viral diarrhea virus", "SPECIES", 0, 27], ["BVDV", "SPECIES", 29, 33], ["classical swine fever virus", "SPECIES", 39, 66], ["CSFV", "SPECIES", 68, 72], ["Bovine viral diarrhea virus", "PROBLEM", 0, 27], ["BVDV", "PROBLEM", 29, 33], ["classical swine fever virus", "PROBLEM", 39, 66], ["flaviviruses", "PROBLEM", 78, 90], ["a papain", "TREATMENT", 109, 117], ["protease", "TREATMENT", 123, 131], ["an IFN antagonist", "TREATMENT", 145, 162], ["the polyubiquitination", "PROBLEM", 187, 209], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["diarrhea virus", "OBSERVATION", 13, 27]]], ["However, NPro protease activity does not appear to be required for this function.", [["NPro protease", "GENE_OR_GENE_PRODUCT", 9, 22], ["NPro", "PROTEIN", 9, 13], ["NPro protease activity", "PROBLEM", 9, 31]]], ["Moreover, NPro from CSFV was itself degraded in a UPS-dependent manner in the absence of IRF3 (Seago et al., 2010).", [["NPro", "GENE_OR_GENE_PRODUCT", 10, 14], ["CSFV", "ORGANISM", 20, 24], ["UPS", "GENE_OR_GENE_PRODUCT", 50, 53], ["IRF3", "GENE_OR_GENE_PRODUCT", 89, 93], ["NPro", "PROTEIN", 10, 14], ["UPS", "PROTEIN", 50, 53], ["IRF3", "PROTEIN", 89, 93], ["CSFV", "SPECIES", 20, 24], ["CSFV", "PROBLEM", 20, 24]]], ["Whether NPro acts as a Ub ligase or recruits a cellular Ub ligase remains to be determined.", [["cellular", "ANATOMY", 47, 55], ["NPro", "CHEMICAL", 8, 12], ["NPro", "GENE_OR_GENE_PRODUCT", 8, 12], ["Ub", "GENE_OR_GENE_PRODUCT", 23, 25], ["cellular Ub", "GENE_OR_GENE_PRODUCT", 47, 58], ["NPro", "PROTEIN", 8, 12], ["Ub ligase", "PROTEIN", 23, 32], ["cellular Ub ligase", "PROTEIN", 47, 65], ["a Ub ligase", "TEST", 21, 32], ["a cellular Ub ligase", "TEST", 45, 65]]], ["The rotavirus NSP1 protein has also been shown to block IFN production by inducing the degradation of IRF3, IRF5, and IRF7 (reviewed in Sherry, 2009).", [["rotavirus", "ORGANISM", 4, 13], ["NSP1", "GENE_OR_GENE_PRODUCT", 14, 18], ["IFN", "GENE_OR_GENE_PRODUCT", 56, 59], ["IRF3", "GENE_OR_GENE_PRODUCT", 102, 106], ["IRF5", "GENE_OR_GENE_PRODUCT", 108, 112], ["IRF7", "GENE_OR_GENE_PRODUCT", 118, 122], ["rotavirus NSP1 protein", "PROTEIN", 4, 26], ["IFN", "PROTEIN", 56, 59], ["IRF3", "PROTEIN", 102, 106], ["IRF5", "PROTEIN", 108, 112], ["IRF7", "PROTEIN", 118, 122], ["rotavirus", "SPECIES", 4, 13], ["The rotavirus NSP1 protein", "TEST", 0, 26], ["block IFN production", "PROBLEM", 50, 70], ["IRF3", "PROBLEM", 102, 106], ["rotavirus", "OBSERVATION", 4, 13], ["NSP1 protein", "OBSERVATION", 14, 26]]], ["Graff et al. (2007) showed that the NSP1 zinc-binding domain is important for IRF3 degradation, and their data suggests that NSP1 may be acting as an E3 Ub ligase.", [["zinc", "CHEMICAL", 41, 45], ["NSP1", "CHEMICAL", 125, 129], ["zinc", "CHEMICAL", 41, 45], ["NSP1", "GENE_OR_GENE_PRODUCT", 36, 40], ["IRF3", "GENE_OR_GENE_PRODUCT", 78, 82], ["NSP1", "GENE_OR_GENE_PRODUCT", 125, 129], ["E3", "GENE_OR_GENE_PRODUCT", 150, 152], ["NSP1 zinc-binding domain", "PROTEIN", 36, 60], ["IRF3", "PROTEIN", 78, 82], ["NSP1", "PROTEIN", 125, 129], ["E3 Ub ligase", "PROTEIN", 150, 162], ["the NSP1 zinc-binding domain", "PROBLEM", 32, 60], ["IRF3 degradation", "PROBLEM", 78, 94], ["NSP1", "PROBLEM", 125, 129]]], ["Herpesviruses have also been shown to inhibit IFN activation by interfering with IRFs.", [["Herpesviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["IFN", "GENE_OR_GENE_PRODUCT", 46, 49], ["IFN", "PROTEIN", 46, 49], ["IRFs", "PROTEIN", 81, 85], ["Herpesviruses", "PROBLEM", 0, 13]]], ["As discussed above, the KSHV RTA protein can function as both a transcriptional activator and an E3 ligase.", [["KSHV", "ORGANISM", 24, 28], ["RTA", "GENE_OR_GENE_PRODUCT", 29, 32], ["E3", "GENE_OR_GENE_PRODUCT", 97, 99], ["KSHV RTA protein", "PROTEIN", 24, 40], ["transcriptional activator", "PROTEIN", 64, 89], ["E3 ligase", "PROTEIN", 97, 106], ["KSHV", "SPECIES", 24, 28], ["the KSHV RTA protein", "TEST", 20, 40], ["an E3 ligase", "TEST", 94, 106]]], ["In addition to its other targets (see above), RTA also induces the ubiquitination and degradation of IRF7 (Yu et al., 2005).", [["RTA", "GENE_OR_GENE_PRODUCT", 46, 49], ["IRF7", "GENE_OR_GENE_PRODUCT", 101, 105], ["RTA", "PROTEIN", 46, 49], ["IRF7", "PROTEIN", 101, 105], ["RTA", "PROBLEM", 46, 49]]], ["HSV encodes the multifunctional protein ICP0, which has been shown to interfere with several stages of the IFN pathway, including the prevention of IRF3 and IRF7 activation (reviewed in Paladino and Mossman, 2009).", [["HSV", "ORGANISM", 0, 3], ["ICP0", "GENE_OR_GENE_PRODUCT", 40, 44], ["IFN", "GENE_OR_GENE_PRODUCT", 107, 110], ["IRF3", "GENE_OR_GENE_PRODUCT", 148, 152], ["IRF7", "GENE_OR_GENE_PRODUCT", 157, 161], ["multifunctional protein", "PROTEIN", 16, 39], ["ICP0", "PROTEIN", 40, 44], ["IFN", "PROTEIN", 107, 110], ["IRF3", "PROTEIN", 148, 152], ["IRF7", "PROTEIN", 157, 161], ["HSV", "SPECIES", 0, 3], ["HSV", "PROBLEM", 0, 3], ["the multifunctional protein ICP0", "TREATMENT", 12, 44], ["the IFN pathway", "TREATMENT", 103, 118], ["IRF3", "PROBLEM", 148, 152], ["IRF7 activation", "PROBLEM", 157, 172], ["IRF3", "OBSERVATION", 148, 152], ["IRF7 activation", "OBSERVATION", 157, 172]]], ["ICP0 E3 Ub ligase activity has been implicated in this function.", [["ICP0 E3", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ub", "GENE_OR_GENE_PRODUCT", 8, 10], ["ICP0 E3", "PROTEIN", 0, 7], ["Ub ligase", "PROTEIN", 8, 17], ["ligase activity", "OBSERVATION", 11, 26]]], ["However, recent data indicates that inhibition of signal transducer and activator of transcription (STAT) or IRF3 pathways does not enhance the replication of ICP0-deleted viruses (Everett et al., 2008).", [["signal transducer and activator of transcription", "GENE_OR_GENE_PRODUCT", 50, 98], ["STAT", "GENE_OR_GENE_PRODUCT", 100, 104], ["IRF3", "GENE_OR_GENE_PRODUCT", 109, 113], ["ICP0", "GENE_OR_GENE_PRODUCT", 159, 163], ["STAT", "PROTEIN", 100, 104], ["IRF3", "PROTEIN", 109, 113], ["ICP0", "PROTEIN", 159, 163], ["transcription (STAT) or IRF3 pathways", "TEST", 85, 122]]], ["These results suggest that ICP0\u2019s role in subversion of the IFN response may be secondary to its involvement in promyelocytic leukemia (PML) and sp100 degradation (see below; Everett and Orr, 2009).", [["promyelocytic leukemia", "ANATOMY", 112, 134], ["PML", "ANATOMY", 136, 139], ["promyelocytic leukemia", "DISEASE", 112, 134], ["ICP0", "GENE_OR_GENE_PRODUCT", 27, 31], ["IFN", "GENE_OR_GENE_PRODUCT", 60, 63], ["promyelocytic leukemia", "CANCER", 112, 134], ["PML", "CANCER", 136, 139], ["sp100", "GENE_OR_GENE_PRODUCT", 145, 150], ["ICP0", "PROTEIN", 27, 31], ["IFN", "PROTEIN", 60, 63], ["ICP0", "PROBLEM", 27, 31], ["promyelocytic leukemia (PML", "PROBLEM", 112, 139], ["sp100 degradation", "PROBLEM", 145, 162], ["ICP0", "OBSERVATION", 27, 31], ["promyelocytic leukemia", "OBSERVATION", 112, 134]]], ["Lastly, HIV-1 has been shown to downregulate IRF3 protein levels in infected cells, and Okumura et al. (2008) have provided evidence that this is due to the action of the HIV-1 E3 Ub adaptor proteins Vif and Vpr (Okumura et al., 2008).", [["cells", "ANATOMY", 77, 82], ["HIV-1", "ORGANISM", 8, 13], ["IRF3", "GENE_OR_GENE_PRODUCT", 45, 49], ["cells", "CELL", 77, 82], ["HIV-1", "ORGANISM", 171, 176], ["Ub", "GENE_OR_GENE_PRODUCT", 180, 182], ["Vif", "GENE_OR_GENE_PRODUCT", 200, 203], ["Vpr", "GENE_OR_GENE_PRODUCT", 208, 211], ["IRF3", "PROTEIN", 45, 49], ["infected cells", "CELL_TYPE", 68, 82], ["HIV-1 E3 Ub adaptor proteins", "PROTEIN", 171, 199], ["Vif", "PROTEIN", 200, 203], ["Vpr", "PROTEIN", 208, 211], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 171, 176], ["HIV", "TEST", 8, 11], ["IRF3 protein levels", "TEST", 45, 64], ["infected cells", "PROBLEM", 68, 82], ["the HIV", "PROBLEM", 167, 174], ["infected cells", "OBSERVATION", 68, 82]]], ["However, while ectopically expressed Vpr and Vif were shown to induce IRF3 ubiquitination and degradation in transfected 293T cells, IRF3 degradation was still observed in T-cells infected with an HIV-1 vpr/vif double mutant.", [["293T cells", "ANATOMY", 121, 131], ["T-cells", "ANATOMY", 172, 179], ["Vpr", "GENE_OR_GENE_PRODUCT", 37, 40], ["Vif", "GENE_OR_GENE_PRODUCT", 45, 48], ["IRF3", "GENE_OR_GENE_PRODUCT", 70, 74], ["293T cells", "CELL", 121, 131], ["IRF3", "GENE_OR_GENE_PRODUCT", 133, 137], ["T-cells", "CELL", 172, 179], ["HIV-1", "ORGANISM", 197, 202], ["vpr", "GENE_OR_GENE_PRODUCT", 203, 206], ["vif", "GENE_OR_GENE_PRODUCT", 207, 210], ["Vpr", "PROTEIN", 37, 40], ["Vif", "PROTEIN", 45, 48], ["IRF3", "PROTEIN", 70, 74], ["transfected 293T cells", "CELL_LINE", 109, 131], ["IRF3", "PROTEIN", 133, 137], ["T-cells", "CELL_TYPE", 172, 179], ["HIV-1", "SPECIES", 197, 202], ["HIV-1", "SPECIES", 197, 202], ["Vpr and Vif", "TREATMENT", 37, 48], ["IRF3 ubiquitination", "PROBLEM", 70, 89], ["degradation in transfected 293T cells", "PROBLEM", 94, 131], ["IRF3 degradation", "PROBLEM", 133, 149], ["an HIV", "TEST", 194, 200], ["vif double mutant", "TREATMENT", 207, 224], ["IRF3 ubiquitination", "OBSERVATION", 70, 89], ["293T cells", "OBSERVATION", 121, 131]]], ["Recent work from another group has confirmed IRF3 downregulation by HIV-1, and while their data supported a significant role for Vpr in that process, Vif did not appear to have an effect (Doehle et al., 2009).NF-\u03baB ::: Downregulation of factors leading to IFN production ::: Evading Innate Immune MechanismsNF-\u03baB activation provides yet another route to IFN production and is thus a target for several viral antagonists.", [["IRF3", "GENE_OR_GENE_PRODUCT", 45, 49], ["HIV-1", "ORGANISM", 68, 73], ["Vpr", "GENE_OR_GENE_PRODUCT", 129, 132], ["Vif", "GENE_OR_GENE_PRODUCT", 150, 153], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 209, 214], ["IFN", "GENE_OR_GENE_PRODUCT", 256, 259], ["IFN", "GENE_OR_GENE_PRODUCT", 354, 357], ["IRF3", "PROTEIN", 45, 49], ["Vpr", "PROTEIN", 129, 132], ["Vif", "PROTEIN", 150, 153], ["NF-\u03baB", "PROTEIN", 209, 214], ["IFN", "PROTEIN", 256, 259], ["-\u03baB", "PROTEIN", 309, 312], ["IFN", "PROTEIN", 354, 357], ["HIV-1", "SPECIES", 68, 73], ["IRF3 downregulation", "PROBLEM", 45, 64], ["HIV", "PROBLEM", 68, 71], ["Vpr", "TREATMENT", 129, 132], ["Downregulation of factors", "PROBLEM", 219, 244], ["several viral antagonists", "TREATMENT", 394, 419], ["IRF3 downregulation", "OBSERVATION", 45, 64]]], ["In addition to its ability to degrade IRF3 (see above), the rotavirus NSP1 protein also mediates the ubiquitination and degradation of the cellular E3 Ub ligase F-box protein beta-transducin repeating containing protein (\u03b2TrCP), which regulates NF-\u03baB activation via the degradation of the NF-\u03baB inhibitor I\u03baB (Graff et al., 2009).", [["cellular", "ANATOMY", 139, 147], ["IRF3", "GENE_OR_GENE_PRODUCT", 38, 42], ["rotavirus", "ORGANISM", 60, 69], ["NSP1", "GENE_OR_GENE_PRODUCT", 70, 74], ["cellular", "CELL", 139, 147], ["F-box protein beta-transducin repeating containing protein (\u03b2TrCP", "GENE_OR_GENE_PRODUCT", 161, 226], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 245, 250], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 289, 294], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 305, 308], ["IRF3", "PROTEIN", 38, 42], ["rotavirus NSP1 protein", "PROTEIN", 60, 82], ["cellular E3 Ub ligase F-box protein", "PROTEIN", 139, 174], ["beta-transducin repeating containing protein", "PROTEIN", 175, 219], ["\u03b2TrCP", "PROTEIN", 221, 226], ["NF-\u03baB", "PROTEIN", 245, 250], ["NF-\u03baB", "PROTEIN", 289, 294], ["I\u03baB", "PROTEIN", 305, 308], ["rotavirus", "SPECIES", 60, 69], ["the rotavirus NSP1 protein", "TEST", 56, 82], ["the ubiquitination", "PROBLEM", 97, 115], ["box protein beta-transducin", "TEST", 163, 190], ["protein", "TEST", 212, 219], ["TrCP", "TEST", 222, 226], ["the NF", "TREATMENT", 285, 291], ["IRF3", "OBSERVATION", 38, 42]]], ["This provides an interesting example of a single virally encoded Ub ligase targeting two separate mechanisms for IFN activation.", [["Ub", "GENE_OR_GENE_PRODUCT", 65, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 113, 116], ["virally encoded Ub ligase", "PROTEIN", 49, 74], ["IFN", "PROTEIN", 113, 116], ["IFN activation", "TREATMENT", 113, 127]]], ["The cowpox host-range protein CP77 has also been found to inhibit NF-\u03baB activation.", [["CP77", "CHEMICAL", 30, 34], ["cowpox", "ORGANISM", 4, 10], ["CP77", "GENE_OR_GENE_PRODUCT", 30, 34], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 66, 71], ["CP77", "PROTEIN", 30, 34], ["NF-\u03baB", "PROTEIN", 66, 71], ["The cowpox host", "TEST", 0, 15], ["protein CP77", "TEST", 22, 34]]], ["CP77 contains both an F-box motif that mediates binding to the SCF complex and a series of ankyrin repeats responsible for binding to NF-\u03baB.", [["CP77", "GENE_OR_GENE_PRODUCT", 0, 4], ["SCF", "GENE_OR_GENE_PRODUCT", 63, 66], ["ankyrin", "GENE_OR_GENE_PRODUCT", 91, 98], ["NF-\u03baB.", "GENE_OR_GENE_PRODUCT", 134, 140], ["CP77", "PROTEIN", 0, 4], ["F-box motif", "DNA", 22, 33], ["SCF complex", "PROTEIN", 63, 74], ["ankyrin repeats", "PROTEIN", 91, 106], ["NF-\u03baB.", "PROTEIN", 134, 140], ["an F-box motif", "TREATMENT", 19, 33], ["ankyrin repeats", "TREATMENT", 91, 106]]], ["While it was expected that CP77 would simply serve as an adaptor targeting NF-\u03baB for ubiquitination by the SCF complex, no CP77-dependent ubiquitination or degradation of NF-\u03baB was observed (Chang et al., 2009).", [["CP77", "CHEMICAL", 27, 31], ["CP77", "SIMPLE_CHEMICAL", 27, 31], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["SCF", "GENE_OR_GENE_PRODUCT", 107, 110], ["CP77", "GENE_OR_GENE_PRODUCT", 123, 127], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["CP77", "PROTEIN", 27, 31], ["NF-\u03baB", "PROTEIN", 75, 80], ["SCF complex", "PROTEIN", 107, 118], ["CP77", "PROTEIN", 123, 127], ["NF-\u03baB", "PROTEIN", 171, 176], ["the SCF complex", "TEST", 103, 118], ["CP77", "TEST", 123, 127]]], ["Curiously, both the CP77 F-box and ankyrin repeats are required in order to prevent NF-\u03baB nuclear translocation.", [["nuclear", "ANATOMY", 90, 97], ["CP77", "GENE_OR_GENE_PRODUCT", 20, 24], ["ankyrin", "GENE_OR_GENE_PRODUCT", 35, 42], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 84, 89], ["CP77 F-box", "DNA", 20, 30], ["ankyrin repeats", "PROTEIN", 35, 50], ["NF-\u03baB", "PROTEIN", 84, 89], ["ankyrin repeats", "TREATMENT", 35, 50], ["NF", "PROBLEM", 84, 86], ["B nuclear translocation", "PROBLEM", 88, 111], ["nuclear translocation", "OBSERVATION", 90, 111]]], ["Because NF-\u03baB was not directly targeted for ubiquitination/degradation, the authors propose that CP77 somehow sequesters NF-\u03baB to prevent its activation and nuclear translocation (Chang et al., 2009).", [["nuclear", "ANATOMY", 157, 164], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 8, 13], ["CP77", "SIMPLE_CHEMICAL", 97, 101], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 121, 126], ["nuclear", "CELLULAR_COMPONENT", 157, 164], ["NF-\u03baB", "PROTEIN", 8, 13], ["CP77", "PROTEIN", 97, 101], ["NF-\u03baB", "PROTEIN", 121, 126], ["ubiquitination/degradation", "PROBLEM", 44, 70]]], ["Measles virus appears to exhibit a cell-type specific suppression of NF-\u03baB activation, which is active in monocytes but not epithelial cells (Indoh et al., 2007).", [["cell", "ANATOMY", 35, 39], ["monocytes", "ANATOMY", 106, 115], ["epithelial cells", "ANATOMY", 124, 140], ["Measles virus", "ORGANISM", 0, 13], ["cell", "CELL", 35, 39], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 69, 74], ["monocytes", "CELL", 106, 115], ["epithelial cells", "CELL", 124, 140], ["NF-\u03baB", "PROTEIN", 69, 74], ["monocytes", "CELL_TYPE", 106, 115], ["epithelial cells", "CELL_TYPE", 124, 140], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "PROBLEM", 0, 13], ["active in monocytes", "PROBLEM", 96, 115], ["epithelial cells", "PROBLEM", 124, 140], ["active", "OBSERVATION_MODIFIER", 96, 102], ["not", "UNCERTAINTY", 120, 123], ["epithelial cells", "OBSERVATION", 124, 140]]], ["This activity is mediated by the viral P protein, which has been shown to transcriptionally upregulate the cellular DUB A20, thus leading to the inhibition of NF-\u03baB-dependent IFN induction via the deubiquitination of TRAF6 (Yokota et al., 2008).", [["cellular", "ANATOMY", 107, 115], ["cellular", "CELL", 107, 115], ["A20", "GENE_OR_GENE_PRODUCT", 120, 123], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 159, 164], ["IFN", "GENE_OR_GENE_PRODUCT", 175, 178], ["TRAF6", "GENE_OR_GENE_PRODUCT", 217, 222], ["viral P protein", "PROTEIN", 33, 48], ["DUB A20", "PROTEIN", 116, 123], ["NF-\u03baB", "PROTEIN", 159, 164], ["IFN", "PROTEIN", 175, 178], ["TRAF6", "PROTEIN", 217, 222], ["the viral P protein", "TEST", 29, 48], ["NF", "TREATMENT", 159, 161], ["B-dependent IFN induction", "TREATMENT", 163, 188], ["the deubiquitination of TRAF6", "TREATMENT", 193, 222], ["cellular DUB A20", "OBSERVATION", 107, 123]]], ["As described in a previous section, A20 induction by EBV LMP1 was shown to inhibit IRF7, which consequently prevents IRF7-dependent IFN induction (Ning and Pagano, 2010).", [["A20", "GENE_OR_GENE_PRODUCT", 36, 39], ["EBV", "ORGANISM", 53, 56], ["LMP1", "GENE_OR_GENE_PRODUCT", 57, 61], ["IRF7", "GENE_OR_GENE_PRODUCT", 83, 87], ["IRF7", "GENE_OR_GENE_PRODUCT", 117, 121], ["IFN", "GENE_OR_GENE_PRODUCT", 132, 135], ["A20", "PROTEIN", 36, 39], ["EBV LMP1", "PROTEIN", 53, 61], ["IRF7", "PROTEIN", 83, 87], ["IRF7", "PROTEIN", 117, 121], ["IFN", "PROTEIN", 132, 135], ["EBV", "SPECIES", 53, 56], ["A20 induction", "TREATMENT", 36, 49], ["EBV LMP1", "TEST", 53, 61], ["IRF7", "PROBLEM", 83, 87], ["IRF7-dependent IFN induction", "TREATMENT", 117, 145]]], ["Influenza (Onose et al., 2006) and hepatitis C (Nguyen et al., 2006) have also been shown to inactivate NF-\u03baB via A20 induction.", [["Influenza", "DISEASE", 0, 9], ["hepatitis C", "DISEASE", 35, 46], ["hepatitis C", "ORGANISM", 35, 46], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 104, 109], ["A20", "GENE_OR_GENE_PRODUCT", 114, 117], ["NF-\u03baB", "PROTEIN", 104, 109], ["A20", "PROTEIN", 114, 117], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["hepatitis C", "PROBLEM", 35, 46], ["A20 induction", "TREATMENT", 114, 127]]], ["Therefore, multiple viruses appear to utilize this cellular DUB as a means to inhibit two separate IFN-induction pathways.", [["cellular", "ANATOMY", 51, 59], ["cellular", "CELL", 51, 59], ["DUB", "GENE_OR_GENE_PRODUCT", 60, 63], ["IFN", "GENE_OR_GENE_PRODUCT", 99, 102], ["DUB", "PROTEIN", 60, 63], ["IFN", "PROTEIN", 99, 102], ["multiple viruses", "PROBLEM", 11, 27], ["this cellular DUB", "PROBLEM", 46, 63], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Finally, HSV appears to hijack a different cellular DUB to evade the immune system.", [["cellular", "ANATOMY", 43, 51], ["immune system", "ANATOMY", 69, 82], ["HSV", "ORGANISM", 9, 12], ["cellular", "CELL", 43, 51], ["DUB", "GENE_OR_GENE_PRODUCT", 52, 55], ["DUB", "PROTEIN", 52, 55], ["HSV", "SPECIES", 9, 12], ["HSV", "PROBLEM", 9, 12], ["cellular DUB", "OBSERVATION", 43, 55], ["immune system", "OBSERVATION", 69, 82]]], ["The viral transcriptional activator ICP0 has been shown to interact with and redirect the cellular DUB USP7 to the cytoplasm where it deubiquitinates TRAF6 and IKK\u03b3, which are required for activation of the canonical NF-\u03baB pathway (Daubeuf et al., 2009).Downregulation of IFN signaling molecules (STATs) ::: Evading Innate Immune MechanismsOnce IFN is produced, it binds to the IFN-receptor on neighboring cells, thereby activating the STAT signaling cascade that ultimately results in the transcriptional activation of many anti-viral IFN-stimulated genes (ISGs).", [["cellular", "ANATOMY", 90, 98], ["cytoplasm", "ANATOMY", 115, 124], ["cells", "ANATOMY", 406, 411], ["ICP0", "GENE_OR_GENE_PRODUCT", 36, 40], ["cellular", "CELL", 90, 98], ["USP7", "GENE_OR_GENE_PRODUCT", 103, 107], ["cytoplasm", "ORGANISM_SUBSTANCE", 115, 124], ["TRAF6", "GENE_OR_GENE_PRODUCT", 150, 155], ["IKK\u03b3", "GENE_OR_GENE_PRODUCT", 160, 164], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 217, 222], ["IFN signaling molecules", "GENE_OR_GENE_PRODUCT", 272, 295], ["STATs", "GENE_OR_GENE_PRODUCT", 297, 302], ["IFN-receptor", "GENE_OR_GENE_PRODUCT", 378, 390], ["cells", "CELL", 406, 411], ["STAT", "GENE_OR_GENE_PRODUCT", 436, 440], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 536, 556], ["viral transcriptional activator", "PROTEIN", 4, 35], ["ICP0", "PROTEIN", 36, 40], ["DUB", "PROTEIN", 99, 102], ["USP7", "PROTEIN", 103, 107], ["TRAF6", "PROTEIN", 150, 155], ["IKK\u03b3", "PROTEIN", 160, 164], ["NF-\u03baB", "PROTEIN", 217, 222], ["IFN signaling molecules", "PROTEIN", 272, 295], ["STATs", "PROTEIN", 297, 302], ["Innate Immune MechanismsOnce IFN", "PROTEIN", 316, 348], ["IFN-receptor", "PROTEIN", 378, 390], ["neighboring cells", "CELL_TYPE", 394, 411], ["STAT", "PROTEIN", 436, 440], ["anti-viral IFN-stimulated genes", "DNA", 525, 556], ["ISGs", "DNA", 558, 562], ["The viral transcriptional activator ICP0", "TREATMENT", 0, 40], ["Downregulation of IFN signaling molecules", "PROBLEM", 254, 295], ["many anti-viral IFN", "TREATMENT", 520, 539], ["viral transcriptional", "OBSERVATION", 4, 25], ["activator ICP0", "OBSERVATION", 26, 40], ["IFN signaling molecules", "OBSERVATION", 272, 295]]], ["This makes targeting STATs another common means by which viruses ablate the IFN response.", [["STATs", "GENE_OR_GENE_PRODUCT", 21, 26], ["IFN", "GENE_OR_GENE_PRODUCT", 76, 79], ["STATs", "PROTEIN", 21, 26], ["IFN", "PROTEIN", 76, 79]]], ["For example, both the flaviviruses and paramyxoviruses have evolved UPS-dependent methods to eliminate STATs.", [["UPS", "GENE_OR_GENE_PRODUCT", 68, 71], ["STATs", "GENE_OR_GENE_PRODUCT", 103, 108], ["UPS", "PROTEIN", 68, 71], ["STATs", "PROTEIN", 103, 108], ["the flaviviruses and paramyxoviruses", "PROBLEM", 18, 54], ["flaviviruses", "OBSERVATION", 22, 34]]], ["The Dengue virus NS5 polymerase interacts with STAT2, leading to STAT2 ubiquitination and proteasome-dependent degradation.", [["Dengue", "DISEASE", 4, 10], ["Dengue virus", "ORGANISM", 4, 16], ["STAT2", "GENE_OR_GENE_PRODUCT", 47, 52], ["STAT2", "GENE_OR_GENE_PRODUCT", 65, 70], ["Dengue virus NS5 polymerase", "PROTEIN", 4, 31], ["STAT2", "PROTEIN", 47, 52], ["STAT2", "PROTEIN", 65, 70], ["proteasome", "PROTEIN", 90, 100], ["Dengue virus", "SPECIES", 4, 16], ["Dengue virus", "SPECIES", 4, 16], ["The Dengue virus NS5 polymerase", "PROBLEM", 0, 31], ["STAT2", "PROBLEM", 47, 52], ["STAT2 ubiquitination", "PROBLEM", 65, 85], ["proteasome-dependent degradation", "PROBLEM", 90, 122], ["virus NS5", "OBSERVATION", 11, 20], ["STAT2 ubiquitination", "OBSERVATION", 65, 85], ["dependent", "OBSERVATION_MODIFIER", 101, 110], ["degradation", "OBSERVATION_MODIFIER", 111, 122]]], ["NS5 is initially expressed as part of a single polyprotein that is cleaved by viral and host proteases into more than 10 individual proteins.", [["NS5", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS5", "PROTEIN", 0, 3], ["viral and host proteases", "PROTEIN", 78, 102], ["NS5", "TREATMENT", 0, 3], ["a single polyprotein", "PROBLEM", 38, 58], ["viral and host proteases", "TREATMENT", 78, 102]]], ["Interestingly, NS5 alone can interact with STAT2, but does not induce degradation except in the context of the polyprotein (Ashour et al., 2009).", [["NS5", "GENE_OR_GENE_PRODUCT", 15, 18], ["STAT2", "GENE_OR_GENE_PRODUCT", 43, 48], ["NS5", "PROTEIN", 15, 18], ["STAT2", "PROTEIN", 43, 48]]], ["It is not known whether a cellular Ub ligase is involved or if the proteolytic processing of the viral polyprotein somehow leads to the degradation of STAT2.", [["cellular", "ANATOMY", 26, 34], ["cellular", "CELL", 26, 34], ["Ub", "GENE_OR_GENE_PRODUCT", 35, 37], ["STAT2", "GENE_OR_GENE_PRODUCT", 151, 156], ["cellular Ub ligase", "PROTEIN", 26, 44], ["STAT2", "PROTEIN", 151, 156], ["a cellular Ub ligase", "TEST", 24, 44], ["the proteolytic processing", "PROBLEM", 63, 89], ["the viral polyprotein", "PROBLEM", 93, 114], ["not known", "UNCERTAINTY", 6, 15], ["ligase", "OBSERVATION", 38, 44], ["viral polyprotein", "OBSERVATION", 97, 114]]], ["NS5 has also been shown to prevent IFN-induced phosphorylation of STAT2, although this does not appear to involve the UPS (Mazzon et al., 2009).", [["NS5", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 35, 38], ["STAT2", "GENE_OR_GENE_PRODUCT", 66, 71], ["NS5", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 35, 38], ["STAT2", "PROTEIN", 66, 71], ["NS5", "TREATMENT", 0, 3], ["IFN", "TREATMENT", 35, 38], ["induced phosphorylation of STAT2", "PROBLEM", 39, 71]]], ["The antagonism of IFN by paramyxoviruses is more complicated due to the varied targeting of multiple STATs by different viral family members.", [["IFN", "CHEMICAL", 18, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["paramyxoviruses", "ORGANISM", 25, 40], ["STATs", "GENE_OR_GENE_PRODUCT", 101, 106], ["IFN", "PROTEIN", 18, 21], ["STATs", "PROTEIN", 101, 106], ["viral family members", "PROTEIN", 120, 140], ["IFN", "PROBLEM", 18, 21], ["paramyxoviruses", "PROBLEM", 25, 40]]], ["For example, among the rubulavirus genus, the human parainfluenza type 2 (HPIV2) V protein directs the ubiquitination and degradation of STAT2 (Parisien et al., 2002), while the PIV5 V protein induces the degradation of STAT1 (Didcock et al., 1999).", [["rubulavirus genus", "ORGANISM", 23, 40], ["human", "ORGANISM", 46, 51], ["parainfluenza type 2", "ORGANISM", 52, 72], ["HPIV2) V", "GENE_OR_GENE_PRODUCT", 74, 82], ["STAT2", "GENE_OR_GENE_PRODUCT", 137, 142], ["PIV5 V", "GENE_OR_GENE_PRODUCT", 178, 184], ["STAT1", "GENE_OR_GENE_PRODUCT", 220, 225], ["human parainfluenza type 2 (HPIV2) V protein", "PROTEIN", 46, 90], ["STAT2", "PROTEIN", 137, 142], ["PIV5 V protein", "PROTEIN", 178, 192], ["STAT1", "PROTEIN", 220, 225], ["human", "SPECIES", 46, 51], ["parainfluenza", "SPECIES", 52, 65], ["human parainfluenza type 2", "SPECIES", 46, 72], ["the rubulavirus genus", "PROBLEM", 19, 40], ["the human parainfluenza type", "TEST", 42, 70], ["the PIV5 V protein", "TREATMENT", 174, 192], ["rubulavirus genus", "ANATOMY", 23, 40], ["parainfluenza", "OBSERVATION", 52, 65]]], ["In addition, the Mumps V protein targets both STAT1 and STAT3 (Ulane et al., 2003).", [["Mumps V", "GENE_OR_GENE_PRODUCT", 17, 24], ["STAT1", "GENE_OR_GENE_PRODUCT", 46, 51], ["STAT3", "GENE_OR_GENE_PRODUCT", 56, 61], ["Mumps V protein", "PROTEIN", 17, 32], ["STAT1", "PROTEIN", 46, 51], ["STAT3", "PROTEIN", 56, 61], ["the Mumps V protein targets", "TEST", 13, 40]]], ["Although the targets are varied, it appears that the V proteins from these three viruses are all able to form similar E3 Ub ligase complexes with DDB1 and Cul4A, which are referred to as V protein-dependent degradation complexes (VDC; Ulane and Horvath, 2002).", [["V", "GENE_OR_GENE_PRODUCT", 53, 54], ["E3", "GENE_OR_GENE_PRODUCT", 118, 120], ["DDB1", "GENE_OR_GENE_PRODUCT", 146, 150], ["Cul4A", "GENE_OR_GENE_PRODUCT", 155, 160], ["V proteins", "PROTEIN", 53, 63], ["E3 Ub ligase complexes", "PROTEIN", 118, 140], ["DDB1", "PROTEIN", 146, 150], ["Cul4A", "PROTEIN", 155, 160], ["V protein-dependent degradation complexes", "PROTEIN", 187, 228], ["the V proteins", "PROBLEM", 49, 63], ["these three viruses", "PROBLEM", 69, 88], ["DDB1", "PROBLEM", 146, 150], ["Cul4A", "TEST", 155, 160], ["V protein", "TEST", 187, 196], ["dependent degradation complexes", "PROBLEM", 197, 228], ["ligase complexes", "OBSERVATION", 124, 140]]], ["Respiratory syncytial virus (RSV), a paramyxovirus from the pneumovirus genus, does not encode a V protein homolog.", [["Respiratory syncytial virus (RSV)", "DISEASE", 0, 33], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["V protein homolog", "PROTEIN", 97, 114], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus (RSV)", "PROBLEM", 0, 33], ["a paramyxovirus from the pneumovirus genus", "PROBLEM", 35, 77], ["a V protein homolog", "TREATMENT", 95, 114], ["syncytial virus", "OBSERVATION", 12, 27], ["paramyxovirus", "OBSERVATION", 37, 50]]], ["However STAT2 is still degraded in a UPS-dependent manner that requires the viral NS1 and NS2 proteins (Spann et al., 2004).", [["STAT2", "GENE_OR_GENE_PRODUCT", 8, 13], ["UPS", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 82, 85], ["NS2", "GENE_OR_GENE_PRODUCT", 90, 93], ["STAT2", "PROTEIN", 8, 13], ["UPS", "PROTEIN", 37, 40], ["viral NS1 and NS2 proteins", "PROTEIN", 76, 102], ["the viral NS1", "TEST", 72, 85]]], ["It has since been discovered that the RSV NS1 protein interacts with ElonginC and Cul2 to direct the ubiquitination and degradation of STAT2 (Elliott et al., 2007).MHC-1, MHC-like molecules, and T-cell activation markers ::: Downregulation of IFN-induced proteins ::: Evading Innate Immune MechanismsThe most well-characterized IFN-induced anti-viral target known to be downregulated by many virus classes is MHC-1.", [["T-cell", "ANATOMY", 195, 201], ["IFN", "CHEMICAL", 328, 331], ["RSV", "ORGANISM", 38, 41], ["NS1", "GENE_OR_GENE_PRODUCT", 42, 45], ["ElonginC", "GENE_OR_GENE_PRODUCT", 69, 77], ["Cul2", "GENE_OR_GENE_PRODUCT", 82, 86], ["STAT2", "GENE_OR_GENE_PRODUCT", 135, 140], ["MHC-1", "GENE_OR_GENE_PRODUCT", 164, 169], ["T-cell", "CELL", 195, 201], ["IFN", "GENE_OR_GENE_PRODUCT", 243, 246], ["IFN", "GENE_OR_GENE_PRODUCT", 328, 331], ["MHC-1", "GENE_OR_GENE_PRODUCT", 409, 414], ["RSV NS1 protein", "PROTEIN", 38, 53], ["ElonginC", "PROTEIN", 69, 77], ["Cul2", "PROTEIN", 82, 86], ["STAT2", "PROTEIN", 135, 140], ["MHC-1, MHC-like molecules", "PROTEIN", 164, 189], ["T-cell activation markers", "PROTEIN", 195, 220], ["IFN", "PROTEIN", 243, 246], ["IFN", "PROTEIN", 328, 331], ["MHC", "PROTEIN", 409, 412], ["RSV", "SPECIES", 38, 41], ["the RSV NS1 protein interacts", "PROBLEM", 34, 63], ["ElonginC", "TREATMENT", 69, 77], ["MHC", "TEST", 164, 167], ["MHC", "TEST", 171, 174], ["IFN-induced anti-viral target", "TREATMENT", 328, 357], ["virus", "OBSERVATION", 392, 397]]], ["The host uses MHC-1 as a means to present viral antigens at the cell surface for recognition by cytotoxic T-cells.", [["cell surface", "ANATOMY", 64, 76], ["cytotoxic T-cells", "ANATOMY", 96, 113], ["MHC-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["cell surface", "CELLULAR_COMPONENT", 64, 76], ["cytotoxic T-cells", "CELL", 96, 113], ["MHC-1", "PROTEIN", 14, 19], ["viral antigens", "PROTEIN", 42, 56], ["cytotoxic T-cells", "CELL_TYPE", 96, 113], ["viral antigens", "PROBLEM", 42, 56]]], ["In response, viruses have developed numerous ways to evade this immune surveillance mechanism.", [["viruses", "PROBLEM", 13, 20], ["viruses", "OBSERVATION", 13, 20]]], ["Several members of the herpesvirus family have been shown to usurp the UPS to downregulate MHC-1 and in some cases T-cell activation markers from the cell surface.", [["T-cell", "ANATOMY", 115, 121], ["cell surface", "ANATOMY", 150, 162], ["herpesvirus", "ORGANISM", 23, 34], ["UPS", "GENE_OR_GENE_PRODUCT", 71, 74], ["MHC-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["T-cell", "CELL", 115, 121], ["cell surface", "CELLULAR_COMPONENT", 150, 162], ["UPS", "PROTEIN", 71, 74], ["MHC-1", "PROTEIN", 91, 96], ["T-cell activation markers", "PROTEIN", 115, 140], ["cell surface", "OBSERVATION", 150, 162]]], ["For example, the HCMV US2 and US11 gene products act in the ER to target MHC-1 for Ub-dependent ER-associated degradation (ERAD; Wiertz et al., 1996a,b).", [["ER", "ANATOMY", 60, 62], ["HCMV", "ORGANISM", 17, 21], ["US2", "GENE_OR_GENE_PRODUCT", 22, 25], ["US11", "GENE_OR_GENE_PRODUCT", 30, 34], ["ER", "GENE_OR_GENE_PRODUCT", 60, 62], ["MHC-1", "GENE_OR_GENE_PRODUCT", 73, 78], ["Ub", "GENE_OR_GENE_PRODUCT", 83, 85], ["ER", "GENE_OR_GENE_PRODUCT", 96, 98], ["HCMV US2 and US11 gene products", "PROTEIN", 17, 48], ["ER", "PROTEIN", 60, 62], ["MHC", "PROTEIN", 73, 76], ["Ub", "PROTEIN", 83, 85], ["ER", "PROTEIN", 96, 98], ["ERAD", "PROTEIN", 123, 127], ["HCMV", "SPECIES", 17, 21], ["the HCMV US2", "TEST", 13, 25], ["US11 gene products", "TREATMENT", 30, 48], ["MHC", "TEST", 73, 76], ["Ub", "TEST", 83, 85], ["associated degradation", "PROBLEM", 99, 121]]], ["ERAD is normally used by the cell to eliminate misfolded proteins from the ER.", [["cell", "ANATOMY", 29, 33], ["ER", "ANATOMY", 75, 77], ["ERAD", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 29, 33], ["ER", "GENE_OR_GENE_PRODUCT", 75, 77], ["ERAD", "PROTEIN", 0, 4], ["misfolded proteins", "PROTEIN", 47, 65], ["ER", "PROTEIN", 75, 77], ["misfolded proteins", "PROBLEM", 47, 65]]], ["US2 and US11 are not Ub ligases.", [["US2", "GENE_OR_GENE_PRODUCT", 0, 3], ["US11", "GENE_OR_GENE_PRODUCT", 8, 12], ["Ub", "GENE_OR_GENE_PRODUCT", 21, 23], ["US2", "PROTEIN", 0, 3], ["US11", "PROTEIN", 8, 12], ["Ub ligases", "PROTEIN", 21, 31], ["US2", "TEST", 0, 3], ["ligases", "OBSERVATION", 24, 31]]], ["Instead, they target MHC-1 for dislocation from the ER into the cytoplasm, where MHC-1 is then subjected to proteasomal degradation.", [["ER", "ANATOMY", 52, 54], ["cytoplasm", "ANATOMY", 64, 73], ["proteasomal", "ANATOMY", 108, 119], ["dislocation", "DISEASE", 31, 42], ["MHC-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["ER", "GENE_OR_GENE_PRODUCT", 52, 54], ["cytoplasm", "ORGANISM_SUBSTANCE", 64, 73], ["MHC-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["MHC", "PROTEIN", 21, 24], ["ER", "PROTEIN", 52, 54], ["MHC-1", "PROTEIN", 81, 86], ["dislocation", "PROBLEM", 31, 42], ["proteasomal degradation", "PROBLEM", 108, 131], ["dislocation", "OBSERVATION", 31, 42], ["cytoplasm", "ANATOMY", 64, 73], ["proteasomal degradation", "OBSERVATION", 108, 131]]], ["Interestingly, although both viral proteins function similarly, they appear to interact with different Ub ligases and translocation machinery complexes.", [["Ub", "GENE_OR_GENE_PRODUCT", 103, 105], ["viral proteins", "PROTEIN", 29, 43], ["Ub ligases", "PROTEIN", 103, 113], ["translocation machinery complexes", "PROTEIN", 118, 151], ["both viral proteins function", "TEST", 24, 52], ["translocation machinery complexes", "PROBLEM", 118, 151], ["viral", "OBSERVATION", 29, 34], ["ligases", "OBSERVATION", 106, 113], ["translocation machinery complexes", "OBSERVATION", 118, 151]]], ["Studies of US11-mediated MHC-1 dislocation facilitated the initial identification of cellular components of the normal ERAD pathway, including Derlin 1, SeL1L, VIMP, p97 ATPase, AUP1, and UbxD8 (Lilley and Ploegh, 2004; Ye et al., 2004; Mueller et al., 2006, 2008).", [["cellular", "ANATOMY", 85, 93], ["US11", "CHEMICAL", 11, 15], ["dislocation", "DISEASE", 31, 42], ["US11", "GENE_OR_GENE_PRODUCT", 11, 15], ["MHC-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["cellular", "CELL", 85, 93], ["ERAD", "GENE_OR_GENE_PRODUCT", 119, 123], ["Derlin 1", "GENE_OR_GENE_PRODUCT", 143, 151], ["SeL1L", "GENE_OR_GENE_PRODUCT", 153, 158], ["VIMP", "GENE_OR_GENE_PRODUCT", 160, 164], ["p97", "GENE_OR_GENE_PRODUCT", 166, 169], ["ATPase", "GENE_OR_GENE_PRODUCT", 170, 176], ["AUP1", "GENE_OR_GENE_PRODUCT", 178, 182], ["UbxD8", "GENE_OR_GENE_PRODUCT", 188, 193], ["US11", "PROTEIN", 11, 15], ["MHC", "PROTEIN", 25, 28], ["ERAD", "PROTEIN", 119, 123], ["Derlin 1", "PROTEIN", 143, 151], ["SeL1L", "PROTEIN", 153, 158], ["VIMP", "PROTEIN", 160, 164], ["p97 ATPase", "PROTEIN", 166, 176], ["AUP1", "PROTEIN", 178, 182], ["UbxD8", "PROTEIN", 188, 193], ["US11", "TEST", 11, 15], ["1 dislocation", "PROBLEM", 29, 42], ["Derlin", "TEST", 143, 149], ["AUP1", "TEST", 178, 182], ["UbxD8", "TEST", 188, 193], ["dislocation", "OBSERVATION", 31, 42], ["normal", "OBSERVATION", 112, 118], ["ERAD pathway", "OBSERVATION", 119, 131]]], ["The E3 Ub ligases associated with Derlin1 are HRD1 and gp78 (Lilley and Ploegh, 2005), however it has not been confirmed whether these ligases are involved in the US11-mediated downregulation of MHC-1.", [["US11", "CHEMICAL", 163, 167], ["E3", "GENE_OR_GENE_PRODUCT", 4, 6], ["Derlin1", "GENE_OR_GENE_PRODUCT", 34, 41], ["HRD1", "GENE_OR_GENE_PRODUCT", 46, 50], ["gp78", "GENE_OR_GENE_PRODUCT", 55, 59], ["US11", "GENE_OR_GENE_PRODUCT", 163, 167], ["MHC-1", "GENE_OR_GENE_PRODUCT", 195, 200], ["E3 Ub ligases", "PROTEIN", 4, 17], ["Derlin1", "PROTEIN", 34, 41], ["HRD1", "PROTEIN", 46, 50], ["gp78", "PROTEIN", 55, 59], ["US11", "PROTEIN", 163, 167], ["MHC-1", "PROTEIN", 195, 200], ["The E3 Ub ligases", "TREATMENT", 0, 17], ["HRD1", "TEST", 46, 50], ["ligases", "OBSERVATION", 10, 17], ["ligases", "OBSERVATION", 135, 142]]], ["In contrast, US2 mediates MHC-1 dislocation through interactions with the signal peptide peptidase (SPP; Loureiro et al., 2006) and the E3 ligase TRC8 (translocation in renal carcinoma; Stagg et al., 2009).", [["renal carcinoma", "ANATOMY", 169, 184], ["dislocation", "DISEASE", 32, 43], ["renal carcinoma", "DISEASE", 169, 184], ["MHC-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["E3", "GENE_OR_GENE_PRODUCT", 136, 138], ["TRC8", "GENE_OR_GENE_PRODUCT", 146, 150], ["renal carcinoma", "CANCER", 169, 184], ["US2", "PROTEIN", 13, 16], ["MHC", "PROTEIN", 26, 29], ["signal peptide peptidase", "PROTEIN", 74, 98], ["SPP", "PROTEIN", 100, 103], ["E3 ligase", "PROTEIN", 136, 145], ["TRC8", "PROTEIN", 146, 150], ["1 dislocation through interactions", "PROBLEM", 30, 64], ["the signal peptide peptidase", "TEST", 70, 98], ["the E3 ligase TRC8", "TREATMENT", 132, 150], ["renal carcinoma", "PROBLEM", 169, 184], ["dislocation", "OBSERVATION", 32, 43], ["renal", "ANATOMY", 169, 174], ["carcinoma", "OBSERVATION", 175, 184]]], ["The gammaherpesviruses also target MHC-1 for degradation, although they accomplish this task by encoding their own E3 Ub ligases.", [["MHC-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["E3", "GENE_OR_GENE_PRODUCT", 115, 117], ["Ub", "GENE_OR_GENE_PRODUCT", 118, 120], ["MHC", "PROTEIN", 35, 38], ["E3 Ub ligases", "PROTEIN", 115, 128], ["gammaherpesviruses", "OBSERVATION", 4, 22]]], ["KSHV encodes the E3 Ub ligases K3 and K5, also known as modulators of immune recognition 1 and 2 (MIR1 and MIR2), respectively, which target MHC-1 for ubiquitination and subsequent lysosomal degradation (Coscoy and Ganem, 2000; Ishido et al., 2000b).", [["lysosomal", "ANATOMY", 181, 190], ["KSHV", "ORGANISM", 0, 4], ["E3", "GENE_OR_GENE_PRODUCT", 17, 19], ["K3", "GENE_OR_GENE_PRODUCT", 31, 33], ["K5", "GENE_OR_GENE_PRODUCT", 38, 40], ["immune recognition 1", "GENE_OR_GENE_PRODUCT", 70, 90], ["2", "GENE_OR_GENE_PRODUCT", 95, 96], ["MIR1", "GENE_OR_GENE_PRODUCT", 98, 102], ["MIR2", "GENE_OR_GENE_PRODUCT", 107, 111], ["MHC-1", "GENE_OR_GENE_PRODUCT", 141, 146], ["lysosomal", "CELLULAR_COMPONENT", 181, 190], ["E3 Ub ligases", "PROTEIN", 17, 30], ["K3", "PROTEIN", 31, 33], ["K5", "PROTEIN", 38, 40], ["immune recognition 1 and 2", "PROTEIN", 70, 96], ["MIR1", "PROTEIN", 98, 102], ["MIR2", "PROTEIN", 107, 111], ["MHC-1", "PROTEIN", 141, 146], ["KSHV", "SPECIES", 0, 4], ["immune recognition", "TEST", 70, 88], ["ubiquitination", "PROBLEM", 151, 165], ["subsequent lysosomal degradation", "PROBLEM", 170, 202], ["lysosomal degradation", "OBSERVATION", 181, 202]]], ["Using a proteomics approach, several groups have recently demonstrated that K5 decorates surface-associated MHC-1 with a mixed-linkage ubiquitin chain, and that this stimulates the Epsin1-dependent endocytosis and subsequent lysosomal degradation of MHC-1 (Boname et al., 2010; Goto et al., 2010).", [["surface", "ANATOMY", 89, 96], ["lysosomal", "ANATOMY", 225, 234], ["K5", "GENE_OR_GENE_PRODUCT", 76, 78], ["surface", "CELLULAR_COMPONENT", 89, 96], ["MHC-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["Epsin1", "GENE_OR_GENE_PRODUCT", 181, 187], ["lysosomal", "CELLULAR_COMPONENT", 225, 234], ["MHC-1", "GENE_OR_GENE_PRODUCT", 250, 255], ["K5", "PROTEIN", 76, 78], ["MHC-1", "PROTEIN", 108, 113], ["mixed-linkage ubiquitin chain", "PROTEIN", 121, 150], ["Epsin1", "PROTEIN", 181, 187], ["MHC", "PROTEIN", 250, 253], ["a proteomics approach", "TREATMENT", 6, 27], ["a mixed-linkage ubiquitin chain", "PROBLEM", 119, 150], ["dependent endocytosis", "PROBLEM", 188, 209], ["ubiquitin chain", "OBSERVATION", 135, 150]]], ["Although they are 40% homologous to one another, K3 and K5 do not target the same molecules.", [["K3", "GENE_OR_GENE_PRODUCT", 49, 51], ["K5", "GENE_OR_GENE_PRODUCT", 56, 58], ["K3", "PROTEIN", 49, 51], ["K5", "PROTEIN", 56, 58]]], ["K3 can downregulate all classes of MHC-1, HLA-A, B, C, and E, while K5 is specific for HLA-A and B (Ishido et al., 2000b).", [["K3", "GENE_OR_GENE_PRODUCT", 0, 2], ["MHC-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["HLA-A", "GENE_OR_GENE_PRODUCT", 42, 47], ["B", "GENE_OR_GENE_PRODUCT", 49, 50], ["C", "GENE_OR_GENE_PRODUCT", 52, 53], ["K5", "GENE_OR_GENE_PRODUCT", 68, 70], ["HLA-A", "GENE_OR_GENE_PRODUCT", 87, 92], ["K3", "PROTEIN", 0, 2], ["MHC", "PROTEIN", 35, 38], ["E", "DNA", 59, 60], ["K5", "PROTEIN", 68, 70], ["MHC", "TEST", 35, 38], ["HLA", "TEST", 42, 45], ["HLA", "TEST", 87, 90]]], ["In contrast, K3 and K5 can each downregulate the IFN\u03b3 receptor (Li et al., 2007).", [["K3", "GENE_OR_GENE_PRODUCT", 13, 15], ["K5", "GENE_OR_GENE_PRODUCT", 20, 22], ["IFN\u03b3 receptor", "GENE_OR_GENE_PRODUCT", 49, 62], ["K3", "PROTEIN", 13, 15], ["K5", "PROTEIN", 20, 22], ["IFN\u03b3 receptor", "PROTEIN", 49, 62]]], ["While the removal of MHC-1 from the cell surface may be a good strategy to prevent cytotoxic T-cell killing, it can also increase the likelihood of being targeted by NK cells, which eliminate cells with low MHC-1 surface expression.", [["cell surface", "ANATOMY", 36, 48], ["T-cell", "ANATOMY", 93, 99], ["NK cells", "ANATOMY", 166, 174], ["cells", "ANATOMY", 192, 197], ["surface", "ANATOMY", 213, 220], ["MHC-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["cell surface", "CELLULAR_COMPONENT", 36, 48], ["T-cell", "CELL", 93, 99], ["NK cells", "CELL", 166, 174], ["cells", "CELL", 192, 197], ["MHC-1", "GENE_OR_GENE_PRODUCT", 207, 212], ["MHC-1", "PROTEIN", 21, 26], ["NK cells", "CELL_TYPE", 166, 174], ["MHC", "PROTEIN", 207, 210], ["the removal of MHC", "TREATMENT", 6, 24], ["cytotoxic T-cell killing", "PROBLEM", 83, 107], ["low MHC", "PROBLEM", 203, 210], ["cell killing", "OBSERVATION", 95, 107], ["NK cells", "OBSERVATION", 166, 174], ["low MHC", "OBSERVATION_MODIFIER", 203, 210]]], ["The differential targeting of MHC-1 molecules by K3 and K5 may be one mechanism for the virus to block CTL killing without overtly activating NK cells.", [["NK cells", "ANATOMY", 142, 150], ["MHC-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["K3", "GENE_OR_GENE_PRODUCT", 49, 51], ["K5", "GENE_OR_GENE_PRODUCT", 56, 58], ["CTL", "CELL", 103, 106], ["NK cells", "CELL", 142, 150], ["MHC-1 molecules", "PROTEIN", 30, 45], ["K3", "PROTEIN", 49, 51], ["K5", "PROTEIN", 56, 58], ["NK cells", "CELL_TYPE", 142, 150], ["MHC", "TEST", 30, 33], ["the virus", "PROBLEM", 84, 93], ["overtly activating NK cells", "PROBLEM", 123, 150], ["NK cells", "OBSERVATION", 142, 150]]], ["In addition, K5 has been shown to downregulate ICAM-1 and B7.2, which are costimulatory molecules for both T-cell and NK cell activation (Coscoy and Ganem, 2001), thus preventing NK cell killing (Ishido et al., 2000a).", [["T-cell", "ANATOMY", 107, 113], ["NK cell", "ANATOMY", 118, 125], ["NK cell", "ANATOMY", 179, 186], ["K5", "GENE_OR_GENE_PRODUCT", 13, 15], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 47, 53], ["B7.2", "GENE_OR_GENE_PRODUCT", 58, 62], ["T-cell", "CELL", 107, 113], ["NK cell", "CELL", 118, 125], ["NK cell", "CELL", 179, 186], ["K5", "PROTEIN", 13, 15], ["ICAM-1", "PROTEIN", 47, 53], ["B7.2", "PROTEIN", 58, 62], ["costimulatory molecules", "PROTEIN", 74, 97], ["ICAM", "TEST", 47, 51], ["B7.2", "TEST", 58, 62], ["NK cell activation", "OBSERVATION", 118, 136], ["preventing", "UNCERTAINTY", 168, 178], ["NK cell", "OBSERVATION", 179, 186]]], ["To further protect cells from NK cytotoxicity, K5 has also been shown to downregulate the NKG2D ligands MHC class I-related chain A (MICA), MICB, and the ligand for NKp80, activation-induced C-type lectin (AICL; Thomas et al., 2008).", [["cells", "ANATOMY", 19, 24], ["NK", "ANATOMY", 30, 32], ["cells", "CELL", 19, 24], ["NK", "CELL", 30, 32], ["K5", "GENE_OR_GENE_PRODUCT", 47, 49], ["NKG2D", "GENE_OR_GENE_PRODUCT", 90, 95], ["MHC class I-related chain A", "GENE_OR_GENE_PRODUCT", 104, 131], ["MICA", "GENE_OR_GENE_PRODUCT", 133, 137], ["MICB", "GENE_OR_GENE_PRODUCT", 140, 144], ["NKp80", "GENE_OR_GENE_PRODUCT", 165, 170], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 191, 204], ["K5", "PROTEIN", 47, 49], ["NKG2D ligands", "PROTEIN", 90, 103], ["MHC class I-related chain A", "PROTEIN", 104, 131], ["MICA", "PROTEIN", 133, 137], ["MICB", "PROTEIN", 140, 144], ["NKp80", "PROTEIN", 165, 170], ["C-type lectin", "PROTEIN", 191, 204], ["AICL", "PROTEIN", 206, 210], ["NK cytotoxicity", "TEST", 30, 45], ["MICB", "TEST", 140, 144], ["the ligand", "TEST", 150, 160], ["NKp80", "TEST", 165, 170], ["activation", "TEST", 172, 182], ["NK cytotoxicity", "OBSERVATION", 30, 45]]], ["CD1d, another NK and T-cell activation marker, is downregulated by both K3 and K5, which decreases CD1d-restricted T-cell activation (Sanchez et al., 2005).", [["NK", "ANATOMY", 14, 16], ["T-cell", "ANATOMY", 21, 27], ["T-cell", "ANATOMY", 115, 121], ["CD1d", "GENE_OR_GENE_PRODUCT", 0, 4], ["NK", "CELL", 14, 16], ["T-cell", "CELL", 21, 27], ["K3", "GENE_OR_GENE_PRODUCT", 72, 74], ["K5", "GENE_OR_GENE_PRODUCT", 79, 81], ["CD1d", "GENE_OR_GENE_PRODUCT", 99, 103], ["T-cell", "CELL", 115, 121], ["CD1d", "PROTEIN", 0, 4], ["K3", "PROTEIN", 72, 74], ["K5", "PROTEIN", 79, 81], ["CD1d", "PROTEIN", 99, 103], ["CD1d", "TEST", 0, 4], ["CD1d", "TEST", 99, 103]]], ["MHV68, the mouse homolog of KSHV, only encodes mK3, which has also been shown to downregulate MHC-1 (Stevenson et al., 2000).", [["MHV68", "GENE_OR_GENE_PRODUCT", 0, 5], ["mouse", "ORGANISM", 11, 16], ["KSHV", "ORGANISM", 28, 32], ["mK3", "GENE_OR_GENE_PRODUCT", 47, 50], ["MHC-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["MHV68", "PROTEIN", 0, 5], ["mK3", "PROTEIN", 47, 50], ["MHC", "PROTEIN", 94, 97], ["mouse", "SPECIES", 11, 16], ["MHV68", "SPECIES", 0, 5], ["mouse", "SPECIES", 11, 16], ["KSHV", "SPECIES", 28, 32]]], ["However, instead of resulting in lysosomal MHC-1 degradation, mK3 appears to function in the ER via interaction with the transporter associated with antigen processing protein (TAP; Lybarger et al., 2003; Wang et al., 2005), thereby targeting MHC-1 for proteasomal degradation (Boname and Stevenson, 2001).", [["ER", "ANATOMY", 93, 95], ["proteasomal", "ANATOMY", 253, 264], ["lysosomal MHC-1", "GENE_OR_GENE_PRODUCT", 33, 48], ["mK3", "GENE_OR_GENE_PRODUCT", 62, 65], ["ER", "GENE_OR_GENE_PRODUCT", 93, 95], ["antigen processing protein", "GENE_OR_GENE_PRODUCT", 149, 175], ["MHC-1", "GENE_OR_GENE_PRODUCT", 243, 248], ["lysosomal MHC-1", "PROTEIN", 33, 48], ["mK3", "PROTEIN", 62, 65], ["ER", "PROTEIN", 93, 95], ["antigen processing protein", "PROTEIN", 149, 175], ["TAP", "PROTEIN", 177, 180], ["MHC-1", "PROTEIN", 243, 248], ["proteasomal degradation", "PROBLEM", 253, 276]]], ["Similarly, the retroperitoneal fibromatosis-associated herpesvirus (RFHV) also encodes a single K3/K5 homolog referred to as rfK3, which appears to downregulate MHC-I and ICAM, but not B7.2, in a Ub-dependent manner (Harris et al., 2010).", [["fibromatosis", "DISEASE", 31, 43], ["retroperitoneal fibromatosis-associated", "GENE_OR_GENE_PRODUCT", 15, 54], ["herpesvirus", "ORGANISM", 55, 66], ["RFHV", "GENE_OR_GENE_PRODUCT", 68, 72], ["K5", "GENE_OR_GENE_PRODUCT", 99, 101], ["rfK3", "GENE_OR_GENE_PRODUCT", 125, 129], ["MHC-I", "GENE_OR_GENE_PRODUCT", 161, 166], ["ICAM", "GENE_OR_GENE_PRODUCT", 171, 175], ["B7.2", "GENE_OR_GENE_PRODUCT", 185, 189], ["Ub", "GENE_OR_GENE_PRODUCT", 196, 198], ["K3", "PROTEIN", 96, 98], ["K5 homolog", "PROTEIN", 99, 109], ["rfK3", "PROTEIN", 125, 129], ["MHC", "PROTEIN", 161, 164], ["ICAM", "PROTEIN", 171, 175], ["B7.2", "PROTEIN", 185, 189], ["Ub", "PROTEIN", 196, 198], ["RFHV", "SPECIES", 68, 72], ["the retroperitoneal fibromatosis", "PROBLEM", 11, 43], ["a single K3/K5 homolog", "TREATMENT", 87, 109], ["retroperitoneal", "ANATOMY", 15, 30], ["fibromatosis", "OBSERVATION", 31, 43]]], ["Members of the Poxviridae also encode their own Ub ligases.", [["Poxviridae", "GENE_OR_GENE_PRODUCT", 15, 25], ["Ub", "GENE_OR_GENE_PRODUCT", 48, 50], ["Poxviridae", "PROTEIN", 15, 25], ["Ub ligases", "PROTEIN", 48, 58], ["ligases", "OBSERVATION", 51, 58]]], ["The rabbit myxomavirus M153R protein contains a RING-CH domain and appears to downregulate both MHC-1 and CD4 in a manner reminiscent of MHC-1 downregulation by K3 and K5 (Mansouri et al., 2003), suggesting a common immune evasion strategy for the large DNA viruses.MHC-1, MHC-like molecules, and T-cell activation markers ::: Downregulation of IFN-induced proteins ::: Evading Innate Immune MechanismsThe HPV E5 protein has recently been shown to downregulate the T-cell activation factor CD1d in a proteasome-dependent manner.", [["T-cell", "ANATOMY", 297, 303], ["T-cell", "ANATOMY", 465, 471], ["rabbit", "ORGANISM", 4, 10], ["myxomavirus M153R", "GENE_OR_GENE_PRODUCT", 11, 28], ["MHC-1", "GENE_OR_GENE_PRODUCT", 96, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 106, 109], ["MHC-1", "GENE_OR_GENE_PRODUCT", 137, 142], ["K3", "GENE_OR_GENE_PRODUCT", 161, 163], ["K5", "GENE_OR_GENE_PRODUCT", 168, 170], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["MHC-1", "GENE_OR_GENE_PRODUCT", 266, 271], ["T-cell", "CELL", 297, 303], ["IFN", "GENE_OR_GENE_PRODUCT", 345, 348], ["HPV", "ORGANISM", 406, 409], ["E5", "GENE_OR_GENE_PRODUCT", 410, 412], ["T-cell", "CELL", 465, 471], ["CD1d", "GENE_OR_GENE_PRODUCT", 490, 494], ["rabbit myxomavirus M153R protein", "PROTEIN", 4, 36], ["RING", "PROTEIN", 48, 52], ["CH domain", "PROTEIN", 53, 62], ["MHC-1", "PROTEIN", 96, 101], ["CD4", "PROTEIN", 106, 109], ["MHC", "PROTEIN", 137, 140], ["K5", "PROTEIN", 168, 170], ["MHC-1, MHC-like molecules", "PROTEIN", 266, 291], ["T-cell activation markers", "PROTEIN", 297, 322], ["IFN", "PROTEIN", 345, 348], ["HPV E5 protein", "PROTEIN", 406, 420], ["T-cell activation factor", "PROTEIN", 465, 489], ["CD1d", "PROTEIN", 490, 494], ["proteasome", "PROTEIN", 500, 510], ["rabbit", "SPECIES", 4, 10], ["rabbit", "SPECIES", 4, 10], ["HPV", "SPECIES", 406, 409], ["The rabbit myxomavirus", "TEST", 0, 22], ["a RING-CH domain", "TREATMENT", 46, 62], ["CD4", "TEST", 106, 109], ["MHC", "TEST", 137, 140], ["a common immune evasion strategy", "TREATMENT", 207, 239], ["the large DNA viruses", "PROBLEM", 244, 265], ["MHC", "TEST", 266, 269], ["MHC", "TEST", 273, 276], ["The HPV E5 protein", "TEST", 402, 420], ["large", "OBSERVATION_MODIFIER", 248, 253], ["DNA viruses", "OBSERVATION", 254, 265]]], ["E5 has been proposed to accomplish this by inhibiting the calnexin-dependent trafficking of CD1d (Miura et al., 2010).", [["E5", "GENE_OR_GENE_PRODUCT", 0, 2], ["calnexin", "GENE_OR_GENE_PRODUCT", 58, 66], ["CD1d", "GENE_OR_GENE_PRODUCT", 92, 96], ["E5", "PROTEIN", 0, 2], ["calnexin", "PROTEIN", 58, 66], ["CD1d", "PROTEIN", 92, 96], ["the calnexin", "TREATMENT", 54, 66]]], ["Interestingly, E5 has also been demonstrated to downregulate MHC-1 (Ashrafi et al., 2005).", [["E5", "GENE_OR_GENE_PRODUCT", 15, 17], ["MHC-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["E5", "PROTEIN", 15, 17], ["MHC", "PROTEIN", 61, 64]]], ["However, this has been attributed to E5\u2019s interaction with the vacuolar ATPase, which leads to endosome acidification and retention of MHC-1 in the Golgi.", [["vacuolar", "ANATOMY", 63, 71], ["endosome", "ANATOMY", 95, 103], ["Golgi", "ANATOMY", 148, 153], ["E5", "GENE_OR_GENE_PRODUCT", 37, 39], ["vacuolar", "CELLULAR_COMPONENT", 63, 71], ["ATPase", "GENE_OR_GENE_PRODUCT", 72, 78], ["endosome", "CELLULAR_COMPONENT", 95, 103], ["MHC-1", "GENE_OR_GENE_PRODUCT", 135, 140], ["Golgi", "CELLULAR_COMPONENT", 148, 153], ["E5", "PROTEIN", 37, 39], ["vacuolar ATPase", "PROTEIN", 63, 78], ["MHC-1", "PROTEIN", 135, 140], ["the vacuolar ATPase", "PROBLEM", 59, 78], ["endosome acidification", "PROBLEM", 95, 117], ["retention of MHC", "PROBLEM", 122, 138], ["vacuolar ATPase", "OBSERVATION", 63, 78], ["endosome acidification", "OBSERVATION", 95, 117]]], ["This has also been one of the proposed models for E5\u2019s retention of EGF-R as described above.", [["E5", "GENE_OR_GENE_PRODUCT", 50, 52], ["EGF-R", "GENE_OR_GENE_PRODUCT", 68, 73], ["E5", "PROTEIN", 50, 52], ["EGF", "PROTEIN", 68, 71], ["EGF", "TEST", 68, 71]]], ["However, like CD1d, MHC-1 also binds to E5 and calnexin in the ER, and E5 can only mediate MHC-1 downregulation in calnexin-expressing cells (Gruener et al., 2007), suggesting a potential role for the UPS in HPV\u2019s immune evasion strategies.MHC-1, MHC-like molecules, and T-cell activation markers ::: Downregulation of IFN-induced proteins ::: Evading Innate Immune MechanismsAn interesting caveat to emerge from the study of these viral Ub ligases is their ability to target non-lysine residues for ubiquitination.", [["ER", "ANATOMY", 63, 65], ["cells", "ANATOMY", 135, 140], ["T-cell", "ANATOMY", 271, 277], ["CD1d", "GENE_OR_GENE_PRODUCT", 14, 18], ["MHC-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["E5", "GENE_OR_GENE_PRODUCT", 40, 42], ["calnexin", "GENE_OR_GENE_PRODUCT", 47, 55], ["ER", "GENE_OR_GENE_PRODUCT", 63, 65], ["E5", "GENE_OR_GENE_PRODUCT", 71, 73], ["MHC-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["calnexin", "GENE_OR_GENE_PRODUCT", 115, 123], ["cells", "CELL", 135, 140], ["UPS", "GENE_OR_GENE_PRODUCT", 201, 204], ["HPV", "ORGANISM", 208, 211], ["MHC-1", "GENE_OR_GENE_PRODUCT", 240, 245], ["T-cell", "CELL", 271, 277], ["IFN", "GENE_OR_GENE_PRODUCT", 319, 322], ["Ub", "GENE_OR_GENE_PRODUCT", 438, 440], ["CD1d", "PROTEIN", 14, 18], ["MHC-1", "PROTEIN", 20, 25], ["E5", "PROTEIN", 40, 42], ["calnexin", "PROTEIN", 47, 55], ["ER", "PROTEIN", 63, 65], ["E5", "PROTEIN", 71, 73], ["MHC", "PROTEIN", 91, 94], ["calnexin", "PROTEIN", 115, 123], ["expressing cells", "CELL_TYPE", 124, 140], ["UPS", "PROTEIN", 201, 204], ["MHC-1, MHC-like molecules", "PROTEIN", 240, 265], ["T-cell activation markers", "PROTEIN", 271, 296], ["IFN", "PROTEIN", 319, 322], ["viral Ub ligases", "PROTEIN", 432, 448], ["HPV", "SPECIES", 208, 211], ["calnexin", "TREATMENT", 47, 55], ["immune evasion strategies", "TREATMENT", 214, 239], ["MHC", "TEST", 240, 243], ["MHC", "TEST", 247, 250], ["the study", "TEST", 413, 422], ["these viral Ub ligases", "TREATMENT", 426, 448], ["ubiquitination", "PROBLEM", 500, 514]]], ["KSHV K3 ubiquitination of MHC-1 provided the first report of an E3 Ub ligase targeting a cysteine for ubiquitination via a thioester linkage (Cadwell and Coscoy, 2005).", [["cysteine", "CHEMICAL", 89, 97], ["cysteine", "CHEMICAL", 89, 97], ["thioester", "CHEMICAL", 123, 132], ["KSHV", "ORGANISM", 0, 4], ["K3", "GENE_OR_GENE_PRODUCT", 5, 7], ["MHC-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["E3", "GENE_OR_GENE_PRODUCT", 64, 66], ["cysteine", "AMINO_ACID", 89, 97], ["KSHV K3", "PROTEIN", 0, 7], ["MHC-1", "PROTEIN", 26, 31], ["E3 Ub ligase", "PROTEIN", 64, 76], ["KSHV", "SPECIES", 0, 4], ["a cysteine", "TREATMENT", 87, 97]]], ["Subsequent studies have revealed that K5 also targets MHC-1 cysteine residues (Cadwell and Coscoy, 2008), and that mK3 conjugates ubiquitin to MHC-1 serine and threonine residues via ester bonds (Wang et al., 2007).", [["threonine", "CHEMICAL", 160, 169], ["ester", "CHEMICAL", 183, 188], ["cysteine", "CHEMICAL", 60, 68], ["serine", "CHEMICAL", 149, 155], ["threonine", "CHEMICAL", 160, 169], ["ester", "CHEMICAL", 183, 188], ["K5", "GENE_OR_GENE_PRODUCT", 38, 40], ["MHC-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["mK3", "GENE_OR_GENE_PRODUCT", 115, 118], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 130, 139], ["MHC-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["serine", "AMINO_ACID", 149, 155], ["threonine", "AMINO_ACID", 160, 169], ["ester", "SIMPLE_CHEMICAL", 183, 188], ["K5", "PROTEIN", 38, 40], ["MHC", "PROTEIN", 54, 57], ["mK3", "PROTEIN", 115, 118], ["MHC", "PROTEIN", 143, 146], ["Subsequent studies", "TEST", 0, 18], ["K5", "PROBLEM", 38, 40], ["MHC", "TEST", 54, 57], ["MHC", "TEST", 143, 146], ["threonine residues via ester bonds", "TREATMENT", 160, 194]]], ["Interestingly, data from a recent mK3 study suggests that while the RING-CH domain of these viral Ub ligases plays a role in targeting non-lysine residues, sequences outside the RING-CH domain are also required for this altered specificity (Herr et al., 2009).Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 ::: Downregulation of IFN-induced proteins ::: Evading Innate Immune MechanismsThe apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) genes encode a family of cytidine deaminases, several of which have been shown to be part of an innate anti-retroviral defense that inhibits retroviral replication (Sheehy et al., 2002).", [["cytidine", "CHEMICAL", 510, 518], ["cytidine", "CHEMICAL", 510, 518], ["RING", "GENE_OR_GENE_PRODUCT", 68, 72], ["Ub", "GENE_OR_GENE_PRODUCT", 98, 100], ["Apolipoprotein B", "GENE_OR_GENE_PRODUCT", 260, 276], ["IFN", "GENE_OR_GENE_PRODUCT", 348, 351], ["apolipoprotein B", "GENE_OR_GENE_PRODUCT", 409, 425], ["editing enzyme catalytic polypeptide-like 3", "GENE_OR_GENE_PRODUCT", 431, 474], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 476, 483], ["cytidine deaminases", "GENE_OR_GENE_PRODUCT", 510, 529], ["retroviral", "ORGANISM", 626, 636], ["RING", "PROTEIN", 68, 72], ["CH domain", "PROTEIN", 73, 82], ["viral Ub ligases", "PROTEIN", 92, 108], ["non-lysine residues", "PROTEIN", 135, 154], ["RING", "PROTEIN", 178, 182], ["CH domain", "PROTEIN", 183, 192], ["Apolipoprotein B mRNA", "RNA", 260, 281], ["IFN", "PROTEIN", 348, 351], ["apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) genes", "DNA", 409, 490], ["cytidine deaminases", "PROTEIN", 510, 529], ["a recent mK3 study", "TEST", 25, 43], ["these viral Ub ligases", "PROBLEM", 86, 108], ["targeting non-lysine residues", "TREATMENT", 125, 154], ["this altered specificity", "PROBLEM", 215, 239], ["Apolipoprotein B mRNA", "TEST", 260, 281], ["enzyme catalytic polypeptide", "TEST", 290, 318], ["The apolipoprotein B mRNA", "TEST", 405, 430], ["enzyme catalytic polypeptide", "TEST", 439, 467], ["cytidine deaminases", "TREATMENT", 510, 529], ["an innate anti-retroviral defense", "TREATMENT", 578, 611], ["retroviral replication", "TREATMENT", 626, 648], ["viral Ub ligases", "OBSERVATION", 92, 108]]], ["Of the family members, APOBEC3G and 3F appear to have the highest anti-viral activity.", [["APOBEC3G", "GENE_OR_GENE_PRODUCT", 23, 31], ["3F", "GENE_OR_GENE_PRODUCT", 36, 38], ["APOBEC3G", "PROTEIN", 23, 31], ["3F", "PROTEIN", 36, 38], ["anti-viral activity", "OBSERVATION", 66, 85]]], ["These enzymes are incorporated into nascent virions where they subsequently deaminate cytosines in the minus DNA strand generated via reverse transcription.", [["virions", "ANATOMY", 44, 51], ["cytosines", "CHEMICAL", 86, 95], ["cytosines", "CHEMICAL", 86, 95], ["cytosines", "SIMPLE_CHEMICAL", 86, 95], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["enzymes", "PROTEIN", 6, 13], ["minus DNA strand", "DNA", 103, 119], ["These enzymes", "TEST", 0, 13], ["nascent virions", "TREATMENT", 36, 51], ["cytosines", "TREATMENT", 86, 95], ["nascent virions", "OBSERVATION", 36, 51], ["deaminate cytosines", "OBSERVATION", 76, 95]]], ["This action results in G to A transitions in the genomic retroviral RNA, which leads to potentially lethal nonsense and missense mutations.", [["G to A", "GENE_OR_GENE_PRODUCT", 23, 29], ["genomic retroviral RNA", "RNA", 49, 71], ["A transitions in the genomic retroviral RNA", "PROBLEM", 28, 71], ["lethal nonsense and missense mutations", "PROBLEM", 100, 138], ["retroviral RNA", "OBSERVATION", 57, 71]]], ["Aside from the \u201cmutator\u201d phenotype, some groups have shown that APOBEC3 might have other deleterious effects on the virus, as mutants without deaminase activity still show anti-retroviral activity (reviewed in Neil and Bieniasz, 2009).", [["APOBEC3", "GENE_OR_GENE_PRODUCT", 64, 71], ["APOBEC3", "PROTEIN", 64, 71], ["the \u201cmutator\u201d phenotype", "PROBLEM", 11, 34], ["APOBEC3", "PROBLEM", 64, 71], ["the virus", "PROBLEM", 112, 121], ["deaminase activity", "TEST", 142, 160], ["anti-retroviral activity", "PROBLEM", 172, 196], ["APOBEC3", "OBSERVATION", 64, 71], ["anti-retroviral activity", "OBSERVATION", 172, 196]]], ["The lentiviral family of retroviruses express the Vif accessory protein that counteracts this restriction by inducing the ubiquitination and subsequent proteasomal degradation of APOBEC3G (Marin et al., 2003; Sheehy et al., 2003).", [["proteasomal", "ANATOMY", 152, 163], ["lentiviral", "ORGANISM", 4, 14], ["retroviruses", "ORGANISM", 25, 37], ["Vif", "GENE_OR_GENE_PRODUCT", 50, 53], ["APOBEC3G", "GENE_OR_GENE_PRODUCT", 179, 187], ["Vif accessory protein", "PROTEIN", 50, 71], ["APOBEC3G", "PROTEIN", 179, 187], ["The lentiviral family of retroviruses", "TREATMENT", 0, 37], ["the Vif accessory protein", "TREATMENT", 46, 71], ["this restriction", "TREATMENT", 89, 105], ["the ubiquitination", "PROBLEM", 118, 136]]], ["Vif harbors a unique SOCS-box motif that allows Vif to complex with the Cul5/ElonginBC/Rbx1 E3 Ub ligase (Yu et al., 2003, 2004).", [["Vif", "GENE_OR_GENE_PRODUCT", 0, 3], ["SOCS", "GENE_OR_GENE_PRODUCT", 21, 25], ["Vif", "GENE_OR_GENE_PRODUCT", 48, 51], ["Cul5", "GENE_OR_GENE_PRODUCT", 72, 76], ["ElonginBC", "GENE_OR_GENE_PRODUCT", 77, 86], ["Rbx1 E3 Ub", "GENE_OR_GENE_PRODUCT", 87, 97], ["Vif", "PROTEIN", 0, 3], ["SOCS-box motif", "DNA", 21, 35], ["Vif", "PROTEIN", 48, 51], ["Cul5", "PROTEIN", 72, 76], ["ElonginBC", "PROTEIN", 77, 86], ["Rbx1 E3 Ub ligase", "PROTEIN", 87, 104], ["box motif", "TREATMENT", 26, 35]]], ["There is currently some debate as to whether Vif induces the direct ubiquitination of APOBEC (Iwatani et al., 2009) or if Vif is itself ubiquitinated and acts as a suicide molecule that delivers APOBEC to the proteasome (Dang et al., 2008).", [["Vif", "GENE_OR_GENE_PRODUCT", 45, 48], ["APOBEC", "GENE_OR_GENE_PRODUCT", 86, 92], ["Vif", "GENE_OR_GENE_PRODUCT", 122, 125], ["APOBEC", "GENE_OR_GENE_PRODUCT", 195, 201], ["Vif", "PROTEIN", 45, 48], ["APOBEC", "PROTEIN", 86, 92], ["Vif", "PROTEIN", 122, 125], ["APOBEC", "PROTEIN", 195, 201], ["proteasome", "PROTEIN", 209, 219], ["Vif", "PROBLEM", 122, 125], ["a suicide molecule", "PROBLEM", 162, 180]]], ["Most recently, one group has demonstrated the Vif-dependent polyubiquitination of an APOBEC mutant devoid of lysine residues (Shao et al., 2010).", [["lysine", "CHEMICAL", 109, 115], ["lysine", "CHEMICAL", 109, 115], ["Vif", "GENE_OR_GENE_PRODUCT", 46, 49], ["APOBEC", "GENE_OR_GENE_PRODUCT", 85, 91], ["lysine", "AMINO_ACID", 109, 115], ["Vif", "PROTEIN", 46, 49], ["APOBEC mutant", "PROTEIN", 85, 98], ["the Vif", "PROBLEM", 42, 49], ["lysine residues", "PROBLEM", 109, 124], ["dependent", "OBSERVATION_MODIFIER", 50, 59], ["polyubiquitination", "OBSERVATION", 60, 78], ["lysine residues", "OBSERVATION", 109, 124]]], ["They later showed that in the absence of lysines, the APOBEC N-terminal-MET residue is targeted for ubiquitination (Wang et al., 2011).", [["lysines", "CHEMICAL", 41, 48], ["APOBEC", "CHEMICAL", 54, 60], ["N", "CHEMICAL", 61, 62], ["APOBEC N-terminal-MET residue", "PROTEIN", 54, 83], ["terminal-MET residue", "PROBLEM", 63, 83]]], ["This same group has shown that APOBEC degradation can occur without simultaneous Vif degradation, weighing against a Vif suicide model (Shao et al., 2010).Disruption of the promyelocytic leukemia nuclear bodies ::: Evading Innate Immune MechanismsThe PML protein was first identified and named for its role in acute promyelocytic leukemia (APL).", [["promyelocytic leukemia nuclear bodies", "ANATOMY", 173, 210], ["acute promyelocytic leukemia", "ANATOMY", 310, 338], ["APL", "ANATOMY", 340, 343], ["promyelocytic leukemia", "DISEASE", 173, 195], ["acute promyelocytic leukemia", "DISEASE", 310, 338], ["APL", "DISEASE", 340, 343], ["APOBEC", "GENE_OR_GENE_PRODUCT", 31, 37], ["Vif", "GENE_OR_GENE_PRODUCT", 81, 84], ["promyelocytic leukemia", "CANCER", 173, 195], ["PML", "GENE_OR_GENE_PRODUCT", 251, 254], ["acute promyelocytic leukemia", "CANCER", 310, 338], ["APL", "CANCER", 340, 343], ["Vif", "PROTEIN", 81, 84], ["PML protein", "PROTEIN", 251, 262], ["APOBEC degradation", "PROBLEM", 31, 49], ["simultaneous Vif degradation", "PROBLEM", 68, 96], ["the promyelocytic leukemia nuclear bodies", "PROBLEM", 169, 210], ["The PML protein", "TEST", 247, 262], ["acute promyelocytic leukemia", "PROBLEM", 310, 338], ["promyelocytic leukemia", "OBSERVATION", 173, 195], ["PML protein", "OBSERVATION", 251, 262], ["acute", "OBSERVATION_MODIFIER", 310, 315], ["promyelocytic leukemia", "OBSERVATION", 316, 338]]], ["The PML protein normally aggregates with other proteins (Daxx, ATRX, SP100, and SUMO) in the nucleus, forming distinct structures that have been shown to be involved in many cellular functions, including cell cycle regulation, DNA damage repair, apoptosis, transcriptional regulation, and IFN response to viral infection (see references in Everett and Chelbi-Alix, 2007).", [["nucleus", "ANATOMY", 93, 100], ["cellular", "ANATOMY", 174, 182], ["cell", "ANATOMY", 204, 208], ["viral infection", "DISEASE", 305, 320], ["PML", "GENE_OR_GENE_PRODUCT", 4, 7], ["Daxx", "GENE_OR_GENE_PRODUCT", 57, 61], ["ATRX", "GENE_OR_GENE_PRODUCT", 63, 67], ["SP100", "GENE_OR_GENE_PRODUCT", 69, 74], ["SUMO", "GENE_OR_GENE_PRODUCT", 80, 84], ["nucleus", "CELLULAR_COMPONENT", 93, 100], ["cellular", "CELL", 174, 182], ["cell", "CELL", 204, 208], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["IFN", "GENE_OR_GENE_PRODUCT", 289, 292], ["PML protein", "PROTEIN", 4, 15], ["Daxx", "PROTEIN", 57, 61], ["ATRX", "PROTEIN", 63, 67], ["SP100", "PROTEIN", 69, 74], ["SUMO", "PROTEIN", 80, 84], ["IFN", "PROTEIN", 289, 292], ["The PML protein", "TEST", 0, 15], ["Daxx", "TREATMENT", 57, 61], ["ATRX", "TEST", 63, 67], ["cell cycle regulation", "TREATMENT", 204, 225], ["DNA damage repair", "TREATMENT", 227, 244], ["apoptosis", "PROBLEM", 246, 255], ["transcriptional regulation", "TREATMENT", 257, 283], ["IFN response", "PROBLEM", 289, 301], ["viral infection", "PROBLEM", 305, 320], ["PML", "OBSERVATION", 4, 7], ["aggregates", "OBSERVATION_MODIFIER", 25, 35], ["nucleus", "ANATOMY", 93, 100], ["cellular functions", "OBSERVATION", 174, 192], ["damage repair", "OBSERVATION", 231, 244], ["viral", "OBSERVATION_MODIFIER", 305, 310], ["infection", "OBSERVATION", 311, 320]]], ["APL results from a chromosomal translocation at the PML locus.", [["chromosomal", "ANATOMY", 19, 30], ["APL", "DISEASE", 0, 3], ["APL", "CANCER", 0, 3], ["chromosomal", "CELLULAR_COMPONENT", 19, 30], ["PML", "GENE_OR_GENE_PRODUCT", 52, 55], ["PML locus", "DNA", 52, 61], ["APL results", "TEST", 0, 11], ["a chromosomal translocation at the PML locus", "PROBLEM", 17, 61], ["PML locus", "OBSERVATION", 52, 61]]], ["This gives rise to a pair of new PML\u2013retinoic acid receptor fusion proteins, neither of which allow for the formation and assembly of functional PML NB (Melnick and Licht, 1999).", [["PML\u2013retinoic acid", "CHEMICAL", 33, 50], ["PML\u2013retinoic acid receptor", "GENE_OR_GENE_PRODUCT", 33, 59], ["PML NB", "CANCER", 145, 151], ["PML\u2013retinoic acid receptor fusion proteins", "PROTEIN", 33, 75], ["new PML\u2013retinoic acid receptor fusion proteins", "TREATMENT", 29, 75]]], ["Herpesviruses and adenoviruses express proteins that disrupt the PML NBs, thus preventing IFN-induced anti-viral responses and resulting in enhanced viral transcription and replication (reviewed in Everett and Chelbi-Alix, 2007).", [["PML NBs", "ANATOMY", 65, 72], ["IFN", "CHEMICAL", 90, 93], ["Herpesviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["adenoviruses", "ORGANISM", 18, 30], ["PML", "GENE_OR_GENE_PRODUCT", 65, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["IFN", "PROTEIN", 90, 93], ["Herpesviruses", "PROBLEM", 0, 13], ["adenoviruses express proteins", "PROBLEM", 18, 47], ["the PML NBs", "PROBLEM", 61, 72], ["IFN", "TREATMENT", 90, 93], ["enhanced viral transcription", "TREATMENT", 140, 168], ["adenoviruses", "OBSERVATION", 18, 30], ["PML NBs", "OBSERVATION", 65, 72]]], ["For simplicity, we discuss all the examples of PML NB disruption in this section, although the impact that these have on viral functions is varied.", [["PML NB", "ANATOMY", 47, 53], ["PML NB", "CANCER", 47, 53], ["PML NB disruption", "PROBLEM", 47, 64], ["this section", "TREATMENT", 68, 80], ["PML NB disruption", "OBSERVATION", 47, 64]]], ["HSV-1 encodes ICP0, which induces the disruption of PML NBs via degradation of the complex proteins PML and SP100.", [["PML NBs", "ANATOMY", 52, 59], ["HSV-1", "ORGANISM", 0, 5], ["ICP0", "GENE_OR_GENE_PRODUCT", 14, 18], ["PML NBs", "GENE_OR_GENE_PRODUCT", 52, 59], ["PML", "GENE_OR_GENE_PRODUCT", 100, 103], ["SP100", "GENE_OR_GENE_PRODUCT", 108, 113], ["ICP0", "PROTEIN", 14, 18], ["complex proteins", "PROTEIN", 83, 99], ["PML", "PROTEIN", 100, 103], ["SP100", "PROTEIN", 108, 113], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["encodes ICP0", "PROBLEM", 6, 18], ["PML NBs", "PROBLEM", 52, 59], ["the complex proteins PML", "PROBLEM", 79, 103], ["PML NBs", "OBSERVATION", 52, 59]]], ["This degradation is proteasome dependent and relies on the ICP0 RING domain E3 Ub ligase function (Boutell et al., 2002; Gu and Roizman, 2009).", [["ICP0", "GENE_OR_GENE_PRODUCT", 59, 63], ["proteasome", "PROTEIN", 20, 30], ["ICP0 RING domain E3 Ub ligase", "PROTEIN", 59, 88], ["proteasome dependent", "PROBLEM", 20, 40], ["proteasome dependent", "OBSERVATION", 20, 40], ["ligase function", "OBSERVATION", 82, 97]]], ["EBV disrupts PML NBs through the action of the viral transactivator EBNA1, in a process that leads to the development of nasopharyngeal carcinoma (Sivachandran et al., 2008).", [["PML NBs", "ANATOMY", 13, 20], ["nasopharyngeal carcinoma", "ANATOMY", 121, 145], ["nasopharyngeal carcinoma", "DISEASE", 121, 145], ["EBV", "ORGANISM", 0, 3], ["PML NBs", "GENE_OR_GENE_PRODUCT", 13, 20], ["EBNA1", "GENE_OR_GENE_PRODUCT", 68, 73], ["nasopharyngeal carcinoma", "CANCER", 121, 145], ["viral transactivator", "PROTEIN", 47, 67], ["EBNA1", "PROTEIN", 68, 73], ["EBV", "SPECIES", 0, 3], ["EBV disrupts PML NBs", "PROBLEM", 0, 20], ["the viral transactivator EBNA1", "PROBLEM", 43, 73], ["nasopharyngeal carcinoma", "PROBLEM", 121, 145], ["PML NBs", "OBSERVATION", 13, 20], ["viral", "OBSERVATION", 47, 52], ["transactivator EBNA1", "OBSERVATION", 53, 73], ["nasopharyngeal", "ANATOMY", 121, 135], ["carcinoma", "OBSERVATION", 136, 145]]], ["A recent study suggests that EBNA1\u2019s disruption of PML NBs requires its interaction with host proteins including the USP7 DUB and the CK2 protein kinase (Sivachandran et al., 2010).", [["PML NBs", "ANATOMY", 51, 58], ["EBNA1", "GENE_OR_GENE_PRODUCT", 29, 34], ["PML NBs", "GENE_OR_GENE_PRODUCT", 51, 58], ["USP7 DUB", "GENE_OR_GENE_PRODUCT", 117, 125], ["CK2", "GENE_OR_GENE_PRODUCT", 134, 137], ["EBNA1", "PROTEIN", 29, 34], ["host proteins", "PROTEIN", 89, 102], ["USP7", "PROTEIN", 117, 121], ["DUB", "PROTEIN", 122, 125], ["CK2 protein kinase", "PROTEIN", 134, 152], ["A recent study", "TEST", 0, 14], ["EBNA1", "PROBLEM", 29, 34], ["PML NBs", "PROBLEM", 51, 58], ["host proteins", "TEST", 89, 102], ["the USP7 DUB", "TEST", 113, 125], ["the CK2 protein kinase", "TEST", 130, 152], ["EBNA1", "OBSERVATION", 29, 34], ["PML NBs", "OBSERVATION", 51, 58]]], ["The phosphorylation of PML by CK2 is important for PML\u2019s subsequent polyubiquitination and proteasomal degradation (Scaglioni et al., 2008).", [["PML", "GENE_OR_GENE_PRODUCT", 23, 26], ["CK2", "GENE_OR_GENE_PRODUCT", 30, 33], ["PML", "GENE_OR_GENE_PRODUCT", 51, 54], ["PML", "PROTEIN", 23, 26], ["CK2", "PROTEIN", 30, 33], ["PML", "PROTEIN", 51, 54], ["The phosphorylation of PML", "PROBLEM", 0, 26], ["PML", "PROBLEM", 51, 54], ["subsequent polyubiquitination", "PROBLEM", 57, 86], ["proteasomal degradation", "PROBLEM", 91, 114], ["PML", "OBSERVATION", 23, 26], ["important for", "UNCERTAINTY", 37, 50], ["polyubiquitination", "OBSERVATION_MODIFIER", 68, 86], ["proteasomal degradation", "OBSERVATION", 91, 114]]], ["Sivachandran et al. (2010) hypothesize that EBNA1 enhances CK2\u2019s effect on PML, but also requires USP7 binding for complete PML NB disruption.", [["PML", "ANATOMY", 75, 78], ["PML NB", "ANATOMY", 124, 130], ["EBNA1", "GENE_OR_GENE_PRODUCT", 44, 49], ["CK2", "GENE_OR_GENE_PRODUCT", 59, 62], ["PML", "GENE_OR_GENE_PRODUCT", 75, 78], ["USP7", "GENE_OR_GENE_PRODUCT", 98, 102], ["PML NB", "CANCER", 124, 130], ["EBNA1", "PROTEIN", 44, 49], ["CK2", "PROTEIN", 59, 62], ["PML", "CELL_TYPE", 75, 78], ["USP7", "PROTEIN", 98, 102], ["PML", "PROBLEM", 75, 78], ["USP7 binding", "PROBLEM", 98, 110], ["complete PML NB disruption", "PROBLEM", 115, 141], ["PML NB disruption", "OBSERVATION", 124, 141]]], ["The role that USP7 plays here is not clear, given that its catalytic domain is not required (Sivachandran et al., 2010).", [["USP7", "GENE_OR_GENE_PRODUCT", 14, 18], ["USP7", "PROTEIN", 14, 18], ["catalytic domain", "PROTEIN", 59, 75]]], ["Daxx is a host-encoded transcription repressor that can inhibit viral gene expression, and is yet another PML NB component targeted for degradation by viruses.", [["Daxx", "GENE_OR_GENE_PRODUCT", 0, 4], ["PML NB", "CANCER", 106, 112], ["Daxx", "PROTEIN", 0, 4], ["transcription repressor", "PROTEIN", 23, 46], ["encoded transcription repressor", "TREATMENT", 15, 46], ["viral gene expression", "PROBLEM", 64, 85], ["another PML NB component", "PROBLEM", 98, 122]]], ["The HCMV tegument protein pp71 induces the proteasomal degradation of Daxx, thereby relieving the IFN-induced inhibition on viral immediate early (IE) gene expression (Saffert and Kalejta, 2006).", [["proteasomal", "ANATOMY", 43, 54], ["IFN", "CHEMICAL", 98, 101], ["HCMV", "ORGANISM", 4, 8], ["pp71", "GENE_OR_GENE_PRODUCT", 26, 30], ["Daxx", "GENE_OR_GENE_PRODUCT", 70, 74], ["IFN", "GENE_OR_GENE_PRODUCT", 98, 101], ["HCMV tegument protein", "PROTEIN", 4, 25], ["pp71", "PROTEIN", 26, 30], ["Daxx", "PROTEIN", 70, 74], ["IFN", "PROTEIN", 98, 101], ["viral immediate early (IE) gene", "DNA", 124, 155], ["HCMV", "SPECIES", 4, 8], ["The HCMV tegument protein pp71", "TEST", 0, 30], ["the proteasomal degradation of Daxx", "TREATMENT", 39, 74], ["the IFN", "TREATMENT", 94, 101], ["HCMV", "OBSERVATION", 4, 8]]], ["While no cellular Ub ligase has been implicated, data has been put forth suggesting that the pp71-mediated degradation of Daxx (Hwang and Kalejta, 2007) may instead involve SUMOylation (Hwang and Kalejta, 2009).", [["cellular", "ANATOMY", 9, 17], ["cellular", "CELL", 9, 17], ["Ub", "GENE_OR_GENE_PRODUCT", 18, 20], ["pp71", "GENE_OR_GENE_PRODUCT", 93, 97], ["Daxx", "GENE_OR_GENE_PRODUCT", 122, 126], ["Ub ligase", "PROTEIN", 18, 27], ["pp71", "PROTEIN", 93, 97], ["Daxx", "PROTEIN", 122, 126], ["cellular Ub ligase", "TEST", 9, 27], ["the pp71", "TEST", 89, 97], ["Daxx", "TREATMENT", 122, 126], ["Ub", "ANATOMY_MODIFIER", 18, 20], ["ligase", "OBSERVATION", 21, 27]]], ["However, a Daxx mutant that is inefficiently SUMOylated was still degraded by pp71 and exhibited no difference in IE gene expression (Hwang and Kalejta, 2009).", [["Daxx", "GENE_OR_GENE_PRODUCT", 11, 15], ["pp71", "GENE_OR_GENE_PRODUCT", 78, 82], ["Daxx", "PROTEIN", 11, 15], ["pp71", "PROTEIN", 78, 82], ["IE gene", "DNA", 114, 121], ["a Daxx mutant", "PROBLEM", 9, 22]]], ["It has recently been shown that adenovirus E1B55K also targets Daxx for ubiquitination and proteasomal destruction (Schreiner et al., 2010).", [["proteasomal", "ANATOMY", 91, 102], ["adenovirus", "ORGANISM", 32, 42], ["E1B55K", "GENE_OR_GENE_PRODUCT", 43, 49], ["Daxx", "GENE_OR_GENE_PRODUCT", 63, 67], ["E1B55K", "PROTEIN", 43, 49], ["Daxx", "PROTEIN", 63, 67], ["adenovirus", "SPECIES", 32, 42], ["adenovirus E1B55K", "TREATMENT", 32, 49], ["Daxx", "TREATMENT", 63, 67], ["ubiquitination", "PROBLEM", 72, 86], ["proteasomal destruction", "PROBLEM", 91, 114], ["proteasomal destruction", "OBSERVATION", 91, 114]]], ["Schreiner et al. (2010) found that knocking down Daxx via siRNA enhanced Ad5 replication, and that unlike E1B55K\u2019s other Ub-dependent functions, E4orf6 was not required.Unknown FunctionsThere are many examples of virus-specific effects on the UPS that we have not described here in detail because their advantage to the virus has not yet been determined.", [["Daxx", "GENE_OR_GENE_PRODUCT", 49, 53], ["Ad5", "GENE_OR_GENE_PRODUCT", 73, 76], ["E1B55K", "GENE_OR_GENE_PRODUCT", 106, 112], ["Ub", "GENE_OR_GENE_PRODUCT", 121, 123], ["E4orf6", "GENE_OR_GENE_PRODUCT", 145, 151], ["Daxx", "PROTEIN", 49, 53], ["E1B55K", "PROTEIN", 106, 112], ["Ub", "PROTEIN", 121, 123], ["E4orf6", "PROTEIN", 145, 151], ["UPS", "PROTEIN", 243, 246], ["Ad5", "SPECIES", 73, 76], ["Daxx via siRNA enhanced Ad5 replication", "TREATMENT", 49, 88], ["E4orf6", "TREATMENT", 145, 151], ["virus", "PROBLEM", 213, 218], ["the virus", "PROBLEM", 316, 325], ["dependent", "OBSERVATION", 124, 133], ["virus", "OBSERVATION", 213, 218]]], ["It is expected that as these \u201cunknown functions\u201d are resolved, they will contribute to the ever-increasing number of instances whereby viruses utilize the host ubiquitin system (Table 5).SummaryAs this review has hopefully made abundantly clear, viruses depend upon ubiquitin at virtually all points within the lifecycle (see Figure 1).", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 160, 169], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 266, 275], ["ubiquitin", "PROTEIN", 266, 275], ["viruses", "PROBLEM", 246, 253], ["viruses", "OBSERVATION", 246, 253]]], ["The prevalence of ubiquitin in normal cellular processes makes this unsurprising; by simply co-evolving with their hosts, viruses have had to learn to \u201cspeak\u201d the ubiquitin language fluently in order to maintain their high level of control in infected cells.", [["cellular", "ANATOMY", 38, 46], ["cells", "ANATOMY", 252, 257], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 18, 27], ["cellular", "CELL", 38, 46], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 163, 172], ["cells", "CELL", 252, 257], ["ubiquitin", "PROTEIN", 18, 27], ["infected cells", "CELL_TYPE", 243, 257], ["infected cells", "PROBLEM", 243, 257], ["ubiquitin", "OBSERVATION_MODIFIER", 18, 27], ["normal cellular processes", "OBSERVATION", 31, 56], ["infected cells", "OBSERVATION", 243, 257]]], ["This can be accomplished via more or less elegant means; viruses with limited coding capacity can utilize small adaptor proteins to redirect or modify the activity of cellular ligases, while more complex viruses can encode their own E3 ligases and DUBs.", [["cellular", "ANATOMY", 167, 175], ["cellular", "CELL", 167, 175], ["E3", "GENE_OR_GENE_PRODUCT", 233, 235], ["DUBs", "GENE_OR_GENE_PRODUCT", 248, 252], ["small adaptor proteins", "PROTEIN", 106, 128], ["cellular ligases", "PROTEIN", 167, 183], ["E3 ligases", "PROTEIN", 233, 243], ["DUBs", "PROTEIN", 248, 252], ["viruses", "PROBLEM", 57, 64], ["limited coding capacity", "PROBLEM", 70, 93], ["small adaptor proteins", "TREATMENT", 106, 128], ["cellular ligases", "PROBLEM", 167, 183], ["cellular ligases", "OBSERVATION", 167, 183]]], ["In many cases, viral manipulation of ubiquitin is required to specifically fend off host countermeasures, while in others ubiquitin must be harnessed for viral replication functions.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 37, 46], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 122, 131], ["ubiquitin", "PROTEIN", 37, 46], ["ubiquitin", "PROTEIN", 122, 131], ["viral manipulation of ubiquitin", "TREATMENT", 15, 46], ["host countermeasures", "TREATMENT", 84, 104], ["viral replication functions", "PROBLEM", 154, 181], ["viral manipulation", "OBSERVATION", 15, 33]]], ["Additionally, although we have focused on ubiquitin in this review, it is readily apparent that viruses can manipulate the other ubiquitin-like modifiers as well (see examples presented in Isaacson and Ploegh, 2009).SummaryWhile much of the current ubiquitin literature has focused on events involving lysine-targeted polyubiquitination of targets and their subsequent degradation via the UPS, the recognition that (a) non-lysine residues can be targeted and (b) that ubiquitination itself comprises myriad different topological variants with a vast array of non-degradation outcomes is already leading the field to cast a wider net regarding ubiquitin-dependent phenotypes.", [["lysine", "CHEMICAL", 302, 308], ["lysine", "CHEMICAL", 302, 308], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 42, 51], ["lysine", "AMINO_ACID", 302, 308], ["UPS", "GENE_OR_GENE_PRODUCT", 389, 392], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 643, 652], ["ubiquitin", "PROTEIN", 42, 51], ["ubiquitin", "PROTEIN", 129, 138], ["UPS", "PROTEIN", 389, 392], ["ubiquitin", "PROTEIN", 643, 652], ["viruses", "PROBLEM", 96, 103], ["lysine", "TREATMENT", 302, 308], ["a) non-lysine residues", "TREATMENT", 416, 438], ["dependent phenotypes", "PROBLEM", 653, 673], ["viruses", "OBSERVATION", 96, 103], ["polyubiquitination", "OBSERVATION", 318, 336], ["topological variants", "OBSERVATION", 517, 537]]], ["The development of new proteomics tools (recently reviewed in Shi et al., 2011) has greatly enhanced our ability to detect and study these events, and such methods will in all likelihood continue to improve.SummaryMany of the current examples of viral manipulation of the host ubiquitin system relate to aspects of innate immunity that must be overcome, but it is clear that many cellular process that are normally controlled by ubiquitin such as the cell cycle or the MVB pathway can be readily reprogrammed to benefit a virus.", [["cellular", "ANATOMY", 380, 388], ["cell", "ANATOMY", 451, 455], ["MVB", "ANATOMY", 469, 472], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 277, 286], ["cellular", "CELL", 380, 388], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 429, 438], ["cell", "CELL", 451, 455], ["MVB", "CELLULAR_COMPONENT", 469, 472], ["ubiquitin", "PROTEIN", 429, 438], ["new proteomics tools", "PROBLEM", 19, 39], ["viral manipulation of the host ubiquitin system", "TREATMENT", 246, 293], ["many cellular process", "PROBLEM", 375, 396], ["the cell cycle", "TREATMENT", 447, 461], ["the MVB pathway", "TREATMENT", 465, 480], ["a virus", "PROBLEM", 520, 527], ["new", "OBSERVATION_MODIFIER", 19, 22], ["proteomics", "OBSERVATION", 23, 33], ["viral", "OBSERVATION", 246, 251], ["cellular process", "OBSERVATION", 380, 396]]], ["This unfortunately does not provide many new drug-able targets, as alterations made to any existing, ubiquitin-dependent host processes by small molecules will likely lead to other off-target pathologies.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 101, 110], ["ubiquitin", "PROTEIN", 101, 110], ["ubiquitin-dependent host processes", "TREATMENT", 101, 135], ["small molecules", "PROBLEM", 139, 154], ["target pathologies", "PROBLEM", 185, 203]]], ["However, in those situations where a viral adaptor protein is used to link a host protein to a Ub-ligase complex, the physical interface between the viral protein and the host protein may provide us with an interaction that can safely be inhibited or prevented.", [["Ub", "GENE_OR_GENE_PRODUCT", 95, 97], ["viral adaptor protein", "PROTEIN", 37, 58], ["Ub-ligase complex", "PROTEIN", 95, 112], ["viral protein", "PROTEIN", 149, 162], ["host protein", "PROTEIN", 171, 183], ["a viral adaptor protein", "TREATMENT", 35, 58], ["the viral protein", "TREATMENT", 145, 162], ["ligase complex", "OBSERVATION", 98, 112], ["viral protein", "OBSERVATION", 149, 162]]], ["In the near term, the catalytic sites of the virally encoded DUBs present the most attractive therapeutic targets and they are in fact the subject of intense investigation by numerous groups (Chen et al., 2007b, 2009; Ratia et al., 2008; Ghosh et al., 2010).Conflict of Interest StatementThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["DUBs", "GENE_OR_GENE_PRODUCT", 61, 65], ["catalytic sites", "PROTEIN", 22, 37], ["virally encoded DUBs", "PROTEIN", 45, 65]]]], "19d2d9cf5d4c91e420fb5cf1520393457203508e": [["However, while the vast majority of the books in this library are pure nonsense, it also contains, somewhere, every coherent book ever written, or that might ever be written, and all useful information, including predictions of the future.", [["nonsense", "OBSERVATION", 71, 79]]], ["Despite, or perhaps because of this glut of information, the books are useless to the reader, leaving the librarians in a state of suicidal despair.PETER BUTTRICKOur current state of affairs is not so apocalyptic and journal editors seem to be holding up, however there is some resonance between the current proliferation of COVID related publications and the Borges metaphoric library.", [["suicidal despair", "DISEASE", 131, 147], ["Borges metaphoric library", "DNA", 360, 385], ["suicidal despair", "PROBLEM", 131, 147], ["some resonance", "PROBLEM", 273, 287]]], ["By one estimate, the COVID-19 literature published between February and May this year included more than 30,000 papers and was doubling every 20 days, 1 among the biggest explosions of scientific literature ever.", [["the COVID", "TEST", 17, 26]]], ["A large plurality of these papers were in non-peer reviewed journals or were presented initially as non-peer reviewed preprints.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["plurality", "OBSERVATION_MODIFIER", 8, 17]]], ["This explosion of literature has provoked the creation of a tranche of analytic tools, some based on natural language processing, designed to build searchable archives, the most prominent of which is probably the CORD-19 data set.", [["most prominent", "OBSERVATION_MODIFIER", 173, 187], ["CORD", "ANATOMY", 213, 217]]], ["3 It currently holds more than 60,000 published articles and preprints, including studies of coronaviruses dating back to the 1950s and which in turn allows some rational filtering and integration of this new, rapidly expanding body of work.", [["body", "ANATOMY", 228, 232], ["coronaviruses", "ORGANISM", 93, 106], ["body", "ORGANISM_SUBDIVISION", 228, 232], ["coronaviruses", "PROBLEM", 93, 106]]], ["Obviously, this outpouring of literature was fueled by the legitimate need for information, any information, that might help navigate the acute phase of the pandemic and it seems likely (although it's still probably premature to make a definitive assessment) that the sheer volume of information that was shared so quickly altered treatments and improved outcomes for thousands of hospitalized patients.PETER BUTTRICKHowever, it is also clear that misleading information also was propagated.", [["patients", "ORGANISM", 394, 402], ["patients", "SPECIES", 394, 402], ["a definitive assessment", "TEST", 234, 257], ["acute", "OBSERVATION_MODIFIER", 138, 143]]], ["The most striking example of this probably related to the very early, small, non-randomized clinical reports claiming efficacy of hydroxychoroquine and azithromycin as treatment for COVID-19 4 which have subsequently been largely disproven and may even have been shown to be harmful in patients with co-incident cardiac disease (despite deafening initial enthusiasm).", [["cardiac", "ANATOMY", 312, 319], ["hydroxychoroquine", "CHEMICAL", 130, 147], ["azithromycin", "CHEMICAL", 152, 164], ["COVID-19 4", "CHEMICAL", 182, 192], ["cardiac disease", "DISEASE", 312, 327], ["hydroxychoroquine", "CHEMICAL", 130, 147], ["azithromycin", "CHEMICAL", 152, 164], ["COVID-19", "CHEMICAL", 182, 190], ["hydroxychoroquine", "SIMPLE_CHEMICAL", 130, 147], ["azithromycin", "SIMPLE_CHEMICAL", 152, 164], ["patients", "ORGANISM", 286, 294], ["cardiac", "ORGAN", 312, 319], ["patients", "SPECIES", 286, 294], ["hydroxychoroquine", "TREATMENT", 130, 147], ["azithromycin", "TREATMENT", 152, 164], ["treatment", "TREATMENT", 168, 177], ["COVID", "TEST", 182, 187], ["co-incident cardiac disease", "PROBLEM", 300, 327], ["probably related to", "UNCERTAINTY", 34, 53], ["very", "OBSERVATION_MODIFIER", 58, 62], ["early", "OBSERVATION_MODIFIER", 63, 68], ["small", "OBSERVATION_MODIFIER", 70, 75], ["cardiac", "ANATOMY", 312, 319], ["disease", "OBSERVATION", 320, 327]]], ["There have also been several high profile retractions of peer-reviewed papers 5 in which the clinical cohorts studied may not have been carefully validated.", [["several high profile retractions", "PROBLEM", 21, 53], ["several", "OBSERVATION_MODIFIER", 21, 28], ["high", "OBSERVATION_MODIFIER", 29, 33], ["profile", "OBSERVATION_MODIFIER", 34, 41], ["retractions", "OBSERVATION", 42, 53]]], ["(An irony was that one of these retractions addressed the utility of hydroxycholoquine) A further problem, identified by the editors of JAMA, 6 is that some of the patients described in various publications have been reported on more than once.", [["hydroxycholoquine", "CHEMICAL", 69, 86], ["hydroxycholoquine", "CHEMICAL", 69, 86], ["hydroxycholoquine", "SIMPLE_CHEMICAL", 69, 86], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["these retractions", "PROBLEM", 26, 43], ["hydroxycholoquine)", "TREATMENT", 69, 87], ["A further problem", "PROBLEM", 88, 105], ["retractions", "OBSERVATION", 32, 43]]], ["Leaving aside the fact that this represents a lapse in ethical standards, describing the same patients in different articles, per the JAMA editorial board, \"creates an inaccurate scientific record, may affect the accuracy of subsequent estimates of prevalence of the disease or outcomes, and may preclude valid metaanalyses\".", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["the disease", "PROBLEM", 263, 274]]], ["In sum, these publication trends have real potential for harm, especially in the case of COVID-19 pandemic research where the therapeutic and epidemiologic landscape is so labile.PETER BUTTRICKSo a valid question that all journal editors and journal readers, need to wrestle with is how do we balance the need for very rapid dissemination of new information with the need for careful scrutiny and validation of that information, a process which of necessity takes a great deal of time and attention.", [["harm", "PROBLEM", 57, 61], ["COVID", "TEST", 89, 94], ["labile", "OBSERVATION_MODIFIER", 172, 178]]], ["Obviously there is no clear answer but as the process has unfolded, it appears as if the very early case descriptions were critical to disseminate as quickly as possible so that clinicians around the world would be alert to a new emerging pathogen and associated clinical syndrome.", [["a new emerging pathogen", "PROBLEM", 224, 247], ["clinical syndrome", "PROBLEM", 263, 280], ["no", "UNCERTAINTY", 19, 21], ["clear", "OBSERVATION", 22, 27], ["unfolded", "OBSERVATION", 58, 66]]], ["This phase of information dissemination recalls the early days of the AIDS epidemic which first appeared in the Morbidity and Mortality Weekly Report (MMWR) of the CDC in 1981 as a description of 5 previously healthy men in Los Angeles with unexplained pneumocystis carinii.", [["AIDS", "DISEASE", 70, 74], ["pneumocystis carinii", "DISEASE", 253, 273], ["men", "ORGANISM", 217, 220], ["pneumocystis carinii", "ORGANISM", 253, 273], ["men", "SPECIES", 217, 220], ["pneumocystis carinii", "SPECIES", 253, 273], ["pneumocystis carinii", "SPECIES", 253, 273], ["the AIDS epidemic", "PROBLEM", 66, 83], ["unexplained pneumocystis carinii", "PROBLEM", 241, 273], ["pneumocystis carinii", "OBSERVATION", 253, 273]]], ["7 This single descriptive report prompted several others from around the county, and in very short order an acquired immune deficiency disorder was recognized by the healthcare community.PETER BUTTRICKHaving gotten past this first descriptive phase with COVID-19, we have now entered into a phase where the possibility and risk of dissemination of misleading information is real, based on the legitimate desire for any new information linked to therapeutic outcomes as well as the desire of journals and journal editors to publish high impact studies.", [["immune deficiency disorder", "DISEASE", 117, 143], ["an acquired immune deficiency disorder", "PROBLEM", 105, 143], ["immune deficiency", "OBSERVATION", 117, 134]]], ["Journal editors can and should demand timely reviews of highly impactful manuscripts but they should insist on exacting attention paid to statistical analysis, transparency around study registration and prespecified analytical plans, and access to primary data.", [["statistical analysis", "TEST", 138, 158], ["study registration", "TEST", 180, 198]]], ["This latter point is very important to emphasize as the lack of this access is what led to the high profile retractions cited above, as well as to the risk of the same patients being described in multiple publications.", [["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["the high profile retractions", "PROBLEM", 91, 119], ["multiple", "OBSERVATION_MODIFIER", 196, 204], ["publications", "OBSERVATION", 205, 217]]], ["The cardiology research community has historically done an excellent job in building searchable data registries through the NCDR, the VA COIN network and others so the burden and responsibility on us in this area is particularly high.", [["high", "OBSERVATION", 229, 233]]], ["It is very likely that new data will be highly nuanced, not adequately captured in a manuscript abstract, and will itself require careful interpretation.", [["careful interpretation", "TEST", 130, 152], ["very likely", "UNCERTAINTY", 6, 17]]], ["As we have seen, much information about COVID-19 ends up on social media platforms even before it is formally reviewed and filtering this so that it is accurate and not politicized is the responsibility of all informed consumers.", [["COVID-19", "DNA", 40, 48], ["COVID", "TEST", 40, 45]]], ["Indeed in the case of COVID related publications, the Altmetric score (a measure of media attention) and the citation index of published works correlate poorly, suggesting a real divergence in interest between biomedical researchers and those who primarily engage with the topic through the media.PETER BUTTRICKSo far the clinical and research communities seem to be navigating this unprecedented path reasonably well, but if we fail, there is a very real risk that a contemporary version of Borges' Library of Babel will emerge.", [["the citation index", "TEST", 105, 123]]]]}